0001729149-20-000047.txt : 20201104 0001729149-20-000047.hdr.sgml : 20201104 20201104172616 ACCESSION NUMBER: 0001729149-20-000047 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201104 DATE AS OF CHANGE: 20201104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIEMED HEALTHCARE, INC. CENTRAL INDEX KEY: 0001729149 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38973 FILM NUMBER: 201287756 BUSINESS ADDRESS: STREET 1: 625 E. KALISTE SALOOM RD. CITY: LAFAYETTE STATE: LA ZIP: 70508 BUSINESS PHONE: 337.504.3802 MAIL ADDRESS: STREET 1: 625 E. KALISTE SALOOM RD. CITY: LAFAYETTE STATE: LA ZIP: 70508 10-Q 1 vmd-20200930.htm 10-Q vmd-20200930
0001729149false2020Q3--12-31P1YP3YP1YP3Y00017291492020-01-012020-09-30xbrli:shares00017291492020-10-31iso4217:USD00017291492020-09-3000017291492019-12-3100017291492020-07-012020-09-3000017291492019-07-012019-09-3000017291492019-01-012019-09-30iso4217:USDxbrli:shares0001729149us-gaap:CommonStockMember2018-12-310001729149us-gaap:AdditionalPaidInCapitalMember2018-12-310001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001729149us-gaap:RetainedEarningsMember2018-12-3100017291492018-12-310001729149us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-3100017291492019-01-012019-03-310001729149us-gaap:CommonStockMember2019-01-012019-03-310001729149us-gaap:RetainedEarningsMember2019-01-012019-03-310001729149us-gaap:CommonStockMember2019-03-310001729149us-gaap:AdditionalPaidInCapitalMember2019-03-310001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310001729149us-gaap:RetainedEarningsMember2019-03-3100017291492019-03-310001729149us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-3000017291492019-04-012019-06-300001729149us-gaap:CommonStockMember2019-04-012019-06-300001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300001729149us-gaap:RetainedEarningsMember2019-04-012019-06-300001729149us-gaap:CommonStockMember2019-06-300001729149us-gaap:AdditionalPaidInCapitalMember2019-06-300001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300001729149us-gaap:RetainedEarningsMember2019-06-3000017291492019-06-300001729149us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300001729149us-gaap:CommonStockMember2019-07-012019-09-300001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001729149us-gaap:RetainedEarningsMember2019-07-012019-09-300001729149us-gaap:CommonStockMember2019-09-300001729149us-gaap:AdditionalPaidInCapitalMember2019-09-300001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300001729149us-gaap:RetainedEarningsMember2019-09-3000017291492019-09-300001729149us-gaap:CommonStockMember2019-12-310001729149us-gaap:AdditionalPaidInCapitalMember2019-12-310001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001729149us-gaap:RetainedEarningsMember2019-12-310001729149us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100017291492020-01-012020-03-310001729149us-gaap:CommonStockMember2020-01-012020-03-310001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001729149us-gaap:RetainedEarningsMember2020-01-012020-03-310001729149us-gaap:CommonStockMember2020-03-310001729149us-gaap:AdditionalPaidInCapitalMember2020-03-310001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001729149us-gaap:RetainedEarningsMember2020-03-3100017291492020-03-310001729149us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-3000017291492020-04-012020-06-300001729149us-gaap:CommonStockMember2020-04-012020-06-300001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001729149us-gaap:RetainedEarningsMember2020-04-012020-06-300001729149us-gaap:CommonStockMember2020-06-300001729149us-gaap:AdditionalPaidInCapitalMember2020-06-300001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001729149us-gaap:RetainedEarningsMember2020-06-3000017291492020-06-300001729149us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001729149us-gaap:CommonStockMember2020-07-012020-09-300001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001729149us-gaap:RetainedEarningsMember2020-07-012020-09-300001729149us-gaap:CommonStockMember2020-09-300001729149us-gaap:AdditionalPaidInCapitalMember2020-09-300001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001729149us-gaap:RetainedEarningsMember2020-09-30vmd:statexbrli:pure0001729149us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMembervmd:MedicareMember2020-01-012020-09-300001729149us-gaap:CustomerConcentrationRiskMembervmd:MedicaidMemberus-gaap:AccountsReceivableMember2020-01-012020-09-300001729149us-gaap:CustomerConcentrationRiskMembervmd:MedicareAndMedicaidMemberus-gaap:AccountsReceivableMember2020-01-012020-09-300001729149us-gaap:CustomerConcentrationRiskMembervmd:MedicareAndMedicaidMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310001729149us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembervmd:MedicareMember2020-07-012020-09-300001729149us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembervmd:MedicareMember2019-07-012019-09-300001729149us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembervmd:MedicareMember2020-01-012020-09-300001729149us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembervmd:MedicareMember2019-01-012019-09-300001729149us-gaap:CustomerConcentrationRiskMembervmd:MedicaidMemberus-gaap:RevenueFromContractWithCustomerMember2020-07-012020-09-300001729149us-gaap:CustomerConcentrationRiskMembervmd:MedicaidMemberus-gaap:RevenueFromContractWithCustomerMember2019-07-012019-09-300001729149us-gaap:CustomerConcentrationRiskMembervmd:MedicaidMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-09-300001729149us-gaap:CustomerConcentrationRiskMembervmd:MedicaidMemberus-gaap:RevenueFromContractWithCustomerMember2019-01-012019-09-300001729149us-gaap:CustomerConcentrationRiskMembervmd:MedicareAndMedicaidMemberus-gaap:RevenueFromContractWithCustomerMember2020-07-012020-09-300001729149us-gaap:CustomerConcentrationRiskMembervmd:MedicareAndMedicaidMemberus-gaap:RevenueFromContractWithCustomerMember2019-07-012019-09-300001729149us-gaap:CustomerConcentrationRiskMembervmd:MedicareAndMedicaidMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-09-300001729149us-gaap:CustomerConcentrationRiskMembervmd:MedicareAndMedicaidMemberus-gaap:RevenueFromContractWithCustomerMember2019-01-012019-09-300001729149vmd:EquipmentMedicalMembersrt:MinimumMember2020-01-012020-09-300001729149srt:MaximumMembervmd:EquipmentMedicalMember2020-01-012020-09-300001729149us-gaap:ComputerEquipmentMember2020-01-012020-09-300001729149us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2020-01-012020-09-300001729149srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2020-01-012020-09-300001729149us-gaap:VehiclesMember2020-01-012020-09-300001729149us-gaap:BuildingMembersrt:MinimumMember2020-01-012020-09-300001729149srt:MaximumMemberus-gaap:BuildingMember2020-01-012020-09-300001729149vmd:VentilatorRentalMember2020-07-012020-09-300001729149vmd:VentilatorRentalMember2019-07-012019-09-300001729149vmd:VentilatorRentalMember2020-01-012020-09-300001729149vmd:VentilatorRentalMember2019-01-012019-09-300001729149vmd:OtherDurableMedicalEquipmentRentalsMember2020-07-012020-09-300001729149vmd:OtherDurableMedicalEquipmentRentalsMember2019-07-012019-09-300001729149vmd:OtherDurableMedicalEquipmentRentalsMember2020-01-012020-09-300001729149vmd:OtherDurableMedicalEquipmentRentalsMember2019-01-012019-09-300001729149vmd:EquipmentSalesMember2020-07-012020-09-300001729149vmd:EquipmentSalesMember2019-07-012019-09-300001729149vmd:EquipmentSalesMember2020-01-012020-09-300001729149vmd:EquipmentSalesMember2019-01-012019-09-300001729149vmd:COVID19ResponseSalesMember2020-07-012020-09-300001729149vmd:COVID19ResponseSalesMember2019-07-012019-09-300001729149vmd:COVID19ResponseSalesMember2020-01-012020-09-300001729149vmd:COVID19ResponseSalesMember2019-01-012019-09-300001729149us-gaap:ServiceMember2020-07-012020-09-300001729149us-gaap:ServiceMember2019-07-012019-09-300001729149us-gaap:ServiceMember2020-01-012020-09-300001729149us-gaap:ServiceMember2019-01-012019-09-300001729149vmd:EquipmentMedicalMember2020-09-300001729149vmd:EquipmentMedicalMember2019-12-310001729149vmd:FurnitureAndEquipmentMember2020-09-300001729149vmd:FurnitureAndEquipmentMember2019-12-310001729149us-gaap:LandMember2020-09-300001729149us-gaap:LandMember2019-12-310001729149us-gaap:BuildingMember2020-09-300001729149us-gaap:BuildingMember2019-12-310001729149us-gaap:LeaseholdImprovementsMember2020-09-300001729149us-gaap:LeaseholdImprovementsMember2019-12-310001729149us-gaap:VehiclesMember2020-09-300001729149us-gaap:VehiclesMember2019-12-310001729149vmd:AssetsHeldUnderFinanceLeasesMember2020-09-300001729149vmd:AssetsHeldUnderFinanceLeasesMember2019-12-310001729149us-gaap:LineOfCreditMember2020-09-300001729149us-gaap:LineOfCreditMemberus-gaap:PrimeRateMember2020-01-012020-09-300001729149us-gaap:LineOfCreditMember2019-12-310001729149us-gaap:NotesPayableToBanksMembervmd:BuildingTermNoteMember2019-05-300001729149us-gaap:NotesPayableToBanksMembervmd:BuildingTermNoteMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-05-302019-05-300001729149us-gaap:NotesPayableToBanksMemberus-gaap:InterestRateSwapMembervmd:BuildingTermNoteMember2019-05-300001729149us-gaap:NotesPayableToBanksMembervmd:TermNoteMember2019-09-190001729149us-gaap:NotesPayableToBanksMembervmd:TermNoteMember2019-10-192019-10-190001729149us-gaap:NotesPayableToBanksMember2020-09-300001729149us-gaap:NotesPayableToBanksMember2019-12-310001729149vmd:MonthlyRentalPaymentsMembersrt:AffiliatedEntityMember2020-01-012020-09-300001729149vmd:MonthlyRentalPaymentsMembersrt:AffiliatedEntityMember2020-07-012020-09-300001729149vmd:MonthlyRentalPaymentsMembersrt:AffiliatedEntityMember2019-07-012019-09-300001729149vmd:MonthlyRentalPaymentsMembersrt:AffiliatedEntityMember2019-01-012019-09-300001729149us-gaap:WarrantMember2020-01-012020-09-300001729149us-gaap:WarrantMember2020-07-012020-09-300001729149us-gaap:WarrantMember2018-12-310001729149us-gaap:WarrantMember2019-01-012019-09-300001729149us-gaap:WarrantMember2019-09-30vmd:swap0001729149us-gaap:InterestRateSwapMember2020-09-300001729149us-gaap:RestrictedStockUnitsRSUMember2020-09-300001729149vmd:OmnibusPlanMember2020-06-110001729149vmd:OmnibusPlanMember2020-06-112020-06-110001729149vmd:OmnibusPlanMemberus-gaap:CommonStockMember2020-06-110001729149us-gaap:EmployeeStockOptionMember2020-07-012020-09-300001729149us-gaap:EmployeeStockOptionMember2019-07-012019-09-300001729149us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001729149us-gaap:EmployeeStockOptionMember2019-01-012019-09-300001729149us-gaap:RestrictedStockUnitsRSUMember2020-07-012020-09-300001729149us-gaap:RestrictedStockUnitsRSUMember2019-07-012019-09-300001729149us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001729149us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-3000017291492019-01-012019-12-310001729149us-gaap:CommonStockMember2020-01-012020-09-300001729149us-gaap:EmployeeStockOptionMembersrt:MinimumMember2020-09-300001729149srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-09-300001729149us-gaap:EmployeeStockOptionMembersrt:MinimumMember2020-01-012020-09-300001729149srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-09-300001729149us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2020-01-012020-09-300001729149srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001729149us-gaap:RestrictedStockUnitsRSUMember2019-12-310001729149us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310001729149us-gaap:PhantomShareUnitsPSUsMember2020-01-012020-09-300001729149us-gaap:PhantomShareUnitsPSUsMember2019-12-310001729149us-gaap:PhantomShareUnitsPSUsMember2020-09-300001729149us-gaap:PhantomShareUnitsPSUsMembersrt:MinimumMember2020-01-012020-09-300001729149srt:MaximumMemberus-gaap:PhantomShareUnitsPSUsMember2020-01-012020-09-300001729149us-gaap:PhantomShareUnitsPSUsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012020-09-300001729149us-gaap:PhantomShareUnitsPSUsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-07-012019-09-300001729149us-gaap:PhantomShareUnitsPSUsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-300001729149us-gaap:PhantomShareUnitsPSUsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-09-300001729149us-gaap:PhantomShareUnitsPSUsMember2019-01-012019-09-3000017291492020-09-232020-09-2300017291492020-04-012020-04-3000017291492020-01-012020-06-300001729149us-gaap:SubsequentEventMember2020-10-012020-11-04

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____

Commission file number: 001-38973
Viemed Healthcare, Inc.
(Exact name of registrant as specified in its charter)
British Columbia, Canada
 N/A
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification Number)
   
 
625 E. Kaliste Saloom Rd.
Lafayette, LA 70508
 
(Address of principal executive offices, including zip code)
 
(337) 504-3802
 
(Registrant’s telephone number, including area code)
   
Securities registered pursuant to Section 12(b) of the Act:
   
Title of each classTrading Symbol(s)Name of exchange on which registered
Common Shares, no par valueVMDThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ Accelerated filer ☐ 
Non-Accelerated filer ☐
 
Smaller reporting company ☒
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  x

As of October 31, 2020, there were 39,145,182 common shares of the registrant outstanding.



VIEMED HEALTHCARE, INC.
TABLE OF CONTENTS
September 30, 2020 and 2019
Page


PART I - FINANCIAL INFORMATION

Item 1. Financial Statements
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Expressed in thousands of U.S. Dollars, except outstanding shares)
NoteAt
September 30, 2020		At
December 31, 2019
(Unaudited)(Audited)
ASSETS
Current assets
Cash and cash equivalents$32,396 $13,355 
Accounts receivable, net of allowance for doubtful accounts of $8,788 and $7,782 at September 30, 2020 and December 31, 2019, respectively
211,489 11,534 
Inventory, net of inventory reserve of $805 and $0 at September 30, 2020 and December 31, 2019, respectively
22,762 1,360 
Prepaid expenses and other assets23,333 1,562 
Total current assets$49,980 $27,811 
Long-term assets
Property and equipment, net356,317 54,772 
Equity method investment79 13 
Deferred tax asset107,593 — 
Total long-term assets$63,989 $54,785 
TOTAL ASSETS$113,969 $82,596 
LIABILITIES
Current liabilities
Trade payables$7,553 $4,700 
Deferred revenue3,612 3,315 
Income taxes payable368 86 
Accrued liabilities412,793 8,968 
Current portion of lease liabilities54,207 7,093 
Current portion of long-term debt51,815 1,750 
Total current liabilities$30,348 $25,912 
Long-term liabilities
Accrued liabilities71,210 2,317 
Long-term lease liabilities5952 3,039 
Long-term debt56,261 7,629 
Total long-term liabilities$8,423 $12,985 
TOTAL LIABILITIES$38,771 $38,897 
Commitments and Contingencies— — 
SHAREHOLDERS' EQUITY
Common stock - No par value: unlimited authorized; 39,145,182 and 37,952,660 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively
79,085 3,366 
Additional paid-in capital6,019 6,377 
Accumulated other comprehensive loss(478)(157)
Retained earnings60,572 34,113 
TOTAL SHAREHOLDERS' EQUITY$75,198 $43,699 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$113,969 $82,596 
See accompanying notes to the condensed consolidated financial statements
Page 3
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(Expressed in thousands of U.S. Dollars, except share and per share amounts)
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
Note2020201920202019
Revenue2$33,447 $20,368 $100,107 $58,808 
Cost of revenue13,994 6,318 39,174 17,045 
Gross profit$19,453 $14,050 $60,933 $41,763 
Operating Expenses
Selling, general and administrative13,550 10,231 40,555 31,207 
Research and development243 208 688 645 
Stock-based compensation71,234 1,064 3,581 2,978 
Depreciation202 193 612 460 
Loss (gain) on disposal of property and equipment203 167 (2,424)308 
     Other (income) expense9(19)1 (3,593)(1)
Income from operations$4,040 $2,186 $21,514 $6,166 
Non-operating expenses
Unrealized gain on warrant conversion liability6— (800)— (363)
(Gain) loss from equity method investment(21)26 (36)77 
Interest expense, net of interest income5116 56 409 102 
Net income before taxes3,945 2,904 21,141 6,350 
Provision (benefit) for income taxes101,141 51 (5,318)213 
Net income$2,804 $2,853 $26,459 $6,137 
Other Comprehensive Income
Change in unrealized gain (loss) on derivative instruments, net of tax24 (88)(321)(236)
Other Comprehensive Loss$24 $(88)$(321)$(236)
Comprehensive Income$2,828 $2,765 $26,138 $5,901 
Net income per share
Basic11$0.07 $0.08 $0.69 $0.17 
Diluted11$0.07 $0.07 $0.66 $0.15 
Weighted average number of common shares outstanding:
Basic 1139,107,640 37,812,921 38,603,267 37,775,775 
Diluted1141,155,668 40,051,422 40,377,608 39,768,877 




See accompanying notes to the condensed consolidated financial statements
Page 4

VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(Expressed in thousands of U.S. Dollars, except share and per share amounts)
(Unaudited)
Common StockAdditional paid-in capitalAccumulated other comprehensive lossTotal Shareholders'
equity
SharesAmountRetained
earnings
Shareholders' equity, December 31, 201837,500,815$71 $5,390 $— $27,110 $32,571 
Stock-based compensation - options— — 578 — — 578 
Stock-based compensation - restricted stock— — 302 — — 302 
Exercise of options2,418 4 — — — 4 
Shares issued for vesting of restricted stock units539,965 2,202 (2,202)— — — 
Shares repurchased and canceled under the Normal Course Issuer Bid(365,100)— — — (1,522)(1,522)
Net Income— — — — 1,958 1,958 
Shareholders' equity, March 31, 201937,678,098 $2,277 $4,068 $— $27,546 $33,891 
Stock-based compensation - options— — 705 — — 705 
Share-based compensation - restricted stock— — 329 — — 329 
Exercise of warrants8,280 16 — — — 16 
Exercise of options4,725 18 — — — 18 
Shares issued for vesting of restricted stock units6,432 39 (39)— — — 
Change in accumulated other comprehensive loss— — — (148)— (148)
Net Income— — — — 1,326 1,326 
Shareholders' equity, June 30, 201937,697,535 $2,350 $5,063 $(148)$28,872 $36,137 
Stock-based compensation - options— — 745— — 745 
Stock-based compensation - restricted stock— — 319— — 319 
Exercise of warrants124,890 245— — — 245 
Exercise of options35,025 114— — — 114 
Shares issued for vesting of restricted stock units95,210 657(657)— — — 
Change in accumulated other comprehensive loss— — — (88)— (88)
Net Income— — — — 2,853 2,853 
Shareholders' equity, September 30, 201937,952,660 $3,366 $5,470 $(236)$31,725 $40,325 
See accompanying notes to the condensed consolidated financial statements
Page 5

VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(Expressed in thousands of U.S. Dollars, except share and per share amounts)
(Unaudited)
Common StockAdditional paid-in capitalAccumulated other comprehensive lossTotal Shareholders'
equity
SharesAmountRetained
earnings
Shareholders' equity, December 31, 201937,952,660 $3,366 $6,377 $(157)$34,113 $43,699 
Stock-based compensation - options— — 891 — — 891 
Stock-based compensation - restricted stock— — 260 — — 260 
Exercise of options4,737 15 — — — 15 
Shares issued for vesting of restricted stock units529,375 3,276 (3,276)— — — 
Change in accumulated other comprehensive loss— — — (312)— (312)
Net Income— — — — 4,243 4,243 
Shareholders' equity, March 31, 202038,486,772 $6,657 $4,252 $(469)$38,356 $48,796 
Stock-based compensation - options— — 933 — — 933 
Stock-based compensation - restricted stock— — 263 — — 263 
Exercise of options596,160 1,757 — — — 1,757 
Change in accumulated other comprehensive loss— — — (33)— (33)
Net Income— — — — 19,412 19,412 
Shareholders' equity, June 30, 202039,082,932 $8,414 $5,448 $(502)$57,768 $71,128 
Stock-based compensation - options— — 945 — — 945 
Stock-based compensation - restricted stock— — 289 — — 289 
Exercise of options2,400 8 — — — 8 
Shares issued for vesting of restricted stock units59,850 663 (663)— — — 
Change in accumulated other comprehensive income— — — 24 — 24 
Net Income— — — — 2,804 2,804 
Shareholders' equity, September 30, 202039,145,182 $9,085 $6,019 $(478)$60,572 $75,198 











See accompanying notes to the condensed consolidated financial statements
Page 6

VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in thousands of U.S. Dollars)
(Unaudited)
Nine Months Ended September 30,
Note20202019
Cash flows from operating activities
Net income$26,459 $6,137 
Adjustments for:
Depreciation6,745 4,398 
Change in allowance for doubtful accounts27,031 6,937 
Share-based compensation73,581 2,978 
Unrealized gain on warrant conversion liability6— (363)
(Gain) loss on equity method investment (36)77 
(Gain) loss on disposal of property and equipment(2,424)308 
Deferred income taxes (benefit)(7,593)— 
Net change in working capital
Increase in accounts receivable(6,986)(9,827)
(Increase) decrease in inventory(1,402)1,621 
Increase in prepaid expenses and other current assets(1,771)(1,321)
Increase (decrease) in trade payables2,739 (1,813)
Increase in deferred revenue297 770 
Increase in accrued liabilities2,397 1,909 
Increase (decrease) in income tax payable282 (124)
Net cash provided by operating activities$29,319 $11,687 
Cash flows from investing activities
Purchase of property and equipment(8,204)(10,582)
Investment in equity method investment(30)— 
Proceeds from sale of property and equipment5,187 350 
Net cash used in investing activities$(3,047)$(10,232)
Cash flows from financing activities
Proceeds from exercise of options1,780 136 
Proceeds from exercise of warrants— 261 
(Principal payments) net proceeds on notes payable5(104)4,837 
(Principal payments) net proceeds on term note5(1,199)4,966 
Shares repurchased and canceled under the Normal Course Issuer Bid— (1,522)
Repayments of lease liabilities(7,708)(7,916)
Net cash (used in) provided by financing activities$(7,231)$762 
Net increase in cash and cash equivalents19,041 2,217 
Cash and cash equivalents at beginning of year13,355 10,413 
Cash and cash equivalents at end of period$32,396 $12,630 
Supplemental disclosures of cash flow information
Cash paid during the period for interest$437 $91 
Cash paid during the period for income taxes, net of refunds received$1,975 $338 
Supplemental disclosures of non-cash transactions
Property and equipment financed through finance leases$3,002 $14,735 
Property and equipment financed through leases under FASB ASC 842$57 $2,052 

See accompanying notes to the condensed consolidated financial statements
Page 7
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
1.    Nature of Business and Operations

Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of in-home durable medical equipment ("DME") and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. The Company currently serves patients in 36 states in the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508.

As of June 30, 2020, the Company determined that it no longer qualifies as a "foreign private issuer," as defined in Rule 3b-4 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), for the purposes of the informational requirements of the Exchange Act. As a result, effective January 1, 2021, the Company will become subject to the proxy solicitation rules under Section 14 of the Exchange Act and Regulation FD, and the Company's officers, directors, and principal shareholders will become subject to the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. The Company will continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the Securities and Exchange Commission (the "SEC").

The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act (the "JOBS Act"), and as such, has elected to comply with certain reduced U.S. public company reporting requirements.

The Company’s shares are traded in Canada on the Toronto Stock Exchange under the symbol VMD.TO and in the U.S. on the Nasdaq Capital Market under the symbol VMD.

2. Summary of Significant Accounting Policies

Principles of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2019 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of our independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

Basis of consolidation

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.

Use of estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates.

As of September 30, 2020, the COVID-19 pandemic is ongoing and the impacts of the pandemic on our business, financial condition and results of operations continue to evolve as of the date of this report. As a result, the impacts remain uncertain and
Page 8
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
difficult to predict and will depend on, among other factors, the duration and severity of the pandemic, as well as any negative economic conditions arising from the pandemic, our ability to assess potential patients in hospitals and set up and treat patients in the home, and the impacts of government actions and administrative regulations on the healthcare industry and broader economy, including through existing and any future stimulus efforts. As events continue to evolve and additional information becomes available, our estimates may change materially in future periods.

Accounts receivable

Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.

The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.

For the nine months ended September 30, 2020, our assessment considered business and market disruptions caused by the COVID-19 pandemic and estimates of expected emerging credit and collectability trends. The continued volatility in market conditions and evolving shifts in credit trends are difficult to predict causing variability and volatility that may have a material impact on our allowance for credit losses in future periods.

The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows:
September 30, 2020September 30, 2019
Balance, beginning of year$7,782 $4,266 
Change in allowance for doubtful accounts7,031 6,937 
Amounts written off(6,025)(3,539)
Balance, end of period$8,788 $7,664 

As of September 30, 2020 and 2019, no one customer represented more than 10% of outstanding accounts receivable. The Company does have receivables at September 30, 2020 from Medicare and Medicaid, representing 59% and 6%, respectively, and 65% combined, of total outstanding receivables (December 31, 2019 - 58%). As these receivables are both from government programs, there is little credit risk associated with these balances; however, these receivables are subject to billing modifications and other adjustments and estimates of the amounts of such adjustments are included in the allowance for doubtful accounts.

Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and nine month periods ended September 30, 2020, were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Medicare Revenues57 %57 %60 %59 %
Medicaid Revenues9 %7 %9 %7 %
Total Medicare and Medicaid66 %64 %69 %66 %

Inventory

Inventory represents non-serialized respiratory supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value. Inventory is presented net of a reserve balance of $805,000 and $0 at September 30, 2020 and December 31, 2019, respectively, that relates to COVID-19 response supplies.

Page 9

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
Property and equipment

Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives.

The estimated useful lives of the property and equipment are as follows:
DescriptionEstimated Useful Lives
Medical Equipment
1 - 10 Years
Computer Equipment5 Years
Office Furniture & Fixtures
5 - 10 Years
Leasehold ImprovementsShorter of Useful Life or Lease
Vehicles5 Years
Building
15 - 39 Years
LandIndefinite Life

Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been deployed to a patient’s address and is put in use and continues through the useful life of the asset. Property and equipment and other non-current assets with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.

Prepaid expenses and other assets

Prepaid expenses and other current assets consists primarily of prepaid expenses such as insurance, rent, and supplier deposits for rental equipment.
Comprehensive income

Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity.

Revenue recognition

Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services.

The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare & Medicaid Services (“CMS”).
Page 10

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.

The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with FASB ASC 842, “Leases,” (Topic 842). For any DME sales and services, the Company recognizes revenue under FASB ASU 2014-09, “Revenue from Contracts with Customers,” (Topic 606) and related amendments.

The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term.

The revenues from each major source are summarized in the following table:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Revenue from rentals under Topic 842
    Ventilator rentals, non-invasive and invasive$19,962 $17,213 $58,672 $50,990 
    Other durable medical equipment rentals2,649 1,449 7,184 3,464 
Revenue from sales and services under Topic 606
    Equipment and supply sales
1,890 1,349 3,962 3,202 
    COVID-19 response sales and services
8,553 — 29,306 — 
    Service revenues
393 357 983 1,152 
Total Revenues$33,447 $20,368 $100,107 $58,808 

Revenue Accounting under Topic 842

The Company leases DME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company considers these rentals to be operating leases.

Under FASB Accounting Standards Codification Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.

Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Revenue Accounting under Topic 606

The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.

The Company also provides sleep study services to customers and recognizes revenue when the results of the sleep study are complete as that is when the performance obligation is met. The transaction price on both equipment sales and sleep studies is the
Page 11

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.

The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.

Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Returns and refunds are not accepted on either equipment sales or sleep study services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of September 30, 2020.

Stock-based compensation

The Company accounts for its stock-based compensation in accordance with ASC 718, "Compensation—Stock Compensation", which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award.

Interest rate swaps

The Company utilizes an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the Term Note (as defined below). 

For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk. These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company includes unrealized gains in Prepaid expenses and other assets, as a component of Long-term Assets, and unrealized losses in Accrued Liabilities, as a component of Long-term Liabilities on the Condensed Consolidated Balance Sheets.

The Company recognizes any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to Accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets. To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in Interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.

Page 12

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
Recently adopted accounting pronouncements

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance modifies the disclosure requirements on fair value measurements. The Company adopted this standard on January 1, 2020 and the adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.

Recently issued accounting pronouncements

The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses,” to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The ASU will be effective for interim and annual periods beginning January 1, 2020 for issuers and annual periods beginning January 1, 2023 for non-issuers. The Company anticipates adopting this ASU on January 1, 2023 given its smaller reporting company status and is still evaluating the impact of adoption on the consolidated financial statements in future periods.

In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments – Credit Losses. Among other things, the ASU expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosures required by ASC 326 to also include certain disclosures required by Topic 320. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. The amendments have the same effective dates as ASU 2016-13 (Topic ASC 326) for entities that have not yet adopted that standard. For entities that early adopted ASU 2016-13 (Topic ASC 326), the amendments are effective for fiscal years beginning after December 15, 2019 and interim periods therein. Entities that early adopted ASU 2016-13 (Topic ASC 326) may early adopt the amendments.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the effect of the new guidance.

3.     Property and Equipment

The Company’s fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment.

The following table details the Company’s fixed assets:
September 30, 2020December 31, 2019
Medical equipment$62,490 $56,202 
Furniture and equipment2,606 2,350 
Land2,138 2,138 
Buildings6,132 6,351 
Leasehold improvements290 301 
Vehicles922 1,110 
Less: Accumulated depreciation(18,261)(13,680)
Property and equipment, net of accumulated depreciation and amortization$56,317 $54,772 
Page 13

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019

Depreciation in the amount of $2,224,000 and $1,465,000 is included in cost of revenue for the three months ended September 30, 2020 and 2019, respectively, and in the amount of $6,133,000 and $3,937,000 for the nine months ended September 30, 2020 and 2019, respectively. Included in medical equipment above is equipment acquired under finance lease obligations whose cost and accumulated depreciation at September 30, 2020 total $8,087,000 and $801,000, respectively. At December 31, 2019, cost and accumulated depreciation on equipment acquired under finance lease obligations was $15,680,000 and $1,337,000, respectively. Medical equipment purchases with a cost of $2,931,000 and $2,817,000 were included in accounts payable at September 30, 2020 and December 31, 2019, respectively.

4.     Current Liabilities

The Company’s short-term accrued liabilities are included within current liabilities and consist of the following:
September 30, 2020December 31, 2019
Accrued trade payables $1,682 $1,023 
Accrued commissions payable321 371 
Accrued bonuses payable4,483 2,292 
Accrued vacation and payroll1,577 1,502 
Current portion of phantom share liability 4,427 3,129 
Accrued other liabilities303 651 
Total accrued liabilities$12,793 $8,968 

5.     Debt and lease liabilities

Senior Credit Facility

On February 20, 2018, the Company entered a Commercial Business Loan Agreement that provides for Term Loans and Lines of Credit with Hancock Whitney Bank.

Line of Credit

The Company maintains a line of credit in the amount of $10.0 million that expires May 1, 2023 under the Commercial Business Loan Agreement. Any amounts advanced on this line will be subject to an interest rate equal to the WSJ prime rate plus a margin of 0.50%, with a 3.50% interest rate floor and will be secured by substantially all of the Company's assets. There were no borrowings against this line of credit at September 30, 2020 or December 31, 2019.

Commercial Term Notes

On May 30, 2019, the Company entered into a term note (the “Building Term Note”) under the Commercial Business Loan Agreement in the principal amount of $4,845,000. The proceeds of the Building Term Note were used to purchase the Company's corporate headquarters. Beginning July 1, 2019, the Company began making monthly payments towards the outstanding balance. The Building Term Note matures on May 30, 2026 and is secured by substantially all of the assets of the borrower, including the real property acquired with the proceeds of the Building Term Note. The Building Term Note bears interest at a variable rate equal to the one month ICE LIBOR index plus a margin of 2.45% per annum. The Company is required to maintain a loan to value ratio of 85% with respect to the appraised value of the real property. In connection with the Building Term Note, the Company entered into an interest rate swap transaction (the "Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at 4.68%.

On September 19, 2019, the Company entered into an additional loan agreement providing for a term note (the “Term Note") under the Commercial Business Loan Agreement in the principal amount of $5,000,000. The proceeds of the Term Note were utilized for general corporate purposes. Beginning October 19, 2019, the Company started making monthly principal payments of $139,000 towards the outstanding balance. The Term Note matures on September 19, 2022 and is secured by substantially all of the assets of the borrower. The Term Note bears interest at the rate of 4.60% per annum.

Page 14

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
The Company incurred immaterial financing costs related to the above term notes. These deferred financing costs are amortized over the term of the loans using the effective interest method.

The Company has recognized these term notes, which have terms greater than twelve months, as follows:
September 30, 2020December 31, 2019
Notes payable$8,076 $9,379 
Less:
Current portion of notes payable(1,815)(1,750)
Net long-term notes payable$6,261 $7,629 

Under the terms of the Commercial Business Loan Agreement, the Company is subject to the following financial covenants:
Financial CovenantRequired RatioRatio at September 30, 2020
Total Debt to Adjusted EBITDA (Quarterly)not more than 1.50:1.000.35
Fixed Charge Coverage Ratio (Quarterly)not less than 1.35:1.002.75
Loan-to-Value Ratio (Quarterly)not more than 0.850.71

The Company was in compliance with all covenants under the Commercial Business Term Loan Agreement in effect at September 30, 2020.

Leases

The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows:
September 30, 2020December 31, 2019
Lease liabilities$5,159 $10,132 
Less:
Current portion of lease liabilities(4,207)(7,093)
Net long-term lease liabilities$952 $3,039 

Finance lease liabilities

The Company has various finance leases for equipment with an implied interest rate at fixed rates up to 9.64%, secured by equipment, due between 2020 and 2022. The Company's weighted average interest rate was 3.17% and 1.83% for all finance lease liabilities outstanding as of September 30, 2020 and 2019, respectively. At September 30, 2020 and 2019, the weighted average lease term was approximately 0.73 years and 1.01 years, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2020 amounted to $34,000 and $128,000, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2019 amounted to $56,000 and $102,000, respectively.

Operating lease liabilities

The Company has recognized operating lease liabilities that relate primarily to the lease of land and buildings. These leases contain renewal options that we have not included as part of the Company's assessment of the lease term as it is not reasonably certain that we will exercise these options. These lease liabilities are recorded at present value based on a discount rate of 5.50%, which was based on the Company's incremental borrowing rate at the time of assessment. At September 30, 2020, the weighted average lease term was approximately 3.41 years. Operating rental expenses were $191,000 and $575,000 for the three and nine months ended September 30, 2020, respectively, and $100,000 and $278,000 for the three and nine months ended September 30, 2019. The related assets for operating lease liabilities have been included with property and equipment on the Condensed Consolidated Balance Sheets.
Page 15

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019

Included within these operating lease liabilities are real property leases for real estate from a related party. Rental payments under these related party lease agreements are $20,000 per month, plus taxes, utilities and maintenance. Total rental payments for the use of these properties were $58,000 and $180,000 for the three and nine months ended September 30, 2020, respectively, and $61,000 and $182,000 for the three and nine months ended September 30, 2019, respectively. The expense for these related party rents has been included within general and administrative expenses.

6.     Fair value measurement

Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. There are three levels to the hierarchy based on the reliability of inputs, as follows:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.

Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.

The Company’s cash and cash equivalents are measured using Level 1 inputs and include cash on hand, deposits in banks, and money market funds. Due to their short-term nature, the carrying amounts reported in the consolidated balance sheets approximate the fair value of cash and cash equivalents.

The fair value of debt is classified as Level 2 for the periods presented and approximates its carrying value.

Warrants

During 2019, the Company had warrants to purchase one common share of the Company denominated in Canadian dollars which is different from the functional currency of the Company, which is U.S. dollars. The conversion feature is treated as a derivative financial liability and the fair value movement during the period is recognized in the Condensed Consolidated Statement of Income and Comprehensive Income. The change in the value of warrants has been recorded as an unrealized (gain) loss on derivative financial liability in the Condensed Consolidated Statements of Income and Comprehensive Income. All unexercised warrants expired during the year ended December 31, 2019.

The warrant derivative financial liability was valued using Level 3 inputs from the fair value hierarchy.

There were no warrants issued or outstanding during the three and nine month periods ended September 30, 2020. A summary of the change in fair value of warrant conversion liability is as follows for the period ended September 30, 2019:
Warrant Conversion Liability
Balance December 31, 2018$363 
Warrants issued— 
Unrealized gain on warrant conversion liability(363)
Balance September 30, 2019$— 

Page 16

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
Derivative instruments and hedging activities

The Company has one interest rate swap contract in place, which became effective on May 31, 2019 and has been designated as a cash flow hedge. This swap contract matures on May 30, 2026. This swap contract converts the variable interest rate to a fixed interest rate on borrowings under the Building Term Note. As of September 30, 2020, the notional amount of the interest rate swap was $4.7 million and will be amortized over the term of the swap. The fair value was $0.5 million (determined based on Level 2 inputs) and is included in Accrued liabilities, as a component of Long-term liabilities as of September 30, 2020.

In the first nine months of 2020, losses recognized as a result of ineffectiveness were immaterial.

7.     Shareholders' Equity

Authorized share capital

The Company’s authorized share capital consists of an unlimited number of common shares.

Issued and outstanding share capital

The Company has only one class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which 39,145,182 and 37,952,660 shares were issued and outstanding as of September 30, 2020 and December 31, 2019, respectively.

Stock-based compensation

The purpose of the Company's RSU and Option Plans (collectively, the "Former Plan") is to provide incentive to employees, directors, officers, management companies, and consultants who provide services to the Company or any of its subsidiaries. The Former Plan is a “fixed” stock plan, whereby the maximum number of the Company's shares reserved for issuance, combined with any equity securities granted under all other compensation arrangements adopted by the Company, may not exceed 7,582,000 shares (equal to 20% of the issued and outstanding shares of the Company as of the date of the adoption of the Plan).

As of September 30, 2020, the Company had outstanding issuances of options of 3,068,000 and restricted stock units of 679,000 under the Former Plan.

Effective June 11, 2020 (the "Effective Date"), the Company’s shareholders approved the Company's 2020 Long Term Incentive Plan (the "Omnibus Plan"), and the Former Plan was frozen. No future awards will be made under the Former Plan, and the common shares that were not settled or awarded under the ‎Former Plan as of the Effective Date are available for awards under the Omnibus Plan. The maximum number of common ‎shares that are available for awards under the Omnibus Plan ‎and under any other security based compensation arrangements adopted by the Company, including the ‎Former Plan, may not exceed 7,758,000 shares (equal to 20% of the issued and outstanding common shares of the Company on the ‎Effective Date). The maximum amount of the foregoing common shares that may be awarded under the Omnibus Plan as “incentive stock options” is 2,600,000 Common Shares.

The following table summarizes stock-based compensation for the three and nine months ended September 30, 2020 and 2019 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Stock-based compensation - options$945 $745 $2,769 $2,028 
Stock-based compensation - restricted stock units289 319 812 950 
Total$1,234 $1,064 $3,581 $2,978 

At September 30, 2020, there was approximately $3,671,000 of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized over a weighted-average period of 2.16 years. As of September 30, 2020, there was approximately $938,000 of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 0.47 years.

Page 17

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
Options

The following table summarizes stock option activity for the nine months ended September 30, 2020:
Number of options
(000's)
Weighted average exercise price(1)
Weighted average remaining contractual life
Aggregate Intrinsic Value(2)
Balance December 31, 20192,683 $3.36 6.7 years$7,790 
Issued1,053 6.10 
Exercised(603)3.20 
Expired / Forfeited(65)4.81 
Balance September 30, 20203,068 $4.29 8.1 years$13,867 
(1) For presentation purposes, stock options issued with a CAD exercise price have been translated to USD based on the prevailing exchange rate on the date of grant.
(2) The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.

The aggregate intrinsic value of options outstanding was $13,867,000 and options exercisable were $5,767,000 at September 30, 2020. For the nine months ended September 30, 2020, 603,297 shares of common stock were issued pursuant to the exercise of stock options.

At September 30, 2020, the Company had 1,008,000 exercisable stock options outstanding with a weighted average exercise price of $2.94 and a weighted average remaining contractual life of 6.8 years. At December 31, 2019, the Company had 1,037,000 exercisable stock options outstanding with a weighted average exercise price of $2.95 and a weighted average remaining contractual life of 3.5 years.

The fair value of the stock options has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, using the Black-Scholes option pricing model calculated using the following assumptions for issuances during the nine months ended September 30, 2020:
Exercise price
$5.70 - $10.44
Risk-free interest rate
0.39% - 1.63%
Expected volatility
65.73% - 85.38%
Expected term
5.63 - 10 years
Expected dividend yieldNil
Fair value on date of grant
$4.10 - $7.23

Page 18

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
Restricted stock units

The Company also grants restricted stock units to directors, officers, and employees. The Company accounts for restricted stock units using fair value. The fair value of the restricted stock units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant. Restricted stock units vest generally over a one or three-year period. The Company accounts for forfeitures on restricted stock units under ASU 2016-09 and recognizes forfeitures in the period in which they occur.

The following table summarizes restricted stock unit activity for the nine months ended September 30, 2020:
Number of Restricted Stock Units (000's)
Weighted average grant price(1)
Weighted average remaining contractual life
Aggregate Intrinsic Value(2)
Balance December 31, 20191,139 $2.16 0.55 years$7,129 
Issued134 7.19 
Vested(589)2.33 
Expired / Forfeited(5)5.70 
Balance September 30, 2020679 $2.97 0.47 years$5,878 
(1) All future equity grants will be awarded in USD, therefore, restricted stock units issued with a CAD grant price have been translated to USD based on the prevailing exchange rate on the date of grant for presentation purposes.
(2) The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.

During the three months ended September 30, 2020, the Company issued 42,147 restricted stock units with a fair value of $10.44 per share. During the nine months ended September 30, 2020, the Company issued 134,235 restricted stock units, with a vesting term of one to three years and a fair value between $5.70 and $10.44 per share.

Phantom share units

The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. Phantom share units granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. Phantom share units vest annually over a three-year period.

The following table summarizes phantom share unit activity for the nine months ended September 30, 2020:
Number of Phantom Share Units (000's)
Balance December 31, 20191,350 
Issued346 
Vested(601)
Expired / Forfeited(76)
Balance September 30, 20201,019 
Page 19

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019

The cash-settled phantom share units are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period. The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities, using a valuation method with the following inputs:
Nine Months Ended
September 30, 2020
Share price (Nasdaq closing price on September 30, 2020)
$8.64
Remaining life of phantom share units
0.61 - 2.61 Years
Calculated fair value of phantom share units$5,159 

The total liability associated with phantom share units at September 30, 2020 is $5,159,000, with $4,427,000 of this amount included in current accrued liabilities and the remaining portion of $732,000 included in long-term accrued liabilities.

Expense associated with the phantom stock units is recorded in "Selling, general, and administrative" within the unaudited Condensed Consolidated Statements of Income and Comprehensive Income. The following table summarizes expense associated with the phantom stock units for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Selling, general, and administrative$459 $1,054 $4,070 $5,654 

The Company paid cash settlements of $4,201,000 and $3,386,000 during the nine months ended September 30, 2020 and 2019, respectively, pertaining to vestings of cash-settled phantom stock units.

8.     Commitments and Contingencies

Litigation

We accrue estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies (“ASC 450”). No less than quarterly, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters.

In March 2020, we (through our subsidiary Sleep Management LLC) entered into a purchase order (the “Purchase Order”) with
Vyaire Medical, Inc. d/b/a CareFusion Respiratory Technologies (“Vyaire”) for respiratory equipment and paid $1.4 million (the “Deposit”) towards the delivery of such respiratory equipment. As of September 30, 2020, outstanding supplier deposits in the amount of $0.9 million related to such Deposit are included within other prepaid and other current assets. Vyaire has been unable to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. On July 29, 2020, we (through our subsidiary Sleep Management LLC) filed a lawsuit against Vyaire in the United States District Court for the Western District of Louisiana (the “Court”) seeking a declaratory judgment that the Company is not required to pay any further funds to Vyaire and demanding Vyaire refund all amounts currently held by Vyaire as a result of the Deposit.

On September 23, 2020, Vyaire filed its Defense and Counterclaim (“Counterclaim”) with the Court alleging breach of contract and seeking damages of $4.7 million, purportedly for the improper cancellation of the Purchase Order. On October 16, 2020, we filed an answer and affirmative defenses with the Court in response to the Counterclaim and intend to pursue further legal action. We continue to believe that we have valid legal and equitable grounds to recover our outstanding Deposit as a result of Vyaire’s failure to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. We have not concluded that a loss
Page 20

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
related to the Counterclaim is probable, nor have we accrued a liability related to this claim. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Counterclaim given that the dispute is in the early stages of the legal process.

9.     Other Income

"CARES" Act Funds Received

The Coronavirus Aid, Relief and Economic Security Act ("CARES Act") created a Provider Relief Fund to support health care-related expenses or lost revenue attributable to the COVID-19 pandemic. The Company received $3.5 million of the Provider Relief Funds in April 2020 and has recognized this amount within other income on its Condensed Consolidated Statements of Income.

The Department of Health and Human Services has stated that Provider Relief Fund payments are not loans and will not need to be repaid. However, as a condition to the receipt of funds, the Company and any other providers must agree to a detailed set of terms and conditions. CMS has indicated that the terms and conditions may be subject to ongoing changes and reporting. To the extent that reporting requirements and terms and conditions are modified, it may affect the Company’s ability to comply and may require the return of funds. In accordance with the terms of acceptance for the grant, the Company has utilized these funds to prevent, prepare for, and respond to the COVID-19 pandemic.

10.     Income Taxes

At September 30, 2020 and 2019, the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense.

The CARES Act which was signed into law on March 27, 2020 includes various income and payroll tax provisions. As of September 30, 2020, the CARES Act has not had a material impact on our condensed consolidated financial statements, however, the Company is still analyzing these provisions of the CARES Act.
 
The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2016. Our annual estimated effective tax benefit rate for 2020 is (19.20)%. Our effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year, in particular due to the uncertainty in our annual forecasts resulting from the unpredictable impact of the COVID-19 pandemic on our operating results. Included in the annual estimated effective tax rate of (19.20)% are discrete permanent differences that make up (3.0)% of the rate and a discrete benefit described below accounting for (31.50)%.

The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. Pursuant to ASC 740, any change in judgment relating to the beginning of the year valuation allowance balance should be recognized discretely in continuing operations in the interim period in which the change occurs. At June 30, 2020, the Company determined that it was more likely than not that the deferred tax asset would be realized, and made an adjustment to the deferred tax asset valuation allowance, which reduced the provision for income taxes by $7.8 million.
Page 21

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
September 30, 2020 and 2019
11.     Earnings Per Share

Income per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year. Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options, restricted stock units, and warrants are used to purchase common shares at the prevailing market rate.

The following reflects the earnings and share data used in the basic and diluted earnings per share computations:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Numerator - basic and diluted:
Net income attributable to shareholders$2,804 $2,853 $26,459 $6,137 
Denominator:
Basic weighted-average number of common shares39,107,640 37,812,921 38,603,267 37,775,775 
Diluted weighted-average number of shares41,155,668 40,051,422 40,377,608 39,768,877 
Basic earnings per share$0.07 $0.08 $0.69 $0.17 
Diluted earnings per share$0.07 $0.07 $0.66 $0.15 
Denominator calculation from basic to diluted:
Basic weighted-average number of common shares39,107,640 37,812,921 38,603,267 37,775,775 
Stock options and other dilutive securities2,048,028 2,238,501 1,774,341 1,993,102 
Diluted weighted-average number of shares41,155,668 40,051,422 40,377,608 39,768,877 

12.     Subsequent Events

Conversion of Accounts Payable into Short-term Capital Lease

Subsequent to September 30, 2020, the Company entered into a capital lease agreement with a third party and, as a result, $2.5 million of accounts payable was converted to a short-term lease payable.
Page 22

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with, and is qualified entirely by, our condensed consolidated financial statements (including Notes to the Condensed Consolidated Financial Statements) and the other consolidated financial information under Item 1 of this Quarterly Report on Form 10-Q. Some of the information in this discussion and analysis includes forward-looking statements that involve risk and uncertainties. Actual results and timing of events could differ from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

On March 11, 2020, the World Health Organization declared the outbreak of the novel coronavirus ("COVID-19") a pandemic. Based on the duration and severity of the impacts of the COVID-19 pandemic, including but not limited to any negative economic conditions arising from the pandemic, our ability to assess potential patients in hospitals and set up and treat patients in the home, and the impacts of government actions and administrative regulations on the healthcare industry and broader economy, including through existing and any future stimulus efforts, we are uncertain of the ultimate impact COVID-19 could have on our business, financial condition and results of operations. The impact of COVID-19 on our financial results are discussed in more detail below.

Forward-Looking Statements

Certain statements and information in this Quarterly Report on Form 10-Q may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Any statements other than statements of historical information, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. These forward-looking statements are made as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except as required by applicable law.
 
Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management regarding future events, and include, but are not limited to, statements with respect to: operating results; profitability; financial condition and resources; anticipated needs for working capital; liquidity; capital resources; capital expenditures; milestones; licensing milestones; information with respect to future growth and growth strategies; anticipated trends in our industry; our future financing plans; timelines; currency fluctuations; government regulation; unanticipated expenses; commercial disputes or claims; limitations on insurance coverage; and availability of cash flow to fund capital requirements.
 
Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology.
 
Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable. We cannot assure you, however, that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.











Page 23

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
By their nature, forward-looking statements involve numerous assumptions, inherent risks and uncertainties, both general and specific, including those identified under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q and the other documents we file with the SEC, including under “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019, and with the securities regulatory authorities in certain provinces of Canada, which contribute to the possibility that the predicted outcomes may not occur or may be delayed. The risks, uncertainties and other factors, many of which are beyond our control, that could influence actual results include, but are not limited to: the general business, market and economic conditions in the regions in which the we operate; the impact of the COVID-19 pandemic and of the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on our patient base and revenues, employees, and equipment and supplies; we may be subject to significant capital requirements and operating risks; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; our novel business model; the risk that the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; the impact of the previously disclosed restatement and correction of our previously issued financial statements; the previously disclosed identified material weakness in our internal control over financial reporting and our ability to remediate that material weakness; the initiation of legal or regulatory proceedings with respect to the restatement and corrections; the adverse effects on our business, results of operations, financial condition and stock price, as a result of the restatement and correction process; our status as an emerging growth company and a foreign private issuer; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the recent COVID-19 pandemic, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control.

General Matters

In this Quarterly Report on Form 10-Q, unless the context otherwise requires, the terms the "Company," "we," "us" and "our" refer to Viemed Healthcare, Inc. and its wholly-owned subsidiaries.

We were incorporated on December 14, 2016 pursuant to the Business Corporations Act (British Columbia). As of June 30, 2020, we determined that we no longer qualify as a "foreign private issuer," as defined in Rule 3b-4 of the Exchange Act, for the purposes of the informational requirements of the Exchange Act. As a result, effective January 1, 2021, we will become subject to the proxy solicitation rules under Section 14 of the Exchange Act and Regulation FD, and our officers, directors, and principal shareholders will become subject to the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. We will continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the SEC.

We are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act (the "JOBS Act"), and as such, we have elected to comply with certain reduced U.S. public company reporting requirements.

Unless otherwise noted herein, all references to "$" or "USD" are to the currency of the United States and references to "CAD$" or "Canadian dollars" are to the currency of Canada.

Overview

We provide an array of home medical equipment, services and supplies, specializing in post-acute respiratory care services in the United States. Our primary objective is to focus on the organic growth of the business and thereby solidify our position as one of the United States’ largest providers of in home therapy for patients suffering from respiratory diseases. Our respiratory care programs are designed specifically for payors to have the ability to treat patients in the home for less total cost and with a superior quality of care. Our services include respiratory disease management (through the rental of various durable medical equipment ("DME") devices), in-home sleep testing and sleep apnea treatment, oxygen therapy, and the sale of associated supplies.



Page 24

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
We derive the majority of our revenue through the rental of non-invasive and invasive ventilators which represented 80.2% of our traditional revenue, excluding the COVID-19 response sales and services, and 84.5% of our revenue for the three months ended September 30, 2020 and 2019, respectively, and 82.9%, excluding the COVID-19 response sales and services, and 86.7% for the nine months ended September 30, 2020 and 2019, respectively. We combine the benefits of home ventilation support with licensed Respiratory Therapists ("RTs") to drive improved patient outcomes and reduce costly hospital readmissions.

We expect to use an organic growth model whereby expansion is accomplished through existing service areas as well as in new regions through a cost efficient launch that reduces location expenses. Our licensed RTs currently serve patients in 36 states. We expect to continue to employ more RTs in order to assure our high service model is accomplished in the home. As of September 30, 2020, we employed approximately 258 licensed RTs, representing more than 52% of our company-wide employee count. By focusing overhead costs on personnel that service the patient rather than physical location costs, we anticipate efficiently scaling our business in regions that are currently not being effectively serviced.

The continued trend of servicing patients in the home rather than in hospitals is aligned with our business objective and we anticipate that this trend will continue to offer growth opportunities for us. We expect to continue to be a solution to the rising health costs in the United States by offering more cost effective, home based solutions while increasing the quality of life for patients fighting serious respiratory diseases.

Trends Affecting our Business

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. Various policies and initiatives have been implemented to reduce the transmission of COVID-19, including travel bans and restrictions, the postponement of non-essential medical surgeries, the limiting of access to medical facilities in certain areas, the promotion of social distancing and the adoption of remote working policies. Local, state and national governments continue to emphasize the importance of essential medical personnel and we remain open to meet the needs of our communities. Employee and patient safety is our first priority, and as a result, we put preparedness plans in place for our employees, especially our clinical personnel, and modified our clinical protocols to limit unnecessary patient encounters in order to ensure the safety of our employees as well as the safety of our patients. These measures do not appear to be negatively impacting our patient attrition rate at this time. In addition, our current ability to assess potential patients in hospitals varies by hospital and city, but overall our business of setting up new patients in the home is continuing although at lower levels than in recent periods.

Many state governments have begun a phased reopening of their economies while adhering to new guidelines and enhanced safety measures, including social distancing and face mask protocols. However, certain states have paused or reversed plans to reopen their economies as new cases of COVID-19 have been on the rise in recent weeks. While governmental and other restrictions have not had a material impact on our consolidated operating results for the nine months ended September 30, 2020, it is possible that more significant disruptions could occur if the COVID-19 pandemic continues for a prolonged period of time.

The COVID-19 pandemic has resulted in a significant economic downturn in the United States and globally and has also led to significant disruptions and volatility in capital and financial markets. Broad economic factors resulting from the current COVID-19 pandemic, including high unemployment and underemployment levels and reduced consumer spending and confidence, could also affect our service mix, revenue mix, payor mix and patient base, as well as our ability to collect outstanding receivables. Business closures and layoffs in the geographic areas in which we operate may lead to increases in the uninsured and under insured populations and adversely affect demand for our services, as well as the ability of patients and other payors to pay for services rendered. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our financial results and require an increased level of working capital. In addition, we may experience supply chain disruptions, including delays and price increases in equipment and supplies. Staffing, equipment and supplies shortages may also impact our ability to assess potential patients in hospitals and set up and treat patients in the home.











Page 25

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
We believe we presently have sufficient liquidity to satisfy our cash needs, however, we continue to evaluate and take action, as necessary, to preserve adequate liquidity and ensure that our business can continue to operate during these uncertain times, such as limiting discretionary spending across the organization. The Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, which was signed into law on March 27, 2020, provides a substantial stimulus and assistance package intended to address the impact of the COVID-19 pandemic, including tax relief and government loans, grants and investments. The legislation provides for $100 billion in relief funds to hospitals and other healthcare providers on the front lines of the coronavirus response to support healthcare-related expenses or lost revenue attributable to COVID-19 and to ensure uninsured Americans can get testing and treatment for COVID-19. As a result, we received a payment from the Provider Relief Fund of $3.5 million in April 2020. Payments from the Provider Relief Fund are intended to compensate healthcare providers for lost revenues and incremental expenses incurred in response to the COVID-19 pandemic. The Department of Health and Human Services has stated that Provider Relief Fund payments are not loans and will not need to be repaid. However, as a condition to the receipt of funds, the Company and any other providers must agree to a detailed set of terms and conditions. CMS has indicated that the terms and conditions may be subject to ongoing changes and reporting. To the extent that reporting requirements and terms and conditions are modified, it may affect our ability to comply and may require the return of funds. In accordance with the terms of acceptance for the grant, we believe we have utilized these funds to prevent, prepare for, and respond to the COVID-19 pandemic.

The CARES Act also provides for a temporary suspension of the 2% payment sequestration adjustment currently applied to all Medicare fee-for-service claims. The suspension is effective for claims with dates of service from May 1, 2020 through December 31, 2020. However, CMS and Medicare Administrative Contractors may issue guidance that affects the implementation of this provision.

As part of the CARES Act legislation, certain Payroll Protection Program ("PPP") loans were authorized for small businesses to pay their employees, subject to potential debt forgiveness. We evaluated the PPP extensively and after evaluation, decided not to submit a PPP loan application.
 
We are continuing to monitor any effects or requirements that may result from the CARES Act as many of the provisions in the CARES Act are temporary and may require us to modify our operations and compliance procedures. CMS and other federal agencies have and are likely to issue rules and regulations to implement the CARES Act. The impact of these rules and regulations are unknown and may affect us. To the extent these provisions will expire as stated in the CARES Act, we will be required to unwind any changes.

While the overall impact of COVID-19 on our consolidated results of operations for the nine months ended September 30, 2020 has resulted in an overall increase in revenues related to additional product sales and services during the period, the overall impact that COVID-19 will have on our consolidated results of operations throughout the remainder of 2020 remains uncertain and difficult to predict and will depend on, among other factors, the duration and severity of the pandemic, as well as any negative economic conditions arising from the pandemic, our ability to assess potential patients in hospitals and set up and treat patients in the home and the impacts of government actions and administrative regulations on the healthcare industry and broader economy, including through existing and any future stimulus efforts. We will continue to evaluate the nature and extent of these potential impacts to our business, consolidated results of operations, liquidity and capital resources. If COVID-19 continues to spread or if the response to contain the COVID-19 pandemic is unsuccessful, we could experience a material adverse effect on our business, financial condition, and results of operations. For additional information, see Part II. Item 1A “Risk Factors.”

In 2019, CMS announced the inclusion of noninvasive ventilator products on the list of products subject to the competitive bidding program for Round 2021, which covers the period of January 1, 2021 through December 31, 2023. Rental revenue from ventilator products represents a significant portion of our revenues (approximately 86% of total revenue in 2019). At the end of 2019, approximately 19% of ventilator product-related revenue was set to be subject to the competitive bidding process under Medicare. On March 9, 2020, CMS announced that due to the COVID-19 pandemic, the President's exercise of the Defense Production Act, public concern regarding access to ventilators, and the non-invasive ventilators product category being new to the competitive bidding program, non-invasive ventilators were removed as a product category from Round 2021. On October 27, 2020, CMS announced that it has removed 13 of the 15 remaining product categories from Round 2021, including oxygen and PAP devices, because the payment amounts did not achieve expected savings. The next competitive bidding round is anticipated to begin on January 1, 2024. As a result of these announcements, we retain the ability to continue to furnish non-invasive ventilators and oxygen and PAP devices for all of our Medicare accredited areas, however, we are uncertain if non-invasive ventilators and oxygen and PAP devices will be included in future competitive bidding programs.

Page 26

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
The below table highlights summary financial and operational metrics for the last eight quarters.
(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)
For the quarter endedSeptember 30,
2020		June 30, 2020March 31, 2020December 31, 2019September 30, 2019June 30, 2019March 31, 2019December 31, 2018
Financial Information:
Revenue$33,447 $42,854 $23,806 $21,448 $20,368 $20,325 $18,115 $18,363 
Gross Profit19,453 25,927 15,553 14,243 14,050 14,639 13,074 13,519 
Gross Profit %58 %61 %65 %66 %69 %72 %72 %74 %
Net Income2,804 19,412 4,243 2,388 2,853 1,326 1,958 2,968 
Cash (As of)32,396 29,707 8,409 13,355 12,630 7,691 7,410 10,413 
Total Assets (As of)113,969 112,178 86,801 82,596 79,981 71,014 58,718 53,653 
Adjusted EBITDA(1)
7,720 16,287 7,869 5,569 4,883 4,116 4,466 4,896 
Operational Information:
Vent Patients(2)
7,788 7,705 7,965 7,759 7,421 7,130 6,393 5,905 
(1) Refer to "Non-GAAP Financial Measures" section below for definition of Adjusted EBITDA.
(2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.

Results of Operations

Comparison of the Three Months Ended September 30, 2020 and 2019:

The following table summarizes our results of operations for the three months ended September 30, 2020 and 2019:
Three Months Ended September 30,
2020% of Total Revenue2019% of Total Revenue$
Change		%
Change
Revenue$33,447 100.0 %$20,368 100.0 %$13,079 64.2 %
Cost of revenue 13,994 41.8 %6,318 31.0 %7,676 121.5 %
Gross profit19,453 58.2 %14,050 69.0 %5,403 38.5 %
Selling, general and administrative13,550 40.5 %10,231 50.2 %3,319 32.4 %
Research and development243 0.7 %208 1.0 %35 16.8 %
Stock-based compensation1,234 3.7 %1,064 5.2 %170 16.0 %
Depreciation202 0.6 %193 0.9 %9 4.7 %
Loss on disposal of property and equipment203 0.6 %167 0.8 %36 21.6 %
Other (income) expense(19)(0.1)%1 — %(20)NM
Income from operations4,040 12.1 %2,186 10.7 %1,854 84.8 %
Non-operating expenses
Unrealized (gain) on warrant conversion liability— — %(800)(3.9)%800 (100.0)%
(Gain) loss from equity investment(21)(0.1)%26 0.1 %(47)NM
Interest expense, net116 0.3 %56 0.3 %60 NM
Net income before taxes3,945 11.8 %2,904 14.3 %1,041 35.8 %
Provision for income taxes1,141 3.4 %51 0.3 %1,090 NM
Net income$2,804 8.4 %$2,853 14.0 %$(49)(1.7)%
Page 27

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019

Revenue

The following table summarizes our revenue for the three months ended September 30, 2020 and 2019:
Three Months Ended September 30,
2020% of Total Revenue2019% of Total Revenue$
Change		%
Change
Net revenue from rentals under Topic 842
Ventilator rentals, non-invasive and invasive$19,962 59.6 %$17,213 84.5 %$2,749 16.0 %
Other durable medical equipment rentals2,649 7.9 %1,449 7.1 %1,200 82.8 %
Net revenue from sales and services under Topic 606
Equipment and supply sales1,890 5.7 %1,349 6.6 %541 40.1 %
COVID-19 response sales and services8,553 25.6 %— — %8,553 100.0 %
Service revenues393 1.2 %357 1.8 %36 10.1 %
Total net revenue$33,447 100.0 %$20,368 100.0 %$13,079 64.2 %

For the three months ended September 30, 2020, revenue totaled $33.4 million, an increase of $13.1 million (or 64.2%) from the comparable period in 2019. The revenue growth was primarily driven by COVID-19 response sales and services of $8.6 million. In response to the COVID-19 pandemic, we have been working in close cooperation with state agencies and hospital systems to source urgently needed medical equipment such as ventilators, ventilator supplies, other respiratory equipment, and personal protective equipment. During the three months ended September 30, 2020, the $8.6 million of COVID-19 response sales and services consisted primarily of PAPs, ventilators, associated supplies, personal protective equipment, and contact tracing services. We expect further COVID-19 response related revenue during the remainder of 2020, but the quantity and impact of such revenue remains uncertain and dependent on the length and intensity of the COVID-19 pandemic and the availability of such equipment, supplies, and services from other suppliers.

Excluding the COVID-19 response sales and services revenue, net revenue increased $4.5 million (or 22.2%) from the comparable period in 2019. The increase was primarily driven by an increase in ventilator rental revenue of $2.7 million (or 16.0%). Rental revenue from other DME grew $1.2 million (or 82.8%) quarter over quarter. This growth was largely attributable to product revenue from percussion vests, PAPs, and oxygen therapy. Non-COVID-19 related equipment sales and services combined increased by $0.6 million (or 33.8%) year over year primarily as a result of increasing demand for respiratory supplies, specifically for PAP resupply patients, that are less impacted by the ongoing pandemic.

As we continue to expand geographically into new states and further expand our presence in our existing territories, we expect continued growth in our active ventilator patient base and ventilator rental revenue, as well as in our other growing respiratory offerings, though in the short term we anticipate growth to continue to occur at a slower rate than in recent periods as a result of the pandemic.

Cost of revenue and gross profit

For the three months ended September 30, 2020, cost of revenue totaled $14.0 million, an increase of $7.7 million (or 121.5%) from the comparable period in 2019. COVID-19 response sales and services accounted for $5.6 million (or 39.8%) of these costs. For the three months ended September 30, 2020 and 2019, gross profit percentage decreased from approximately 69.0% to approximately 58.2%. The decreased margins were primarily the result of the above mentioned COVID-19 response sales and services which contributed a weighted average gross profit percentage of 34.8%. Excluding COVID-19 response sales and services, gross profit percentage for the three months ended September 30, 2020 was 66.2%. The reduction in gross profit percentage is partly a reflection of our current product mix, but is also due in part to direct labor cost for respiratory therapists. While our active ventilator patient base growth was impacted by the current pandemic in the short term, we have not experienced a corresponding change in the number of respiratory therapists employed. We believe it to be in the long term interest of our patients and the business to continue to employ these essential employees. We expect our gross profit percentage for our normal operations (non-COVID-19 related) to remain relatively consistent with the current quarter through the end of 2020.

Page 28

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
Selling, general & administrative expense

For the three months ended September 30, 2020, selling, general and administrative expenses totaled $13.6 million, an increase of $3.3 million (or 32.4%) from the comparable prior period. Selling, general, and administrative expenses as a percentage of revenue decreased to 40.5% for the three months ended September 30, 2020 compared to 50.2% for the three months ended September 30, 2019. Selling general and administrative expenses for the three months ended September 30, 2020 include $512,000 for direct selling expenses related to COVID-19 response sales and services. Excluding both the impact of the COVID-19 response sales and services and direct expenses, selling, general, and administrative expenses as a percentage of revenue was 52.4% for the three months ended September 30, 2020.

The increase in overall selling, general and administrative expense as compared to the prior year period is attributable to additional employee related expenses to accommodate the overall growth of the Company, as well as additional public company expenses relating to our NASDAQ listing in August 2019, partially offset by a decrease in travel, meals, and entertainment due to COVID-19 related restrictions. Employee compensation expenses increased $0.9 million (or 14.5%) as a result of higher incentive based compensation and an overall increase in our employee headcount. Our full time employee count increased from 411 on September 30, 2019 to 499 on September 30, 2020, an increase of 21.4%. Partially offsetting these increases, was a $0.6 million reduction in employee compensation expense related to the impact of our phantom stock plan. Our phantom stock plan is measured at fair value as of the reporting period and is driven primarily by the number of eligible employees and our stock price. For the three months ended September 30, 2020 our stock price declined by 10.0% compared to an increase of 2.4% during the three months ended September 30, 2019, resulting in lower comparable expenses related to these awards in the current period. Additionally, professional fees increased $1.0 million for the comparable period, driven by higher legal and consulting fees and public company expenses. As we continue to respond to the COVID-19 pandemic, grow into new markets and increase our employee count, we expect selling, general, and administrative expenses will trend accordingly. We expect that selling, general and administrative expenses, in absolute terms, will remain relatively consistent with the current quarter through the end of 2020.

Loss on disposal of property and equipment

For the three months ended September 30, 2020, we recorded a loss on disposal of property and equipment of $0.2 million. This was consistent with the prior period and remained less than 1% of revenue. In prior 2020 periods, as a result of our efforts for the COVID-19 response, certain of our previously placed in service property and equipment was sold and substantial gains resulting from these disposals was recognized. No such disposals occurred in the current period. We expect disposals of equipment to generally remain consistent with historical trends, with the exception of any gains that could be realized from any additional COVID-19 response sales, but the impact of such sales remains uncertain and dependent on the length and intensity of the COVID-19 pandemic and the availability of such equipment and supplies from other suppliers.

Stock-based compensation

For the three months ended September 30, 2020, stock-based compensation totaled $1.2 million, an increase of $0.2 million (or 16.0%) from the comparable period in 2019. This increase is attributable to the expense of additional stock-based awards during 2020. We expect that as we continue to increase our employee count and utilize stock-based awards as an aspect of employee compensation, stock-based compensation expense will increase accordingly. Stock-based compensation as a percentage of revenue has historically remained near or below 5%.

Interest expense, net

For the three months ended September 30, 2020, net interest expense totaled $0.1 million, which remained consistent with the comparable period in 2019. We expect net interest expense to remain relatively consistent through the end of 2020.

Provision for income taxes

For the three months ended September 30, 2020, the provision for income taxes was a $1.1 million expense, compared to a $0.1 million expense during the 2019 period. The increase in income tax expense was primarily due to a higher effective tax rate during the current period. Excluding the impact of the current year discrete items for the release of valuation allowances and the recognition of a deferred tax asset, our estimated tax rate for the year was 12.3%.

Page 29

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019

Comparison of the Nine Months Ended September 30, 2020 and 2019:

The following table summarizes our results of operations for the nine months ended September 30, 2020 and 2019:
Nine Months Ended September 30,
2020% of Total Revenue2019% of Total Revenue$
Change		%
Change
Revenue$100,107 100.0 %$58,808 100.0 %$41,299 70.2 %
Cost of revenue39,174 39.1 %17,045 29.0 %22,129 129.8 %
Gross profit60,933 60.9 %41,763 71.0 %19,170 45.9 %
Selling, general and administrative40,555 40.5 %31,207 53.1 %9,348 30.0 %
Research and development688 0.7 %645 1.1 %43 6.7 %
Stock-based compensation3,581 3.6 %2,978 5.1 %603 20.2 %
Depreciation612 0.6 %460 0.8 %152 33.0 %
(Gain) loss on disposal of property and equipment(2,424)(2.4)%308 0.5 %(2,732)NM
Other (income) expense(3,593)(3.6)%(1)— %(3,592)NM
Income from operations21,514 21.5 %6,166 10.5 %15,348 248.9 %
Non-operating expenses
Unrealized (gain) on warrant conversion liability— — %(363)(0.6)%363 (100.0)%
(Gain) loss from equity investment(36)— %77 0.1 %(113)(146.8)%
Interest expense, net409 0.4 %102 0.2 %307 NM
Net income before taxes21,141 21.1 %6,350 10.8 %14,791 232.9 %
(Benefit) provision for income taxes(5,318)(5.3)%213 0.4 %(5,531)NM
Net income$26,459 26.4 %$6,137 10.4 %$20,322 331.1 %

Revenue

The following table summarizes our revenue for the nine months ended September 30, 2020 and 2019:
Nine Months Ended September 30,
2020% of Total Revenue2019% of Total Revenue$
Change		%
Change
Net revenue from rentals under Topic 842
Ventilator rentals, non-invasive and invasive$58,672 58.6 %$50,990 86.7 %$7,682 15.1 %
Other durable medical equipment rentals7,184 7.2 %3,464 5.9 %3,720 107.4 %
Net revenue from sales and services under Topic 606
Equipment and supply sales3,962 3.9 %3,202 5.4 %760 23.7 %
COVID-19 response sales and services29,306 29.3 %— — %29,306 100.0 %
Service revenues983 1.0 %1,152 2.0 %(169)(14.7)%
Total net revenue$100,107 100.0 %$58,808 100.0 %$41,299 70.2 %
Page 30

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019

For the nine months ended September 30, 2020, revenue totaled $100.1 million, an increase of $41.3 million (or 70.2%) from the comparable period in 2019. The revenue growth was primarily driven by COVID-19 response sales and services of $29.3 million as described in more detail above. We expect further COVID-19 response revenue during the remainder of 2020, but the quantity and impact of such revenue remains uncertain and dependent on the length and intensity of the COVID-19 pandemic and the availability of such equipment and supplies from other suppliers.

Excluding the COVID-19 response sales and services, net revenue increased $12.0 million (or 20.4%) from the comparable period in 2019. Ventilator rental revenue increased $7.7 million (or 15.1%) due to our organic growth in active ventilator patient base. In addition to the ventilator rental revenue growth, rental revenue from other DME grew $3.7 million (or 107.4%) which primarily consisted of product revenue from percussion vests, PAPs, and oxygen therapy. Non-COVID-19 related equipment sales and services combined increased by $0.6 million (or 13.6%) year over year primarily as a result of increasing demand for respiratory supplies, specifically for PAP resupply patients, that are less impacted by the ongoing pandemic.

As we continue to expand geographically into new states and further expand our presence in our existing territories, we expect continued growth in our active ventilator patient base and ventilator rental revenue, as well as in our other growing respiratory offerings, though in the short term we anticipate growth to continue to occur at a slower rate than in recent periods as a result of the pandemic.

Cost of revenue and gross profit

For the nine months ended September 30, 2020, cost of revenue totaled $39.2 million, an increase of $22.1 million (or 129.8%) from the comparable period in 2019. For the nine months ended September 30, 2020 and 2019, gross profit percentage decreased from approximately 71.0% to approximately 60.9%. The lower margins are primarily the result of the high volume of COVID-19 response sales and services. Historically the majority of our revenue has come from equipment rentals. For the nine months ended September 30, 2020, COVID-19 response sales and services accounted for 29.3% of total revenue, thus driving margin lower. Excluding COVID-19 response sales and services, gross profit percentage for the nine months ended September 30, 2020 was 66.3%. The reduction in gross profit percentage is partly a reflection of our current product mix, but is also due in part to direct labor cost for respiratory therapists. While our active ventilator patient base growth was impacted by the pandemic in the short term, we have not experienced a corresponding change in the number of respiratory therapists employed. We believe it to be in the long term interest of our patients and the business to continue to employ these essential employees. We expect our gross profit percentage for our normal operations (non-COVID-19 related) to remain relatively consistent with the current quarter through the end of 2020.

Selling, general & administrative expense

For the nine months ended September 30, 2020, selling, general and administrative expenses totaled $40.6 million, an increase of $9.3 million (or 30.0%) from the comparable period in 2019. Selling, general, and administrative expenses as a percentage of revenue decreased to 40.5% for the nine months ended September 30, 2020, compared to 53.1% and for the nine months ended September 30, 2019. Excluding the impact of the COVID-19 response sales and services, selling, general, and administrative expenses as a percentage of revenue was 56.6% for the nine months ended September 30, 2020.

The increase in overall selling, general and administrative expense as compared to the prior year period is attributable to additional employee related expenses to accommodate the overall growth of the Company as well as additional public company expenses relating to our NASDAQ listing in August 2019, partially offset by a decrease in travel, meals, and entertainment due to COVID-19 related restrictions. Employee compensation increased $2.8 million (or 15%) as a result of higher incentive based compensation and an overall increase in our employee headcount. Our full time employee count increased from 411 on September 30, 2019 to 499 on September 30, 2020, an increase of 21.4%. Partially offsetting these increases, was a $1.6 million reduction in employee compensation expense related to the impact of our phantom stock plan. Our phantom stock plan is measured at fair value as of the reporting period and is driven primarily by the number of eligible employees and our stock price. For the nine months ended September 30, 2020 our stock price increased by 39.4% compared to an increase of 74.8% during the nine months ended September 30, 2019, resulting in lower comparable expenses related to these awards in the current period.

Additionally, professional fees increased $1.9 million (or 135%) from the comparable period in 2019, driven by higher legal and consulting fees and public company expenses. As we continue to respond to the COVID-19 pandemic, grow into new markets and increase our employee count, we expect selling, general, and administrative expenses will trend accordingly. We expect that selling, general and administrative expenses as a percentage of revenue will trend higher towards historical percentages toward the end of 2020.

Page 31

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
(Gain) loss on disposal of property and equipment

For the nine months ended September 30, 2020, we recorded a gain on disposal of property and equipment of $2.4 million, compared to a loss of $0.3 million during the comparable period in 2019. As a result of our efforts for the COVID-19 response as described above, certain of our previously placed in service property and equipment was sold. As a result, during the nine months ended September 30, 2020, we recorded sales proceeds on used equipment of $5.0 million which resulted in a net gain on disposal for related equipment of $3.5 million. We expect disposals of equipment to generally remain consistent with historical trends, with the exception of additional gains that could be realized from any additional COVID-19 response sales, but the impact of such sales remains uncertain and dependent on the length and intensity of the COVID-19 pandemic and the availability of such equipment and supplies from other suppliers.

Other (income) expense

For the nine months ended September 30, 2020, other income totaled $3.6 million, an increase of $3.6 million from the comparable prior period. We received a payment from the Provider Relief Fund of $3.5 million in April 2020. Payments from the Provider Relief Fund are intended to compensate healthcare providers for lost revenues and incremental expenses incurred in response to the COVID-19 pandemic as described in detail above.

Stock-based compensation

For the nine months ended September 30, 2020, stock-based compensation totaled $3.6 million, an increase of $0.6 million (or 20.2%) from the comparable period in 2019. We expect that as we continue to increase our employee count and utilize stock-based awards as an aspect of employee compensation, stock-based compensation expense will increase accordingly. Stock-based compensation as a percentage of revenue has historically remained near or below 5%.

Interest expense, net

For the nine months ended September 30, 2020, net interest expense totaled $0.4 million, an increase of $0.3 million from the comparable period in 2019. We expect net interest expense to remain materially consistent through the end of 2020.

(Benefit) provision for income taxes

For the nine months ended September 30, 2020, the provision for income taxes was a $5.3 million benefit, compared to a $0.2 million expense during the 2019 period. The decrease in income tax expense was primarily due to a lower effective tax rate which was caused by the release of a valuation allowance and recognition of a deferred tax asset during the current period. Excluding the impact of this current year discrete item, our estimated tax rate for the year was 12.3%.


Non-GAAP Financial Measures

Our management regularly monitors certain financial measures to track the progress of our business against internal goals and targets. We believe that one of the most important measures for our company is Adjusted EBITDA. Adjusted EBITDA is a non-GAAP financial measure. We believe Adjusted EBITDA provides helpful information with respect to our operating performance as viewed by management, including a view of our business that is not dependent on the impact of our capitalization structure and items that are not part of our day-to-day operations. Management uses Adjusted EBITDA (i) to compare our operating performance on a consistent basis, (ii) to calculate incentive compensation for our employees, (iii) for planning purposes including the preparation of our internal annual operating budget, and (iv) to evaluate the performance and effectiveness of our operational strategies. Accordingly, we believe that Adjusted EBITDA provides useful information in understanding and evaluating our operating performance in the same manner as management.

In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income including interest, taxes and depreciation of property and equipment. Set forth below are descriptions of the financial items that have been excluded from net income to calculate Adjusted EBITDA and the material limitations associated with using this non-GAAP financial measure as compared to net income.

–Depreciation may be useful for investors to consider because it generally represents the wear and tear on the property and equipment used in our operations. However, we do not believe these charges necessarily reflect the current and ongoing cash charges related to our operating costs.

Page 32

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
–The amount of interest expense we incur or interest income we generate may be useful for investors to consider and may result in current cash inflows or outflows. However, we do not consider the amount of interest expense or interest income to be a representative component of the day-to-day operating performance of our business.

–Unrealized loss on warrant conversion liability may be useful for investors to consider as it represents changes in the fair value of warrants and exchangeable shares of subsidiaries, driven predominantly by changes in our share price and exchange rates. These changes are non-cash, as is the settlement of the underlying derivative liability, which occurs upon the conversion of the derivative instrument into common shares of the Company.

–Stock-based compensation may be useful for investors to consider because it is an estimate of the non-cash component of compensation received by the Company’s directors, officers, employees and consultants. However, stock-based compensation is being excluded from our operating expenses because the decisions which gave rise to these expenses were not made to increase revenue in a particular period, but were made for the Company’s long-term benefit over multiple periods. While strategic decisions, such as those to issue stock-based awards are made to further our long-term strategic objectives and do impact our earnings under GAAP, these items affect multiple periods and management is not able to change or affect these items within any period.

–Income tax expense may be useful for investors to consider because it generally represents the taxes which may be payable for the period and the change in deferred income taxes and may reduce or increase the amount of funds otherwise available for use. However, we do not consider the amount of income tax expense to be a representative component of the day-to-day operating performance of our business.

The following table is a reconciliation of Net income, the most directly comparable GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:
For the quarter endedSeptember 30, 2020June 30, 2020March 31, 2020December 31, 2019September 30, 2019June 30, 2019March 31, 2019December 31, 2018
Net Income$2,804 $19,412 $4,243 $2,388 $2,853 $1,326 $1,958 $2,968 
Add back:
Depreciation2,425 2,190 2,130 2,003 1,659 1,444 1,295 1,177 
Interest expense116 135 158 212 56 20 26 30 
Unrealized (gain) loss on warrant conversion liability— — — — (800)268 169 (210)
Stock-based compensation1,234 1,196 1,151 908 1,064 1,034 880 804 
Income tax expense (benefit)1,141 (6,646)187 58 51 24 138 127 
Adjusted EBITDA$7,720 $16,287 $7,869 $5,569 $4,883 $4,116 $4,466 $4,896 

Use of Non-GAAP Financial Measures

Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. It is not a measurement of our financial performance under GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with GAAP and may not be comparable to other similarly titled measures of other businesses. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our operating results as reported under GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of ongoing operations; and other companies in our industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

Liquidity and Capital Resources

Cash and cash equivalents at September 30, 2020 was $32.4 million, compared to $13.4 million at December 31, 2019. Based on our current plan of operations, including potential acquisitions, we believe this amount, when combined with expected cash flows from operations and amounts available under our line of credit will be sufficient to fund our growth strategy and to meet our anticipated operating expenses, capital expenditures, and debt service obligations for at least the next 12 months from the date of this filing. The Company utilizes short term leases with a major supplier that could be extended over a longer term if there was a need for additional liquidity. Additionally, the Company maintains a $10.0 million line of credit with Hancock Whitney Bank which was fully undrawn as of September 30, 2020.
Page 33

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019

Cash Flows

The following table summarizes our cash flows for the periods indicated:
Nine Months Ended September 30,
20202019
Net Cash provided by (used in):
Operating activities$29,319 $11,687 
Investing activities(3,047)(10,232)
Financing activities(7,231)762 
Net increase in cash and cash equivalents$19,041 $2,217 

Net Cash Provided by Operating Activities

Net cash provided by operating activities during the nine months ended September 30, 2020 was $29.3 million, resulting from net income of $26.5 million and non-cash net income adjustments of $7.3 million and an increase in net operating liabilities of $5.7 million, which was partially offset by an increase in net operating assets of $10.2 million. The non-cash net income adjustments primarily consisted of $7.0 million in change of allowance for doubtful accounts, $6.7 million of depreciation, $2.4 million of gains on disposal of property and equipment, change in deferred tax asset of $7.6 million and $3.6 million of stock-based compensation. The uses of cash related to changes in operating assets primarily consisted of an increase in accounts receivable of $7.0 million and an increase in inventory of $1.4 million. The changes in operating liabilities primarily consisted of an increase in accounts payable of $2.7 million and an increase in accrued liabilities of $2.4 million. The increase in our operating assets was primarily driven by accounts receivable related to COVID-19 response sales and services occurring during the period. Included in our operating cash flows for the period is the receipt of $3.5 million in Provider Relief Funds.

Net cash provided by operating activities during the nine months ended September 30, 2019 was $11.7 million, resulting from net income of $6.1 million, non-cash net income adjustments of $14.3 million, and an increase in net operating liabilities of $0.8 million, which was partially offset by an increase in net operating assets of $9.5 million. The non-cash net income adjustments primarily consisted of $6.9 million in change of allowance for doubtful accounts, $4.4 million of depreciation and $3.0 million of stock-based compensation. The uses of cash related to changes in operating assets primarily consisted of an increase in accounts receivable of $9.8 million as a result of increased revenue growth, which was partially offset by a decrease in inventory of $1.6 million. The changes in operating liabilities primarily consisted of a decrease in accounts payable of $1.8 million, partially offset by increases in accrued liabilities of $1.9 million and deferred revenue of $0.8 million.

Net Cash Used in Investing Activities

Net cash used in investing activities during the nine months ended September 30, 2020 was $3.0 million, consisting of $8.2 million of purchases of property and equipment, partially offset by $5.2 million of COVID-19 response sales proceeds from the disposal of property and equipment. Purchases of property and equipment were primarily related to medical equipment rented to our patients. Combining cash purchases of property and equipment of $8.2 million and equipment financed through finance leases of $3.0 million, our total capital expenditures for the nine months ended September 30, 2020 were $11.2 million. This represents a $14.1 million, (or 55.7%), decrease year over year.

Net cash used in investing activities during the nine months ended September 30, 2019 was $10.2 million, consisting of $10.6 million of purchases of property and equipment, partially offset by $0.4 million of proceeds from the disposal of property and equipment. Purchases of property and equipment were primarily related to the purchase of our new corporate headquarters in addition to medical equipment rented to our patients. Combining cash purchases of property and equipment of $10.6 million and equipment financed through finance leases of $14.7 million, our total capital expenditures for the nine months ended September 30, 2019 was $25.3 million.

Net Cash (Used in) Provided by Financing Activities

Net cash used in financing activities during the nine months ended September 30, 2020 was $7.2 million, consisting of $1.2 million in principal payments on the Term Note (as defined below) and $7.7 million in repayments of finance lease liabilities, partially offset by $1.8 million proceeds from the exercise of stock options.

Page 34

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
Net cash provided by financing activities during the nine months ended September 30, 2019 was $0.8 million, consisting of $4.8 million in proceeds from the Building Term Note (as defined below) to finance the purchase of our corporate headquarters, $5.0 million in proceeds from the Term Note, partially offset by $7.9 million in repayments of finance lease liabilities and $1.5 million of shares repurchased and canceled under our normal course issuer bid.

Line of Credit

The Company maintains a line of credit in the amount of $10.0 million that expires May 1, 2023 under the Commercial Business Loan Agreement. Any amounts advanced on this line will be subject to an interest rate equal to the WSJ prime rate plus a margin of 0.50%, with a 3.50% interest rate floor and will be secured by substantially all of the Company's assets. There were no borrowings against this line of credit at September 30, 2020 or December 31, 2019. While we currently have no immediate plans to draw on this line of credit, the line of credit allows flexibility in funding our future operations subject to compliance with the covenants described above.

Commercial Term Notes

On May 30, 2019, the Company entered into an amendment to the loan agreement providing for a term note (the “Building Term Note”) in favor of Hancock Whitney Bank in the principal amount of $4.8 million. The proceeds of the Building Term Note were used to purchase a building to utilize as a new corporate headquarters for the Company. Beginning July 1, 2019, the Company makes monthly payments towards the outstanding balance. The Building Term Note matures on May 30, 2026 and is secured by substantially all of the assets of the borrower, including the real property acquired with the proceeds of the Building Term Note. The Building Term Note bears interest at a variable rate equal to the one month ICE LIBOR index plus a margin of 2.45% per annum. The Company is required to maintain a loan to value ratio of 85% with respect to the appraised value of the real property. In connection with the Building Term Note, the Company entered into an interest rate swap transaction (the "Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at 4.68%.

On September 19, 2019, the Company entered into a third amendment to the loan agreement providing for a term note (the “Term Note") in favor of Hancock Whitney Bank in the principal amount of $5.0 million. The proceeds of the Term Note will be used for general corporate purposes. Beginning October 19, 2019, the Company makes monthly payments towards the outstanding balance. The Term Note matures on September 19, 2022 and is secured by substantially all of the assets of the borrower. The Term Note bears interest at the rate of 4.60% per annum.

Under the terms of the Commercial Business Loan Agreement, the Company is subject to the following financial covenants:
Financial CovenantRequired RatioRatio at September 30, 2020
Total Debt to Adjusted EBITDA (Quarterly)not more than 1.50:1.00 0.35
Fixed Charge Coverage Ratio (Quarterly)not less than 1.35:1.002.75
Loan-to-Value Ratio (Quarterly)not more than 0.850.71

The Company was in compliance with all covenants under the Commercial Business Loan Agreement in effect at September 30, 2020.

Sources of funds

Our cash provided by operating activities in the nine months ended September 30, 2020 was $29.3 million compared to $11.7 million in the nine months ended September 30, 2019.

HHS Provider Relief Funds

The Company received $3.5 million of Provider Relief Funds from the United States Department of Health and Human Services (“HHS”) provided to eligible healthcare providers out of the $100 billion Public Health and Social Services Emergency Fund provided for in the CARES Act. The funds are allocated to eligible healthcare providers for expenses and lost revenue attributable to the COVID-19 pandemic. The Department of Health and Human Services has stated that Provider Relief Fund payments are not loans and will not need to be repaid. However, as a condition to the receipt of funds, the Company and any other providers must agree to a detailed set of terms and conditions. CMS has indicated that the terms and conditions may be subject to ongoing changes and reporting. To the extent that reporting requirements and terms and conditions are modified, it may affect the Company's ability to comply and may require the return of funds. In accordance with the terms of acceptance for the grant, the Company has utilized these funds to prevent, prepare for, and respond to the COVID-19 pandemic.
Page 35

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019

As of September 30, 2020, we had cash and cash equivalents of $32.4 million.

Use of funds

Our principal uses of cash are funding our new rental assets and other capital purchases, operations, and other working capital requirements. Over the past two years, our revenue has increased significantly from year-to-year and, as a result, our cash provided by operating activities has increased over time and now is a significant source of capital to the business, which we expect to continue in the future.

We may need to raise additional funds to support our investing operations, and such funding may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds when needed, our operations and ability to execute our business strategy could be adversely affected. We may seek to raise additional funds through equity, equity-linked or debt financings. If we raise additional funds through the incurrence of indebtedness, such indebtedness would have rights that are senior to holders of our equity securities and could contain covenants that restrict our operations. Any additional equity financing may be dilutive to our stockholders.

Leases

Leases under which we assume substantially all the risks and rewards of ownership are classified as capital leases. Upon initial recognition, the leased asset is measured at an amount equal to the lesser of its fair value and the present value of the minimum lease payments. Subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to the asset. The associated lease liability is drawn down over the life of the lease by allocating a portion of each lease payment to the liability with the remainder being recognized as finance charges. Leases that do not transfer the risks and rewards of ownership to the Company are treated as operating leases and are expensed as incurred.

Retirement Plan

The Company maintains a 401(k) retirement plan for employees to which eligible employees can contribute a percentage of their pre-tax compensation. Matching employer contributions to the 401(k) plan totaled $175,000 and $120,000 for the three months ended September 30, 2020 and 2019, respectively, and $577,000 and $455,000 for the nine months ended September 30, 2020 and 2019, respectively.

Off balance sheet arrangements

The Company has no material undisclosed off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its results of operations or financial condition.

Accounting and Disclosure Matters

Critical Accounting Principles and Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. We evaluate our estimates on an ongoing basis, including those estimates related to allowance for doubtful accounts, inventory adjustments, impaired assets, income taxes, deferred tax valuation allowances and stock-based compensation costs.

We state these accounting policies in the notes to the consolidated financial statements and at relevant sections in the Management's Discussion and Analysis of Financial Condition and Results of Operations. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.

We believe that the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our consolidated financial statements:

Page 36

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
Revenue recognition

Revenue Accounting under Topic 842

We lease DME such as non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company considers these rentals to be operating leases.

Under FASB Accounting Standards Codification Topic 842, “Leases”, we recognize rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.

Due to the nature of the industry and the reimbursement environment in which we operate, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Revenue Accounting under Topic 606

We sell DME, replacement parts and supplies to customers and recognize revenue based on contractual payment rates as determined by the payors at the point in time when control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold.

We also provide sleep study services to customers and recognize revenue when the results of the sleep study are complete as that is when the performance obligation is met. The transaction price on both equipment sales and sleep studies is the amount that we expect to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what we are ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. We do not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.

We determine our estimates of contractual allowances and discounts based upon contractual agreements, our policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. We include in the transaction price only the amount that we expect to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.

Due to the nature of the industry and the reimbursement environment in which we operate, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Returns and refunds are not accepted on either equipment sales or sleep study services. We do not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. We do not have any partially or unfilled performance obligations related to contracts with customers and as such, we have no contract liabilities as of September 30, 2020.

Allowance for doubtful accounts

We estimate that a certain portion of receivables from customers may not be collected and maintain an allowance for doubtful accounts. We evaluate the net realizable value of accounts receivable as of the date of consolidated balance sheets. Specifically, we consider historical realization data including current and historical cash collections, accounts receivable aging trends, other operating trends and relevant business conditions. Because of continuing changes in the health care industry and third-party
Page 37

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
reimbursement, it is possible that the estimates could change, which could have a material impact on the operations and cash flows. If circumstances related to certain customers change or actual results differ from expectations, our estimate of the recoverability of receivables could fluctuate from that provided for in our consolidated financial statements. A change in estimate could impact bad debt expense and accounts receivable. Our allowance for doubtful accounts was $8.8 million and $7.7 million as of September 30, 2020 and 2019, respectively, and based on our analysis, we believe the reserve is adequate for any exposure to credit losses.

Stock-based compensation

We account for our stock-based compensation in accordance with ASC 718—Compensation—Stock Compensation, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation cost for restricted stock units are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period.

Interest rate swaps

We utilize an interest rate swap contract to reduce our exposure to fluctuations in variable interest rates for future interest payments on Term Note.

For determining the fair value of our interest rate swap contract, we use significant other observable market data or assumptions (Level 2 inputs) that we believe market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk. Our fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. We include unrealized gains in Other Assets, as a component of Long-term Assets, and unrealized losses in Accrued Liabilities, as a component of Long-term Liabilities on the Condensed Consolidated Balance Sheets.

We recognize any differences between the variable interest rate payments and the fixed interest rate settlements from our swap counterparty as an adjustment to interest expense over the life of the swap. If determined to be effective cash flow hedges, we record the changes in the estimated fair value of the swaps to Accumulated other comprehensive income or loss on our Condensed Consolidated Balance Sheets. To the extent our interest rate swaps are determined to be ineffective, we recognize the changes in the estimated fair value of our swaps in Interest and other non-operating expenses, net on our Condensed Consolidated Statements of Income.

Income taxes

We are subject to income taxes in numerous jurisdictions. Significant judgment is required in determining the provision for income taxes. Our income tax provisions reflect management’s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. We recognize assets and liabilities for taxation when it is probable that we will receive refunds or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact our effective tax rate as well as our business and operations.

Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted or substantively enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the consolidated statements of financial position and a charge to or recovery of income tax expense.

Page 38

VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
September 30, 2020 and 2019
Recently Issued Accounting Pronouncements

See Note 2 – Summary of significant account policies of the Notes to Condensed Consolidated Financial Statements for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial positions and cash flows.
Page 39



VIEMED HEALTHCARE, INC.
September 30, 2020 and 2019
Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company's management, including its Chief Executive Officer and Chief Financial Officer, completed an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15 of the Exchange Act. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded:

i.that the Company's disclosure controls and procedures are designed to ensure (a) that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and (b) that such information is accumulated and communicated to the Company's management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure; and

ii.that the Company's disclosure controls and procedures are effective.

Notwithstanding the foregoing, there can be no assurance that the Company's disclosures controls and procedures will detect or uncover all failures of persons within the Company and its consolidated subsidiaries to disclose material information otherwise required to be set forth in the Company's periodic reports. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures.

Changes in Internal Control Over Financial Reporting

There have been no changes in the Company's internal control over financial reporting during the three months ended September 30, 2020 that have materially affected, or that are reasonably likely to materially affect, the Company's internal control over financial reporting.
Page 40



VIEMED HEALTHCARE, INC.
September 30, 2020 and 2019
PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be subject to various ongoing or threatened legal actions and proceedings, including those that arise in the ordinary course of business, which may include employment matters and breach of contract disputes. Please read Note 8—Commitments and Contingencies to our condensed consolidated financial statements for more information. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. In the opinion of management, the outcome of such routine ongoing litigation is not expected to have a material adverse effect on our results of operations or financial condition.

Item 1A. Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 4, 2020, which could materially affect our business, financial condition or future results. Except as set forth below, there have been no material changes in our risk factors from those disclosed in that Annual Report. 

The COVID-19 pandemic could adversely affect our business, financial condition and results of operations.

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. Various policies and initiatives have been implemented to reduce the transmission of COVID-19, including travel bans and restrictions, the postponement of non-essential medical surgeries, the limiting of access to medical facilities in certain areas, the promotion of social distancing and the adoption of remote working policies. Local, state and national governments continue to emphasize the importance of essential medical personnel and we remain open to meet the needs of our communities. Employee and patient safety is our first priority, and as a result, we put preparedness plans in place for our employees, especially our clinical personnel, and modified our clinical protocols to limit unnecessary patient encounters in order to ensure the safety of our employees as well as the safety of our patients. These measures do not appear to be negatively impacting our patient attrition rate at this time. In addition, our current ability to assess potential patients in hospitals varies by hospital and city, but overall our business of setting up new patients in the home is continuing although at lower levels than in recent periods. Many state governments have begun a phased reopening of their economies while adhering to new guidelines and enhanced safety measures, including social distancing and face mask protocols. However, certain states have paused or reversed plans to reopen their economies as new cases of COVID-19 have been on the rise in recent weeks. While governmental and other restrictions have not had a material impact on our consolidated operating results for the nine months ended September 30, 2020, it is possible that more significant disruptions could occur if the COVID-19 pandemic continues for a prolonged period of time.

The COVID-19 pandemic has resulted in a significant economic downturn in the United States and globally and has also led to significant disruptions and volatility in capital and financial markets. Broad economic factors resulting from the current COVID-19 pandemic, including high unemployment and underemployment levels and reduced consumer spending and confidence, could also affect our service mix, revenue mix, payor mix and patient base, as well as our ability to collect outstanding receivables. Business closures and layoffs in the geographic areas in which we operate may lead to increases in the uninsured and under insured populations and adversely affect demand for our services, as well as the ability of patients and other payors to pay for services rendered. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our financial results and require an increased level of working capital. In addition, we may experience supply chain disruptions, including delays and price increases in equipment and supplies. Staffing, equipment and supplies shortages may also impact our ability to assess potential patients in hospitals and set up and treat patients in the home.

We believe we presently have sufficient liquidity to satisfy our cash needs, however, we continue to evaluate and take action, as necessary, to preserve adequate liquidity and ensure that our business can continue to operate during these uncertain times, such as limiting discretionary spending across the organization. In addition, we have received, and may continue to receive, payments, grants or other relief under the CARES Act and other stimulus efforts. While the overall impact of COVID-19 on our consolidated results of operations for the three and nine months ended September 30, 2020 has resulted in an overall increase in revenues related to additional product sales and services during the periods, the overall impact that COVID-19 will have on our consolidated results of operations throughout the remainder of 2020 remains uncertain, and difficult to predict and will depend on, among other factors, the duration and severity of the pandemic, as well as any negative economic conditions arising from the pandemic, our ability to assess potential patients in hospitals and set up and treat patients in the home and the impacts of government actions and administrative regulations on the healthcare industry and broader economy, including through existing and any future stimulus efforts. We will continue to evaluate the nature and extent of these potential impacts to our business, consolidated results of
Page 41



VIEMED HEALTHCARE, INC.
September 30, 2020 and 2019
operations, liquidity and capital resources. If COVID-19 continues to spread or if the response to contain the COVID-19 pandemic is unsuccessful, we could experience a material adverse effect on our business, financial condition, and results of operations.

Further, the COVID-19 pandemic, and the volatile economic conditions stemming from the pandemic, could also precipitate or aggravate the other risk factors that we identify in our Annual Report on Form 10-K for the year ended December 31, 2019, which could materially adversely affect our business, financial condition and results of operations. In addition, COVID-19 may also affect our operating and financial results in a manner that is not presently known to us or that we currently do not consider to present significant risks to our operations.

Our products are currently subject to the competitive bidding process under Medicare, which may negatively affect our business and financial condition.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 required the Secretary of Health and Human Services to establish and implement programs under which competitive acquisition areas are established throughout the United States for purposes of awarding contracts for the furnishing of competitively priced items of DME.

CMS, the agency responsible for administering the Medicare program, conducts a competition for each competitive acquisition area under which providers submit bids to supply certain covered items of DME. Under the competitive bidding program, DME suppliers compete to become Medicare contract suppliers by submitting bids to furnish certain items in competitive bidding areas. As part of the competitive bidding process, single payment amounts ("SPAs") replace the current Medicare DME fee schedule payment amounts for selected items in certain areas of the country. The SPAs are determined by using bids submitted by DME suppliers.

Successful bidders must meet certain program quality standards in order to be awarded a contract and only successful bidders can supply the covered items to Medicare beneficiaries in the acquisition area. There are, however, regulations in place that allow non-contracted providers to continue to provide products and services to their existing customers at the new competitive bidding payment amounts. The contracts are expected to be re-bid every three years. CMS is required to award contracts to multiple entities submitting bids in each area for an item or service, but has the authority to limit the number of contractors in a competitive acquisition area to the number it determines to be necessary to meet projected demand.

In 2019, CMS announced the inclusion of non-invasive ventilator products on the list of products subject to the competitive bidding program in Round 2021 which covers the period of January 1 2021 through December 31, 2023. Rental revenue from ventilator products represents a significant portion of our revenues (approximately 86% of total revenue in 2019). At the end of 2019, approximately 19% of ventilator product-related revenue is subject to the competitive bidding process under Medicare. On March 9, 2020, CMS announced that due to the COVID-19 pandemic, the President’s exercise of the Defense Production Act, public concern regarding access to ventilators, and the non-invasive ventilators product category being new to the competitive bidding program, non-invasive ventilators were removed as a product category from Round 2021. On October 27, 2020, CMS announced that it has removed 13 of the 15 remaining product categories from Round 2021, including oxygen and PAP devices, because the payment amounts did not achieve expected savings. The next competitive bidding round is anticipated to begin on January 1, 2024. As a result of these announcements, we retain the ability to continue to furnish non-invasive ventilators and oxygen and PAP devices for all of our Medicare accredited areas. However, we cannot assure you that non-invasive ventilators and oxygen and PAP devices will not be included on the list of products subject to the competitive bidding program in the future.

The change from foreign private issuer to U.S. domestic issuer effective as of January 1, 2021 may result in significant additional costs and expenses to us.

As of June 30, 2020, we have determined that we no longer qualify as a “foreign private issuer,” as defined under U.S. securities law. As a result, effective as of January 1, 2021, we will no longer be eligible to use the rules designed for foreign private issuers and we will be considered a U.S. domestic issuer. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than the costs incurred as a foreign private issuer. In anticipation of losing our foreign private issuer status, we have filed annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K with the SEC as if we were a U.S. domestic issuer. However, effective as of January 1, 2021, we will be required to comply with U.S. proxy requirements and Regulation FD and our officers, directors and principal shareholders will become subject to the beneficial ownership reporting and short-swing profit recovery requirements in Section 16 of the Exchange Act. In addition, we will also no longer be eligible to rely upon exemptions from corporate governance requirements that are available to foreign private issuers or to benefit from other accommodations for foreign private issuers under the rules of the SEC or Nasdaq and may be required to modify certain of our policies to comply with good governance practices applicable to U.S. domestic issuers, which would involve additional costs and expenses.
Page 42



VIEMED HEALTHCARE, INC.
September 30, 2020 and 2019


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

Not applicable.

Share Repurchases

The Company did not repurchase any equity securities during the quarter ended September 30, 2020.

Dividends

We have not declared or paid any cash or stock dividends on our common shares since our inception and do not anticipate declaring or paying any cash or stock dividends in the foreseeable future. Our subsidiaries are restricted from making distributions or dividend payments to us by the Loan Agreement, subject to certain exceptions.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Page 43



VIEMED HEALTHCARE, INC.
September 30, 2020 and 2019

Item 6. Exhibits

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index below.
Exhibit NumberExhibit Title
#2.1
#2.2
#2.3
#2.4
3.1
3.2
4.1
4.2
*31.1
*31.2
**32.1
**32.2
*101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
*101.SCHInline XBRL Taxonomy Extension Schema Document.
Page 44



VIEMED HEALTHCARE, INC.
September 30, 2020 and 2019
*101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
*101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
*101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
*101.DEFInline XBRL Taxonomy Extension Definition Document.
*104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
* Filed herewith.
** Furnished in accordance with Item 601(b)(32)(ii) of Regulation S-K.
# Schedules and similar attachments have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange of Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
VIEMED HEALTHCARE, INC.
(Registrant)
By:/s/ Casey Hoyt
Casey Hoyt
Chief Executive Officer
By:/s/ Trae Fitzgerald
Trae Fitzgerald
Chief Financial Officer
Date: November 4, 2020

Page 45

 EX-31.1 2 q32020exhibit311.htm EX-31.1 Document

Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Casey Hoyt, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Viemed Healthcare, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
c)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 4, 2020
 
/s/ Casey Hoyt
 

Casey Hoyt
Chief Executive Officer


 EX-31.2 3 q32020exhibit312.htm EX-31.2 Document

Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Trae Fitzgerald, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Viemed Healthcare, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
c)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 4, 2020
 
/s/ Trae Fitzgerald
 

Trae Fitzgerald
Chief Financial Officer



 EX-32.1 4 q32020exhibit321.htm EX-32.1 Document

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Casey Hoyt, the Chief Executive Officer of Viemed Healthcare, Inc. (the “Company”), hereby certify, that, to my knowledge:
1.The Quarterly Report on Form 10-Q for the period ended September 30, 2020 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 4, 2020
/s/ Casey Hoyt
Casey Hoyt
Chief Executive Officer


 EX-32.2 5 q32020exhibit322.htm EX-32.2 Document

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Trae Fitzgerald, the Chief Financial Officer of Viemed Healthcare, Inc. (the “Company”), hereby certify, that, to my knowledge:
1.The Quarterly Report on Form 10-Q for the period ended September 30, 2020 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 4, 2020
/s/ Trae Fitzgerald
Trae Fitzgerald
Chief Financial Officer


 EX-101.SCH 6 vmd-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Nature of Business and Operations link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Nature of Business and Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Summary of Significant Accounting Policies (Customer Percentages) (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Summary of Significant Accounting Policies (Revenue Recognition) (Details) link:presentationLink link:calculationLink link:definitionLink 2110103 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Property and Equipment (Schedule of Fixed Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - Property and Equipment (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2114104 - Disclosure - Current Liabilities link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Debt and lease liabilities link:presentationLink link:calculationLink link:definitionLink 2318304 - Disclosure - Debt and lease liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Debt and lease liabilities (Line of Credit Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Debt and lease liabilities (Commercial Term Notes Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Debt and lease liabilities (Schedule of Notes Payable) (Details) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - Debt and lease liabilities (Financial Covenant) (Details) link:presentationLink link:calculationLink link:definitionLink 2423413 - Disclosure - Debt and lease liabilities (Lease Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2424414 - Disclosure - Debt and lease liabilities (Finance Lease Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2425415 - Disclosure - Debt and lease liabilities (Operating Lease Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2126106 - Disclosure - Fair value measurement link:presentationLink link:calculationLink link:definitionLink 2327305 - Disclosure - Fair value measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2428416 - Disclosure - Fair value measurement (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2429417 - Disclosure - Fair value measurement (Warrant Conversion Liability) (Details) link:presentationLink link:calculationLink link:definitionLink 2130107 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2331306 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2432418 - Disclosure - Shareholders' Equity (Issued and Outstanding Share Capital) (Details) link:presentationLink link:calculationLink link:definitionLink 2433419 - Disclosure - Shareholders' Equity (Stock-based Compensation) (Details) link:presentationLink link:calculationLink link:definitionLink 2434420 - Disclosure - Shareholders' Equity (Options, Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2435421 - Disclosure - Shareholders' Equity (Options, Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2436422 - Disclosure - Shareholders' Equity (Options, Fair Value Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 2437423 - Disclosure - Shareholders' Equity (Restricted Stock Units) (Details) link:presentationLink link:calculationLink link:definitionLink 2438424 - Disclosure - Shareholders' Equity (Phantom Share Units) (Details) link:presentationLink link:calculationLink link:definitionLink 2139108 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2440425 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2141109 - Disclosure - Other Income link:presentationLink link:calculationLink link:definitionLink 2442426 - Disclosure - Other Income (Details) link:presentationLink link:calculationLink link:definitionLink 2143110 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2444427 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2145111 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2346307 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2447428 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2148112 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2449429 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vmd-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vmd-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vmd-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Document Type Document Type Aggregate Intrinsic Value Aggregate intrinsic value, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Other (income) expense Other Nonoperating Income (Expense) Other Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Related Party [Axis] Related Party [Axis] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Service revenues Service [Member] Vested (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Exercise of warrants Stock Issued During Period, Value, Warrants Exercised Stock Issued During Period, Value, Warrants Exercised Building Term Note Building Term Note [Member] Building Term Note [Member] Total rental payments Related Party Transaction, Expenses from Transactions with Related Party Proceeds from exercise of warrants Proceeds from Warrant Exercises Statistical Measurement [Domain] Statistical Measurement [Domain] Line of Credit Line of Credit [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Security Exchange Name Security Exchange Name Income from operations Operating Income (Loss) Total current liabilities Liabilities, Current Accounts receivable Accounts Receivable [Policy Text Block] Prepaid expenses and other assets Prepaid Expense and Other Assets, Current Beginning balance (USD per share) Ending balance (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Variable Rate [Domain] Variable Rate [Domain] Outstanding deposit Deposits Assets Variable Rate [Axis] Variable Rate [Axis] Commitments and Contingencies Commitments and Contingencies Provisional income tax benefit, rate Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Shares repurchased and canceled under the Normal Course Issuer Bid Payments for Repurchase of Common Stock ASSETS Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Office Furniture & Fixtures Furniture and Fixtures [Member] Entity Address, State or Province Entity Address, State or Province Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Exercise price (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price Retained earnings Retained Earnings (Accumulated Deficit) Accrued commissions payable Accrued Sales Commission, Current Options outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Customer [Axis] Customer [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Operating rental expenses Lease, Cost Building Buildings Building [Member] Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Deferred tax asset Deferred Income Tax Assets, Net Expired / Forfeited (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Liability Class [Axis] Liability Class [Axis] Rental payments Related Party Transaction, Amounts of Transaction Exercise of warrants (in shares) Stock Issued During Period, Shares, Warrants Exercised Stock Issued During Period, Shares, Warrants Exercised Expired / Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Inventory, net of inventory reserve of $805 and $0 at September 30, 2020 and December 31, 2019, respectively Inventory, Net Revenue from sales and services under Topic 606 Revenue from Contract with Customer, Excluding Assessed Tax Capital lease Assets Held Under Finance Leases [Member] Assets Held Under Finance Leases [Member] Fair value on date of grant (USD per share) Share price (USD per share) Share Price Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Concentration risk, percentage Concentration Risk, Percentage Statement [Line Items] Statement [Line Items] Class of Stock [Domain] Class of Stock [Domain] Computer Equipment Computer Equipment [Member] Omnibus Plan Omnibus Plan [Member] Omnibus Plan Statement [Table] Statement [Table] Amounts written off Accounts Receivable, Allowance for Credit Loss, Writeoff Statistical Measurement [Axis] Statistical Measurement [Axis] Credit Facility [Axis] Credit Facility [Axis] Current portion of lease liabilities Current portion of lease liabilities Lease, Liability, Current Lease, Liability, Current Schedule of Current Liabilities Other Current Liabilities [Table Text Block] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract] Entity Small Business Entity Small Business Basis of consolidation Consolidation, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Stock-based compensation - restricted stock APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition Weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Selling, general, and administrative Selling, General and Administrative Expenses [Member] Number of interest rate swaps Derivative, Number of Instruments Held Amendment Flag Amendment Flag Schedule of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Assumptions Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] December 31, 2018 September 30, 2019 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Maximum shares in Plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Accrued other liabilities Other Accrued Liabilities, Current Borrowings against facility Long-term Line of Credit Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Related Party [Domain] Related Party [Domain] Accrued trade payables Accrued Trade Payables, Current Accrued Trade Payables, Current Derivative Instrument [Axis] Derivative Instrument [Axis] Government grant received Coronavirus Aid, Relief, and Economic Security, Government Grant Received Coronavirus Aid, Relief, and Economic Security, Government Grant Received (Principal payments) net proceeds on notes payable Proceeds from Issuance of Other Long-term Debt Interest rate swaps Derivatives, Policy [Policy Text Block] Subsequent Events Subsequent Events [Text Block] Provisional income tax benefit Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Unrealized gain on warrant conversion liability Fair Value Adjustment of Warrants Unrecognized pre-tax stock option expense Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Stock options and other dilutive securities (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Allowance for doubtful accounts Balance, beginning of year Balance, end of period Accounts Receivable, Allowance for Credit Loss, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Stock-based compensation - options APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Selling, general and administrative Selling, General and Administrative Expense Furniture and equipment Furniture And Equipment [Member] Furniture And Equipment [Member] Notional amount Derivative, Notional Amount Accrued bonuses payable Accrued Bonuses, Current Line of Credit Facility [Table] Line of Credit Facility [Table] Plan Name [Axis] Plan Name [Axis] Property and equipment financed through leases under FASB ASC 842 Assets Obtained In Exchange For Lease Liability Assets Obtained In Exchange For Lease Liability Concentration Risk [Table] Concentration Risk [Table] TOTAL ASSETS Assets Warrants issued Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Revenue Revenue from Contract with Customer Benchmark [Member] RSUs outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Title of 12(b) Security Title of 12(b) Security Depreciation Depreciation, Nonproduction Income taxes payable Accrued Income Taxes, Current Subsequent Event Type [Axis] Subsequent Event Type [Axis] Monthly Rental Payments Monthly Rental Payments [Member] Monthly Rental Payments [Member] Product and Service [Axis] Product and Service [Axis] TOTAL LIABILITIES Liabilities Weighted-average period of recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Damages sought Loss Contingency, Damages Sought, Value Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] (Increase) decrease in inventory Increase (Decrease) in Inventories Phantom Share Units Phantom Share Units (PSUs) [Member] Number of states in which entity provides DME and health care solutions Number of States in which Entity Operates Number of Restricted Stock Units (000's) Number of Phantom Share Units (000's) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Medicare Medicare [Member] Medicare [Member] Debt Instrument [Axis] Debt Instrument [Axis] Additional paid-in capital Additional Paid-in Capital [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Increase in accrued liabilities Increase (Decrease) in Accrued Liabilities Fair value Derivative Liability Adjustments for: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Interest expense Finance Lease, Interest Expense Outstanding (in shares) Shareholders' equity, beginning balance (in shares) Shareholders' equity, ending balance (in shares) Shares outstanding (in shares) Common Stock, Shares, Outstanding Equity method investment Equity Method Investments Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Long-term lease liabilities Net long-term lease liabilities Lease, Liability, Noncurrent Lease, Liability, Noncurrent Net income before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development Research and Development Expense Subsequent Event Subsequent Event [Member] Beginning balance (USD per share) Ending balance (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Comprehensive income Comprehensive Income, Policy [Policy Text Block] Notes Payable Notes Payable to Banks [Member] Schedule of Restricted Stock Units Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Property and equipment, gross Property, Plant and Equipment, Gross Proceeds from exercise of options Proceeds from Stock Options Exercised Revenue recognition Revenue [Policy Text Block] Income Statement [Abstract] Income Statement [Abstract] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Increase in prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Medical equipment Equipment, Medical [Member] Equipment, Medical [Member] Use of estimates Use of Estimates, Policy [Policy Text Block] Current assets Assets, Current [Abstract] Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Increase (decrease) in trade payables Increase (Decrease) in Accounts Payable, Trade Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Document Period End Date Document Period End Date Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Repayments of lease liabilities Lease, Payments Lease, Payments (Gain) loss from equity method investment Income (Loss) from Equity Method Investments Schedule of Revenue by Source Disaggregation of Revenue [Table Text Block] Lease liabilities Lease, Liability Lease, Liability Term Note Term Note [Member] Term Note [Member] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Share-based compensation Share-based Payment Arrangement, Noncash Expense Shares issued for vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Cover [Abstract] Cover [Abstract] Shares repurchased and canceled under the Normal Course Issuer Bid (in shares) Stock Repurchased and Retired During Period, Shares Useful life Property, Plant and Equipment, Useful Life Long-term accrued liabilities Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent Related Party Affiliated Entity [Member] Notes payable Long-term Debt Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Increase in deferred revenue Increase (Decrease) in Contract with Customer, Liability Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Other Income Other Income and Other Expense Disclosure [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Cost of revenue Cost of Goods and Services Sold Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of Phantom Share Units Share-based Payment Arrangement, Activity [Table Text Block] Equity Components [Axis] Equity Components [Axis] Change in unrealized gain (loss) on derivative instruments, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Calculated fair value of phantom share units Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Fair Value Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Fair Value Land Land [Member] Percent of issued and outstanding shares Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding Unrecognized pre-tax compensation expense, restricted stock units Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Expired / Forfeited (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule of Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Exercised (USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Fair value measurement Fair Value Disclosures [Text Block] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Purchase obligation Purchase Obligation Schedule of Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Accounts Receivable Accounts Receivable [Member] Interest Rate Interest Rate Swap [Member] Stock-based compensation Share-based Payment Arrangement [Policy Text Block] Customer [Domain] Customer [Domain] Weighted average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Accounts payable Accounts Payable Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] Total long-term assets Assets, Noncurrent Allowance for Doubtful Accounts Accounts Receivable, Allowance for Credit Loss [Roll Forward] Prepaid expenses and other assets Prepaid Expenses And Other Assets, Policy [Policy Text Block] Prepaid Expenses And Other Assets, Policy [Policy Text Block] Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Other durable medical equipment rentals Other Durable Medical Equipment Rentals [Member] Other Durable Medical Equipment Rentals [Member] Weighted average exercise price(1) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Vehicles Vehicles [Member] Denominator calculation from basic to diluted: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] COVID-19 response sales and services COVID-19 Response Sales [Member] COVID-19 Response Sales [Member] Loan-to-Value Ratio (Quarterly) Debt Instrument, Covenant, Loan To Value Ratio, Quarterly Maximum Debt Instrument, Covenant, Loan To Value Ratio, Quarterly Maximum Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable, net of allowance for doubtful accounts of $8,788 and $7,782 at September 30, 2020 and December 31, 2019, respectively Accounts Receivable, after Allowance for Credit Loss, Current Revenue from rentals under Topic 842 Operating Lease, Lease Income (Gain) loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Entity Address, Postal Zip Code Entity Address, Postal Zip Code Medicaid Medicaid [Member] Medicaid [Member] Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Other Comprehensive Loss Change in accumulated other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Document Transition Report Document Transition Report Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Warrant Warrant [Member] Increase (decrease) in income tax payable Increase (Decrease) in Income Taxes Payable Shares repurchased and canceled under the Normal Course Issuer Bid Stock Repurchased and Retired During Period, Value Floor rate Debt Instrument, Interest Rate, Floor Rate Debt Instrument, Interest Rate, Floor Rate Non-operating expenses Nonoperating Income (Expense) [Abstract] Principal amount Debt Instrument, Face Amount (Gain) loss on equity method investment Equity Securities, FV-NI, Realized Gain (Loss) Document Quarterly Report Document Quarterly Report Fixed interest rate Derivative, Fixed Interest Rate Deferred revenue Contract with Customer, Liability, Current Subsequent Event [Line Items] Subsequent Event [Line Items] Trade payables Accounts Payable, Trade, Current Issued (USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Customer Concentration Customer Concentration Risk [Member] Credit Facility [Domain] Credit Facility [Domain] Derivative Contract [Domain] Derivative Contract [Domain] Diluted (in shares) Diluted weighted-average number of shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Basic (in dollars per share) Basic earnings per share (in dollars per share) Earnings Per Share, Basic Other Income and Expenses [Abstract] Expected term Remaining life of phantom share units Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Entity File Number Entity File Number Expired / Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Weighted average lease term Operating Lease, Weighted Average Remaining Lease Term Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Inventory reserve Inventory Valuation Reserves Stock-based compensation Stock-based compensation, expense Share-based Payment Arrangement, Expense Common stock - No par value: unlimited authorized; 39,145,182 and 37,952,660 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively Common Stock, Value, Issued Total liability Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Document Fiscal Year Focus Document Fiscal Year Focus (Principal payments) net proceeds on term note Proceeds from Issuance of Secured Debt Long-term assets Assets, Noncurrent [Abstract] Aggregate intrinsic value, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Current portion of long-term debt Current portion of notes payable Long-term Debt, Current Maturities Accounts Receivable, Allowance for Doubtful Accounts Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Related Party Transaction [Axis] Related Party Transaction [Axis] Subsequent Event [Table] Subsequent Event [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Issued (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Debt And Leases [Abstract] Debt And Leases [Abstract] Debt And Leases [Abstract] Long-term debt Net long-term notes payable Long-term Debt, Excluding Current Maturities Increase in accounts receivable Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] TOTAL SHAREHOLDERS' EQUITY Shareholders' equity, beginning balance Shareholders' equity, ending balance Stockholders' Equity Attributable to Parent Concentration Risk Type [Domain] Concentration Risk Type [Domain] TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity (Principal payments) net proceeds on notes payable Repayments of Other Long-term Debt Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Total long-term liabilities Liabilities, Noncurrent Entity Address, City or Town Entity Address, City or Town Depreciation Cost, Depreciation Schedules of Revenue by Customer Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Accrued vacation and payroll Employee-related Liabilities, Current Restricted Stock Units Restricted Stock Units (RSUs) [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Weighted average lease term Finance Lease, Weighted Average Remaining Lease Term Entity Ex Transition Period Entity Ex Transition Period Equity Component [Domain] Equity Component [Domain] LIABILITIES Liabilities [Abstract] Debt and lease liabilities Debt and Lease Disclosure [Text Block] Debt and Lease Disclosure [Text Block] Gross profit Gross Profit Property and equipment, net Property and equipment, net of accumulated depreciation and amortization Property, Plant and Equipment, Net Revenue Accounting under Topic 606 Revenue from Contract with Customer [Policy Text Block] Interest expense, net of interest income Interest Income (Expense), Nonoperating, Net Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Net income Net Income Net income attributable to shareholders Net Income (Loss) Attributable to Parent Net change in working capital Increase (Decrease) in Operating Capital [Abstract] ICE LIBOR London Interbank Offered Rate (LIBOR) [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating Expenses Operating Expenses [Abstract] Net income per share Earnings Per Share [Abstract] SHAREHOLDERS' EQUITY Stockholders' Equity Attributable to Parent [Abstract] Number of options (000's) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Period Focus Document Fiscal Period Focus Equipment and supply sales Equipment Sales [Member] Equipment Sales [Member] Shares issued for vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Gross Accrued liabilities Accounts Payable and Accrued Liabilities, Noncurrent Required loan to value ratio Debt Instrument, Covenant, Loan To Value Ratio Debt Instrument, Covenant, Loan To Value Ratio Supplemental disclosures of cash flow information Supplemental Cash Flow Information [Abstract] Discrete permanent differences, rate Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Recognition period Lessor, Operating Lease, Term of Contract Entity Filer Category Entity Filer Category Schedule of Stock-based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Discount rate Lessee, Operating Lease, Discount Rate Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Monthly principal payments Debt Instrument, Periodic Payment, Principal Weighted average interest rate Finance Lease, Weighted Average Discount Rate, Percent Schedule of Estimated Useful Lives Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Leasehold improvements Leasehold Improvements [Member] Conversion of accounts payable into short-term capital lease Lease Obligation Incurred Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Current portion of phantom share liability Current accrued liabilities Deferred Compensation Share-based Arrangements, Liability, Current Change in allowance for doubtful accounts Change in allowance for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Less: Accumulated depreciation Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Supplemental disclosures of non-cash transactions Noncash Investing and Financing Items [Abstract] Exercise of options (in shares) Exercised (in shares) Common stock issued pursuant to stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Options Share-based Payment Arrangement, Option [Member] Principles of Presentation Basis of Accounting, Policy [Policy Text Block] Basic (in shares) Basic weighted-average number of common shares (in shares) Weighted Average Number of Shares Outstanding, Basic Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Subsequent Events [Abstract] Subsequent Events [Abstract] Cash settlement Share-based Payment Arrangement, Cash Used to Settle Award Fixed Charge Coverage Ratio (Quarterly) Debt Instrument, Covenant, Fixed Charge Coverage Ratio, Quarterly Minimum Debt Instrument, Covenant, Fixed Charge Coverage Ratio, Quarterly Minimum Plan Name [Domain] Plan Name [Domain] Cash paid during the period for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Nature of Business and Operations Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Revenue Accounting under Topic 842 Revenue Recognition, Leases [Policy Text Block] Shareholders' Equity Shareholders' Equity and Share-based Payments [Text Block] Revenue Revenue Revenues Class of Stock [Axis] Class of Stock [Axis] Inventory Inventory, Policy [Policy Text Block] Investment in equity method investment Payments to Acquire Other Productive Assets Provision (benefit) for income taxes Income Tax Expense (Benefit) Cash paid during the period for income taxes, net of refunds received Income Taxes Paid, Net Medicare and Medicaid Medicare And Medicaid [Member] Medicare And Medicaid [Member] Cash and cash equivalents at beginning of year Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Property and equipment Property, Plant and Equipment, Policy [Policy Text Block] Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Diluted (in dollars per share) Diluted earnings per share (in dollars per share) Earnings Per Share, Diluted Local Phone Number Local Phone Number Schedule of Covenants Schedule of Debt [Table Text Block] Schedule of Warrants Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Warrant Conversion Liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Total Debt to Adjusted EBITDA (Quarterly) Debt Instrument, Covenant, Total Debt To Adjusted EBITDA Ratio, Quarterly Maximum Debt Instrument, Covenant, Total Debt To Adjusted EBITDA Ratio, Quarterly Maximum Schedule of Notes Payable Schedule of Long-term Debt Instruments [Table Text Block] Depreciation Depreciation Entity Address, Address Line One Entity Address, Address Line One Prime Rate Prime Rate [Member] Related Party Transaction [Domain] Related Party Transaction [Domain] Entity Emerging Growth Company Entity Emerging Growth Company Exercise of options Stock Issued During Period, Value, Stock Options Exercised Property and equipment financed through finance leases Property Plant And Equipment Obtained In Exchange For Finance Lease Property Plant And Equipment Obtained In Exchange For Finance Lease Deferred income taxes (benefit) Deferred Income Tax Expense (Benefit) Ventilator rentals, non-invasive and invasive Ventilator Rental [Member] Ventilator Rental [Member] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Weighted average grant price(1) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] (Principal payments) net proceeds on term note Repayments of Secured Debt Maximum Maximum [Member] Retained earnings Retained Earnings [Member] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Weighted average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Interest rate Lessee, Finance Lease, Discount Rate Weighted average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Domain] Award Type [Domain] Long-term liabilities Liabilities, Noncurrent [Abstract] Trading Symbol Trading Symbol Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted average exercise price (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Weighted average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Earnings Per Share Earnings Per Share [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current liabilities Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company Schedule of Lease Liabilities Liabilities, Lessee [Table Text Block] Liabilities, Lessee [Table Text Block] Recently adopted accounting pronouncements and Recently issued accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 10 vmd-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 vmd-20200930_htm.xml IDEA: XBRL DOCUMENT 0001729149 2020-01-01 2020-09-30 0001729149 2020-10-31 0001729149 2020-09-30 0001729149 2019-12-31 0001729149 2020-07-01 2020-09-30 0001729149 2019-07-01 2019-09-30 0001729149 2019-01-01 2019-09-30 0001729149 us-gaap:CommonStockMember 2018-12-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001729149 us-gaap:RetainedEarningsMember 2018-12-31 0001729149 2018-12-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001729149 2019-01-01 2019-03-31 0001729149 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001729149 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001729149 us-gaap:CommonStockMember 2019-03-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001729149 us-gaap:RetainedEarningsMember 2019-03-31 0001729149 2019-03-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001729149 2019-04-01 2019-06-30 0001729149 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001729149 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001729149 us-gaap:CommonStockMember 2019-06-30 0001729149 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001729149 us-gaap:RetainedEarningsMember 2019-06-30 0001729149 2019-06-30 0001729149 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001729149 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001729149 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001729149 us-gaap:CommonStockMember 2019-09-30 0001729149 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001729149 us-gaap:RetainedEarningsMember 2019-09-30 0001729149 2019-09-30 0001729149 us-gaap:CommonStockMember 2019-12-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001729149 us-gaap:RetainedEarningsMember 2019-12-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001729149 2020-01-01 2020-03-31 0001729149 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001729149 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001729149 us-gaap:CommonStockMember 2020-03-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001729149 us-gaap:RetainedEarningsMember 2020-03-31 0001729149 2020-03-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001729149 2020-04-01 2020-06-30 0001729149 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001729149 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001729149 us-gaap:CommonStockMember 2020-06-30 0001729149 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001729149 us-gaap:RetainedEarningsMember 2020-06-30 0001729149 2020-06-30 0001729149 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001729149 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001729149 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001729149 us-gaap:CommonStockMember 2020-09-30 0001729149 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001729149 us-gaap:RetainedEarningsMember 2020-09-30 0001729149 vmd:MedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001729149 vmd:MedicaidMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001729149 vmd:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001729149 vmd:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001729149 vmd:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001729149 vmd:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001729149 vmd:MedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001729149 vmd:MedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001729149 vmd:MedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001729149 vmd:MedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001729149 srt:MinimumMember vmd:EquipmentMedicalMember 2020-01-01 2020-09-30 0001729149 srt:MaximumMember vmd:EquipmentMedicalMember 2020-01-01 2020-09-30 0001729149 us-gaap:ComputerEquipmentMember 2020-01-01 2020-09-30 0001729149 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-09-30 0001729149 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-09-30 0001729149 us-gaap:VehiclesMember 2020-01-01 2020-09-30 0001729149 srt:MinimumMember us-gaap:BuildingMember 2020-01-01 2020-09-30 0001729149 srt:MaximumMember us-gaap:BuildingMember 2020-01-01 2020-09-30 0001729149 vmd:VentilatorRentalMember 2020-07-01 2020-09-30 0001729149 vmd:VentilatorRentalMember 2019-07-01 2019-09-30 0001729149 vmd:VentilatorRentalMember 2020-01-01 2020-09-30 0001729149 vmd:VentilatorRentalMember 2019-01-01 2019-09-30 0001729149 vmd:OtherDurableMedicalEquipmentRentalsMember 2020-07-01 2020-09-30 0001729149 vmd:OtherDurableMedicalEquipmentRentalsMember 2019-07-01 2019-09-30 0001729149 vmd:OtherDurableMedicalEquipmentRentalsMember 2020-01-01 2020-09-30 0001729149 vmd:OtherDurableMedicalEquipmentRentalsMember 2019-01-01 2019-09-30 0001729149 vmd:EquipmentSalesMember 2020-07-01 2020-09-30 0001729149 vmd:EquipmentSalesMember 2019-07-01 2019-09-30 0001729149 vmd:EquipmentSalesMember 2020-01-01 2020-09-30 0001729149 vmd:EquipmentSalesMember 2019-01-01 2019-09-30 0001729149 vmd:COVID19ResponseSalesMember 2020-07-01 2020-09-30 0001729149 vmd:COVID19ResponseSalesMember 2019-07-01 2019-09-30 0001729149 vmd:COVID19ResponseSalesMember 2020-01-01 2020-09-30 0001729149 vmd:COVID19ResponseSalesMember 2019-01-01 2019-09-30 0001729149 us-gaap:ServiceMember 2020-07-01 2020-09-30 0001729149 us-gaap:ServiceMember 2019-07-01 2019-09-30 0001729149 us-gaap:ServiceMember 2020-01-01 2020-09-30 0001729149 us-gaap:ServiceMember 2019-01-01 2019-09-30 0001729149 vmd:EquipmentMedicalMember 2020-09-30 0001729149 vmd:EquipmentMedicalMember 2019-12-31 0001729149 vmd:FurnitureAndEquipmentMember 2020-09-30 0001729149 vmd:FurnitureAndEquipmentMember 2019-12-31 0001729149 us-gaap:LandMember 2020-09-30 0001729149 us-gaap:LandMember 2019-12-31 0001729149 us-gaap:BuildingMember 2020-09-30 0001729149 us-gaap:BuildingMember 2019-12-31 0001729149 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001729149 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001729149 us-gaap:VehiclesMember 2020-09-30 0001729149 us-gaap:VehiclesMember 2019-12-31 0001729149 vmd:AssetsHeldUnderFinanceLeasesMember 2020-09-30 0001729149 vmd:AssetsHeldUnderFinanceLeasesMember 2019-12-31 0001729149 us-gaap:LineOfCreditMember 2020-09-30 0001729149 us-gaap:LineOfCreditMember us-gaap:PrimeRateMember 2020-01-01 2020-09-30 0001729149 us-gaap:LineOfCreditMember 2019-12-31 0001729149 vmd:BuildingTermNoteMember us-gaap:NotesPayableToBanksMember 2019-05-30 0001729149 vmd:BuildingTermNoteMember us-gaap:NotesPayableToBanksMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-05-30 2019-05-30 0001729149 vmd:BuildingTermNoteMember us-gaap:InterestRateSwapMember us-gaap:NotesPayableToBanksMember 2019-05-30 0001729149 vmd:TermNoteMember us-gaap:NotesPayableToBanksMember 2019-09-19 0001729149 vmd:TermNoteMember us-gaap:NotesPayableToBanksMember 2019-10-19 2019-10-19 0001729149 us-gaap:NotesPayableToBanksMember 2020-09-30 0001729149 us-gaap:NotesPayableToBanksMember 2019-12-31 0001729149 vmd:MonthlyRentalPaymentsMember srt:AffiliatedEntityMember 2020-01-01 2020-09-30 0001729149 vmd:MonthlyRentalPaymentsMember srt:AffiliatedEntityMember 2020-07-01 2020-09-30 0001729149 vmd:MonthlyRentalPaymentsMember srt:AffiliatedEntityMember 2019-07-01 2019-09-30 0001729149 vmd:MonthlyRentalPaymentsMember srt:AffiliatedEntityMember 2019-01-01 2019-09-30 0001729149 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001729149 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001729149 us-gaap:WarrantMember 2018-12-31 0001729149 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001729149 us-gaap:WarrantMember 2019-09-30 0001729149 us-gaap:InterestRateSwapMember 2020-09-30 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001729149 vmd:OmnibusPlanMember 2020-06-11 0001729149 vmd:OmnibusPlanMember 2020-06-11 2020-06-11 0001729149 vmd:OmnibusPlanMember us-gaap:CommonStockMember 2020-06-11 0001729149 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001729149 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001729149 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001729149 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001729149 2019-01-01 2019-12-31 0001729149 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001729149 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-09-30 0001729149 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-09-30 0001729149 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001729149 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001729149 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001729149 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001729149 us-gaap:PhantomShareUnitsPSUsMember 2020-01-01 2020-09-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember 2019-12-31 0001729149 us-gaap:PhantomShareUnitsPSUsMember 2020-09-30 0001729149 srt:MinimumMember us-gaap:PhantomShareUnitsPSUsMember 2020-01-01 2020-09-30 0001729149 srt:MaximumMember us-gaap:PhantomShareUnitsPSUsMember 2020-01-01 2020-09-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember 2019-01-01 2019-09-30 0001729149 2020-09-23 2020-09-23 0001729149 2020-04-01 2020-04-30 0001729149 2020-01-01 2020-06-30 0001729149 us-gaap:SubsequentEventMember 2020-10-01 2020-11-04 shares iso4217:USD iso4217:USD shares vmd:state pure vmd:swap 0001729149 false 2020 Q3 --12-31 P1Y P3Y P1Y P3Y 10-Q true 2020-09-30 false 001-38973 Viemed Healthcare, Inc. Z4 625 E. Kaliste Saloom Rd. Lafayette LA 70508 337 504-3802 Common Shares, no par value VMD NASDAQ Yes Yes Non-accelerated Filer true true false false 39145182 32396000 13355000 8788000 7782000 11489000 11534000 805000000 0 2762000 1360000 3333000 1562000 49980000 27811000 56317000 54772000 79000 13000 7593000 0 63989000 54785000 113969000 82596000 7553000 4700000 3612000 3315000 368000 86000 12793000 8968000 4207000 7093000 1815000 1750000 30348000 25912000 1210000 2317000 952000 3039000 6261000 7629000 8423000 12985000 38771000 38897000 0 0 39145182 39145182 37952660 37952660 9085000 3366000 6019000 6377000 -478000 -157000 60572000 34113000 75198000 43699000 113969000 82596000 33447000 20368000 100107000 58808000 13994000 6318000 39174000 17045000 19453000 14050000 60933000 41763000 13550000 10231000 40555000 31207000 243000 208000 688000 645000 1234000 1064000 3581000 2978000 202000 193000 612000 460000 -203000 -167000 2424000 -308000 19000 -1000 3593000 1000 4040000 2186000 21514000 6166000 0 -800000 0 -363000 21000 -26000 36000 -77000 -116000 -56000 -409000 -102000 3945000 2904000 21141000 6350000 1141000 51000 -5318000 213000 2804000 2853000 26459000 6137000 24000 -88000 -321000 -236000 24000 -88000 -321000 -236000 2828000 2765000 26138000 5901000 0.07 0.08 0.69 0.17 0.07 0.07 0.66 0.15 39107640 37812921 38603267 37775775 41155668 40051422 40377608 39768877 37500815 71000 5390000 0 27110000 32571000 578000 578000 302000 302000 2418 4000 4000 539965 2202000 -2202000 0 365100 1522000 1522000 1958000 1958000 37678098 2277000 4068000 0 27546000 33891000 705000 705000 329000 329000 8280 16000 16000 4725 18000 18000 6432 39000 -39000 0 -148000 -148000 1326000 1326000 37697535 2350000 5063000 -148000 28872000 36137000 745000 745000 319000 319000 124890 245000 245000 35025 114000 114000 95210 657000 -657000 0 -88000 -88000 2853000 2853000 37952660 3366000 5470000 -236000 31725000 40325000 37952660 3366000 6377000 -157000 34113000 43699000 891000 891000 260000 260000 4737 15000 15000 529375 3276000 -3276000 0 -312000 -312000 4243000 4243000 38486772 6657000 4252000 -469000 38356000 48796000 933000 933000 263000 263000 596160 1757000 1757000 -33000 -33000 19412000 19412000 39082932 8414000 5448000 -502000 57768000 71128000 945000 945000 289000 289000 2400 8000 8000 59850 663000 -663000 0 24000 24000 2804000 2804000 39145182 9085000 6019000 -478000 60572000 75198000 26459000 6137000 6745000 4398000 7031000 6937000 3581000 2978000 0 -363000 36000 -77000 2424000 -308000 -7593000 0 6986000 9827000 1402000 -1621000 1771000 1321000 2739000 -1813000 297000 770000 2397000 1909000 282000 -124000 29319000 11687000 8204000 10582000 30000 0 5187000 350000 -3047000 -10232000 1780000 136000 0 261000 104000 4837000 1199000 4966000 0 1522000 7708000 7916000 -7231000 762000 19041000 2217000 13355000 10413000 32396000 12630000 437000 91000 1975000 338000 3002000 14735000 57000 2052000 Nature of Business and Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of in-home durable medical equipment ("DME") and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. The Company currently serves patients in 36 states in the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2020, the Company determined that it no longer qualifies as a "foreign private issuer," as defined in Rule 3b-4 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), for the purposes of the informational requirements of the Exchange Act. As a result, effective January 1, 2021, the Company will become subject to the proxy solicitation rules under Section 14 of the Exchange Act and Regulation FD, and the Company's officers, directors, and principal shareholders will become subject to the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. The Company will continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the Securities and Exchange Commission (the "SEC").</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act (the "JOBS Act"), and as such, has elected to comply with certain reduced U.S. public company reporting requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s shares are traded in Canada on the Toronto Stock Exchange under the symbol VMD.TO and in the U.S. on the Nasdaq Capital Market under the symbol VMD.</span></div> 36 Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Principles of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2019 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of our independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2020, the COVID-19 pandemic is ongoing and the impacts of the pandemic on our business, financial condition and results of operations continue to evolve as of the date of this report. As a result, the impacts remain uncertain and </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">difficult to predict and will depend on, among other factors, the duration and severity of the pandemic, as well as any negative economic conditions arising from the pandemic, our ability to assess potential patients in hospitals and set up and treat patients in the home, and the impacts of government actions and administrative regulations on the healthcare industry and broader economy, including through existing and any future stimulus efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As events continue to evolve and additional information becomes available, our estimates may change materially in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable</span></div><div><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2020, our assessment considered business and market disruptions caused by the COVID-19 pandemic and estimates of expected emerging credit and collectability trends. The continued volatility in market conditions and evolving shifts in credit trends are difficult to predict causing variability and volatility that may have a material impact on our allowance for credit losses in future periods.</span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows:</span></div><div style="margin-bottom:5.1pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.568%"><tr><td style="width:1.0%"/><td style="width:46.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,782 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts written off</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,025)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,788</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,664</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:0.1pt;padding-left:27pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2020 and 2019, no one customer represented more than 10% of outstanding accounts receivable. The Company does have receivables at September 30, 2020 from Medicare and Medicaid, representing 59% and 6%, respectively, and 65% combined, of total outstanding receivables (December 31, 2019 - 58%). As these receivables are both from government programs, there is little credit risk associated with these balances; however, these receivables are subject to billing modifications and other adjustments and estimates of the amounts of such adjustments are included in the allowance for doubtful accounts. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and nine month periods ended September 30, 2020, were as follows:</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.827%"><tr><td style="width:1.0%"/><td style="width:33.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.509%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Medicare and Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory represents non-serialized respiratory supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value. Inventory is presented net of a reserve balance of $805,000 and $0 at September 30, 2020 and December 31, 2019, respectively, that relates to COVID-19 response supplies.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated useful lives of the property and equipment are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.235%"><tr><td style="width:1.0%"/><td style="width:52.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 - 10 Years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 Years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Furniture &amp; Fixtures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 - 10 Years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of Useful Life or Lease</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 - 39 Years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite Life</span></td></tr></table></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been deployed to a patient’s address and is put in use and continues through the useful life of the asset. Property and equipment and other non-current assets with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. </span></div><div><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other assets</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consists primarily of prepaid expenses such as insurance, rent, and supplier deposits for rental equipment.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive income</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare &amp; Medicaid Services (“CMS”). </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with FASB ASC 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">“Leases,”</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 842). For any DME sales and services, the Company recognizes revenue under FASB ASU 2014-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">“Revenue from Contracts with Customers,”</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 606) and related amendments. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:0.1pt;padding-left:27pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The revenues from each major source are summarized in the following table:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from rentals under Topic 842</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Ventilator rentals, non-invasive and invasive</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Other durable medical equipment rentals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from sales and services under Topic 606</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Equipment and supply sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    COVID-19 response sales and services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33,447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,368</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">100,107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58,808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 842</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company leases DME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company considers these rentals to be operating leases.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under FASB Accounting Standards Codification Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 606</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also provides sleep study services to customers and recognizes revenue when the results of the sleep study are complete as that is when the performance obligation is met. The transaction price on both equipment sales and sleep studies is the </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Returns and refunds are not accepted on either equipment sales or sleep study services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of September 30, 2020.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC 718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, "Compensation—Stock Compensation"</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company utilizes an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the Term Note (as defined below). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk. These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company includes unrealized gains in Prepaid expenses and other assets, as a component of Long-term Assets, and unrealized losses in Accrued Liabilities, as a component of Long-term Liabilities on the Condensed Consolidated Balance Sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to Accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets. To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in Interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance modifies the disclosure requirements on fair value measurements. The Company adopted this standard on January 1, 2020 and the adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses,” to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The ASU will be effective for interim and annual periods beginning January 1, 2020 for issuers and annual periods beginning January 1, 2023 for non-issuers. The Company anticipates adopting this ASU on January 1, 2023 given its smaller reporting company status and is still evaluating the impact of adoption on the consolidated financial statements in future periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments – Credit Losses. Among other things, the ASU expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosures required by ASC 326 to also include certain disclosures required by Topic 320. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. The amendments have the same effective dates as ASU 2016-13 (Topic ASC 326) for entities that have not yet adopted that standard. For entities that early adopted ASU 2016-13 (Topic ASC 326), the amendments are effective for fiscal years beginning after December 15, 2019 and interim periods therein. Entities that early adopted ASU 2016-13 (Topic ASC 326) may early adopt the amendments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the effect of the new guidance.</span></div> Principles of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2019 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of our independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. Basis of consolidationThese consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated. <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2020, the COVID-19 pandemic is ongoing and the impacts of the pandemic on our business, financial condition and results of operations continue to evolve as of the date of this report. As a result, the impacts remain uncertain and </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">difficult to predict and will depend on, among other factors, the duration and severity of the pandemic, as well as any negative economic conditions arising from the pandemic, our ability to assess potential patients in hospitals and set up and treat patients in the home, and the impacts of government actions and administrative regulations on the healthcare industry and broader economy, including through existing and any future stimulus efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As events continue to evolve and additional information becomes available, our estimates may change materially in future periods.</span> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable</span></div><div><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2020, our assessment considered business and market disruptions caused by the COVID-19 pandemic and estimates of expected emerging credit and collectability trends. The continued volatility in market conditions and evolving shifts in credit trends are difficult to predict causing variability and volatility that may have a material impact on our allowance for credit losses in future periods.</span></div> <div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows:</span></div><div style="margin-bottom:5.1pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.568%"><tr><td style="width:1.0%"/><td style="width:46.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,782 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts written off</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,025)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,788</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,664</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7782000 4266000 7031000 6937000 6025000 3539000 8788000 7664000 0.59 0.06 0.65 0.58 <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and nine month periods ended September 30, 2020, were as follows:</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.827%"><tr><td style="width:1.0%"/><td style="width:33.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.509%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Medicare and Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr></table></div> 0.57 0.57 0.60 0.59 0.09 0.07 0.09 0.07 0.66 0.64 0.69 0.66 InventoryInventory represents non-serialized respiratory supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value 805000000 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives. </span></div>Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been deployed to a patient’s address and is put in use and continues through the useful life of the asset. Property and equipment and other non-current assets with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated useful lives of the property and equipment are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.235%"><tr><td style="width:1.0%"/><td style="width:52.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 - 10 Years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 Years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Furniture &amp; Fixtures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 - 10 Years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of Useful Life or Lease</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 - 39 Years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite Life</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company’s fixed assets:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,490 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,202 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,261)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56,317</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54,772</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P1Y P10Y P5Y P5Y P10Y P5Y P15Y P39Y <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other assets</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consists primarily of prepaid expenses such as insurance, rent, and supplier deposits for rental equipment.</span></div> <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive income</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity.</span></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare &amp; Medicaid Services (“CMS”). </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with FASB ASC 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">“Leases,”</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 842). For any DME sales and services, the Company recognizes revenue under FASB ASU 2014-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">“Revenue from Contracts with Customers,”</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 606) and related amendments. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> P1M <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The revenues from each major source are summarized in the following table:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from rentals under Topic 842</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Ventilator rentals, non-invasive and invasive</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Other durable medical equipment rentals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from sales and services under Topic 606</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Equipment and supply sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    COVID-19 response sales and services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33,447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,368</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">100,107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58,808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 19962000 17213000 58672000 50990000 2649000 1449000 7184000 3464000 1890000 1349000 3962000 3202000 8553000 0 29306000 0 393000 357000 983000 1152000 33447000 20368000 100107000 58808000 <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 842</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company leases DME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company considers these rentals to be operating leases.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under FASB Accounting Standards Codification Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.</span></div>Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial. <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 606</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also provides sleep study services to customers and recognizes revenue when the results of the sleep study are complete as that is when the performance obligation is met. The transaction price on both equipment sales and sleep studies is the </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Returns and refunds are not accepted on either equipment sales or sleep study services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of September 30, 2020.</span></div> Stock-based compensation<span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC 718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, "Compensation—Stock Compensation"</span>, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company utilizes an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the Term Note (as defined below). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk. These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company includes unrealized gains in Prepaid expenses and other assets, as a component of Long-term Assets, and unrealized losses in Accrued Liabilities, as a component of Long-term Liabilities on the Condensed Consolidated Balance Sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to Accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets. To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in Interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance modifies the disclosure requirements on fair value measurements. The Company adopted this standard on January 1, 2020 and the adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses,” to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The ASU will be effective for interim and annual periods beginning January 1, 2020 for issuers and annual periods beginning January 1, 2023 for non-issuers. The Company anticipates adopting this ASU on January 1, 2023 given its smaller reporting company status and is still evaluating the impact of adoption on the consolidated financial statements in future periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments – Credit Losses. Among other things, the ASU expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosures required by ASC 326 to also include certain disclosures required by Topic 320. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. The amendments have the same effective dates as ASU 2016-13 (Topic ASC 326) for entities that have not yet adopted that standard. For entities that early adopted ASU 2016-13 (Topic ASC 326), the amendments are effective for fiscal years beginning after December 15, 2019 and interim periods therein. Entities that early adopted ASU 2016-13 (Topic ASC 326) may early adopt the amendments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the effect of the new guidance.</span></div> Property and Equipment<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company’s fixed assets:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,490 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,202 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,261)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56,317</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54,772</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation in the amount of $2,224,000 and $1,465,000 is included in cost of revenue for the three months ended September 30, 2020 and 2019, respectively, and in the amount of $6,133,000 and $3,937,000 for the nine months ended September 30, 2020 and 2019, respectively. Included in medical equipment above is equipment acquired under finance lease obligations whose cost and accumulated depreciation at September 30, 2020 total $8,087,000 and $801,000, respectively. At December 31, 2019, cost and accumulated depreciation on equipment acquired under finance lease obligations was $15,680,000 and $1,337,000, respectively. Medical equipment purchases with a cost of $2,931,000 and $2,817,000 were included in accounts payable at September 30, 2020 and December 31, 2019, respectively. 62490000 56202000 2606000 2350000 2138000 2138000 6132000 6351000 290000 301000 922000 1110000 18261000 13680000 56317000 54772000 2224000 1465000 6133000 3937000 8087000 801000 15680000 1337000 2931000 2817000 Current Liabilities<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s short-term accrued liabilities are included within current liabilities and consist of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.798%"><tr><td style="width:1.0%"/><td style="width:56.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued trade payables </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued commissions payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued bonuses payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation and payroll</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of phantom share liability </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,793</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,968</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s short-term accrued liabilities are included within current liabilities and consist of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.798%"><tr><td style="width:1.0%"/><td style="width:56.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued trade payables </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued commissions payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued bonuses payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation and payroll</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of phantom share liability </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,793</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,968</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1682000 1023000 321000 371000 4483000 2292000 1577000 1502000 4427000 3129000 303000 651000 12793000 8968000 Debt and lease liabilities<div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Senior Credit Facility </span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 20, 2018, the Company entered a Commercial Business Loan Agreement that provides for Term Loans and Lines of Credit with Hancock Whitney Bank.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Line of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company maintains a line of credit in the amount of $10.0 million that expires May 1, 2023 under the Commercial Business Loan Agreement. Any amounts advanced on this line will be subject to an interest rate equal to the WSJ prime rate plus a margin of 0.50%, with a 3.50% interest rate floor and will be secured by substantially all of the Company's assets. There were no borrowings against this line of credit at September 30, 2020 or December 31, 2019. </span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commercial Term Notes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 30, 2019, the Company entered into a term note (the “Building Term Note”) under the Commercial Business Loan Agreement in the principal amount of $4,845,000. The proceeds of the Building Term Note were used to purchase the Company's corporate headquarters. Beginning July 1, 2019, the Company began making monthly payments towards the outstanding balance. The Building Term Note matures on May 30, 2026 and is secured by substantially all of the assets of the borrower, including the real property acquired with the proceeds of the Building Term Note. The Building Term Note bears interest at a variable rate equal to the one month ICE LIBOR index plus a margin of 2.45% per annum. The Company is required to maintain a loan to value ratio of 85% with respect to the appraised value of the real property. In connection with the Building Term Note, the Company entered into an interest rate swap transaction (the "Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at 4.68%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On September 19, 2019, the Company entered into an additional loan agreement providing for a term note (the “Term Note") under the Commercial Business Loan Agreement in the principal amount of $5,000,000. The proceeds of the Term Note were utilized for general corporate purposes. Beginning October 19, 2019, the Company started making monthly principal payments of $139,000 towards the outstanding balance. The Term Note matures on September 19, 2022 and is secured by substantially all of the assets of the borrower. The Term Note bears interest at the rate of 4.60% per annum.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company incurred immaterial financing costs related to the above term notes. These deferred financing costs are amortized over the term of the loans using the effective interest method.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recognized these term notes, which have terms greater than twelve months, as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.281%"><tr><td style="width:1.0%"/><td style="width:61.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.412%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,076 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,261</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,629</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the Commercial Business Loan Agreement, the Company is subject to the following financial covenants:</span></div><div style="margin-bottom:6pt;padding-right:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%"><tr><td style="width:1.0%"/><td style="width:34.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.004%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Covenant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Required Ratio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ratio at September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Debt to Adjusted EBITDA (Quarterly)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">not more than 1.50:1.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.35</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed Charge Coverage Ratio (Quarterly)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">not less than 1.35:1.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loan-to-Value Ratio (Quarterly)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">not more than 0.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.71</span></td></tr></table></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company was in compliance with all covenants under the Commercial Business Term Loan Agreement in effect at September 30, 2020.</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:60.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,132 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,093)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">952</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,039</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Finance lease liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has various finance leases for equipment with an implied interest rate at fixed rates up to 9.64%, secured by equipment, due between 2020 and 2022. The Company's weighted average interest rate was 3.17% and 1.83% for all finance lease liabilities outstanding as of September 30, 2020 and 2019, respectively. At September 30, 2020 and 2019, the weighted average lease term was approximately 0.73 years and 1.01 years, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2020 amounted to $34,000 and $128,000, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2019 amounted to $56,000 and $102,000, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Operating lease liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recognized operating lease liabilities that relate primarily to the lease of land and buildings. These leases contain renewal options that we have not included as part of the Company's assessment of the lease term as it is not reasonably certain that we will exercise these options. These lease liabilities are recorded at present value based on a discount rate of 5.50%, which was based on the Company's incremental borrowing rate at the time of assessment. At September 30, 2020, the weighted average lease term was approximately 3.41 years. Operating rental expenses were $191,000 and $575,000 for the three and nine months ended September 30, 2020, respectively, and $100,000 and $278,000 for the three and nine months ended September 30, 2019. The related assets for operating lease liabilities have been included with property and equipment on the Condensed Consolidated Balance Sheets.</span></div>Included within these operating lease liabilities are real property leases for real estate from a related party. Rental payments under these related party lease agreements are $20,000 per month, plus taxes, utilities and maintenance. Total rental payments for the use of these properties were $58,000 and $180,000 for the three and nine months ended September 30, 2020, respectively, and $61,000 and $182,000 for the three and nine months ended September 30, 2019, respectively. The expense for these related party rents has been included within general and administrative expenses. 10000000.0 0.0050 0.0350 0 0 4845000 0.0245 0.85 0.0468 5000000 139000 0.0460 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recognized these term notes, which have terms greater than twelve months, as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.281%"><tr><td style="width:1.0%"/><td style="width:61.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.412%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,076 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,261</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,629</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8076000 9379000 1815000 1750000 6261000 7629000 <div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the Commercial Business Loan Agreement, the Company is subject to the following financial covenants:</span></div><div style="margin-bottom:6pt;padding-right:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%"><tr><td style="width:1.0%"/><td style="width:34.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.004%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Covenant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Required Ratio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ratio at September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Debt to Adjusted EBITDA (Quarterly)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">not more than 1.50:1.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.35</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed Charge Coverage Ratio (Quarterly)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">not less than 1.35:1.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loan-to-Value Ratio (Quarterly)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">not more than 0.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.71</span></td></tr></table></div> 0.35 2.75 0.71 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:60.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,132 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,093)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">952</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,039</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5159000 10132000 4207000 7093000 952000 3039000 0.0964 0.0317 0.0183 P0Y8M23D P1Y3D 34000 128000 56000 102000 0.0550 P3Y4M28D 191000 575000 100000 278000 20000 58000 180000 61000 182000 Fair value measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. There are three levels to the hierarchy based on the reliability of inputs, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s cash and cash equivalents are measured using Level 1 inputs and include cash on hand, deposits in banks, and money market funds. Due to their short-term nature, the carrying amounts reported in the consolidated balance sheets approximate the fair value of cash and cash equivalents.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of debt is classified as Level 2 for the periods presented and approximates its carrying value.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Warrants </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During 2019, the Company had warrants to purchase one common share of the Company denominated in Canadian dollars which is different from the functional currency of the Company, which is U.S. dollars. The conversion feature is treated as a derivative financial liability and the fair value movement during the period is recognized in the Condensed Consolidated Statement of Income and Comprehensive Income. The change in the value of warrants has been recorded as an unrealized (gain) loss on derivative financial liability in the Condensed Consolidated Statements of Income and Comprehensive Income. All unexercised warrants expired during the year ended December 31, 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The warrant derivative financial liability was valued using Level 3 inputs from the fair value hierarchy. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no warrants issued or outstanding during the three and nine month periods ended September 30, 2020. A summary of the change in fair value of warrant conversion liability is as follows for the period ended September 30, 2019: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.408%"><tr><td style="width:1.0%"/><td style="width:67.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.673%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Warrant Conversion Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on warrant conversion liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Derivative instruments and hedging activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has one interest rate swap contract in place, which became effective on May 31, 2019 and has been designated as a cash flow hedge. This swap contract matures on May 30, 2026. This swap contract converts the variable interest rate to a fixed interest rate on borrowings under the Building Term Note. As of September 30, 2020, the notional amount of the interest rate swap was $4.7 million and will be amortized over the term of the swap. The fair value was $0.5 million (determined based on Level 2 inputs) and is included in Accrued liabilities, as a component of Long-term liabilities as of September 30, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first nine months of 2020, losses recognized as a result of ineffectiveness were immaterial.</span></div> 0 0 A summary of the change in fair value of warrant conversion liability is as follows for the period ended September 30, 2019: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.408%"><tr><td style="width:1.0%"/><td style="width:67.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.673%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Warrant Conversion Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on warrant conversion liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 363000 0 -363000 0 1 4700000 500000 Shareholders' Equity<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Authorized share capital</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s authorized share capital consists of an unlimited number of common shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Issued and outstanding share capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has only one class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which 39,145,182 and 37,952,660 shares were issued and outstanding as of September 30, 2020 and December 31, 2019, respectively.</span></div><div><span><br/></span></div><div style="padding-left:49.5pt;padding-right:6.75pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The purpose of the Company's RSU and Option Plans (collectively, the "Former Plan") is to provide incentive to employees, directors, officers, management companies, and consultants who provide services to the Company or any of its subsidiaries. The Former Plan is a “fixed” stock plan, whereby the maximum number of the Company's shares reserved for issuance, combined with any equity securities granted under all other compensation arrangements adopted by the Company, may not exceed 7,582,000 shares (equal to 20% of the issued and outstanding shares of the Company as of the date of the adoption of the Plan). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2020, the Company had outstanding issuances of options of 3,068,000 and restricted stock units of 679,000 under the Former Plan.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective June 11, 2020 (the "Effective Date"), the Company’s shareholders approved the Company's 2020 Long Term Incentive Plan (the "Omnibus Plan"), and the Former Plan was frozen. No future awards will be made under the Former Plan, and the common shares that were not settled or awarded under the ‎Former Plan as of the Effective Date are available for awards under the Omnibus Plan. The maximum number of common ‎shares that are available for awards under the Omnibus Plan ‎and under any other security based compensation arrangements adopted by the Company, including the ‎Former Plan, may not exceed 7,758,000 shares (equal to 20% of the issued and outstanding common shares of the Company on the ‎Effective Date). The maximum amount of the foregoing common shares that may be awarded under the Omnibus Plan as “incentive stock options” is 2,600,000 Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,769 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,234</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,064</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,581</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,978</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At September 30, 2020, there was approximately $3,671,000 of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized over a weighted-average period of 2.16 years. As of September 30, 2020, there was approximately $938,000 of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 0.47 years.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of options<br/> (000's)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average exercise price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,683</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,790</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,068</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,867</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For presentation purposes, stock options issued with a CAD exercise price have been translated to USD based on the prevailing exchange rate on the date of grant.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding was $13,867,000 and options exercisable were $5,767,000 at September 30, 2020. For the nine months ended September 30, 2020, 603,297 shares of common stock were issued pursuant to the exercise of stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At September 30, 2020, the Company had 1,008,000 exercisable stock options outstanding with a weighted average exercise price of $2.94 and a weighted average remaining contractual life of 6.8 years. At December 31, 2019, the Company had 1,037,000 exercisable stock options outstanding with a weighted average exercise price of $2.95 and a weighted average remaining contractual life of 3.5 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of the stock options has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, using the Black-Scholes option pricing model calculated using the following assumptions for issuances during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.775%"><tr><td style="width:1.0%"/><td style="width:63.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.816%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5.70 - $10.44</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.39% - 1.63%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.73% - 85.38%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.63 - 10 years</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value on date of grant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4.10 - $7.23</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also grants restricted stock units to directors, officers, and employees. The Company accounts for restricted stock units using fair value. The fair value of the restricted stock units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant. Restricted stock units vest generally over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhmNDUwMDI2OTNkMzQ4ZGJhMzhhMmJkMDg4NDczNTRjL3NlYzo4ZjQ1MDAyNjkzZDM0OGRiYTM4YTJiZDA4ODQ3MzU0Y181NS9mcmFnOmJkYjZmYTliMWI2MDRkNzM5MjJiMjgyZDIzMTVjZThlL3RleHRyZWdpb246YmRiNmZhOWIxYjYwNGQ3MzkyMmIyODJkMjMxNWNlOGVfNDE4OQ_492021ac-b6f2-4970-a2d8-e0f89db0edc8">one</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhmNDUwMDI2OTNkMzQ4ZGJhMzhhMmJkMDg4NDczNTRjL3NlYzo4ZjQ1MDAyNjkzZDM0OGRiYTM4YTJiZDA4ODQ3MzU0Y181NS9mcmFnOmJkYjZmYTliMWI2MDRkNzM5MjJiMjgyZDIzMTVjZThlL3RleHRyZWdpb246YmRiNmZhOWIxYjYwNGQ3MzkyMmIyODJkMjMxNWNlOGVfNDE5NQ_aa5d1f48-d71b-45f3-a3fb-cd2416baaab2">three</span>-year period. The Company accounts for forfeitures on restricted stock units under ASU 2016-09 and recognizes forfeitures in the period in which they occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Restricted Stock Units (000's)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average grant price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,139</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.55 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">679</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.97</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.47 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,878</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All future equity grants will be awarded in USD, therefore, restricted stock units issued with a CAD grant price have been translated to USD based on the prevailing exchange rate on the date of grant for presentation purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, the Company issued 42,147 restricted stock units with a fair value of $10.44 per share. During the nine months ended September 30, 2020, the Company issued 134,235 restricted stock units, with a vesting term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhmNDUwMDI2OTNkMzQ4ZGJhMzhhMmJkMDg4NDczNTRjL3NlYzo4ZjQ1MDAyNjkzZDM0OGRiYTM4YTJiZDA4ODQ3MzU0Y181NS9mcmFnOmJkYjZmYTliMWI2MDRkNzM5MjJiMjgyZDIzMTVjZThlL3RleHRyZWdpb246YmRiNmZhOWIxYjYwNGQ3MzkyMmIyODJkMjMxNWNlOGVfNDc2Mw_b466d98d-8f69-409d-b6cd-061a60b6f054">one</span> to three years and a fair value between $5.70 and $10.44 per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Phantom share units</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. Phantom share units granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. Phantom share units vest annually over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhmNDUwMDI2OTNkMzQ4ZGJhMzhhMmJkMDg4NDczNTRjL3NlYzo4ZjQ1MDAyNjkzZDM0OGRiYTM4YTJiZDA4ODQ3MzU0Y181NS9mcmFnOmJkYjZmYTliMWI2MDRkNzM5MjJiMjgyZDIzMTVjZThlL3RleHRyZWdpb246YmRiNmZhOWIxYjYwNGQ3MzkyMmIyODJkMjMxNWNlOGVfNTA4MQ_7c2b39be-74cd-4fc3-b7ef-16127127cac1">three</span>-year period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes phantom share unit activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.775%"><tr><td style="width:1.0%"/><td style="width:63.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Phantom Share Units (000's)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,350</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The cash-settled phantom share units are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period. The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities, using a valuation method with the following inputs:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.017%"><tr><td style="width:1.0%"/><td style="width:69.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.604%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share price (Nasdaq closing price on September 30, 2020)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.64</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remaining life of phantom share units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.61 - 2.61 Years</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Calculated fair value of phantom share units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:31.5pt;text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The total liability associated with phantom share units at September 30, 2020 is $5,159,000, with $4,427,000 of this amount included in current accrued liabilities and the remaining portion of $732,000 included in long-term accrued liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expense associated with the phantom stock units is recorded in "Selling, general, and administrative" within the unaudited Condensed Consolidated Statements of Income and Comprehensive Income. The following table summarizes expense associated with the phantom stock units for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,654 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company paid cash settlements of $4,201,000 and $3,386,000 during the nine months ended September 30, 2020 and 2019, respectively, pertaining to vestings of cash-settled phantom stock units.</span></div> 39145182 39145182 37952660 7582000 0.20 3068000 679000 7758000 0.20 2600000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,769 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,234</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,064</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,581</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="4" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,978</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table summarizes expense associated with the phantom stock units for the three and nine months ended September 30, 2020 and 2019 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,654 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 945000 745000 2769000 2028000 289000 319000 812000 950000 1234000 1064000 3581000 2978000 3671000 P2Y1M28D 938000 P0Y5M19D <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of options<br/> (000's)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average exercise price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,683</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,790</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,068</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,867</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For presentation purposes, stock options issued with a CAD exercise price have been translated to USD based on the prevailing exchange rate on the date of grant.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.</span></div> 2683000 3.36 P6Y8M12D 7790000 1053000 6.10 603000 3.20 65000 4.81 3068000 4.29 P8Y1M6D 13867000 13867000 5767000 603297 1008000 2.94 P6Y9M18D 1037000 2.95 P3Y6M <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of the stock options has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, using the Black-Scholes option pricing model calculated using the following assumptions for issuances during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.775%"><tr><td style="width:1.0%"/><td style="width:63.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.816%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5.70 - $10.44</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.39% - 1.63%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.73% - 85.38%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.63 - 10 years</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value on date of grant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4.10 - $7.23</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 5.70 10.44 0.0039 0.0163 0.6573 0.8538 P5Y7M17D P10Y 0 4.10 7.23 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Restricted Stock Units (000's)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average grant price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,139</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.55 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">679</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.97</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.47 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,878</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All future equity grants will be awarded in USD, therefore, restricted stock units issued with a CAD grant price have been translated to USD based on the prevailing exchange rate on the date of grant for presentation purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.</span></div> 1139000 2.16 P0Y6M18D 7129000 134000 7.19 589000 2.33 5000 5.70 679000 2.97 P0Y5M19D 5878000 42147 10.44 134235 P3Y 5.70 10.44 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes phantom share unit activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.775%"><tr><td style="width:1.0%"/><td style="width:63.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Phantom Share Units (000's)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,350</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities, using a valuation method with the following inputs:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.017%"><tr><td style="width:1.0%"/><td style="width:69.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.604%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share price (Nasdaq closing price on September 30, 2020)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.64</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remaining life of phantom share units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.61 - 2.61 Years</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Calculated fair value of phantom share units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 1350000 346000 601000 76000 1019000 8.64 P0Y7M9D P2Y7M9D 5159000 5159000 4427000 732000 459000 1054000 4070000 5654000 4201000 3386000 Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We accrue estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies (“ASC 450”). No less than quarterly, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, we (through our subsidiary Sleep Management LLC) entered into a purchase order (the “Purchase Order”) with </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vyaire Medical, Inc. d/b/a CareFusion Respiratory Technologies (“Vyaire”) for respiratory equipment and paid $1.4 million (the “Deposit”) towards the delivery of such respiratory equipment. As of September 30, 2020, outstanding supplier deposits in the amount of $0.9 million related to such Deposit are included within other prepaid and other current assets. Vyaire has been unable to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. On July 29, 2020, we (through our subsidiary Sleep Management LLC) filed a lawsuit against Vyaire in the United States District Court for the Western District of Louisiana (the “Court”) seeking a declaratory judgment that the Company is not required to pay any further funds to Vyaire and demanding Vyaire refund all amounts currently held by Vyaire as a result of the Deposit. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On September 23, 2020, Vyaire filed its Defense and Counterclaim (“Counterclaim”) with the Court alleging breach of contract and seeking damages of $4.7 million, purportedly for the improper cancellation of the Purchase Order. On October 16, 2020, we filed an answer and affirmative defenses with the Court in response to the Counterclaim and intend to pursue further legal action. We continue to believe that we have valid legal and equitable grounds to recover our outstanding Deposit as a result of Vyaire’s failure to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. We have not concluded that a loss </span></div>related to the Counterclaim is probable, nor have we accrued a liability related to this claim. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Counterclaim given that the dispute is in the early stages of the legal process. 1400000 900000 4700000 Other Income<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">"CARES" Act Funds Received</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief and Economic Security Act ("CARES Act") created a Provider Relief Fund to support health care-related expenses or lost revenue attributable to the COVID-19 pandemic. The Company received $3.5 million of the Provider Relief Funds in April 2020 and has recognized this amount within other income on its Condensed Consolidated Statements of Income. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Department of Health and Human Services has stated that Provider Relief Fund payments are not loans and will not need to be repaid. However, as a condition to the receipt of funds, the Company and any other providers must agree to a detailed set of terms and conditions. CMS has indicated that the terms and conditions may be subject to ongoing changes and reporting. To the extent that reporting requirements and terms and conditions are modified, it may affect the Company’s ability to comply and may require the return of funds. In accordance with the terms of acceptance for the grant, the Company has utilized these funds to prevent, prepare for, and respond to the COVID-19 pandemic.</span></div> 3500000 Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At September 30, 2020 and 2019, the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The CARES Act which was signed into law on March 27, 2020 includes various income and payroll tax provisions. As of September 30, 2020, the CARES Act has not had a material impact on our condensed consolidated financial statements, however, the Company is still analyzing these provisions of the CARES Act.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2016. Our annual estimated effective tax benefit rate for 2020 is (19.20)%. Our effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year, in particular due to the uncertainty in our annual forecasts resulting from the unpredictable impact of the COVID-19 pandemic on our operating results. Included in the annual estimated effective tax rate of (19.20)% are discrete permanent differences that make up (3.0)% of the rate and a discrete benefit described below accounting for (31.50)%.</span></div>The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. Pursuant to ASC 740, any change in judgment relating to the beginning of the year valuation allowance balance should be recognized discretely in continuing operations in the interim period in which the change occurs. At June 30, 2020, the Company determined that it was more likely than not that the deferred tax asset would be realized, and made an adjustment to the deferred tax asset valuation allowance, which reduced the provision for income taxes by $7.8 million. -0.1920 -0.1920 -0.030 -0.3150 -7800000 Earnings Per Share<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options, restricted stock units, and warrants are used to purchase common shares at the prevailing market rate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following reflects the earnings and share data used in the basic and diluted earnings per share computations:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.704%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.836%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.840%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator - basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,459 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,107,640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,812,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,603,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,775,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,155,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,051,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,377,608 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,768,877 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator calculation from basic to diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,107,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,812,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,603,267 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,775,775 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and other dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,048,028 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,238,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774,341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,993,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,155,668 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,051,422 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,377,608 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,768,877 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following reflects the earnings and share data used in the basic and diluted earnings per share computations:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.704%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.836%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.840%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator - basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,459 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,107,640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,812,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,603,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,775,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,155,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,051,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,377,608 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,768,877 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator calculation from basic to diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,107,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,812,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,603,267 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,775,775 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and other dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,048,028 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,238,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774,341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,993,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,155,668 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,051,422 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,377,608 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,768,877 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2804000 2853000 26459000 6137000 39107640 37812921 38603267 37775775 41155668 40051422 40377608 39768877 0.07 0.08 0.69 0.17 0.07 0.07 0.66 0.15 39107640 37812921 38603267 37775775 2048028 2238501 1774341 1993102 41155668 40051422 40377608 39768877 Subsequent Events<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Conversion of Accounts Payable into Short-term Capital Lease</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsequent to September 30, 2020, the Company entered into a capital lease agreement with a third party and, as a result, $2.5 million of accounts payable was converted to a short-term lease payable.</span></div> 2500000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover - shares
 9 Months Ended
Sep. 30, 2020
Oct. 31, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 001-38973  
Entity Registrant Name Viemed Healthcare, Inc.  
Entity Incorporation, State or Country Code Z4  
Entity Address, Address Line One 625 E. Kaliste Saloom Rd.  
Entity Address, City or Town Lafayette  
Entity Address, State or Province LA  
Entity Address, Postal Zip Code 70508  
City Area Code 337  
Local Phone Number 504-3802  
Title of 12(b) Security Common Shares, no par value  
Trading Symbol VMD  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   39,145,182
Entity Central Index Key 0001729149  
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Period Focus Q3  
Current Fiscal Year End Date --12-31  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets    
Cash and cash equivalents $ 32,396 $ 13,355
Accounts receivable, net of allowance for doubtful accounts of $8,788 and $7,782 at September 30, 2020 and December 31, 2019, respectively 11,489 11,534
Inventory, net of inventory reserve of $805 and $0 at September 30, 2020 and December 31, 2019, respectively 2,762 1,360
Prepaid expenses and other assets 3,333 1,562
Total current assets 49,980 27,811
Long-term assets    
Property and equipment, net 56,317 54,772
Equity method investment 79 13
Deferred tax asset 7,593 0
Total long-term assets 63,989 54,785
TOTAL ASSETS 113,969 82,596
Current liabilities    
Trade payables 7,553 4,700
Deferred revenue 3,612 3,315
Income taxes payable 368 86
Accrued liabilities 12,793 8,968
Current portion of lease liabilities 4,207 7,093
Current portion of long-term debt 1,815 1,750
Total current liabilities 30,348 25,912
Long-term liabilities    
Accrued liabilities 1,210 2,317
Long-term lease liabilities 952 3,039
Long-term debt 6,261 7,629
Total long-term liabilities 8,423 12,985
TOTAL LIABILITIES 38,771 38,897
Commitments and Contingencies 0 0
SHAREHOLDERS' EQUITY    
Common stock - No par value: unlimited authorized; 39,145,182 and 37,952,660 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively 9,085 3,366
Additional paid-in capital 6,019 6,377
Accumulated other comprehensive loss (478) (157)
Retained earnings 60,572 34,113
TOTAL SHAREHOLDERS' EQUITY 75,198 43,699
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 113,969 $ 82,596
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 8,788 $ 7,782
Inventory reserve $ 805,000 $ 0
Issued (in shares) 39,145,182 37,952,660
Outstanding (in shares) 39,145,182 37,952,660
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Revenue $ 33,447 $ 20,368 $ 100,107 $ 58,808
Cost of revenue 13,994 6,318 39,174 17,045
Gross profit 19,453 14,050 60,933 41,763
Operating Expenses        
Selling, general and administrative 13,550 10,231 40,555 31,207
Research and development 243 208 688 645
Stock-based compensation 1,234 1,064 3,581 2,978
Depreciation 202 193 612 460
(Gain) loss on disposal of property and equipment 203 167 (2,424) 308
Other (income) expense (19) 1 (3,593) (1)
Income from operations 4,040 2,186 21,514 6,166
Non-operating expenses        
Unrealized gain on warrant conversion liability 0 (800) 0 (363)
(Gain) loss from equity method investment (21) 26 (36) 77
Interest expense, net of interest income 116 56 409 102
Net income before taxes 3,945 2,904 21,141 6,350
Provision (benefit) for income taxes 1,141 51 (5,318) 213
Net income 2,804 2,853 26,459 6,137
Other Comprehensive Income        
Change in unrealized gain (loss) on derivative instruments, net of tax 24 (88) (321) (236)
Other Comprehensive Loss 24 (88) (321) (236)
Comprehensive Income $ 2,828 $ 2,765 $ 26,138 $ 5,901
Net income per share        
Basic (in dollars per share) $ 0.07 $ 0.08 $ 0.69 $ 0.17
Diluted (in dollars per share) $ 0.07 $ 0.07 $ 0.66 $ 0.15
Weighted average number of common shares outstanding:        
Basic (in shares) 39,107,640 37,812,921 38,603,267 37,775,775
Diluted (in shares) 41,155,668 40,051,422 40,377,608 39,768,877
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional paid-in capital
Accumulated other comprehensive loss
Retained earnings
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2018   37,500,815      
Shareholders' equity, beginning balance at Dec. 31, 2018 $ 32,571 $ 71 $ 5,390 $ 0 $ 27,110
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation - options 578   578    
Stock-based compensation - restricted stock 302   302    
Exercise of options (in shares)   2,418      
Exercise of options 4 $ 4      
Shares issued for vesting of restricted stock units (in shares)   539,965      
Shares issued for vesting of restricted stock units 0 $ 2,202 (2,202)    
Shares repurchased and canceled under the Normal Course Issuer Bid (in shares)   (365,100)      
Shares repurchased and canceled under the Normal Course Issuer Bid (1,522)       (1,522)
Net Income 1,958       1,958
Shareholders' equity, ending balance (in shares) at Mar. 31, 2019   37,678,098      
Shareholders' equity, ending balance at Mar. 31, 2019 33,891 $ 2,277 4,068 0 27,546
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2018   37,500,815      
Shareholders' equity, beginning balance at Dec. 31, 2018 32,571 $ 71 5,390 0 27,110
Increase (Decrease) in Stockholders' Equity          
Change in accumulated other comprehensive loss (236)        
Net Income 6,137        
Shareholders' equity, ending balance (in shares) at Sep. 30, 2019   37,952,660      
Shareholders' equity, ending balance at Sep. 30, 2019 40,325 $ 3,366 5,470 (236) 31,725
Shareholders' equity, beginning balance (in shares) at Mar. 31, 2019   37,678,098      
Shareholders' equity, beginning balance at Mar. 31, 2019 33,891 $ 2,277 4,068 0 27,546
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation - options 705   705    
Stock-based compensation - restricted stock 329   329    
Exercise of options (in shares)   4,725      
Exercise of options 18 $ 18      
Exercise of warrants (in shares)   8,280      
Exercise of warrants 16 $ 16      
Shares issued for vesting of restricted stock units (in shares)   6,432      
Shares issued for vesting of restricted stock units 0 $ 39 (39)    
Change in accumulated other comprehensive loss (148)     (148)  
Net Income 1,326       1,326
Shareholders' equity, ending balance (in shares) at Jun. 30, 2019   37,697,535      
Shareholders' equity, ending balance at Jun. 30, 2019 36,137 $ 2,350 5,063 (148) 28,872
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation - options 745   745    
Stock-based compensation - restricted stock 319   319    
Exercise of options (in shares)   35,025      
Exercise of options 114 $ 114      
Exercise of warrants (in shares)   124,890      
Exercise of warrants 245 $ 245      
Shares issued for vesting of restricted stock units (in shares)   95,210      
Shares issued for vesting of restricted stock units 0 $ 657 (657)    
Change in accumulated other comprehensive loss (88)     (88)  
Net Income 2,853       2,853
Shareholders' equity, ending balance (in shares) at Sep. 30, 2019   37,952,660      
Shareholders' equity, ending balance at Sep. 30, 2019 $ 40,325 $ 3,366 5,470 (236) 31,725
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2019 37,952,660 37,952,660      
Shareholders' equity, beginning balance at Dec. 31, 2019 $ 43,699 $ 3,366 6,377 (157) 34,113
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation - options 891   891    
Stock-based compensation - restricted stock 260   260    
Exercise of options (in shares)   4,737      
Exercise of options 15 $ 15      
Shares issued for vesting of restricted stock units (in shares)   529,375      
Shares issued for vesting of restricted stock units 0 $ 3,276 (3,276)    
Change in accumulated other comprehensive loss (312)     (312)  
Net Income 4,243       4,243
Shareholders' equity, ending balance (in shares) at Mar. 31, 2020   38,486,772      
Shareholders' equity, ending balance at Mar. 31, 2020 $ 48,796 $ 6,657 4,252 (469) 38,356
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2019 37,952,660 37,952,660      
Shareholders' equity, beginning balance at Dec. 31, 2019 $ 43,699 $ 3,366 6,377 (157) 34,113
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 603,000        
Change in accumulated other comprehensive loss $ (321)        
Net Income $ 26,459        
Shareholders' equity, ending balance (in shares) at Sep. 30, 2020 39,145,182 39,145,182      
Shareholders' equity, ending balance at Sep. 30, 2020 $ 75,198 $ 9,085 6,019 (478) 60,572
Shareholders' equity, beginning balance (in shares) at Mar. 31, 2020   38,486,772      
Shareholders' equity, beginning balance at Mar. 31, 2020 48,796 $ 6,657 4,252 (469) 38,356
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation - options 933   933    
Stock-based compensation - restricted stock 263   263    
Exercise of options (in shares)   596,160      
Exercise of options 1,757 $ 1,757      
Change in accumulated other comprehensive loss (33)     (33)  
Net Income 19,412       19,412
Shareholders' equity, ending balance (in shares) at Jun. 30, 2020   39,082,932      
Shareholders' equity, ending balance at Jun. 30, 2020 71,128 $ 8,414 5,448 (502) 57,768
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation - options 945   945    
Stock-based compensation - restricted stock 289   289    
Exercise of options (in shares)   2,400      
Exercise of options 8 $ 8      
Shares issued for vesting of restricted stock units (in shares)   59,850      
Shares issued for vesting of restricted stock units 0 $ 663 (663)    
Change in accumulated other comprehensive loss 24     24  
Net Income $ 2,804       2,804
Shareholders' equity, ending balance (in shares) at Sep. 30, 2020 39,145,182 39,145,182      
Shareholders' equity, ending balance at Sep. 30, 2020 $ 75,198 $ 9,085 $ 6,019 $ (478) $ 60,572
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash flows from operating activities    
Net Income $ 26,459 $ 6,137
Adjustments for:    
Depreciation 6,745 4,398
Change in allowance for doubtful accounts 7,031 6,937
Share-based compensation 3,581 2,978
Unrealized gain on warrant conversion liability 0 (363)
(Gain) loss on equity method investment (36) 77
(Gain) loss on disposal of property and equipment (2,424) 308
Deferred income taxes (benefit) (7,593) 0
Net change in working capital    
Increase in accounts receivable (6,986) (9,827)
(Increase) decrease in inventory (1,402) 1,621
Increase in prepaid expenses and other current assets (1,771) (1,321)
Increase (decrease) in trade payables 2,739 (1,813)
Increase in deferred revenue 297 770
Increase in accrued liabilities 2,397 1,909
Increase (decrease) in income tax payable 282 (124)
Net cash provided by operating activities 29,319 11,687
Cash flows from investing activities    
Purchase of property and equipment (8,204) (10,582)
Investment in equity method investment (30) 0
Proceeds from sale of property and equipment 5,187 350
Net cash used in investing activities (3,047) (10,232)
Cash flows from financing activities    
Proceeds from exercise of options 1,780 136
Proceeds from exercise of warrants 0 261
(Principal payments) net proceeds on notes payable (104)  
(Principal payments) net proceeds on notes payable   4,837
(Principal payments) net proceeds on term note   4,966
(Principal payments) net proceeds on term note (1,199)  
Shares repurchased and canceled under the Normal Course Issuer Bid 0 (1,522)
Repayments of lease liabilities (7,708) (7,916)
Net cash (used in) provided by financing activities (7,231) 762
Net increase in cash and cash equivalents 19,041 2,217
Cash and cash equivalents at beginning of year 13,355 10,413
Cash and cash equivalents at end of period 32,396 12,630
Supplemental disclosures of cash flow information    
Cash paid during the period for interest 437 91
Cash paid during the period for income taxes, net of refunds received 1,975 338
Supplemental disclosures of non-cash transactions    
Property and equipment financed through finance leases 3,002 14,735
Property and equipment financed through leases under FASB ASC 842 $ 57 $ 2,052
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Nature of Business and Operations
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business and Operations Nature of Business and Operations
Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of in-home durable medical equipment ("DME") and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. The Company currently serves patients in 36 states in the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508.

As of June 30, 2020, the Company determined that it no longer qualifies as a "foreign private issuer," as defined in Rule 3b-4 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), for the purposes of the informational requirements of the Exchange Act. As a result, effective January 1, 2021, the Company will become subject to the proxy solicitation rules under Section 14 of the Exchange Act and Regulation FD, and the Company's officers, directors, and principal shareholders will become subject to the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. The Company will continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the Securities and Exchange Commission (the "SEC").

The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act (the "JOBS Act"), and as such, has elected to comply with certain reduced U.S. public company reporting requirements.

The Company’s shares are traded in Canada on the Toronto Stock Exchange under the symbol VMD.TO and in the U.S. on the Nasdaq Capital Market under the symbol VMD.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Principles of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2019 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of our independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

Basis of consolidation

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.

Use of estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates.

As of September 30, 2020, the COVID-19 pandemic is ongoing and the impacts of the pandemic on our business, financial condition and results of operations continue to evolve as of the date of this report. As a result, the impacts remain uncertain and
difficult to predict and will depend on, among other factors, the duration and severity of the pandemic, as well as any negative economic conditions arising from the pandemic, our ability to assess potential patients in hospitals and set up and treat patients in the home, and the impacts of government actions and administrative regulations on the healthcare industry and broader economy, including through existing and any future stimulus efforts. As events continue to evolve and additional information becomes available, our estimates may change materially in future periods.

Accounts receivable

Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.

The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.

For the nine months ended September 30, 2020, our assessment considered business and market disruptions caused by the COVID-19 pandemic and estimates of expected emerging credit and collectability trends. The continued volatility in market conditions and evolving shifts in credit trends are difficult to predict causing variability and volatility that may have a material impact on our allowance for credit losses in future periods.

The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows:
September 30, 2020September 30, 2019
Balance, beginning of year$7,782 $4,266 
Change in allowance for doubtful accounts7,031 6,937 
Amounts written off(6,025)(3,539)
Balance, end of period$8,788 $7,664 

As of September 30, 2020 and 2019, no one customer represented more than 10% of outstanding accounts receivable. The Company does have receivables at September 30, 2020 from Medicare and Medicaid, representing 59% and 6%, respectively, and 65% combined, of total outstanding receivables (December 31, 2019 - 58%). As these receivables are both from government programs, there is little credit risk associated with these balances; however, these receivables are subject to billing modifications and other adjustments and estimates of the amounts of such adjustments are included in the allowance for doubtful accounts.

Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and nine month periods ended September 30, 2020, were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Medicare Revenues57 %57 %60 %59 %
Medicaid Revenues9 %7 %9 %7 %
Total Medicare and Medicaid66 %64 %69 %66 %

Inventory

Inventory represents non-serialized respiratory supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value. Inventory is presented net of a reserve balance of $805,000 and $0 at September 30, 2020 and December 31, 2019, respectively, that relates to COVID-19 response supplies.
Property and equipment

Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives.

The estimated useful lives of the property and equipment are as follows:
DescriptionEstimated Useful Lives
Medical Equipment
1 - 10 Years
Computer Equipment5 Years
Office Furniture & Fixtures
5 - 10 Years
Leasehold ImprovementsShorter of Useful Life or Lease
Vehicles5 Years
Building
15 - 39 Years
LandIndefinite Life

Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been deployed to a patient’s address and is put in use and continues through the useful life of the asset. Property and equipment and other non-current assets with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.

Prepaid expenses and other assets

Prepaid expenses and other current assets consists primarily of prepaid expenses such as insurance, rent, and supplier deposits for rental equipment.
Comprehensive income

Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity.

Revenue recognition

Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services.

The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare & Medicaid Services (“CMS”).
For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.

The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with FASB ASC 842, “Leases,” (Topic 842). For any DME sales and services, the Company recognizes revenue under FASB ASU 2014-09, “Revenue from Contracts with Customers,” (Topic 606) and related amendments.

The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term.

The revenues from each major source are summarized in the following table:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Revenue from rentals under Topic 842
    Ventilator rentals, non-invasive and invasive$19,962 $17,213 $58,672 $50,990 
    Other durable medical equipment rentals2,649 1,449 7,184 3,464 
Revenue from sales and services under Topic 606
    Equipment and supply sales
1,890 1,349 3,962 3,202 
    COVID-19 response sales and services
8,553 — 29,306 — 
    Service revenues
393 357 983 1,152 
Total Revenues$33,447 $20,368 $100,107 $58,808 

Revenue Accounting under Topic 842

The Company leases DME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company considers these rentals to be operating leases.

Under FASB Accounting Standards Codification Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.

Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Revenue Accounting under Topic 606

The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.

The Company also provides sleep study services to customers and recognizes revenue when the results of the sleep study are complete as that is when the performance obligation is met. The transaction price on both equipment sales and sleep studies is the
amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.

The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.

Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Returns and refunds are not accepted on either equipment sales or sleep study services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of September 30, 2020.

Stock-based compensation

The Company accounts for its stock-based compensation in accordance with ASC 718, "Compensation—Stock Compensation", which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award.

Interest rate swaps

The Company utilizes an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the Term Note (as defined below). 

For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk. These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company includes unrealized gains in Prepaid expenses and other assets, as a component of Long-term Assets, and unrealized losses in Accrued Liabilities, as a component of Long-term Liabilities on the Condensed Consolidated Balance Sheets.

The Company recognizes any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to Accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets. To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in Interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.
Recently adopted accounting pronouncements

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance modifies the disclosure requirements on fair value measurements. The Company adopted this standard on January 1, 2020 and the adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.

Recently issued accounting pronouncements

The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses,” to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The ASU will be effective for interim and annual periods beginning January 1, 2020 for issuers and annual periods beginning January 1, 2023 for non-issuers. The Company anticipates adopting this ASU on January 1, 2023 given its smaller reporting company status and is still evaluating the impact of adoption on the consolidated financial statements in future periods.

In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments – Credit Losses. Among other things, the ASU expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosures required by ASC 326 to also include certain disclosures required by Topic 320. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. The amendments have the same effective dates as ASU 2016-13 (Topic ASC 326) for entities that have not yet adopted that standard. For entities that early adopted ASU 2016-13 (Topic ASC 326), the amendments are effective for fiscal years beginning after December 15, 2019 and interim periods therein. Entities that early adopted ASU 2016-13 (Topic ASC 326) may early adopt the amendments.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the effect of the new guidance.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment
 9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and Equipment
The Company’s fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment.

The following table details the Company’s fixed assets:
September 30, 2020December 31, 2019
Medical equipment$62,490 $56,202 
Furniture and equipment2,606 2,350 
Land2,138 2,138 
Buildings6,132 6,351 
Leasehold improvements290 301 
Vehicles922 1,110 
Less: Accumulated depreciation(18,261)(13,680)
Property and equipment, net of accumulated depreciation and amortization$56,317 $54,772 
Depreciation in the amount of $2,224,000 and $1,465,000 is included in cost of revenue for the three months ended September 30, 2020 and 2019, respectively, and in the amount of $6,133,000 and $3,937,000 for the nine months ended September 30, 2020 and 2019, respectively. Included in medical equipment above is equipment acquired under finance lease obligations whose cost and accumulated depreciation at September 30, 2020 total $8,087,000 and $801,000, respectively. At December 31, 2019, cost and accumulated depreciation on equipment acquired under finance lease obligations was $15,680,000 and $1,337,000, respectively. Medical equipment purchases with a cost of $2,931,000 and $2,817,000 were included in accounts payable at September 30, 2020 and December 31, 2019, respectively.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Current Liabilities
 9 Months Ended
Sep. 30, 2020
Payables and Accruals [Abstract]  
Current Liabilities Current Liabilities
The Company’s short-term accrued liabilities are included within current liabilities and consist of the following:
September 30, 2020December 31, 2019
Accrued trade payables $1,682 $1,023 
Accrued commissions payable321 371 
Accrued bonuses payable4,483 2,292 
Accrued vacation and payroll1,577 1,502 
Current portion of phantom share liability 4,427 3,129 
Accrued other liabilities303 651 
Total accrued liabilities$12,793 $8,968 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and lease liabilities
 9 Months Ended
Sep. 30, 2020
Debt And Leases [Abstract]  
Debt and lease liabilities Debt and lease liabilities
Senior Credit Facility

On February 20, 2018, the Company entered a Commercial Business Loan Agreement that provides for Term Loans and Lines of Credit with Hancock Whitney Bank.

Line of Credit

The Company maintains a line of credit in the amount of $10.0 million that expires May 1, 2023 under the Commercial Business Loan Agreement. Any amounts advanced on this line will be subject to an interest rate equal to the WSJ prime rate plus a margin of 0.50%, with a 3.50% interest rate floor and will be secured by substantially all of the Company's assets. There were no borrowings against this line of credit at September 30, 2020 or December 31, 2019.

Commercial Term Notes

On May 30, 2019, the Company entered into a term note (the “Building Term Note”) under the Commercial Business Loan Agreement in the principal amount of $4,845,000. The proceeds of the Building Term Note were used to purchase the Company's corporate headquarters. Beginning July 1, 2019, the Company began making monthly payments towards the outstanding balance. The Building Term Note matures on May 30, 2026 and is secured by substantially all of the assets of the borrower, including the real property acquired with the proceeds of the Building Term Note. The Building Term Note bears interest at a variable rate equal to the one month ICE LIBOR index plus a margin of 2.45% per annum. The Company is required to maintain a loan to value ratio of 85% with respect to the appraised value of the real property. In connection with the Building Term Note, the Company entered into an interest rate swap transaction (the "Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at 4.68%.

On September 19, 2019, the Company entered into an additional loan agreement providing for a term note (the “Term Note") under the Commercial Business Loan Agreement in the principal amount of $5,000,000. The proceeds of the Term Note were utilized for general corporate purposes. Beginning October 19, 2019, the Company started making monthly principal payments of $139,000 towards the outstanding balance. The Term Note matures on September 19, 2022 and is secured by substantially all of the assets of the borrower. The Term Note bears interest at the rate of 4.60% per annum.
The Company incurred immaterial financing costs related to the above term notes. These deferred financing costs are amortized over the term of the loans using the effective interest method.

The Company has recognized these term notes, which have terms greater than twelve months, as follows:
September 30, 2020December 31, 2019
Notes payable$8,076 $9,379 
Less:
Current portion of notes payable(1,815)(1,750)
Net long-term notes payable$6,261 $7,629 

Under the terms of the Commercial Business Loan Agreement, the Company is subject to the following financial covenants:
Financial CovenantRequired RatioRatio at September 30, 2020
Total Debt to Adjusted EBITDA (Quarterly)not more than 1.50:1.000.35
Fixed Charge Coverage Ratio (Quarterly)not less than 1.35:1.002.75
Loan-to-Value Ratio (Quarterly)not more than 0.850.71

The Company was in compliance with all covenants under the Commercial Business Term Loan Agreement in effect at September 30, 2020.

Leases

The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows:
September 30, 2020December 31, 2019
Lease liabilities$5,159 $10,132 
Less:
Current portion of lease liabilities(4,207)(7,093)
Net long-term lease liabilities$952 $3,039 

Finance lease liabilities

The Company has various finance leases for equipment with an implied interest rate at fixed rates up to 9.64%, secured by equipment, due between 2020 and 2022. The Company's weighted average interest rate was 3.17% and 1.83% for all finance lease liabilities outstanding as of September 30, 2020 and 2019, respectively. At September 30, 2020 and 2019, the weighted average lease term was approximately 0.73 years and 1.01 years, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2020 amounted to $34,000 and $128,000, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2019 amounted to $56,000 and $102,000, respectively.

Operating lease liabilities

The Company has recognized operating lease liabilities that relate primarily to the lease of land and buildings. These leases contain renewal options that we have not included as part of the Company's assessment of the lease term as it is not reasonably certain that we will exercise these options. These lease liabilities are recorded at present value based on a discount rate of 5.50%, which was based on the Company's incremental borrowing rate at the time of assessment. At September 30, 2020, the weighted average lease term was approximately 3.41 years. Operating rental expenses were $191,000 and $575,000 for the three and nine months ended September 30, 2020, respectively, and $100,000 and $278,000 for the three and nine months ended September 30, 2019. The related assets for operating lease liabilities have been included with property and equipment on the Condensed Consolidated Balance Sheets.
Included within these operating lease liabilities are real property leases for real estate from a related party. Rental payments under these related party lease agreements are $20,000 per month, plus taxes, utilities and maintenance. Total rental payments for the use of these properties were $58,000 and $180,000 for the three and nine months ended September 30, 2020, respectively, and $61,000 and $182,000 for the three and nine months ended September 30, 2019, respectively. The expense for these related party rents has been included within general and administrative expenses.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Fair value measurement
 9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Fair value measurement Fair value measurement
Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. There are three levels to the hierarchy based on the reliability of inputs, as follows:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.

Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.

The Company’s cash and cash equivalents are measured using Level 1 inputs and include cash on hand, deposits in banks, and money market funds. Due to their short-term nature, the carrying amounts reported in the consolidated balance sheets approximate the fair value of cash and cash equivalents.

The fair value of debt is classified as Level 2 for the periods presented and approximates its carrying value.

Warrants

During 2019, the Company had warrants to purchase one common share of the Company denominated in Canadian dollars which is different from the functional currency of the Company, which is U.S. dollars. The conversion feature is treated as a derivative financial liability and the fair value movement during the period is recognized in the Condensed Consolidated Statement of Income and Comprehensive Income. The change in the value of warrants has been recorded as an unrealized (gain) loss on derivative financial liability in the Condensed Consolidated Statements of Income and Comprehensive Income. All unexercised warrants expired during the year ended December 31, 2019.

The warrant derivative financial liability was valued using Level 3 inputs from the fair value hierarchy.

There were no warrants issued or outstanding during the three and nine month periods ended September 30, 2020. A summary of the change in fair value of warrant conversion liability is as follows for the period ended September 30, 2019:
Warrant Conversion Liability
Balance December 31, 2018$363 
Warrants issued— 
Unrealized gain on warrant conversion liability(363)
Balance September 30, 2019$— 
Derivative instruments and hedging activities

The Company has one interest rate swap contract in place, which became effective on May 31, 2019 and has been designated as a cash flow hedge. This swap contract matures on May 30, 2026. This swap contract converts the variable interest rate to a fixed interest rate on borrowings under the Building Term Note. As of September 30, 2020, the notional amount of the interest rate swap was $4.7 million and will be amortized over the term of the swap. The fair value was $0.5 million (determined based on Level 2 inputs) and is included in Accrued liabilities, as a component of Long-term liabilities as of September 30, 2020.

In the first nine months of 2020, losses recognized as a result of ineffectiveness were immaterial.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity
 9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
Shareholders' Equity Shareholders' Equity
Authorized share capital

The Company’s authorized share capital consists of an unlimited number of common shares.

Issued and outstanding share capital

The Company has only one class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which 39,145,182 and 37,952,660 shares were issued and outstanding as of September 30, 2020 and December 31, 2019, respectively.

Stock-based compensation

The purpose of the Company's RSU and Option Plans (collectively, the "Former Plan") is to provide incentive to employees, directors, officers, management companies, and consultants who provide services to the Company or any of its subsidiaries. The Former Plan is a “fixed” stock plan, whereby the maximum number of the Company's shares reserved for issuance, combined with any equity securities granted under all other compensation arrangements adopted by the Company, may not exceed 7,582,000 shares (equal to 20% of the issued and outstanding shares of the Company as of the date of the adoption of the Plan).

As of September 30, 2020, the Company had outstanding issuances of options of 3,068,000 and restricted stock units of 679,000 under the Former Plan.

Effective June 11, 2020 (the "Effective Date"), the Company’s shareholders approved the Company's 2020 Long Term Incentive Plan (the "Omnibus Plan"), and the Former Plan was frozen. No future awards will be made under the Former Plan, and the common shares that were not settled or awarded under the ‎Former Plan as of the Effective Date are available for awards under the Omnibus Plan. The maximum number of common ‎shares that are available for awards under the Omnibus Plan ‎and under any other security based compensation arrangements adopted by the Company, including the ‎Former Plan, may not exceed 7,758,000 shares (equal to 20% of the issued and outstanding common shares of the Company on the ‎Effective Date). The maximum amount of the foregoing common shares that may be awarded under the Omnibus Plan as “incentive stock options” is 2,600,000 Common Shares.

The following table summarizes stock-based compensation for the three and nine months ended September 30, 2020 and 2019 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Stock-based compensation - options$945 $745 $2,769 $2,028 
Stock-based compensation - restricted stock units289 319 812 950 
Total$1,234 $1,064 $3,581 $2,978 

At September 30, 2020, there was approximately $3,671,000 of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized over a weighted-average period of 2.16 years. As of September 30, 2020, there was approximately $938,000 of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 0.47 years.
Options

The following table summarizes stock option activity for the nine months ended September 30, 2020:
Number of options
(000's)
Weighted average exercise price(1)
Weighted average remaining contractual life
Aggregate Intrinsic Value(2)
Balance December 31, 20192,683 $3.36 6.7 years$7,790 
Issued1,053 6.10 
Exercised(603)3.20 
Expired / Forfeited(65)4.81 
Balance September 30, 20203,068 $4.29 8.1 years$13,867 
(1) For presentation purposes, stock options issued with a CAD exercise price have been translated to USD based on the prevailing exchange rate on the date of grant.
(2) The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.

The aggregate intrinsic value of options outstanding was $13,867,000 and options exercisable were $5,767,000 at September 30, 2020. For the nine months ended September 30, 2020, 603,297 shares of common stock were issued pursuant to the exercise of stock options.

At September 30, 2020, the Company had 1,008,000 exercisable stock options outstanding with a weighted average exercise price of $2.94 and a weighted average remaining contractual life of 6.8 years. At December 31, 2019, the Company had 1,037,000 exercisable stock options outstanding with a weighted average exercise price of $2.95 and a weighted average remaining contractual life of 3.5 years.

The fair value of the stock options has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, using the Black-Scholes option pricing model calculated using the following assumptions for issuances during the nine months ended September 30, 2020:
Exercise price
$5.70 - $10.44
Risk-free interest rate
0.39% - 1.63%
Expected volatility
65.73% - 85.38%
Expected term
5.63 - 10 years
Expected dividend yieldNil
Fair value on date of grant
$4.10 - $7.23
Restricted stock units

The Company also grants restricted stock units to directors, officers, and employees. The Company accounts for restricted stock units using fair value. The fair value of the restricted stock units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant. Restricted stock units vest generally over a one or three-year period. The Company accounts for forfeitures on restricted stock units under ASU 2016-09 and recognizes forfeitures in the period in which they occur.

The following table summarizes restricted stock unit activity for the nine months ended September 30, 2020:
Number of Restricted Stock Units (000's)
Weighted average grant price(1)
Weighted average remaining contractual life
Aggregate Intrinsic Value(2)
Balance December 31, 20191,139 $2.16 0.55 years$7,129 
Issued134 7.19 
Vested(589)2.33 
Expired / Forfeited(5)5.70 
Balance September 30, 2020679 $2.97 0.47 years$5,878 
(1) All future equity grants will be awarded in USD, therefore, restricted stock units issued with a CAD grant price have been translated to USD based on the prevailing exchange rate on the date of grant for presentation purposes.
(2) The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.

During the three months ended September 30, 2020, the Company issued 42,147 restricted stock units with a fair value of $10.44 per share. During the nine months ended September 30, 2020, the Company issued 134,235 restricted stock units, with a vesting term of one to three years and a fair value between $5.70 and $10.44 per share.

Phantom share units

The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. Phantom share units granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. Phantom share units vest annually over a three-year period.

The following table summarizes phantom share unit activity for the nine months ended September 30, 2020:
Number of Phantom Share Units (000's)
Balance December 31, 20191,350 
Issued346 
Vested(601)
Expired / Forfeited(76)
Balance September 30, 20201,019 
The cash-settled phantom share units are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period. The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities, using a valuation method with the following inputs:
Nine Months Ended
September 30, 2020
Share price (Nasdaq closing price on September 30, 2020)
$8.64
Remaining life of phantom share units
0.61 - 2.61 Years
Calculated fair value of phantom share units$5,159 

The total liability associated with phantom share units at September 30, 2020 is $5,159,000, with $4,427,000 of this amount included in current accrued liabilities and the remaining portion of $732,000 included in long-term accrued liabilities.

Expense associated with the phantom stock units is recorded in "Selling, general, and administrative" within the unaudited Condensed Consolidated Statements of Income and Comprehensive Income. The following table summarizes expense associated with the phantom stock units for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Selling, general, and administrative$459 $1,054 $4,070 $5,654 

The Company paid cash settlements of $4,201,000 and $3,386,000 during the nine months ended September 30, 2020 and 2019, respectively, pertaining to vestings of cash-settled phantom stock units.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Litigation

We accrue estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies (“ASC 450”). No less than quarterly, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters.

In March 2020, we (through our subsidiary Sleep Management LLC) entered into a purchase order (the “Purchase Order”) with
Vyaire Medical, Inc. d/b/a CareFusion Respiratory Technologies (“Vyaire”) for respiratory equipment and paid $1.4 million (the “Deposit”) towards the delivery of such respiratory equipment. As of September 30, 2020, outstanding supplier deposits in the amount of $0.9 million related to such Deposit are included within other prepaid and other current assets. Vyaire has been unable to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. On July 29, 2020, we (through our subsidiary Sleep Management LLC) filed a lawsuit against Vyaire in the United States District Court for the Western District of Louisiana (the “Court”) seeking a declaratory judgment that the Company is not required to pay any further funds to Vyaire and demanding Vyaire refund all amounts currently held by Vyaire as a result of the Deposit.

On September 23, 2020, Vyaire filed its Defense and Counterclaim (“Counterclaim”) with the Court alleging breach of contract and seeking damages of $4.7 million, purportedly for the improper cancellation of the Purchase Order. On October 16, 2020, we filed an answer and affirmative defenses with the Court in response to the Counterclaim and intend to pursue further legal action. We continue to believe that we have valid legal and equitable grounds to recover our outstanding Deposit as a result of Vyaire’s failure to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. We have not concluded that a loss
related to the Counterclaim is probable, nor have we accrued a liability related to this claim. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Counterclaim given that the dispute is in the early stages of the legal process.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Other Income
 9 Months Ended
Sep. 30, 2020
Other Income and Expenses [Abstract]  
Other Income Other Income
"CARES" Act Funds Received

The Coronavirus Aid, Relief and Economic Security Act ("CARES Act") created a Provider Relief Fund to support health care-related expenses or lost revenue attributable to the COVID-19 pandemic. The Company received $3.5 million of the Provider Relief Funds in April 2020 and has recognized this amount within other income on its Condensed Consolidated Statements of Income.

The Department of Health and Human Services has stated that Provider Relief Fund payments are not loans and will not need to be repaid. However, as a condition to the receipt of funds, the Company and any other providers must agree to a detailed set of terms and conditions. CMS has indicated that the terms and conditions may be subject to ongoing changes and reporting. To the extent that reporting requirements and terms and conditions are modified, it may affect the Company’s ability to comply and may require the return of funds. In accordance with the terms of acceptance for the grant, the Company has utilized these funds to prevent, prepare for, and respond to the COVID-19 pandemic.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes
 9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
At September 30, 2020 and 2019, the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense.

The CARES Act which was signed into law on March 27, 2020 includes various income and payroll tax provisions. As of September 30, 2020, the CARES Act has not had a material impact on our condensed consolidated financial statements, however, the Company is still analyzing these provisions of the CARES Act.
 
The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2016. Our annual estimated effective tax benefit rate for 2020 is (19.20)%. Our effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year, in particular due to the uncertainty in our annual forecasts resulting from the unpredictable impact of the COVID-19 pandemic on our operating results. Included in the annual estimated effective tax rate of (19.20)% are discrete permanent differences that make up (3.0)% of the rate and a discrete benefit described below accounting for (31.50)%.
The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. Pursuant to ASC 740, any change in judgment relating to the beginning of the year valuation allowance balance should be recognized discretely in continuing operations in the interim period in which the change occurs. At June 30, 2020, the Company determined that it was more likely than not that the deferred tax asset would be realized, and made an adjustment to the deferred tax asset valuation allowance, which reduced the provision for income taxes by $7.8 million.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Income per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year. Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options, restricted stock units, and warrants are used to purchase common shares at the prevailing market rate.

The following reflects the earnings and share data used in the basic and diluted earnings per share computations:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Numerator - basic and diluted:
Net income attributable to shareholders$2,804 $2,853 $26,459 $6,137 
Denominator:
Basic weighted-average number of common shares39,107,640 37,812,921 38,603,267 37,775,775 
Diluted weighted-average number of shares41,155,668 40,051,422 40,377,608 39,768,877 
Basic earnings per share$0.07 $0.08 $0.69 $0.17 
Diluted earnings per share$0.07 $0.07 $0.66 $0.15 
Denominator calculation from basic to diluted:
Basic weighted-average number of common shares39,107,640 37,812,921 38,603,267 37,775,775 
Stock options and other dilutive securities2,048,028 2,238,501 1,774,341 1,993,102 
Diluted weighted-average number of shares41,155,668 40,051,422 40,377,608 39,768,877 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events
 9 Months Ended
Sep. 30, 2020
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Conversion of Accounts Payable into Short-term Capital Lease

Subsequent to September 30, 2020, the Company entered into a capital lease agreement with a third party and, as a result, $2.5 million of accounts payable was converted to a short-term lease payable.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Principles of Presentation Principles of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2019 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of our independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.
Basis of consolidation Basis of consolidationThese consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.
Use of estimates
Use of estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates.

As of September 30, 2020, the COVID-19 pandemic is ongoing and the impacts of the pandemic on our business, financial condition and results of operations continue to evolve as of the date of this report. As a result, the impacts remain uncertain and
difficult to predict and will depend on, among other factors, the duration and severity of the pandemic, as well as any negative economic conditions arising from the pandemic, our ability to assess potential patients in hospitals and set up and treat patients in the home, and the impacts of government actions and administrative regulations on the healthcare industry and broader economy, including through existing and any future stimulus efforts. As events continue to evolve and additional information becomes available, our estimates may change materially in future periods.
Accounts receivable
Accounts receivable

Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.

The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.

For the nine months ended September 30, 2020, our assessment considered business and market disruptions caused by the COVID-19 pandemic and estimates of expected emerging credit and collectability trends. The continued volatility in market conditions and evolving shifts in credit trends are difficult to predict causing variability and volatility that may have a material impact on our allowance for credit losses in future periods.
Inventory InventoryInventory represents non-serialized respiratory supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value
Property and equipment
Property and equipment

Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives.
Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been deployed to a patient’s address and is put in use and continues through the useful life of the asset. Property and equipment and other non-current assets with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.
Prepaid expenses and other assets
Prepaid expenses and other assets

Prepaid expenses and other current assets consists primarily of prepaid expenses such as insurance, rent, and supplier deposits for rental equipment.
Comprehensive income
Comprehensive income

Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity.
Revenue recognition
Revenue recognition

Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services.

The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare & Medicaid Services (“CMS”).
For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.

The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with FASB ASC 842, “Leases,” (Topic 842). For any DME sales and services, the Company recognizes revenue under FASB ASU 2014-09, “Revenue from Contracts with Customers,” (Topic 606) and related amendments.

The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term.
Revenue Accounting under Topic 842
Revenue Accounting under Topic 842

The Company leases DME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company considers these rentals to be operating leases.

Under FASB Accounting Standards Codification Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.
Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.
Revenue Accounting under Topic 606
Revenue Accounting under Topic 606

The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.

The Company also provides sleep study services to customers and recognizes revenue when the results of the sleep study are complete as that is when the performance obligation is met. The transaction price on both equipment sales and sleep studies is the
amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.

The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.

Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Returns and refunds are not accepted on either equipment sales or sleep study services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of September 30, 2020.
Stock-based compensation Stock-based compensationThe Company accounts for its stock-based compensation in accordance with ASC 718, "Compensation—Stock Compensation", which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award.
Interest rate swaps
Interest rate swaps

The Company utilizes an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the Term Note (as defined below). 

For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk. These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company includes unrealized gains in Prepaid expenses and other assets, as a component of Long-term Assets, and unrealized losses in Accrued Liabilities, as a component of Long-term Liabilities on the Condensed Consolidated Balance Sheets.

The Company recognizes any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to Accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets. To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in Interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.
Recently adopted accounting pronouncements and Recently issued accounting pronouncements
Recently adopted accounting pronouncements

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance modifies the disclosure requirements on fair value measurements. The Company adopted this standard on January 1, 2020 and the adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.

Recently issued accounting pronouncements

The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses,” to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The ASU will be effective for interim and annual periods beginning January 1, 2020 for issuers and annual periods beginning January 1, 2023 for non-issuers. The Company anticipates adopting this ASU on January 1, 2023 given its smaller reporting company status and is still evaluating the impact of adoption on the consolidated financial statements in future periods.

In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments – Credit Losses. Among other things, the ASU expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosures required by ASC 326 to also include certain disclosures required by Topic 320. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. The amendments have the same effective dates as ASU 2016-13 (Topic ASC 326) for entities that have not yet adopted that standard. For entities that early adopted ASU 2016-13 (Topic ASC 326), the amendments are effective for fiscal years beginning after December 15, 2019 and interim periods therein. Entities that early adopted ASU 2016-13 (Topic ASC 326) may early adopt the amendments.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the effect of the new guidance.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Accounts Receivable, Allowance for Doubtful Accounts
The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows:
September 30, 2020September 30, 2019
Balance, beginning of year$7,782 $4,266 
Change in allowance for doubtful accounts7,031 6,937 
Amounts written off(6,025)(3,539)
Balance, end of period$8,788 $7,664 
Schedules of Revenue by Customer
Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and nine month periods ended September 30, 2020, were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Medicare Revenues57 %57 %60 %59 %
Medicaid Revenues9 %7 %9 %7 %
Total Medicare and Medicaid66 %64 %69 %66 %
Schedule of Estimated Useful Lives
The estimated useful lives of the property and equipment are as follows:
DescriptionEstimated Useful Lives
Medical Equipment
1 - 10 Years
Computer Equipment5 Years
Office Furniture & Fixtures
5 - 10 Years
Leasehold ImprovementsShorter of Useful Life or Lease
Vehicles5 Years
Building
15 - 39 Years
LandIndefinite Life
The following table details the Company’s fixed assets:
September 30, 2020December 31, 2019
Medical equipment$62,490 $56,202 
Furniture and equipment2,606 2,350 
Land2,138 2,138 
Buildings6,132 6,351 
Leasehold improvements290 301 
Vehicles922 1,110 
Less: Accumulated depreciation(18,261)(13,680)
Property and equipment, net of accumulated depreciation and amortization$56,317 $54,772 
Schedule of Revenue by Source
The revenues from each major source are summarized in the following table:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Revenue from rentals under Topic 842
    Ventilator rentals, non-invasive and invasive$19,962 $17,213 $58,672 $50,990 
    Other durable medical equipment rentals2,649 1,449 7,184 3,464 
Revenue from sales and services under Topic 606
    Equipment and supply sales
1,890 1,349 3,962 3,202 
    COVID-19 response sales and services
8,553 — 29,306 — 
    Service revenues
393 357 983 1,152 
Total Revenues$33,447 $20,368 $100,107 $58,808 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Tables)
 9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
The estimated useful lives of the property and equipment are as follows:
DescriptionEstimated Useful Lives
Medical Equipment
1 - 10 Years
Computer Equipment5 Years
Office Furniture & Fixtures
5 - 10 Years
Leasehold ImprovementsShorter of Useful Life or Lease
Vehicles5 Years
Building
15 - 39 Years
LandIndefinite Life
The following table details the Company’s fixed assets:
September 30, 2020December 31, 2019
Medical equipment$62,490 $56,202 
Furniture and equipment2,606 2,350 
Land2,138 2,138 
Buildings6,132 6,351 
Leasehold improvements290 301 
Vehicles922 1,110 
Less: Accumulated depreciation(18,261)(13,680)
Property and equipment, net of accumulated depreciation and amortization$56,317 $54,772 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Current Liabilities (Tables)
 9 Months Ended
Sep. 30, 2020
Payables and Accruals [Abstract]  
Schedule of Current Liabilities
The Company’s short-term accrued liabilities are included within current liabilities and consist of the following:
September 30, 2020December 31, 2019
Accrued trade payables $1,682 $1,023 
Accrued commissions payable321 371 
Accrued bonuses payable4,483 2,292 
Accrued vacation and payroll1,577 1,502 
Current portion of phantom share liability 4,427 3,129 
Accrued other liabilities303 651 
Total accrued liabilities$12,793 $8,968 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and lease liabilities (Tables)
 9 Months Ended
Sep. 30, 2020
Debt And Leases [Abstract]  
Schedule of Notes Payable
The Company has recognized these term notes, which have terms greater than twelve months, as follows:
September 30, 2020December 31, 2019
Notes payable$8,076 $9,379 
Less:
Current portion of notes payable(1,815)(1,750)
Net long-term notes payable$6,261 $7,629 
Schedule of Covenants
Under the terms of the Commercial Business Loan Agreement, the Company is subject to the following financial covenants:
Financial CovenantRequired RatioRatio at September 30, 2020
Total Debt to Adjusted EBITDA (Quarterly)not more than 1.50:1.000.35
Fixed Charge Coverage Ratio (Quarterly)not less than 1.35:1.002.75
Loan-to-Value Ratio (Quarterly)not more than 0.850.71
Schedule of Lease Liabilities
The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows:
September 30, 2020December 31, 2019
Lease liabilities$5,159 $10,132 
Less:
Current portion of lease liabilities(4,207)(7,093)
Net long-term lease liabilities$952 $3,039 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Fair value measurement (Tables)
 9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Schedule of Warrants A summary of the change in fair value of warrant conversion liability is as follows for the period ended September 30, 2019:
Warrant Conversion Liability
Balance December 31, 2018$363 
Warrants issued— 
Unrealized gain on warrant conversion liability(363)
Balance September 30, 2019$— 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense
The following table summarizes stock-based compensation for the three and nine months ended September 30, 2020 and 2019 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Stock-based compensation - options$945 $745 $2,769 $2,028 
Stock-based compensation - restricted stock units289 319 812 950 
Total$1,234 $1,064 $3,581 $2,978 
The following table summarizes expense associated with the phantom stock units for the three and nine months ended September 30, 2020 and 2019 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Selling, general, and administrative$459 $1,054 $4,070 $5,654 
Schedule of Option Activity
The following table summarizes stock option activity for the nine months ended September 30, 2020:
Number of options
(000's)
Weighted average exercise price(1)
Weighted average remaining contractual life
Aggregate Intrinsic Value(2)
Balance December 31, 20192,683 $3.36 6.7 years$7,790 
Issued1,053 6.10 
Exercised(603)3.20 
Expired / Forfeited(65)4.81 
Balance September 30, 20203,068 $4.29 8.1 years$13,867 
(1) For presentation purposes, stock options issued with a CAD exercise price have been translated to USD based on the prevailing exchange rate on the date of grant.
(2) The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.
Schedule of Stock Options, Valuation Assumptions
The fair value of the stock options has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, using the Black-Scholes option pricing model calculated using the following assumptions for issuances during the nine months ended September 30, 2020:
Exercise price
$5.70 - $10.44
Risk-free interest rate
0.39% - 1.63%
Expected volatility
65.73% - 85.38%
Expected term
5.63 - 10 years
Expected dividend yieldNil
Fair value on date of grant
$4.10 - $7.23
Schedule of Restricted Stock Units
The following table summarizes restricted stock unit activity for the nine months ended September 30, 2020:
Number of Restricted Stock Units (000's)
Weighted average grant price(1)
Weighted average remaining contractual life
Aggregate Intrinsic Value(2)
Balance December 31, 20191,139 $2.16 0.55 years$7,129 
Issued134 7.19 
Vested(589)2.33 
Expired / Forfeited(5)5.70 
Balance September 30, 2020679 $2.97 0.47 years$5,878 
(1) All future equity grants will be awarded in USD, therefore, restricted stock units issued with a CAD grant price have been translated to USD based on the prevailing exchange rate on the date of grant for presentation purposes.
(2) The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.
Schedule of Phantom Share Units
The following table summarizes phantom share unit activity for the nine months ended September 30, 2020:
Number of Phantom Share Units (000's)
Balance December 31, 20191,350 
Issued346 
Vested(601)
Expired / Forfeited(76)
Balance September 30, 20201,019 
The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities, using a valuation method with the following inputs:
Nine Months Ended
September 30, 2020
Share price (Nasdaq closing price on September 30, 2020)
$8.64
Remaining life of phantom share units
0.61 - 2.61 Years
Calculated fair value of phantom share units$5,159 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share (Tables)
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share
The following reflects the earnings and share data used in the basic and diluted earnings per share computations:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Numerator - basic and diluted:
Net income attributable to shareholders$2,804 $2,853 $26,459 $6,137 
Denominator:
Basic weighted-average number of common shares39,107,640 37,812,921 38,603,267 37,775,775 
Diluted weighted-average number of shares41,155,668 40,051,422 40,377,608 39,768,877 
Basic earnings per share$0.07 $0.08 $0.69 $0.17 
Diluted earnings per share$0.07 $0.07 $0.66 $0.15 
Denominator calculation from basic to diluted:
Basic weighted-average number of common shares39,107,640 37,812,921 38,603,267 37,775,775 
Stock options and other dilutive securities2,048,028 2,238,501 1,774,341 1,993,102 
Diluted weighted-average number of shares41,155,668 40,051,422 40,377,608 39,768,877 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Nature of Business and Operations (Details)
Sep. 30, 2020
state
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of states in which entity provides DME and health care solutions 36
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Allowance for Doubtful Accounts    
Balance, beginning of year $ 7,782 $ 4,266
Change in allowance for doubtful accounts 7,031 6,937
Amounts written off (6,025) (3,539)
Balance, end of period $ 8,788 $ 7,664
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Customer Percentages) (Details) - Customer Concentration
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Medicare and Medicaid | Accounts Receivable          
Concentration Risk [Line Items]          
Concentration risk, percentage     65.00%   58.00%
Medicare and Medicaid | Revenue          
Concentration Risk [Line Items]          
Concentration risk, percentage 66.00% 64.00% 69.00% 66.00%  
Medicare | Accounts Receivable          
Concentration Risk [Line Items]          
Concentration risk, percentage     59.00%    
Medicare | Revenue          
Concentration Risk [Line Items]          
Concentration risk, percentage 57.00% 57.00% 60.00% 59.00%  
Medicaid | Accounts Receivable          
Concentration Risk [Line Items]          
Concentration risk, percentage     6.00%    
Medicaid | Revenue          
Concentration Risk [Line Items]          
Concentration risk, percentage 9.00% 7.00% 9.00% 7.00%  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Inventory reserve $ 805,000 $ 0
Medical equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Useful life 1 year  
Medical equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Useful life 10 years  
Computer Equipment    
Property, Plant and Equipment [Line Items]    
Useful life 5 years  
Office Furniture & Fixtures | Minimum    
Property, Plant and Equipment [Line Items]    
Useful life 5 years  
Office Furniture & Fixtures | Maximum    
Property, Plant and Equipment [Line Items]    
Useful life 10 years  
Vehicles    
Property, Plant and Equipment [Line Items]    
Useful life 5 years  
Building | Minimum    
Property, Plant and Equipment [Line Items]    
Useful life 15 years  
Building | Maximum    
Property, Plant and Equipment [Line Items]    
Useful life 39 years  
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Revenue Recognition) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Disaggregation of Revenue [Line Items]        
Recognition period 1 month   1 month  
Revenue $ 33,447 $ 20,368 $ 100,107 $ 58,808
Ventilator rentals, non-invasive and invasive        
Disaggregation of Revenue [Line Items]        
Revenue from rentals under Topic 842 19,962 17,213 58,672 50,990
Other durable medical equipment rentals        
Disaggregation of Revenue [Line Items]        
Revenue from rentals under Topic 842 2,649 1,449 7,184 3,464
Equipment and supply sales        
Disaggregation of Revenue [Line Items]        
Revenue from sales and services under Topic 606 1,890 1,349 3,962 3,202
COVID-19 response sales and services        
Disaggregation of Revenue [Line Items]        
Revenue from sales and services under Topic 606 8,553 0 29,306 0
Service revenues        
Disaggregation of Revenue [Line Items]        
Revenue from sales and services under Topic 606 $ 393 $ 357 $ 983 $ 1,152
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Schedule of Fixed Assets) (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Less: Accumulated depreciation $ (18,261) $ (13,680)
Property and equipment, net of accumulated depreciation and amortization 56,317 54,772
Medical equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 62,490 56,202
Furniture and equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 2,606 2,350
Land    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 2,138 2,138
Buildings    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 6,132 6,351
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 290 301
Vehicles    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 922 $ 1,110
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Property, Plant and Equipment [Line Items]          
Depreciation $ 2,224 $ 1,465 $ 6,133 $ 3,937  
Accumulated depreciation 18,261   18,261   $ 13,680
Capital lease          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 8,087   8,087   15,680
Accumulated depreciation 801   801   1,337
Medical equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 62,490   62,490   56,202
Accounts payable $ 2,931   $ 2,931   $ 2,817
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Current Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Payables and Accruals [Abstract]    
Accrued trade payables $ 1,682 $ 1,023
Accrued commissions payable 321 371
Accrued bonuses payable 4,483 2,292
Accrued vacation and payroll 1,577 1,502
Current portion of phantom share liability 4,427 3,129
Accrued other liabilities 303 651
Total accrued liabilities $ 12,793 $ 8,968
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and lease liabilities (Line of Credit Narrative) (Details) - Line of Credit - USD ($)
 9 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Line of Credit Facility [Line Items]    
Maximum borrowing capacity $ 10,000,000.0  
Floor rate 3.50%  
Borrowings against facility $ 0 $ 0
Prime Rate    
Line of Credit Facility [Line Items]    
Basis spread on variable rate 0.50%  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and lease liabilities (Commercial Term Notes Narrative) (Details) - Notes Payable - USD ($)
Oct. 19, 2019
May 30, 2019
Sep. 19, 2019
Building Term Note      
Debt Instrument [Line Items]      
Principal amount   $ 4,845,000  
Required loan to value ratio   85.00%  
Building Term Note | Interest Rate      
Debt Instrument [Line Items]      
Fixed interest rate   4.68%  
Building Term Note | ICE LIBOR      
Debt Instrument [Line Items]      
Basis spread on variable rate   2.45%  
Term Note      
Debt Instrument [Line Items]      
Principal amount     $ 5,000,000
Monthly principal payments $ 139,000    
Stated interest rate     4.60%
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and lease liabilities (Schedule of Notes Payable) (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Debt Instrument [Line Items]    
Current portion of notes payable $ (1,815) $ (1,750)
Net long-term notes payable 6,261 7,629
Notes Payable    
Debt Instrument [Line Items]    
Notes payable 8,076 9,379
Current portion of notes payable (1,815) (1,750)
Net long-term notes payable $ 6,261 $ 7,629
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and lease liabilities (Financial Covenant) (Details) - Notes Payable
Sep. 30, 2020
Line of Credit Facility [Line Items]  
Total Debt to Adjusted EBITDA (Quarterly) 0.35
Fixed Charge Coverage Ratio (Quarterly) 2.75
Loan-to-Value Ratio (Quarterly) 0.71
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and lease liabilities (Lease Liabilities) (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Debt And Leases [Abstract]    
Lease liabilities $ 5,159 $ 10,132
Current portion of lease liabilities (4,207) (7,093)
Net long-term lease liabilities $ 952 $ 3,039
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and lease liabilities (Finance Lease Liabilities) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Debt And Leases [Abstract]        
Interest rate 9.64%   9.64%  
Weighted average interest rate 3.17% 1.83% 3.17% 1.83%
Weighted average lease term 8 months 23 days 1 year 3 days 8 months 23 days 1 year 3 days
Interest expense $ 34 $ 56 $ 128 $ 102
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and lease liabilities (Operating Lease Liabilities) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Lessee, Lease, Description [Line Items]        
Discount rate 5.50%   5.50%  
Weighted average lease term 3 years 4 months 28 days   3 years 4 months 28 days  
Operating rental expenses $ 191 $ 100 $ 575 $ 278
Monthly Rental Payments | Related Party        
Lessee, Lease, Description [Line Items]        
Rental payments     20  
Total rental payments $ 58 $ 61 $ 180 $ 182
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Fair value measurement (Narrative) (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
swap
Sep. 30, 2020
USD ($)
swap
Sep. 30, 2019
USD ($)
Interest Rate      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Number of interest rate swaps | swap 1 1  
Notional amount $ 4,700,000 $ 4,700,000  
Fair value 500,000 500,000  
Warrant      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Warrants issued $ 0 $ 0 $ 0
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Fair value measurement (Warrant Conversion Liability) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Warrant Conversion Liability        
Unrealized gain on warrant conversion liability $ 0 $ (800,000) $ 0 $ (363,000)
Warrant        
Warrant Conversion Liability        
December 31, 2018       363,000
Warrants issued $ 0   $ 0 0
Unrealized gain on warrant conversion liability       (363,000)
September 30, 2019   $ 0   $ 0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity (Issued and Outstanding Share Capital) (Details) - shares
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Shares outstanding (in shares) 39,145,182     37,952,660        
Common Stock                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Shares outstanding (in shares) 39,145,182 39,082,932 38,486,772 37,952,660 37,952,660 37,697,535 37,678,098 37,500,815
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity (Stock-based Compensation) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jun. 11, 2020
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Maximum shares in Plan (in shares)   7,582,000   7,582,000    
Percent of issued and outstanding shares       20.00%    
Options outstanding (in shares)   3,068,000   3,068,000   2,683,000
Stock-based compensation, expense   $ 1,234 $ 1,064 $ 3,581 $ 2,978  
Unrecognized pre-tax stock option expense   3,671   $ 3,671    
Weighted-average period of recognition       2 years 1 month 28 days    
Omnibus Plan            
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Maximum shares in Plan (in shares) 7,758,000          
Percent of issued and outstanding shares 20.00%          
Omnibus Plan | Common Stock            
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Maximum shares in Plan (in shares) 2,600,000          
Options            
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Stock-based compensation, expense   $ 945 745 $ 2,769 2,028  
Restricted Stock Units            
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
RSUs outstanding (in shares)   679,000   679,000   1,139,000
Stock-based compensation, expense   $ 289 $ 319 $ 812 $ 950  
Weighted-average period of recognition       5 months 19 days    
Unrecognized pre-tax compensation expense, restricted stock units   $ 938   $ 938    
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity (Options, Stock Option Activity) (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
$ / shares
shares
Number of options (000's)    
Beginning balance (in shares) | shares 2,683  
Issued (in shares) | shares 1,053  
Exercised (in shares) | shares (603)  
Expired / Forfeited (in shares) | shares (65)  
Ending balance (in shares) | shares 3,068 2,683
Weighted average exercise price(1)    
Beginning balance (USD per share) | $ / shares $ 3.36  
Issued (USD per share) | $ / shares 6.10  
Exercised (USD per share) | $ / shares 3.20  
Expired / Forfeited (USD per share) | $ / shares 4.81  
Ending balance (USD per share) | $ / shares $ 4.29 $ 3.36
Weighted average remaining contractual life    
Weighted average remaining contractual life 8 years 1 month 6 days 6 years 8 months 12 days
Aggregate Intrinsic Value    
Aggregate Intrinsic Value | $ $ 13,867 $ 7,790
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity (Options, Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Aggregate intrinsic value, outstanding $ 13,867 $ 7,790
Aggregate intrinsic value, exercisable $ 5,767  
Common stock issued pursuant to stock options (in shares) 603,000  
Exercisable (in shares) 1,008,000 1,037,000
Weighted average exercise price (USD per share) $ 2.94 $ 2.95
Weighted average remaining contractual term 6 years 9 months 18 days 3 years 6 months
Common Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Common stock issued pursuant to stock options (in shares) 603,297  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity (Options, Fair Value Assumptions) (Details) - Options
 9 Months Ended
Sep. 30, 2020
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected dividend yield 0.00%
Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Exercise price (USD per share) $ 5.70
Risk-free interest rate 0.39%
Expected volatility 65.73%
Expected term 5 years 7 months 17 days
Fair value on date of grant (USD per share) $ 4.10
Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Exercise price (USD per share) $ 10.44
Risk-free interest rate 1.63%
Expected volatility 85.38%
Expected term 10 years
Fair value on date of grant (USD per share) $ 7.23
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity (Restricted Stock Units) (Details) - Restricted Stock Units - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Dec. 31, 2019
Number of Restricted Stock Units (000's)      
Beginning balance (in shares)   1,139,000  
Issued (in shares) 42,147 134,235  
Vested (in shares)   (589,000)  
Expired / Forfeited (in shares)   (5,000)  
Ending balance (in shares) 679,000 679,000 1,139,000
Weighted average grant price(1)      
Beginning balance (USD per share)   $ 2.16  
Issued (USD per share)   7.19  
Vested (USD per share)   2.33  
Expired / Forfeited (USD per share)   5.70  
Ending balance (USD per share) $ 2.97 $ 2.97 $ 2.16
Weighted average remaining contractual life      
Weighted average remaining contractual life   5 months 19 days 6 months 18 days
Aggregate Intrinsic Value      
Aggregate Intrinsic Value $ 5,878 $ 5,878 $ 7,129
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period   1 year  
Weighted average grant price(1)      
Issued (USD per share)   $ 5.70  
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period   3 years  
Weighted average grant price(1)      
Issued (USD per share)   $ 10.44  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity (Phantom Share Units) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Fair Value Assumptions          
Current accrued liabilities $ 4,427   $ 4,427   $ 3,129
Stock-based compensation $ 1,234 $ 1,064 $ 3,581 $ 2,978  
Phantom Share Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period     3 years    
Number of Phantom Share Units (000's)          
Beginning balance (in shares)     1,350    
Issued (in shares)     346    
Vested (in shares)     (601)    
Expired / Forfeited (in shares)     (76)    
Ending balance (in shares) 1,019   1,019    
Fair Value Assumptions          
Share price (USD per share) $ 8.64   $ 8.64    
Calculated fair value of phantom share units     $ 5,159    
Total liability $ 5,159   5,159    
Current accrued liabilities 4,427   4,427    
Long-term accrued liabilities 732   732    
Cash settlement     4,201 3,386  
Phantom Share Units | Selling, general, and administrative          
Fair Value Assumptions          
Stock-based compensation $ 459 $ 1,054 $ 4,070 $ 5,654  
Phantom Share Units | Minimum          
Fair Value Assumptions          
Remaining life of phantom share units     7 months 9 days    
Phantom Share Units | Maximum          
Fair Value Assumptions          
Remaining life of phantom share units     2 years 7 months 9 days    
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies (Details) - USD ($)
$ in Thousands
Sep. 23, 2020
Sep. 30, 2020
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]      
Purchase obligation     $ 1,400
Outstanding deposit   $ 900  
Damages sought $ 4,700    
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Other Income (Details)
$ in Millions
 1 Months Ended
Apr. 30, 2020
USD ($)
Other Income and Expenses [Abstract]  
Government grant received $ 3.5
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes (Details) - USD ($)
$ in Millions
 6 Months Ended 9 Months Ended
Jun. 30, 2020
Sep. 30, 2020
Income Tax Disclosure [Abstract]    
Effective tax rate   (19.20%)
Provisional income tax benefit, rate   (31.50%)
Discrete permanent differences, rate   (3.00%)
Provisional income tax benefit $ 7.8  
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Earnings Per Share [Abstract]                
Net income attributable to shareholders $ 2,804 $ 19,412 $ 4,243 $ 2,853 $ 1,326 $ 1,958 $ 26,459 $ 6,137
Denominator:                
Basic weighted-average number of common shares (in shares) 39,107,640     37,812,921     38,603,267 37,775,775
Diluted weighted-average number of shares (in shares) 41,155,668     40,051,422     40,377,608 39,768,877
Basic earnings per share (in dollars per share) $ 0.07     $ 0.08     $ 0.69 $ 0.17
Diluted earnings per share (in dollars per share) $ 0.07     $ 0.07     $ 0.66 $ 0.15
Denominator calculation from basic to diluted:                
Basic weighted-average number of common shares (in shares) 39,107,640     37,812,921     38,603,267 37,775,775
Stock options and other dilutive securities (in shares) 2,048,028     2,238,501     1,774,341 1,993,102
Diluted weighted-average number of shares (in shares) 41,155,668     40,051,422     40,377,608 39,768,877
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events (Details)
$ in Millions
 1 Months Ended
Nov. 04, 2020
USD ($)
Subsequent Event  
Subsequent Event [Line Items]  
Conversion of accounts payable into short-term capital lease $ 2.5
EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 186 328 1 false 43 0 false 6 false false R1.htm 0001001 - Document - Cover Sheet http://www.viemed.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Sheet http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Sheet http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101101 - Disclosure - Nature of Business and Operations Sheet http://www.viemed.com/role/NatureofBusinessandOperations Nature of Business and Operations Notes 7 false false R8.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2110103 - Disclosure - Property and Equipment Sheet http://www.viemed.com/role/PropertyandEquipment Property and Equipment Notes 9 false false R10.htm 2114104 - Disclosure - Current Liabilities Sheet http://www.viemed.com/role/CurrentLiabilities Current Liabilities Notes 10 false false R11.htm 2117105 - Disclosure - Debt and lease liabilities Sheet http://www.viemed.com/role/Debtandleaseliabilities Debt and lease liabilities Notes 11 false false R12.htm 2126106 - Disclosure - Fair value measurement Sheet http://www.viemed.com/role/Fairvaluemeasurement Fair value measurement Notes 12 false false R13.htm 2130107 - Disclosure - Shareholders' Equity Sheet http://www.viemed.com/role/ShareholdersEquity Shareholders' Equity Notes 13 false false R14.htm 2139108 - Disclosure - Commitments and Contingencies Sheet http://www.viemed.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 14 false false R15.htm 2141109 - Disclosure - Other Income Sheet http://www.viemed.com/role/OtherIncome Other Income Notes 15 false false R16.htm 2143110 - Disclosure - Income Taxes Sheet http://www.viemed.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 2145111 - Disclosure - Earnings Per Share Sheet http://www.viemed.com/role/EarningsPerShare Earnings Per Share Notes 17 false false R18.htm 2148112 - Disclosure - Subsequent Events Sheet http://www.viemed.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.viemed.com/role/SummaryofSignificantAccountingPolicies 19 false false R20.htm 2305301 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.viemed.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 2311302 - Disclosure - Property and Equipment (Tables) Sheet http://www.viemed.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.viemed.com/role/PropertyandEquipment 21 false false R22.htm 2315303 - Disclosure - Current Liabilities (Tables) Sheet http://www.viemed.com/role/CurrentLiabilitiesTables Current Liabilities (Tables) Tables http://www.viemed.com/role/CurrentLiabilities 22 false false R23.htm 2318304 - Disclosure - Debt and lease liabilities (Tables) Sheet http://www.viemed.com/role/DebtandleaseliabilitiesTables Debt and lease liabilities (Tables) Tables http://www.viemed.com/role/Debtandleaseliabilities 23 false false R24.htm 2327305 - Disclosure - Fair value measurement (Tables) Sheet http://www.viemed.com/role/FairvaluemeasurementTables Fair value measurement (Tables) Tables http://www.viemed.com/role/Fairvaluemeasurement 24 false false R25.htm 2331306 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.viemed.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.viemed.com/role/ShareholdersEquity 25 false false R26.htm 2346307 - Disclosure - Earnings Per Share (Tables) Sheet http://www.viemed.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.viemed.com/role/EarningsPerShare 26 false false R27.htm 2402401 - Disclosure - Nature of Business and Operations (Details) Sheet http://www.viemed.com/role/NatureofBusinessandOperationsDetails Nature of Business and Operations (Details) Details http://www.viemed.com/role/NatureofBusinessandOperations 27 false false R28.htm 2406402 - Disclosure - Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details) Details http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables 28 false false R29.htm 2407403 - Disclosure - Summary of Significant Accounting Policies (Customer Percentages) (Details) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails Summary of Significant Accounting Policies (Customer Percentages) (Details) Details http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables 29 false false R30.htm 2408404 - Disclosure - Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details) Details http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables 30 false false R31.htm 2409405 - Disclosure - Summary of Significant Accounting Policies (Revenue Recognition) (Details) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies (Revenue Recognition) (Details) Details http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables 31 false false R32.htm 2412406 - Disclosure - Property and Equipment (Schedule of Fixed Assets) (Details) Sheet http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails Property and Equipment (Schedule of Fixed Assets) (Details) Details http://www.viemed.com/role/PropertyandEquipmentTables 32 false false R33.htm 2413407 - Disclosure - Property and Equipment (Narrative) (Details) Sheet http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails Property and Equipment (Narrative) (Details) Details http://www.viemed.com/role/PropertyandEquipmentTables 33 false false R34.htm 2416408 - Disclosure - Current Liabilities (Details) Sheet http://www.viemed.com/role/CurrentLiabilitiesDetails Current Liabilities (Details) Details http://www.viemed.com/role/CurrentLiabilitiesTables 34 false false R35.htm 2419409 - Disclosure - Debt and lease liabilities (Line of Credit Narrative) (Details) Sheet http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails Debt and lease liabilities (Line of Credit Narrative) (Details) Details http://www.viemed.com/role/DebtandleaseliabilitiesTables 35 false false R36.htm 2420410 - Disclosure - Debt and lease liabilities (Commercial Term Notes Narrative) (Details) Notes http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails Debt and lease liabilities (Commercial Term Notes Narrative) (Details) Details http://www.viemed.com/role/DebtandleaseliabilitiesTables 36 false false R37.htm 2421411 - Disclosure - Debt and lease liabilities (Schedule of Notes Payable) (Details) Notes http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails Debt and lease liabilities (Schedule of Notes Payable) (Details) Details http://www.viemed.com/role/DebtandleaseliabilitiesTables 37 false false R38.htm 2422412 - Disclosure - Debt and lease liabilities (Financial Covenant) (Details) Sheet http://www.viemed.com/role/DebtandleaseliabilitiesFinancialCovenantDetails Debt and lease liabilities (Financial Covenant) (Details) Details http://www.viemed.com/role/DebtandleaseliabilitiesTables 38 false false R39.htm 2423413 - Disclosure - Debt and lease liabilities (Lease Liabilities) (Details) Sheet http://www.viemed.com/role/DebtandleaseliabilitiesLeaseLiabilitiesDetails Debt and lease liabilities (Lease Liabilities) (Details) Details http://www.viemed.com/role/DebtandleaseliabilitiesTables 39 false false R40.htm 2424414 - Disclosure - Debt and lease liabilities (Finance Lease Liabilities) (Details) Sheet http://www.viemed.com/role/DebtandleaseliabilitiesFinanceLeaseLiabilitiesDetails Debt and lease liabilities (Finance Lease Liabilities) (Details) Details http://www.viemed.com/role/DebtandleaseliabilitiesTables 40 false false R41.htm 2425415 - Disclosure - Debt and lease liabilities (Operating Lease Liabilities) (Details) Sheet http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails Debt and lease liabilities (Operating Lease Liabilities) (Details) Details http://www.viemed.com/role/DebtandleaseliabilitiesTables 41 false false R42.htm 2428416 - Disclosure - Fair value measurement (Narrative) (Details) Sheet http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails Fair value measurement (Narrative) (Details) Details http://www.viemed.com/role/FairvaluemeasurementTables 42 false false R43.htm 2429417 - Disclosure - Fair value measurement (Warrant Conversion Liability) (Details) Sheet http://www.viemed.com/role/FairvaluemeasurementWarrantConversionLiabilityDetails Fair value measurement (Warrant Conversion Liability) (Details) Details http://www.viemed.com/role/FairvaluemeasurementTables 43 false false R44.htm 2432418 - Disclosure - Shareholders' Equity (Issued and Outstanding Share Capital) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails Shareholders' Equity (Issued and Outstanding Share Capital) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 44 false false R45.htm 2433419 - Disclosure - Shareholders' Equity (Stock-based Compensation) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails Shareholders' Equity (Stock-based Compensation) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 45 false false R46.htm 2434420 - Disclosure - Shareholders' Equity (Options, Stock Option Activity) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails Shareholders' Equity (Options, Stock Option Activity) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 46 false false R47.htm 2435421 - Disclosure - Shareholders' Equity (Options, Narrative) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails Shareholders' Equity (Options, Narrative) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 47 false false R48.htm 2436422 - Disclosure - Shareholders' Equity (Options, Fair Value Assumptions) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails Shareholders' Equity (Options, Fair Value Assumptions) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 48 false false R49.htm 2437423 - Disclosure - Shareholders' Equity (Restricted Stock Units) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails Shareholders' Equity (Restricted Stock Units) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 49 false false R50.htm 2438424 - Disclosure - Shareholders' Equity (Phantom Share Units) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails Shareholders' Equity (Phantom Share Units) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 50 false false R51.htm 2440425 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.viemed.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.viemed.com/role/CommitmentsandContingencies 51 false false R52.htm 2442426 - Disclosure - Other Income (Details) Sheet http://www.viemed.com/role/OtherIncomeDetails Other Income (Details) Details http://www.viemed.com/role/OtherIncome 52 false false R53.htm 2444427 - Disclosure - Income Taxes (Details) Sheet http://www.viemed.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.viemed.com/role/IncomeTaxes 53 false false R54.htm 2447428 - Disclosure - Earnings Per Share (Details) Sheet http://www.viemed.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.viemed.com/role/EarningsPerShareTables 54 false false R55.htm 2449429 - Disclosure - Subsequent Events (Details) Sheet http://www.viemed.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.viemed.com/role/SubsequentEvents 55 false false All Reports Book All Reports vmd-20200930.htm q32020exhibit311.htm q32020exhibit312.htm q32020exhibit321.htm q32020exhibit322.htm vmd-20200930.xsd vmd-20200930_cal.xml vmd-20200930_def.xml vmd-20200930_lab.xml vmd-20200930_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 73 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vmd-20200930.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 186, "dts": { "calculationLink": { "local": [ "vmd-20200930_cal.xml" ] }, "definitionLink": { "local": [ "vmd-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "vmd-20200930.htm" ] }, "labelLink": { "local": [ "vmd-20200930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "vmd-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "vmd-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 415, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 4, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 9 }, "keyCustom": 20, "keyStandard": 308, "memberCustom": 14, "memberStandard": 28, "nsprefix": "vmd", "nsuri": "http://www.viemed.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.viemed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114104 - Disclosure - Current Liabilities", "role": "http://www.viemed.com/role/CurrentLiabilities", "shortName": "Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "vmd:DebtandLeaseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Debt and lease liabilities", "role": "http://www.viemed.com/role/Debtandleaseliabilities", "shortName": "Debt and lease liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "vmd:DebtandLeaseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126106 - Disclosure - Fair value measurement", "role": "http://www.viemed.com/role/Fairvaluemeasurement", "shortName": "Fair value measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130107 - Disclosure - Shareholders' Equity", "role": "http://www.viemed.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139108 - Disclosure - Commitments and Contingencies", "role": "http://www.viemed.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141109 - Disclosure - Other Income", "role": "http://www.viemed.com/role/OtherIncome", "shortName": "Other Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143110 - Disclosure - Income Taxes", "role": "http://www.viemed.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145111 - Disclosure - Earnings Per Share", "role": "http://www.viemed.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148112 - Disclosure - Subsequent Events", "role": "http://www.viemed.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Property and Equipment (Tables)", "role": "http://www.viemed.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - Current Liabilities (Tables)", "role": "http://www.viemed.com/role/CurrentLiabilitiesTables", "shortName": "Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318304 - Disclosure - Debt and lease liabilities (Tables)", "role": "http://www.viemed.com/role/DebtandleaseliabilitiesTables", "shortName": "Debt and lease liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327305 - Disclosure - Fair value measurement (Tables)", "role": "http://www.viemed.com/role/FairvaluemeasurementTables", "shortName": "Fair value measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331306 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.viemed.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2346307 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.viemed.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Nature of Business and Operations (Details)", "role": "http://www.viemed.com/role/NatureofBusinessandOperationsDetails", "shortName": "Nature of Business and Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i80594c9695e3449ab7c0f8991d3587f7_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details)", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails", "shortName": "Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i60c90b9317704927ad3397e89cdb8987_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic048b729abad4471911f830aeaf2aa59_D20200101-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies (Customer Percentages) (Details)", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails", "shortName": "Summary of Significant Accounting Policies (Customer Percentages) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic048b729abad4471911f830aeaf2aa59_D20200101-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details)", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails", "shortName": "Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i57554327d2c44d49844cf68f047256ca_D20200101-20200930", "decimals": null, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeaseTermOfContract", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies (Revenue Recognition) (Details)", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "Summary of Significant Accounting Policies (Revenue Recognition) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i7d5f669e8d4349319d4fd0fde5ccb838_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - Property and Equipment (Schedule of Fixed Assets) (Details)", "role": "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails", "shortName": "Property and Equipment (Schedule of Fixed Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ife7cee8793274f90bed611d06355536c_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id1bab7435b9b40458e912e50c72760bc_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - Property and Equipment (Narrative) (Details)", "role": "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "shortName": "Property and Equipment (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id1bab7435b9b40458e912e50c72760bc_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "vmd:AccruedTradePayablesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Current Liabilities (Details)", "role": "http://www.viemed.com/role/CurrentLiabilitiesDetails", "shortName": "Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "vmd:AccruedTradePayablesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i911e84178c5a42ffa32a6a5c008b0186_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Debt and lease liabilities (Line of Credit Narrative) (Details)", "role": "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails", "shortName": "Debt and lease liabilities (Line of Credit Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i911e84178c5a42ffa32a6a5c008b0186_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ie7e77ac877c14f989f3b540b0edb7027_I20190530", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Debt and lease liabilities (Commercial Term Notes Narrative) (Details)", "role": "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "shortName": "Debt and lease liabilities (Commercial Term Notes Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ie7e77ac877c14f989f3b540b0edb7027_I20190530", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Debt and lease liabilities (Schedule of Notes Payable) (Details)", "role": "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails", "shortName": "Debt and lease liabilities (Schedule of Notes Payable) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i9fcb19e04ff642dfb6db5f37f3f8327a_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i9fcb19e04ff642dfb6db5f37f3f8327a_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "vmd:DebtInstrumentCovenantTotalDebtToAdjustedEBITDARatioQuarterlyMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - Debt and lease liabilities (Financial Covenant) (Details)", "role": "http://www.viemed.com/role/DebtandleaseliabilitiesFinancialCovenantDetails", "shortName": "Debt and lease liabilities (Financial Covenant) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i9fcb19e04ff642dfb6db5f37f3f8327a_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "vmd:DebtInstrumentCovenantTotalDebtToAdjustedEBITDARatioQuarterlyMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vmd:LiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "vmd:LeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423413 - Disclosure - Debt and lease liabilities (Lease Liabilities) (Details)", "role": "http://www.viemed.com/role/DebtandleaseliabilitiesLeaseLiabilitiesDetails", "shortName": "Debt and lease liabilities (Lease Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vmd:LiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "vmd:LeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id1bab7435b9b40458e912e50c72760bc_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME", "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id1bab7435b9b40458e912e50c72760bc_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeaseDiscountRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424414 - Disclosure - Debt and lease liabilities (Finance Lease Liabilities) (Details)", "role": "http://www.viemed.com/role/DebtandleaseliabilitiesFinanceLeaseLiabilitiesDetails", "shortName": "Debt and lease liabilities (Finance Lease Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id1bab7435b9b40458e912e50c72760bc_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDiscountRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425415 - Disclosure - Debt and lease liabilities (Operating Lease Liabilities) (Details)", "role": "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails", "shortName": "Debt and lease liabilities (Operating Lease Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id1bab7435b9b40458e912e50c72760bc_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i84e764cbdb07430ba17da40f9c44216d_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "reportCount": 1, "unitRef": "swap", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - Fair value measurement (Narrative) (Details)", "role": "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails", "shortName": "Fair value measurement (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id1bab7435b9b40458e912e50c72760bc_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429417 - Disclosure - Fair value measurement (Warrant Conversion Liability) (Details)", "role": "http://www.viemed.com/role/FairvaluemeasurementWarrantConversionLiabilityDetails", "shortName": "Fair value measurement (Warrant Conversion Liability) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "iedea7df0bd284d479ebd872f276aaeea_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432418 - Disclosure - Shareholders' Equity (Issued and Outstanding Share Capital) (Details)", "role": "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails", "shortName": "Shareholders' Equity (Issued and Outstanding Share Capital) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433419 - Disclosure - Shareholders' Equity (Stock-based Compensation) (Details)", "role": "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails", "shortName": "Shareholders' Equity (Stock-based Compensation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": "INF", "lang": "en-US", "name": "vmd:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i80594c9695e3449ab7c0f8991d3587f7_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434420 - Disclosure - Shareholders' Equity (Options, Stock Option Activity) (Details)", "role": "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails", "shortName": "Shareholders' Equity (Options, Stock Option Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435421 - Disclosure - Shareholders' Equity (Options, Narrative) (Details)", "role": "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "shortName": "Shareholders' Equity (Options, Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic51495294f3b49e08874bc48ec53fa13_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436422 - Disclosure - Shareholders' Equity (Options, Fair Value Assumptions) (Details)", "role": "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "shortName": "Shareholders' Equity (Options, Fair Value Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic51495294f3b49e08874bc48ec53fa13_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id1ba71a83649477aa97c0f33051a7c25_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437423 - Disclosure - Shareholders' Equity (Restricted Stock Units) (Details)", "role": "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "shortName": "Shareholders' Equity (Restricted Stock Units) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i3c92527f80ec4c54a81967168f6cd719_D20200701-20200930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib9eb22e1a9b14d15959d65eff6c6bdbe_I20181231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i5cee15ae64394007b34c8465d61edba1_D20190101-20190331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ic07d5cd4176b44a68637ea72dc288398_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438424 - Disclosure - Shareholders' Equity (Phantom Share Units) (Details)", "role": "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "shortName": "Shareholders' Equity (Phantom Share Units) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "idb99845f37124a14a0de03b68d3674c1_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id535ae97e14348418d2f2e9a1e1707e2_I20200331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440425 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.viemed.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id535ae97e14348418d2f2e9a1e1707e2_I20200331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i21110709ec7c4601859986df1e288468_D20200401-20200430", "decimals": "-5", "first": true, "lang": "en-US", "name": "vmd:CoronavirusAidReliefandEconomicSecurityGovernmentGrantReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442426 - Disclosure - Other Income (Details)", "role": "http://www.viemed.com/role/OtherIncomeDetails", "shortName": "Other Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "i21110709ec7c4601859986df1e288468_D20200401-20200430", "decimals": "-5", "first": true, "lang": "en-US", "name": "vmd:CoronavirusAidReliefandEconomicSecurityGovernmentGrantReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444427 - Disclosure - Income Taxes (Details)", "role": "http://www.viemed.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id1bab7435b9b40458e912e50c72760bc_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447428 - Disclosure - Earnings Per Share (Details)", "role": "http://www.viemed.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "id1bab7435b9b40458e912e50c72760bc_D20200701-20200930", "decimals": "0", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "iacdfc058867c417fa07547995dfdfe51_D20201001-20201104", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CapitalLeaseObligationsIncurred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449429 - Disclosure - Subsequent Events (Details)", "role": "http://www.viemed.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "iacdfc058867c417fa07547995dfdfe51_D20201001-20201104", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CapitalLeaseObligationsIncurred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Nature of Business and Operations", "role": "http://www.viemed.com/role/NatureofBusinessandOperations", "shortName": "Nature of Business and Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110103 - Disclosure - Property and Equipment", "role": "http://www.viemed.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20200930.htm", "contextRef": "ib93f295116b440b998122aa0ef040545_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 43, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r445" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r448" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r447" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r442" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r248", "r367", "r368", "r369", "r440" ], "lang": { "en-US": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Related Party" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r178", "r236", "r240", "r428" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r249", "r250", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r426", "r429" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r249", "r250", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r426", "r429" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r178", "r236", "r240", "r428" ], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r176", "r236", "r238", "r380", "r425", "r427" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r176", "r236", "r238", "r380", "r425", "r427" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r247", "r249", "r250", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r426", "r429" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r247", "r249", "r250", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r426", "r429" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities, Noncurrent", "terseLabel": "Accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r399", "r417" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r8", "r45" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade payables" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r29", "r179", "r180" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $8,788 and $7,782 at September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r7", "r8", "r49" ], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Accrued bonuses payable" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r23", "r396", "r410" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrent": { "auth_ref": [ "r7", "r8", "r49" ], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Sales Commission, Current", "terseLabel": "Accrued commissions payable" } } }, "localname": "AccruedSalesCommissionCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r43", "r203" ], "calculation": { "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation", "terseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r32", "r64", "r65", "r66", "r412", "r434", "r435" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r63", "r66", "r67", "r114", "r115", "r116", "r320", "r430", "r431" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r30" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r114", "r115", "r116", "r284", "r285", "r286" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition", "terseLabel": "Stock-based compensation - restricted stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Stock-based compensation - options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments for:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r252", "r279", "r289" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation", "verboseLabel": "Stock-based compensation, expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r36", "r185", "r193" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of year", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Allowance for Doubtful Accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r195" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Amounts written off" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r108", "r164", "r168", "r174", "r191", "r316", "r321", "r344", "r394", "r409" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r59", "r108", "r191", "r316", "r321", "r344" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r14", "r15", "r16", "r17", "r18", "r19", "r20", "r21", "r108", "r191", "r316", "r321", "r344" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total long-term assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Long-term assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r253", "r282" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Principles of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building", "verboseLabel": "Buildings" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r101", "r102" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in lease obligation from new lease.", "label": "Lease Obligation Incurred", "terseLabel": "Conversion of accounts payable into short-term capital lease" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r39", "r99" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r93", "r99", "r103" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r345" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r107", "r108", "r129", "r130", "r131", "r133", "r135", "r145", "r146", "r147", "r191", "r344" ], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r211", "r400", "r416" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r208", "r209", "r210", "r214" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r114", "r115" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r28", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Shareholders' equity, ending balance (in shares)", "periodStartLabel": "Shareholders' equity, beginning balance (in shares)", "terseLabel": "Outstanding (in shares)", "verboseLabel": "Shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r28" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - No par value: unlimited authorized; 39,145,182 and 37,952,660 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r70", "r72", "r73", "r78", "r404", "r420" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r154", "r155", "r178", "r341", "r342" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r154", "r155", "r178", "r341", "r342", "r436" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r154", "r155", "r178", "r341", "r342", "r436" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r154", "r155", "r178", "r341", "r342" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r152", "r154", "r155", "r156", "r341", "r343" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r154", "r155", "r178", "r341", "r342" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r104", "r318" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r225", "r226", "r237" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r83", "r380" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldDepreciation": { "auth_ref": [ "r81", "r201" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.", "label": "Cost, Depreciation", "terseLabel": "Depreciation" } } }, "localname": "CostOfGoodsAndServicesSoldDepreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r153", "r178" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r22", "r23", "r24", "r395", "r397", "r408" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r354", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Monthly principal payments" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r52", "r110", "r219", "r220", "r221", "r222", "r353", "r354", "r355", "r407" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 }, "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).", "label": "Deferred Compensation Share-based Arrangements, Liability, Current", "terseLabel": "Current portion of phantom share liability", "verboseLabel": "Current accrued liabilities" } } }, "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).", "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent", "terseLabel": "Long-term accrued liabilities" } } }, "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.", "label": "Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent", "totalLabel": "Total liability" } } }, "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r293", "r294" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r97", "r109", "r300", "r305", "r306", "r307" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssets": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.", "label": "Deposits Assets", "terseLabel": "Outstanding deposit" } } }, "localname": "DepositsAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r97", "r201" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationNonproduction": { "auth_ref": [ "r97", "r201" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.", "label": "Depreciation, Nonproduction", "terseLabel": "Depreciation" } } }, "localname": "DepreciationNonproduction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Fixed interest rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r330", "r331", "r332", "r334" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r60", "r61", "r340" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Fair value" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r325", "r327" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "auth_ref": [ "r325", "r327" ], "lang": { "en-US": { "role": { "documentation": "The number of derivative instruments of a particular group held by the entity.", "label": "Derivative, Number of Instruments Held", "terseLabel": "Number of interest rate swaps" } } }, "localname": "DerivativeNumberOfInstrumentsHeld", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r104", "r111", "r324", "r326", "r328", "r329", "r335" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Interest rate swaps" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r244" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Revenue by Source" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r79", "r119", "r120", "r121", "r122", "r123", "r127", "r129", "r133", "r134", "r135", "r139", "r140", "r405", "r421" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r79", "r119", "r120", "r121", "r122", "r123", "r129", "r133", "r134", "r135", "r139", "r140", "r405", "r421" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r136", "r137", "r138", "r141" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r296", "r308" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Provisional income tax benefit, rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r296", "r308" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Discrete permanent differences, rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued vacation and payroll" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.", "label": "Share-based Payment Arrangement, Cash Used to Settle Award", "terseLabel": "Cash settlement" } } }, "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period of recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized pre-tax compensation expense, restricted stock units" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized pre-tax stock option expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r114", "r115", "r116", "r118", "r124", "r126", "r144", "r192", "r218", "r223", "r284", "r285", "r286", "r301", "r302", "r346", "r347", "r348", "r349", "r350", "r351", "r430", "r431", "r432" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r40", "r165", "r190" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r189", "r422" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "negatedLabel": "(Gain) loss on equity method investment" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r97", "r217" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Unrealized gain on warrant conversion liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/FairvaluemeasurementWarrantConversionLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r338", "r339" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails", "http://www.viemed.com/role/FairvaluemeasurementWarrantConversionLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r338" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurement" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/Fairvaluemeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails", "http://www.viemed.com/role/FairvaluemeasurementWarrantConversionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Warrant Conversion Liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementWarrantConversionLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails", "http://www.viemed.com/role/FairvaluemeasurementWarrantConversionLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r336", "r339" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails", "http://www.viemed.com/role/FairvaluemeasurementWarrantConversionLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r336", "r339" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Warrants" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r337" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Warrants issued" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails", "http://www.viemed.com/role/FairvaluemeasurementWarrantConversionLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r336" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "September 30, 2019", "periodStartLabel": "December 31, 2018" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementWarrantConversionLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r356", "r359", "r363" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r361", "r363" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average interest rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesFinanceLeaseLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r360", "r363" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average lease term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesFinanceLeaseLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Office Furniture & Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r97", "r200", "r205" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedTerseLabel": "(Gain) loss on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r82", "r108", "r164", "r167", "r170", "r173", "r175", "r191", "r344" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r75", "r164", "r167", "r170", "r173", "r175", "r393", "r402", "r406", "r423" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net income before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r76", "r97", "r162", "r190", "r401", "r418" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "(Gain) loss from equity method investment" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r297", "r298", "r299", "r303", "r309", "r311", "r312", "r313" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r125", "r126", "r163", "r295", "r304", "r310", "r424" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision (benefit) for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "negatedTerseLabel": "Provisional income tax benefit" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid during the period for income taxes, net of refunds received" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r96" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Increase (decrease) in trade payables" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Increase in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r96" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Increase (decrease) in income tax payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Increase in accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r96" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Increase in deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "(Increase) decrease in inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Net change in working capital" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r96" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Increase in prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "negatedTerseLabel": "Interest expense, net of interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r92", "r94", "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r57" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, net of inventory reserve of $805 and $0 at September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r10", "r58", "r104", "r142", "r196", "r197", "r199" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r57", "r112", "r198" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Inventory reserve" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r362", "r363" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Operating rental expenses" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeFinanceLeaseDiscountRate": { "auth_ref": [ "r357" ], "lang": { "en-US": { "role": { "documentation": "Discount rate used by lessee to determine present value of finance lease payments.", "label": "Lessee, Finance Lease, Discount Rate", "terseLabel": "Interest rate" } } }, "localname": "LesseeFinanceLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesFinanceLeaseLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r357" ], "lang": { "en-US": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Recognition period" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r48", "r108", "r169", "r191", "r317", "r321", "r322", "r344" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r35", "r108", "r191", "r344", "r398", "r414" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50", "r108", "r191", "r317", "r321", "r322", "r344" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r11", "r12", "r13", "r24", "r25", "r108", "r191", "r317", "r321", "r322", "r344" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r24", "r397", "r408" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Borrowings against facility" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesFinancialCovenantDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r46", "r110" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesFinancialCovenantDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "ICE LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r24", "r216", "r397", "r411" ], "calculation": { "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Notes payable" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Current portion of notes payable", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Net long-term notes payable" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesFinancialCovenantDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r52", "r215" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesFinancialCovenantDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r211", "r212", "r213" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Damages sought" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r95", "r98" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r68", "r71", "r77", "r98", "r108", "r117", "r119", "r120", "r121", "r122", "r125", "r126", "r132", "r164", "r167", "r170", "r173", "r175", "r191", "r344", "r403", "r419" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income attributable to shareholders", "totalLabel": "Net income", "verboseLabel": "Net Income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently adopted accounting pronouncements and Recently issued accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosures of non-cash transactions" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Non-operating expenses" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesFinancialCovenantDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesScheduleofNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states in which entity provides DME and health care solutions" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/NatureofBusinessandOperationsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r164", "r167", "r170", "r173", "r175" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r143", "r364", "r366" ], "calculation": { "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "terseLabel": "Revenue from rentals under Topic 842" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r360", "r363" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r323" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business and Operations" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/NatureofBusinessandOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r49" ], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r62", "r64" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Change in unrealized gain (loss) on derivative instruments, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r69", "r72", "r314", "r315", "r319" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Change in accumulated other comprehensive loss", "totalLabel": "Other Comprehensive Loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r246", "r291" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/OtherIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other (income) expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r90" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Shares repurchased and canceled under the Normal Course Issuer Bid" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r87" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedTerseLabel": "Investment in equity method investment" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r87" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PhantomShareUnitsPSUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded as phantom share or unit.", "label": "Phantom Share Units (PSUs) [Member]", "terseLabel": "Phantom Share Units" } } }, "localname": "PhantomShareUnitsPSUsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r253", "r282" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r37", "r38" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "auth_ref": [ "r89" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.", "label": "Proceeds from Issuance of Other Long-term Debt", "terseLabel": "(Principal payments) net proceeds on notes payable" } } }, "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r89" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "(Principal payments) net proceeds on term note" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r86" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r88", "r283" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r88" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r43", "r204" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r207", "r437", "r438", "r439" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r42", "r202" ], "calculation": { "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r204", "r415" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net of accumulated depreciation and amortization" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r41", "r104", "r204", "r437", "r438" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r17", "r204" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment", "verboseLabel": "Schedule of Estimated Useful Lives" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentTables", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r17", "r202" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r80", "r194" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Change in allowance for doubtful accounts", "verboseLabel": "Change in allowance for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Purchase obligation" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r248", "r367", "r368" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r367", "r369" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Rental payments" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r248", "r367", "r368", "r369" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r367" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Total rental payments" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r248", "r367", "r369", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r91" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-term Debt", "negatedLabel": "(Principal payments) net proceeds on notes payable" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r91" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments of Secured Debt", "negatedTerseLabel": "(Principal payments) net proceeds on term note" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r292", "r441" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r31", "r223", "r287", "r413", "r433", "r435" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r114", "r115", "r116", "r118", "r124", "r126", "r192", "r284", "r285", "r286", "r301", "r302", "r430", "r432" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r160", "r161", "r166", "r171", "r172", "r176", "r177", "r178", "r235", "r236", "r380" ], "calculation": { "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue from sales and services under Topic 606" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r154", "r178" ], "lang": { "en-US": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r105", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r245" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Accounting under Topic 606" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionLeases": { "auth_ref": [ "r104", "r106" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition for leases entered into by lessor.", "label": "Revenue Recognition, Leases [Policy Text Block]", "terseLabel": "Revenue Accounting under Topic 842" } } }, "localname": "RevenueRecognitionLeases", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r105", "r106" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r74", "r108", "r160", "r161", "r166", "r171", "r172", "r176", "r177", "r178", "r191", "r344", "r406" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 }, "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue", "totalLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Accounts Receivable, Allowance for Doubtful Accounts" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r52", "r110", "r219", "r220", "r221", "r222", "r353", "r354", "r355", "r407" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Notes Payable" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Covenants" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r252", "r278", "r289" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r252", "r278", "r289" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r43", "r204" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r264", "r269", "r270" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Schedule of Phantom Share Units" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r253", "r282" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Units" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r257", "r269", "r270" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Stock Options, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r152", "r154", "r155", "r156", "r341", "r343" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Revenue by Customer" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general, and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenues" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted average remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Expired / Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Expired / Forfeited (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Issued (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "RSUs outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Restricted Stock Units (000's)", "verboseLabel": "Number of Phantom Share Units (000's)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (USD per share)", "periodStartLabel": "Beginning balance (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average grant price(1)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted average remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Fair Value Assumptions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Exercise price (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Maximum shares in Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted average remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Expired / Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired / Forfeited (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r282" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value", "verboseLabel": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r259", "r282" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of options (000's)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (USD per share)", "periodStartLabel": "Beginning balance (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price(1)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r251", "r255" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Issued (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r104", "r253", "r256" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (USD per share)", "verboseLabel": "Fair value on date of grant (USD per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r273", "r288" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Remaining life of phantom share units", "verboseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r282" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r224", "r290" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-based Payments [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r26", "r27", "r28", "r107", "r108", "r129", "r130", "r131", "r133", "r135", "r145", "r146", "r147", "r191", "r218", "r344" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r55", "r114", "r115", "r116", "r118", "r124", "r126", "r144", "r192", "r218", "r223", "r284", "r285", "r286", "r301", "r302", "r346", "r347", "r348", "r349", "r350", "r351", "r430", "r431", "r432" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r114", "r115", "r116", "r144", "r380" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r218", "r223" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Shares issued for vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r27", "r28", "r218", "r223", "r261" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)", "terseLabel": "Exercise of options (in shares)", "verboseLabel": "Common stock issued pursuant to stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r27", "r28", "r218", "r223" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Shares issued for vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r55", "r218", "r223" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r27", "r28", "r218", "r223" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "negatedTerseLabel": "Shares repurchased and canceled under the Normal Course Issuer Bid (in shares)" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r27", "r28", "r218", "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Shares repurchased and canceled under the Normal Course Issuer Bid" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r28", "r33", "r34", "r108", "r187", "r191", "r344" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Shareholders' equity, ending balance", "periodStartLabel": "Shareholders' equity, beginning balance", "totalLabel": "TOTAL SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r352", "r371" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r352", "r371" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r352", "r371" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r352", "r371" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r370", "r372" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r181", "r182", "r183", "r184", "r186", "r188" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r148", "r149", "r150", "r151", "r157", "r158", "r159" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails", "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]", "terseLabel": "Vehicles" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/FairvaluemeasurementNarrativeDetails", "http://www.viemed.com/role/FairvaluemeasurementWarrantConversionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r135" ], "calculation": { "http://www.viemed.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Stock options and other dilutive securities (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Denominator calculation from basic to diluted:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r128", "r135" ], "calculation": { "http://www.viemed.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average number of shares (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average number of common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r127", "r135" ], "calculation": { "http://www.viemed.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted-average number of common shares (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "vmd_AccruedTradePayablesCurrent": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Trade Payables, Current", "label": "Accrued Trade Payables, Current", "terseLabel": "Accrued trade payables" } } }, "localname": "AccruedTradePayablesCurrent", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vmd_AssetsHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets Held Under Finance Leases [Member]", "label": "Assets Held Under Finance Leases [Member]", "terseLabel": "Capital lease" } } }, "localname": "AssetsHeldUnderFinanceLeasesMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "domainItemType" }, "vmd_AssetsObtainedInExchangeForLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Assets Obtained In Exchange For Lease Liability", "label": "Assets Obtained In Exchange For Lease Liability", "terseLabel": "Property and equipment financed through leases under FASB ASC 842" } } }, "localname": "AssetsObtainedInExchangeForLeaseLiability", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "vmd_BuildingTermNoteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Building Term Note [Member]", "label": "Building Term Note [Member]", "terseLabel": "Building Term Note" } } }, "localname": "BuildingTermNoteMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "vmd_COVID19ResponseSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "COVID-19 Response Sales [Member]", "label": "COVID-19 Response Sales [Member]", "terseLabel": "COVID-19 response sales and services" } } }, "localname": "COVID19ResponseSalesMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "vmd_CoronavirusAidReliefandEconomicSecurityGovernmentGrantReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Coronavirus Aid, Relief, and Economic Security, Government Grant Received", "label": "Coronavirus Aid, Relief, and Economic Security, Government Grant Received", "terseLabel": "Government grant received" } } }, "localname": "CoronavirusAidReliefandEconomicSecurityGovernmentGrantReceived", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/OtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "vmd_DebtAndLeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt And Leases [Abstract]", "label": "Debt And Leases [Abstract]", "terseLabel": "Debt And Leases [Abstract]" } } }, "localname": "DebtAndLeasesAbstract", "nsuri": "http://www.viemed.com/20200930", "xbrltype": "stringItemType" }, "vmd_DebtInstrumentCovenantFixedChargeCoverageRatioQuarterlyMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant, Fixed Charge Coverage Ratio, Quarterly Minimum", "label": "Debt Instrument, Covenant, Fixed Charge Coverage Ratio, Quarterly Minimum", "terseLabel": "Fixed Charge Coverage Ratio (Quarterly)" } } }, "localname": "DebtInstrumentCovenantFixedChargeCoverageRatioQuarterlyMinimum", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesFinancialCovenantDetails" ], "xbrltype": "pureItemType" }, "vmd_DebtInstrumentCovenantLoanToValueRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant, Loan To Value Ratio", "label": "Debt Instrument, Covenant, Loan To Value Ratio", "terseLabel": "Required loan to value ratio" } } }, "localname": "DebtInstrumentCovenantLoanToValueRatio", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "vmd_DebtInstrumentCovenantLoanToValueRatioQuarterlyMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant, Loan To Value Ratio, Quarterly Maximum", "label": "Debt Instrument, Covenant, Loan To Value Ratio, Quarterly Maximum", "terseLabel": "Loan-to-Value Ratio (Quarterly)" } } }, "localname": "DebtInstrumentCovenantLoanToValueRatioQuarterlyMaximum", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesFinancialCovenantDetails" ], "xbrltype": "pureItemType" }, "vmd_DebtInstrumentCovenantTotalDebtToAdjustedEBITDARatioQuarterlyMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant, Total Debt To Adjusted EBITDA Ratio, Quarterly Maximum", "label": "Debt Instrument, Covenant, Total Debt To Adjusted EBITDA Ratio, Quarterly Maximum", "terseLabel": "Total Debt to Adjusted EBITDA (Quarterly)" } } }, "localname": "DebtInstrumentCovenantTotalDebtToAdjustedEBITDARatioQuarterlyMaximum", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesFinancialCovenantDetails" ], "xbrltype": "pureItemType" }, "vmd_DebtInstrumentInterestRateFloorRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Interest Rate, Floor Rate", "label": "Debt Instrument, Interest Rate, Floor Rate", "terseLabel": "Floor rate" } } }, "localname": "DebtInstrumentInterestRateFloorRate", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesLineofCreditNarrativeDetails" ], "xbrltype": "percentItemType" }, "vmd_DebtandLeaseDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt and Lease Disclosure [Text Block]", "label": "Debt and Lease Disclosure [Text Block]", "terseLabel": "Debt and lease liabilities" } } }, "localname": "DebtandLeaseDisclosureTextBlock", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/Debtandleaseliabilities" ], "xbrltype": "textBlockItemType" }, "vmd_EquipmentMedicalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment, Medical [Member]", "label": "Equipment, Medical [Member]", "terseLabel": "Medical equipment" } } }, "localname": "EquipmentMedicalMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "vmd_EquipmentSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment Sales [Member]", "label": "Equipment Sales [Member]", "terseLabel": "Equipment and supply sales" } } }, "localname": "EquipmentSalesMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "vmd_FurnitureAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Furniture And Equipment [Member]", "label": "Furniture And Equipment [Member]", "terseLabel": "Furniture and equipment" } } }, "localname": "FurnitureAndEquipmentMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "vmd_LeaseLiability": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/DebtandleaseliabilitiesLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability", "label": "Lease, Liability", "totalLabel": "Lease liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vmd_LeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.viemed.com/role/DebtandleaseliabilitiesLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "vmd_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability, Current", "label": "Lease, Liability, Current", "negatedTerseLabel": "Current portion of lease liabilities", "terseLabel": "Current portion of lease liabilities" } } }, "localname": "LeaseLiabilityCurrent", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/DebtandleaseliabilitiesLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vmd_LeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://www.viemed.com/role/DebtandleaseliabilitiesLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vmd_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability, Noncurrent", "label": "Lease, Liability, Noncurrent", "terseLabel": "Long-term lease liabilities", "verboseLabel": "Net long-term lease liabilities" } } }, "localname": "LeaseLiabilityNoncurrent", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/DebtandleaseliabilitiesLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vmd_LeasePayments": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Payments", "label": "Lease, Payments", "negatedTerseLabel": "Repayments of lease liabilities" } } }, "localname": "LeasePayments", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "vmd_LiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Liabilities, Lessee [Table Text Block]", "label": "Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of Lease Liabilities" } } }, "localname": "LiabilitiesLesseeTableTextBlock", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesTables" ], "xbrltype": "textBlockItemType" }, "vmd_MedicaidMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicaid [Member]", "label": "Medicaid [Member]", "terseLabel": "Medicaid" } } }, "localname": "MedicaidMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "vmd_MedicareAndMedicaidMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare And Medicaid [Member]", "label": "Medicare And Medicaid [Member]", "terseLabel": "Medicare and Medicaid" } } }, "localname": "MedicareAndMedicaidMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "vmd_MedicareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare [Member]", "label": "Medicare [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "vmd_MonthlyRentalPaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Monthly Rental Payments [Member]", "label": "Monthly Rental Payments [Member]", "terseLabel": "Monthly Rental Payments" } } }, "localname": "MonthlyRentalPaymentsMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesOperatingLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "vmd_OmnibusPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Omnibus Plan", "label": "Omnibus Plan [Member]", "terseLabel": "Omnibus Plan" } } }, "localname": "OmnibusPlanMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "vmd_OtherDurableMedicalEquipmentRentalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Durable Medical Equipment Rentals [Member]", "label": "Other Durable Medical Equipment Rentals [Member]", "terseLabel": "Other durable medical equipment rentals" } } }, "localname": "OtherDurableMedicalEquipmentRentalsMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "vmd_PrepaidExpensesAndOtherAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prepaid Expenses And Other Assets, Policy [Policy Text Block]", "label": "Prepaid Expenses And Other Assets, Policy [Policy Text Block]", "terseLabel": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpensesAndOtherAssetsPolicyPolicyTextBlock", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vmd_PropertyPlantAndEquipmentObtainedInExchangeForFinanceLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Property Plant And Equipment Obtained In Exchange For Finance Lease", "label": "Property Plant And Equipment Obtained In Exchange For Finance Lease", "terseLabel": "Property and equipment financed through finance leases" } } }, "localname": "PropertyPlantAndEquipmentObtainedInExchangeForFinanceLease", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Fair Value", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Fair Value", "terseLabel": "Calculated fair value of phantom share units" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValue", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding", "terseLabel": "Percent of issued and outstanding shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "percentItemType" }, "vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "vmd_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period, Shares, Warrants Exercised", "label": "Stock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "vmd_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period, Value, Warrants Exercised", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "vmd_TermNoteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Note [Member]", "label": "Term Note [Member]", "terseLabel": "Term Note" } } }, "localname": "TermNoteMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/DebtandleaseliabilitiesCommercialTermNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "vmd_VentilatorRentalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ventilator Rental [Member]", "label": "Ventilator Rental [Member]", "terseLabel": "Ventilator rentals, non-invasive and invasive" } } }, "localname": "VentilatorRentalMember", "nsuri": "http://www.viemed.com/20200930", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r246": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(k)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121561866&loc=SL77919311-209978" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r372": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r442": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r443": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r444": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r445": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r446": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r447": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r448": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" } }, "version": "2.1" } ZIP 74 0001729149-20-000047-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001729149-20-000047-xbrl.zip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�"ES4>*MJ2%!TUH-SRJWR,(#@!Q0+V6!RG>/+703JIYLNM%N;'IF($]BNH M,9/JM^_8CSL;3-^&X_TSQ+;:\,P9PM??FY!]KM2Y4=J!%GJ\ ,1$J].:UJCB M/@=M:# <355; /$%O]::3&+4*O@7>^+#&\4Q\-JDZA?M**KR<+8/]KN*=Q;U3>6H$TKTY9.JAV.'6]$K,*0!A\00[:*M1+ MX\C IN^9,6?>3&]Y\N*L)F1N$W$'@*].\$YP%@A0(GH088=(L7KA$CLO:G9>]TR M.SY$4AS--JWYW9CXG#KQLWWRPU,1E93ZQ L$J!.@VQ'NQ@'ZM.TP +@59;KS>QK =<".4 /#N,99 M/E83OE7X:?1)M?.A],,9$Q94&+1FD2%>H:BY1(&"P=BI?P>9HJF^-:%IQ8O4XL7J<6#U.K!XGMA4FWXH^+W=& M?2M^%%#JRLA?U>K#5\!>+V-:#5#P,J/I7:E)1Z9J:&UF20R,X3I-:[>'N'ER M6FJ#&/&8#8:!SI:GR+K?_HG@& MZX.N7MB]^%HE-)1C*LW3]0E:+Y4F<':6/&RV4^:DN5"*':)&?Q)\Y;G$A49O M-O71/,5#E]/4RD2?)]S)\N,_<6J1;M)K&GCM#J3^JTCSWKK,(K==YO"=?;;A M.38V/C]R.VGG[+.O6^=^_W)^W.J='7]LVT=GXNKH[,1?\'RTX+OP_./^A[,C M=]_MM,[MXV[O]/CCE_.#[YWSHYLO:>?FK_2@U4O:W5VG<_+#IY39KO*('?J4 MT,"/" L\GTC'Y4&<2!H*9V%BH.V[=IP(APF;Q@'\(V6@8MO'3HO"9O.Y11KP M12.U9TPENG.;OT3,+2>$'505#W>L76#.'[1OY(L2"OBP?&4N7)-LGH&(NDRS M<6[MIK(!9^VE*M$JRA[K%/%03I; K1",C=Q,T>Q"2P 74 @[C"-9C3*TG@\*H,C MVC]V\&V_11QF 7RD@GTUK6JZ?%9 3- V4 (3E%"N 3P1_2_#= 9]A&TB%&)=]OB M$GY^QGBV=_U#@%R) \%("&H&H8Q+PB-%">-"18H)ZD3VSCLPU%='\DJG[A(4 MU8K4[D66]J:Z.4;G*N-?J^UH9\)]J6E4B4P.;*1[]+9\==&@KHET\4RGK>)! M_S;DCN#\>]SG&"W2*?YF'"VFZ96>VZ6,X\(T_#=)8*B,]X:P.Y/)!)>J7QHH M8P%H#1_CKDWK[^$5<)"L87S50%TR+=5UXW<&@KK0^].QO\9,Q%#[[C'1J8CE MFFV!%0'PM/@)=HG3B3V@^'/M]L^5"?.!&5"D@94/S)O6^_:A/BKHLZF8GE;G MI"WY0FFKY./XK# +AH.3(?K?3;987N19%@./@?F9,\&]3^*?TW'(1=ASFD2\ M])D(W/Y0ZK["#4!BO0FNRRRJD)GX^$OS"U/8,$G.P R_5#RO@/)HG TF0&X: MC79_,1ET"@O,#Q3H.M!OEA&:$V2"LW>$$!V/8!>&,#$=;1+%O=#2 [Z@P_"9 M7J=10 U#+7*U)%DC;+ 10XB^!$/(L6M+Z DM(2,"NOSG]AD^G3+DV^_ M+K]/?\P^ZGW'BTS7([>OC+H9PO_47BI?<([O3;]L=_/?L^!ST M O>H>^YW6KU>Y^;3V='9IU[G.[SS_1CD^SX]V/VAXL /7>40SW$IUJJ&)(XX M)3*,!$L\X8-E-&_XN+'O\,06C@_?B9.(>5$"2ISPDUA0+Q+SAD_15!K OD8- MQ3VMF[OW,KOW"(PY-V*.#^H+Q:%8K@@CJN>HQ4GB>[_&&EI.EKM+QWE,*[YF MF;,$P3QQ&D^:AB4ZL@XRH<@R50-053!)M>)5+%0[?$Z1 M[HP;J+Q:F"ZO4I.;&'A%BOP5:FRPGS*WN<>O4.DMDJ7#E"B)O3:K] 8(<*7P9O+JJT"3);;IRYTC>5BZ:-L)JBKB M3^5!ZB>?U*W$U[B:SBXB<$826!G _K&U$$!8A,)]__;(0N5U^5V M)^K(%]BJR4P; R0.+E2F@3/-*B;N;Z:>'+1.KK&[(Y4L"0@5CDNHI*"<)(E# MP@C4=N8'RO:Q!1IKNHN5U'_\CT&66=S0. &H4-8V(7XHP7/M1S-H9;*L\DJ) M4M(;B]$8OUFI:0.L+M-XB[2J2=XI(FX#Z0.-\E28H.YXXDR;B-(1U@1I]ED\ MNMQ,7FP"J4)7IYFO@6T%]JQQS)7L-UEN595\>6A025NE^EA-=(-,9J_HZ-GM MU&3JKY*:>%X0\;2[^S\/=A])/MI#(<%.RK >#Z#:YP/T=L@T*7(%\Z+&CI\# M=EX\,X:X]\20+PJS%M->JI&C@_J*!++&R/!\SZ/?#U^J-1QG>W;G\P\O9C(, M&2,VCWU"'3 )N7(9H:%O4PFV5B02]/PNQ9PRU119A_;L3?&H%,Z@K(HLC8'= MQ*HWO-+^J?' <#P0V=O-;69QZ;VVDO8'Y6@Q^)"I"<*<<8H7OM-T:Q M[K[7_OPCY&X<>W%(/!Q,APGFA%%7$B\4OA2)+R(;3'"EZK-V7UE7GYLRGTE5N7%37!;#NM2)R>E7 M&!< 0FH4)J_F%^/16!<+@4V98_$Z=B#XF>J.-WAP$\A4_8MAAE56%?F%[NKA MF1Y87ZY2?MX8.@W\FUST0$?2I\&A PJ+:B>^;:TJZH0CH:,O$^VCB1GT^1C+ M_0$\F.,44KNA_2M%"3KH7Y,2*I/Y;IKU('1BK+G1SZSHE'JD>%%]7W(4T&1[ M^M_\=#C&@BA5#9^5;+>G-4TQ49(J^RS50.V72?LHZ-.A5@Z- HSO%1O6=?7H M.1A9G\:#(F]JSFU0W.HD0:L(O0#'1T_& ML8113XG E0E(4SDOC8+%R/9$'*U=W#054(\63K\ZU/U+U9_N"79^"R53H"38 MQ&8"Y%1('<*\2!*7*1Z[C@ID+';>A![2>[?:G]E70]3U\/4]3#;5P_C M;+@>9OUP=6A/PM5U$4U=1%,7T=1%-*^@B*9,M]%-I_\,M'1?/M?X&5-NG%_6 M\W./9VCCY?]1F6Z_NR6Y*%Y[HH!_.3/M!L[MH^Z'L_;9E_08/G_P\>O5D;OG MM_N?;PZZQVG[X^?K>07\^&/;M!OH?CEM?V]?=SY^ZK7[^_2X^]<9*.+7L >_ MT]^_.FY]2CIGXN)**%.>*>RP6SI8@# M1^)4D C@+<.$)9[-5_<[!;YH8J4'=VB8=COPQ$, M.\1Z+][#D!;Z3,8Y^A)4"=0R=U#[*N H*4:9,+Y[BL5DN#I&V8"=H6YE_+BZ M>12NG,^T/:BDE>!B]\Q#6T\17 \0S0WFP*WW1.MK7IY]A&5LXPQKS+ ]++T42P(*^VHJUS3"5P%WE.17#J<:X*IE].9NKIMA?:XF!:**5R. M28]/3:' M#>BBK6(^K2J8A$#+)376:) ,3;M&W?U:MS3"U.!I+^NB_R+/,)O5P&6FC5I]GY\ID$VPJX^AII0?/+7Z;5;M;K-+QXO.GIL69HT[5,S_N]YSO1 M@[YYVV8=KPG(66_V"3;K-B,O>$&;I1MQEVS2L;B60_#IO2S16N9M]Q2+B]HZ M:=G:6QRSL8GY\B\*(!ULJ[ F/)X1J1[AEGI^&*)JM@G$>6&'GO,(_1Z'KF_Z M;@?HO>?6W>$9?>IAEFMR2C3@L).B11:5Z3_7P(I[SP?=.&P?\X!ZDR][D_Q!!#H'@[4'^"Z!W2\9T[L>!-] ]TC>RMP'1E0ICP[9)0QR;T@%(D713;C 7/+J9WA)J9V J8: M3SNVIMZ6F;L/=<45,W?WG?:-/&O?B.OCCY]O].S%UH?3=O=;O^-^23O?OYP= M?#QR.]\_T_F9N^VSKS<=MWW3N?ET#GO$V8MV^_O>S\[W(^_XX[YS_+$-YSAR MCENG2?O:OBYF[E[]B&F0V(HE)(Q]1BCS$\*8'9*$QJ"IA"*F,@:MI1'9CQZX MNYP'/NG,\)KEO'J68P>L!SFVK'B,B8!AUNA-*$D]EU%&)45\ MXI%E3C6?>"X^X4[XA!TDPN4L(-SU):'<]PAHE8(PY<,E2F#WO@-\(FA0?W$< MTJV,HN8'OST_\'C,HT"&KDA<*F40)YX;A&X8X>@]-W8V.2Z^Y@>/X =TP@_\ MQ+5)7=4W5 M=U#U(SV]-55O"55/'<'*29PXH!0L.,Z JL.0Q$R%A*E$!G;B!+Z-C9+"1N2X M#885Q355OS:J?J1?MJ;J+:'JJ=LVUINHMH>JI\]5Q;>ZAK'9"/R14138!!2PD M;N@J$85AZ,I0R^HP]/&_+:+J5^ 96TZ312WB;=Z&1[@9UG4UW<;DULVC>9%, M[M>[&0H$6.!U-9N[#YNKIL/!#?(H48P$O@3EQ743PMR8$B4C6]APU6!I[KRC M3L/Q_480+/8PV[8$E9JN7Z"CH:;KS="U78D=L=!3:6;H=)*QE?L\(3A .$PPM:A M<'?<JZS[H( M"Y.IRZYHF_6(N75Z >'5>>6XGY"W8A(UPY O8Y<$D<>)TELJRCP M&94AW7EG-^U'Q^2VSZU5Z9^KNR)H#/ 4'F#H5;4J%4%*0P/$C M0B,>DMAC#DD"5TD>^8HZ6CEP?IT[\?75)+56]JA^BOJC1V<\;@?0UK>TEIWK M=3#3I_;G%(A9L]/[E,1W=T?MU/ZI6>HN%L5+[DE.HC".@:%&,8D\R8"_.F[D M>Z$=.&(S/IWMR[.N.9ZC2"ND' P31,@D2 3L-"T&YL M2FC(I.,HW^.NK]U$0![EH-C$ M/HDCVR=.*,(@C$'?<;AV1VUA/=OCTMY>;D.C;5EC.S_Z"IR8=[8!FPSH1$:L M)UR:$2*CX=9,$*G7>$%KO/(TSB=M1E97$VY]E7#="F$#:F.[ZG1_[G9DVY=. M6=/UKZ\2KNEZ(W1=<7$_=T.RNDKX]5<)UU2Z&2J=2M^G;3!6$^,KKA*NB7$C MQ%CQH#YM7[ ZK>\6XCL<#<6Y-;Q ,.9Z?NYP= IVO?:!I9?*RI489^DHK?N, MOT[3?E7/@UUY-LY'?348U9SM7ISM<]7(CVTWC$/)B2-#@?DN(>$>';=??Q5TC@O]H]4!/XY@E\*L$9V!XQ#2CA+ #; M1 81B?S0)IY0?NRYTI>1VGGG@%E"&QZM"?P5$OBO=CG4!+YQ J^F;WG2CQS' M)2YE0."QM F/74ZB( QD+$(9*Q<)G#&OX=B/;NJY!3W)XV$F549&PXL_\='Y ML)=*JZ2TK?=8O)B&Y6N#^?5PRE_MS*A;.&Z(0WZM.C%"3TI) YNH.)2$!@ZZ M9VT&>E# (AXQ/Y+R"?J9WX=-O90TAM^0)_QJ_T?-$S;&$RI^#Y>ZCA<)3IC' M;4)5'(/6I'SB)+X7"EOZOA\^02_T7\03[D/ZOQ^%_VH'2$WAFZ/PJ=1W/2\) M!4^(+QV/4#=0) YCGPB/>SQ(6"+#Y.%]U&M"WD)"_M6.CIJ0-T;(%0>'S=V8 M1LHC0C%4WWE F A\PB3]Q3\*]/+=^4& 6F M*(3Y&Q$Y'8QU/<^[_ZL_9O8;9_]^-]F[?AU^&"2*$NK;MALP3WHTDC'W(H"5 MM*.(AIY/!5@^.]4OS3(1@OZ0/[V@)/QT(-5@]"?!5S9#XXY[5U63BT3NN$W+ MW-'BS_\[ ZH-R.U9,CXB:<=A?) MM-.#[_YLMSY?'_?A>S>"ML]VO>.S3[WC[M>;MOO5!Y+KJ;^_7!]_EQ>Q2X/. MS=>?[>\?SN$]V.?>5:?UJ0][/.O M2AA\/ G\6.Q8"CC?!8!\E(W5SKLIP"T#\45BF$?U @(-:CD_7 ?";'TPP3:U<(,"]&N?4??HVL MQ4H'HZ%U>#K,1F2DLK[UGE_@TM8_BN=J :BW,Y?G@L JT:_/6\$4/)FZ&"GM M'_7LAH7DW+!&I\IZ/^S#AJXM^)C*E#1@X)8H3M_#TUO\)%,*XPS653HZA;=' MIVDFK0N>C:XQ9ZQA\1Q>!9$][HT:UO^^KY#@VK:H-VOC\0XRRKU, 'OQOS MZIY[/Q(>@=K'&'%L'A$J74DB$8>@[ONN'48LD ZP'[>YF'QI <;V"K+B)5E= M%&1U!9@A-.6ASU[C5CXE,H->Q6>;LX2T5*C/U:M3UO2!&"Z&>8H?^3-36-![ MJ=Y>I7)T6NK E>\9U>)/>_H5'H/* CKGRJ]4J%AH*L$">7VV60T(B+G'+W+U M9_G+6YGF%SU^_6?536M8H-->UFO#_-F M:)=?7?KVK=^]]4WJ1$W[H5^^]4W/67_A%4T+W%N:%CQ_U?S=+178TA3]^P3; M[D#/-65,-^VKW.JH*^O+L,\'JY10>RU+\S\8@D,_WPP-KU#@;Y6@U9_W4-79 M1%4_S:;P/5$DSA0_)SP!V/S)>U?\.M_Y]PP(^^E@>A9/S2L#>[O]_F^0GN<;:>1H-O^WOMO9;U M]][N/]V_W^]^V6M8^YWWS75TT%^PV_9N9_AU=H_?/_U\'#_H&/M M=EKPW^X_1X?[AZLXQNH;ON42S1F?TN\V98?KVQ\:%F^Z/![W>&;QOE&1U,\+ MT)ASK72#1CT"K]%"T:7JZ CYIE;XUMEX8(Q;-(D;^MNP_G_'L-TDQ3[I8+F .7)MQ=<-_4Q\ MDAH@N<-OFOPXFD33K>0C> &O/;?>I /1&R.*6IWA")0T,)R,M5ZN\;ZZQA03 M#B=K_*&WA%\R!5TK'IH.C/ELS'1@$I9&0P=! %9^;GT>@Y6O,CC(%W4!AIL% M'_P 7[$: <#+XRA7/).D-A^=XW@H41J=\ M!!^\'/8N ?1I?JZ7 +@#+^+I &O2FM:N& ',)S>G#YWV<278E=(N,C@[WI], MDP3.IWL]X7;+K\ N1);&A@\/,ROM7_3P!N-K_;%;-HCF*6RDY.!K(.!:@OI% MT^'! !A8)DXMQZGZF;X/,[B"OQ7OC4ZM@^R$#](;@RE2"9!TJL#5\4BKZR5* M#8:7"HDT&P[X99J-@31VWA]\VV\1A^T BEMP4*GZJ6A:?W&DBZ&Y"#DVQ*N! MGP,:9.GH>H*G_0LN#)5KHBK6FZS5L*;D%X]'L(F1U0.<*CT8@VMKH$ZTH\%2 M@ /#OO&L&T8". BXBM^=8-IT860$/$Y[N!M<"L1_GEL70.. SH#&%["J1BU MJ--AKOU5>7&(D36^,/@-$!K-?!0?<@J4V)@0?>6,)P##;*#==\9C8Q;D$J@D MS4>9.4BF3HIN:'D)Q%-]6P*5CG0@ ;DR[>VSXFS(D5.8LU]7P34ZS8;CDU/0 M6F!E?,$@_[65C$?C#*VDM#_NP36J!.AJ!/K-%6@T\,:$JLM; =),@9>4)YG> MDB'F4PY[1I\3 #0> [@!CHW[\?6FU9T "M^9/*%8=KK8A+G 1@O"-C3?'^(K M"O;= _$ I+]!^E[/[(W="K&5T+SG 7\U#[V58[XO$+\B6+0VL42:WBJ,K3Z_UF)^E([& M0#C_YW]%KHN[726_] >K&9WG<,%=&.2E,N(96&PI%92KYP7L''&!.:U;M@;R"[Q;!OE-5"U\*ED3X M80MAB*";,WQO4[$TC\YO5<(0#'V01PCL FU1R07IE:EATK2^*Z/8CO@YP@O M749^<*,78_A3P/[&%_I;<(Y,7:9X0)1:MSP6_8G3I\$OUY.M@%0[51K+*G$Q MW-Q 7944DK5-+C#Y$WS\+3YE)&MFMS'U;? MJ@X@*42,A9LI7IBA0*U:),B)-"94Z1R_4E ZWGQ_8M2CI@5/UPIB]1F%#6GL MHH96/$L*GRJ?C>IF=3 6D.M"/W_X9ZG;P,H%6;ZU+K)A DJD43G?WJ8@@M P65Q8I7T*(X'/@F/ J M7" PG.$ ?PL O-C-^B[:@08_ ,&!4>". "O3$R.WVM;ZOJ]%1G?@L\ MIOIH?>YG\)W@((2;@N(1Q9Z#W#S0B_3"%>H8(WR1<-!%EY.\X*W M*#G_5CR6)VHT_^K$HIQ_(Q>G2HY[B^M,-('Y-^"8"M!MR:8&(Z2O^9>G9+#P MEN:'EXNO Y,ZFSGVT$C6TLI&]4-+'752>CMB$ M^LI@_CM# 5QI\3LQZF.G"%M9>;,*PD(U0L45-&_#@C#U)].:!+Z6#H"J3JYK MGK%9C0)E>%QU366*Y\.!!GM%Y6[,J.*EEU3WX[I(!R6V5[0(K?(".O=P&_A> M:D)*L']5ZB;X$KR :F21GV-$8J.0;:,9K]5 3I@,F&5@60TO^H5B KJ& JSD MI?&$=L8P*PBKLJF2P%$J:7=Y3UUR]#MI%6-R[D+M%VDFQGU,\0:=P>*CJC8- M?VG27J+H&]Y\=9K"VVC+ />X5,4307T:PLG$2.O]Q7;,O!Z.&];I\ I]CXWE!]*47MT]1^J&MTT^W:)C M>U8GG?%J+[>TJBI)>:BJ<859D%H512L:@QLJFX0[\"P@HX0VG\;Z,E.MF>"\ MA-4&VSTH="9MNI(U?6]O3;U0O=!K6*C.:JRS&NNLQNW+:O0VG-58)RC6"8IU M@N(V[+9.4*P3%+=GQ8@M(XD#K#\$%)EU:J0# M=-RAJSS-SY?$%<&6'XY.K1,U4!D8NSK1!4SR-)G-PC'6;,6_:E+5"N_7%TP- M^V!<$J7[2UOWO5Q=X?/7C)_/)LS)H1@7=CK&";"6"0,2^('#O??5W4O#/$_+ M;*72AP(\0:;:33()^*(7!MT%VCN)KL4B^BS!<+E6TB3:: QHS(65IPWG"Y=2 M ]U).L1A-J7=9^IZB)\S292C;-AK5./1Z2#IC8W/:]9E)F ><(I7C,C5,.W('Q45CP S6F=YA^:S')4M5\;U8J4A T][-XHN7 M:C#&':K^16]XK501U,20U(5)0$,"'V,(&V-C5ZK$E'RLDR!PTSDP/:1_]!LN M"VH53M%)I!/1ZNU\8AWF*\E2BAB12,LWRLIF\/+Y 8L5)5;PV8&JRO MERM38PQ:7&2I4"4ASXP^-)LP&8N39?M#( *###J#=4)& MBNSMDH OJEA]9D M]U7B%G![F-.#F[>,?7^I*BB.!96CL;R>$&$\_1CPN4R9U9%,&OA[@SP_9Z2J=KR&QLLGF1'-/%+YZKZQ*C\;LG&?I<30;5!495"H0U MX6Y5W-@I"%M].9I=8[RPP!<=+[Y0H]0$E3' :R+X)?KEZD0#\RWN*1M?3'@2 MW @?C;@XG\D>%]<@.$CQQA\EY59CER,E3DWD!TD/$!FF;R-'5J?\,D6L'18LML@5!;T4U %IUDX /] I;O+5BZKT MU& %PA+ 7$I*4&BFR3\:@@GP&4#>:WWRDX*CP*W#E[@H8)C,4V#_])E*41I5A/LD=TZA688'H_P=X M%F]@N7>1_#&1/\6SM?Y2K/@6KW)D>)PI"\?'3,)<79VZD1( J2T:Q%&T*%@3(>E'\!D7.0S,,+X$Z5= *3 M-V^IBU1K7D6P'?5>A$&9!F+.A=;KL@H$?4J=(U2 8E)0H+\_?=ATX84H;:G: MEEKLC&H[T5"FJNW;175\B>[]_"GN_K(4]VU-9O]8 +T-0A=HY.75^]SJ&=A? MQY!&(Z^'J*6U.M/M99K86BKSN2D,,NDH^-M.T8NFL6/M7"G\.:67@6XI\L"@FPO*4AK4_$,U)RL/5Z;#7NR;#*TPL!\LB!U'%47=[@=57 MM][&=[0XLR+KX0*1T:293#P&#M4>@\#HQWPPX?#E@7YAH=A?)0-Z7^Q=ZY"[ M8O04>[MU)]:;OU!1R4]A*[UQ/TXY%@UHX?5I#!;$M&/2E:[VTLHP\T;=%D!#=:>9_X &CYVC+5>HX^8Y&"ALZ=JF5N%)_A MSVOMG!5%WJJ5P?[SP@EV6$AE9^EABO+D4ONU/K0:$S5GB*JO0@>03%&V:U^0 M-M0S0._T I4P-+.!MG66RBU[G-6A3+NA7%=E%K84K(]J5V&.FE*-F5K.R3&" MY;#\7L"H[.6FLW#113]SX7,+XR%^4]$Y/_-^!]? M(2O3L8.!M;-";UN@&X3$IW'_ I0^$$ '@$,3EG*(+XTO-#NQWFCA\NG@KT/\ M<^#@"HO9X1T6I0.&5V_O>.+@C[>MC:T;=;T.?$%BUHZ^M M>V1UV5]I(<^L\WZW52PU*0R3)ORT&39^ M5Z4S$9D&SS*N[QVKH"VTDM'M,/$[-R8.J1D/=,,$F^ ,-R:E'UU_<":!,1"T MB=/,&,RZ!GJR1,%[9M"VJ1D0R*H^"M-)21^6.*)L&(KQI*QZJ*O?1"B*8 MV&.% 9JIV,A9B0J%]D\4R5W:P!NHI=2#@28G?&L!;9R@AW?B;]49P@,#'ER= M7^CJMFD5>3[&/-*)E5D]O01BQZQZ<\8%N, S3C+>+\JC%?KOU32,9U)2]9.N M=P4+[*\IA,F=U6+DT' M@Y8=K)K!_*:L8#>*A Z^5)R6V%< /<,+&&:]V6FU]W;^P,QI?-X?Z$TE>O]Y M3ZD+[7"?J"3Z%7XQ4'SJ'V]8H%F!R5Y>S[26/^<]XXW/\Z%(M9)?8O#_S]Z7 M-JF-9(O^%87'GBE'J#1([/:]'5%MN[OK1GMY+G=WW$\W!$I 8R$Q6@HSO_Z= MD[G/.J<1YWS6+^=0YCSKG M4><\ZIQ'G?-X 3F/?Z'M$OO",IFZ_XIDR["(C!Y*;3*JK8,P"J_]\-Y-\''> MQ4'\ \-T/D5=$Y'#$#-$,+P_S^@U+.>5?$4:NSP.1_Y#>ATA6IX"J220Y4E> M:!K(_F#O'U6P+V'#:S(;3PIU2JZ>5Y;WGZ(_=8H7N0C%.P=V7K M-JJIG/J\&]"Y^0/_D@U/$$;4$BA<]FU0]ILQ%]X,^#6\C?I9)93N@8T6DPE% M4I;:Q@E\09>"FZB1;>#*F'8CLR_E@RYW"S ,(O@\V28+*2G33<7=)$80B:P< MV9V#NP@*3/B62/\[W"%N@94\$LT.SP-)".V*LZM1 )[YR!O#X7J4F>7QN*6H M#$:2Q 2P_) <2LLP45P@,AI5-<1CSF2VI8>91W'T@])KX !.NU_FLSB-"@QQS)^7G!'%J6W@>R98#=4GC:$B1@L3J(P MA)/P+$-Q.)Z#RBD&J$RVWC)FDT5"+I3\5F@EWA P+ULN;A1O!'Y.[U9237C* MJT0&E^?Y%I?(LQHI[TA&O,35PMX\RS@SDOPF NXT7X@7^U,B)IV7 F!5#C;U M6DI])Q$E ^[.(YY9 GSAXR1G7.G61)8K.C]I#RO!LHB*UJ4'5$V]);&0;2(Q M+)0W$IE1*&-^O.6F2+WA2%GEI\6LL4AZ.HD$)./@AS$Y2'C'!OD2DMW4MX"2 MYJ3 4QR.@3]B97_J"*]%L#)R'59Z5)\D/M&W'Q2?6#MT]4B!BV^\?=,-OQI! M]S+$=V:$^X"NN>AG)U]PKG=1UL$XB ;42%;VQ?U3N*YE)J504'F.(/;J('?\ M@+&PR)KG85"ATY#*&,/9A"*C]DHM%>G$+J6^NV&>H)W&ONRV(^I)4M ,N:== MZ,UH;/'>M]*G#D)R3*G6_"$JV! 9U2(=&5-1Q8]'[A!C"$M5+J0VF#)A81KE M&>F1;,25BK9?TL>NYJW'#)Y@>/AA?)(7-,-L%?L!DV9B9N3]VJ*$)&+4%&U.\Q M5@L]F(BE!3Q:E=.:98,;QOC:?(@+"15 M!.-9JF+%0E*L>*R$CBI DV]/52%7?R:9MNPV.07LP8YUAA?Q'F"S&99C<=DC M.RIAFC"E'4O6)#?IIFG, W54LY%+0A\5N5M 3H_;>:(MO$CXV+\K]#WEM*% MR\T-RB"A2\62)YE67A;;J ZDM.EL1KITI4[@YWA,5!*@*P3U[!1K$A@&Y " M2:XSB$16BL1YR=GI51]=V4*V1.F"N+_MDXUUQ-<+U M)ES_@+O&"QAGH&U3TT%>+15.D$5X$DDE-JJ\MIJ1C9 TIV[RO: GR_A-]B : MJGV&Q>9G+J72\ZZGF-+M"4HG]L_YSM(9@()PTT-7Y*+EXJ>0([+3%2:)%,@Q M9^P[ZG4$@W)U6YYVK,H,OB!UN'4Q8SM/=Y?9_J%,2RX&&ZQTP-S+RP 03A'S M\P(@GF:/6J):E:96WO 21%[XZ*\K\Y,2@>_&Q=NAA$%/$ RA"K*',R.;;Y70 MF+@RIUWT?2X!-R^Y]*)YF&9Q6*W&4_M/4G4"GM&/JP)7!.G!E9=U%X:_+1?W MR;HSHJ"\0$%4H8'5B]WNBVW)Q/BEK/PB_Z@RG;^@7++\LY!+IKR@@=1>Y3/! M7@O/$I\:@C76F%G!*W9X)40X\JD8S12X2$!P26GF-1'2R^#_,'-7(/V#,C+P MKR5E 4V?H%0>YF*RX%9%2@O\C1;+TTW0=L&!JKS[N-Q\7B5) MX0*JH\-T8E]8/WEC/ [BU9<7\S4+B'/C>N6$:R88$$)1CJ)!DEM6@1'"B5ZE M:J/?)8U%5.PJ?08I$V6!A5RP>8705)RG.O!$9O,.6?DRJZN#+:3T$9Q@;*[Y M!<_L=<>B )WP7HJ&IQVSL:?9KK_ Z0BN![80/E/NP)$[P-VT[.W% MR12EN*NPK+TL%E',1)V]ATXHI45!'GK!'AD1*06L\ M@Q1X/1OLA M1@G<.;H >=C,Z4H/GJAX2:@R9( >BI0W\!"#!WFT(^&.4W2 #K^CBL.'68@! MCYX7R_+U+1V\2O$O]P=WL#[(&$Q34VT? M)O.EBN6N^7RD8KX-NC""B%I)<<<2!3\&&=>X8(TB.!EZ2JBF<-[<3!G.+@LY MKHXQP*54RA2=IQ 6E4]W5;0D./0>XS7I3*X*J+&^(+?,K #@-2$;PI=I10$$"7LE4>;20CD MC?,B&=@EAQ-^A PN'_4P/T;Y3.[-@]S_N M7&D1BZB$AW*&BF8EEO/MX1T?%=GG#XK1%TXGR M Q6MZ*)P')$O3'0IXMXS4>L+,.=G DF%(!>I9E65P!R5J]Y),RU$1)2B#^3) M*CQX);\K%27S!DV+W(O'H4J.<@E4B\]*0<<=S7<@1I<7CXOY+SR8/N-<4 9) MB$,102GBCX1>AO[R__ IO3B/3[*?&6%R:LIH,2YERO#_+.)$7XVSYQCL0.'% M.QV@-[+$R%V /,;_28)F*$-E,@6"QWF5,ZX$;I;QN;Q8[.GA6>B+(JV-6HP) M806T^)'R!Q#XC%W#NZZESY]W$.+<07FGGR@-($;Y-#*.(Q[%5_*L,<99X$=7 MMHAHY$F72XU)D6_FY(_$AUB0;^VF/&[X'383$J$4&DB)O3$H$DH(R5/Y1'V(J"ZGD#AW/#)A!PR,QSQ2-'+$51*$*Z(*YB,$>0DZ>B=<477I5K M7+WX\N7+B]>"?5.[&-%,%*F98A93Q*&BS9V,9XC ;Y'AH7#&PI7NL0$)YS'< M*C[/$_>$:LMS:V #G$DF/&V"V#R-SQ2_H[-X;.BC&$7!0LK' +- 7'H:-Z_V MU7M(@L&S7!OGO'7=G6BRH21V8%)1%/HI\B<0O'D_M[@LOT2[N85LRY9K10K# M2_+.O2+M2G96$8$3Y:N"S0,I[?%>5U[T4#N;S;H)A$1+W?/ PQ6CG# M$>W+F,<;2H]92$EO),1EVMMRQ!5F_84PV(Q*S^<^T*G M$CK,N?%)GDVB-M%7W0D!6G "RP3?/1R@I0RJ_$&:Z8C[*P;6\ M;2-FHS"9C[4H-\E?*J*1YI08&Y>[0(#+8V^IZC96N5>*R(#Z_W,7$^=0.;-6H>,BCPH5A!D65]'D];Q):&XEBVY>:_*Q M?,3D)*-DXE$6",\<)L^H Q2+A+-RN].=.JGG-M#JH2WLZ*5R@-)$\ 2,W"^H M^=W>PN'Y,(&J00>6\)&=&3\'HY67^7%Y'D89I4+RAG> Z=)F"D%K62VRE,PT M)Z, 2('R9^3G2ZWB\M;%F+KHDXM=]K,A6? 5RR%D8SPQ)0%Q0>')U":PW$1O MK874M(ROW,^3UV0BFZHZ0%ZKE2PER)&#H>A:G$N7JW+U5Z]#15V\9XY\F\^A MB^T-Q<1R[@H34R5*"]A]6F!U;[D34*Y*GEF6"D_0;A"F/'Z>M"5-1,O(JR#Z MTIN[C 78#S];[P+>D]&Z%_#N7Y=LN"P0H&\ MG0G/)BV_B7"JP%R"ZV=@&HB(A:.\ K1^*G0:OKK=E%"SVT(%$'M4WTR036S=B[K$0T2(34L3=/)^;@6*F<3&6-G'OL6DUU[]# M;"M;!42J8:+B-748/"+GV*?DY#*YMDKNY$+"2>"((;CD9< :B;H6'$'4M:D2)VQ=2+?-'#WJUM!U$DRS2 M9H76L %+G\"8T E@.@%,)X#5+P&LHQ/ = *83@#3"6 Z 4PG@%U M@WZB6$ MX[>XZ*"!7?@]>A"FU..W[Q@ Z.SU^L=7 +U+:>UFP#:9]6NU>QV#[YJ MS^K9AY?!3[/J4\&UTSG\JCU00OI/ M?=\+62C3O=>DB^WC,(/IQ_L"SZ[JGX M7\1$=A![A<6UVG1F.&1L-'K[)#KB(4&\$:"_"-8O^#V/(9;@\C!PK%4/'@JN MI\?)[OZJ QF/J#X< &*K$#D%<)3F#ETL%'@P0&:7/0D83@02*S/ +QD8RV;& M94-#8167#0B56UPV)):Y16^[1M;9 !71!O#$-;+<7+\MTBW>/ A+ML'C[1X1 MA[JMKE]0XQ<\U):J$7%6!YF^\DR296K_FHV=.+]2,Z@O<33RT[5^56>_@U821ET0J6^VVOLB4O5E/I3'G"-8G;;9=_9U M+FFP;L76MMG6V'IXL+9,IZ7!^@1@;;0;&JR'!VNGV==@/318FV:CNZ_36X-U M!["V[2-BZ]F&6U5-W7CU(%U]5R.V)JC4/HX'\=G.=Q&7V+'U)9[^)1['*Z)PPKK[$@U[BOJJ5OL3Z';+KZ$O4EZ@O\?B'W-L!<-*7>+91K$\L-6[# M831=R48^1Q>+8_8:VG'U%)%!>U^>KL&Z-;=8AUJ>A 4T>_MZQS14=V"L.MIZ M>,9J-IU]70\:JMNAVM_;/ZZANIT#]/?.6];!J^UP?8>C%:]NL!G-ZTNP*YL@ MH/O'+9LY1[ Z?;/;.&X-XSF"M6>V&L?Q*Y\S5.VFV6P?-YW]+,'JF)WFOEEF M&JQ;/:%FIW^<4/UY0[5E:UP]. MH %AU-IZR=F]MD@ MJ_M[A]:U.;T=KHYI=[6;XN *>\?L-?:5UAJL6\'JF.V]K78-UJU*4-_L]S2V M'ARLMMFP=1SX\%GG9M?6(NO@8&V:G6,&UY[;M9Y/57H6Z-YX.%:"><:'GV^_ MO;^1 #[ ^]O6\DB:JAU43'W#%HG7CH7[7X:1FS!"7AWY,%W:]QC.ML<5JEK,) MPPBMN4VOU;]\Z"_/VW'Q)PZA^R*&T)V,V\*Y++?%WJ4&6F/9 :H-G1MV>*CV MC]2JXKRAVFUKK\43I(8Y.N'N\%"U=7+HX;N.F,V^]K =WAO M_$^K(^V5M8J)]<^CF#N/B2<:!S0BMEZCP^>@C5ALI)'QXE,47O]Z<_.%WVDQ MO/ C\$ M+F-UL[[WWR_\WJC5;C2<3K_I-5L];^ V>ZXS\!J]7JO;;+>&_]=OO=@'3W^B M>>'/CM_+0%CQ>R)VT\L]-HRX\_,-\%\6+]MTG,F/$1UIPDQ@?XI66A0"\Y>W<]]()ZCY6@_0?Z=44ZXNO+?IJ21'BWS7;5KO97?MUP[+7 M?K=IV9[E-/L/6G7S&SN=P^^U:S6[#UOU^?>JX:KWVK-Z]FXXL"7.L3W$M?K; M"M/OZ:>][Q99W28W]^G;MD?T[P0@@_)LA_CR>1WZ%4I_7GVW9JSVV8, U9>+ M.[2^]Y]>&J30OYNXX?CR3O]J[>G/H!=0]9'7(/JV![AMSB M5I=O/8Z^]US&W0]]5/]V]6F;3;/5ZCZGPX]>^S"/^LZ0/D008P\R7LOF=@B$ M/(YD:H)%Y"_02/2,(NE!V9U;T%9S]W/C[GS&NR9,S=TU=]?<77/W\^+N-!VS MKPE3<_?'8%&G93D:AX[%W,^V3=V[*$G1<1IS3Y*Q5J2=4?\4[%#7KTFWGT-4 MI)W1U;1LZSC]@I[MA ]3&B\0%3IFLRZ]H_3-E)W1MK5O78 FTO-$A:[9Z=:D MRZ.^F:7>[K:U;T7$25/IV09Y?XVC)#%F<33RT\<,?#D+,QA'"[:;VA#6SI3' M8%&[IYTI)^\IOSBLM5MFHZTC/!J+'N=([NLHH>9]IX:U;;/5T&J?1J+'95'V MK+;&(1U#._ -WS&J8S>-,0M9[ 940NIZ4S_TDS2FFOX+":NUV\=Q#&MGX):P M6N.R?($:%=93:<-TFC69(*2OIJSC-BQ'4ZE&!=14S:9=DQF*^F:6QM%;QTD= MTF&UPQ[S*TN8&P\GI*U[[)X%T6S*PD>%V$X%B9U635H0/I/WXE3NI6$=9_Q2 MS16 "\0$IU&31N'Z7LKFT]ZI;YI"SQ,3FC7ICJZO96F(X=X9Y"=-H>?K54^C MX?=K['B+!YO.6)A0/\>+<*6;3E,7J-3Q9II[:^@G;?UK3-A HXV.IM$ZWDQ; MN]$U)G :[>IX="WOI7-9%61GZT1_CS,@AO[#%?,3LRZ=QKZB15O]S^,X/\[, MXIJ+_ O$!+LNT[7TO2Q1Z''F'FH*K1N@:C+_4M]*.47TLD+/9^LV_QV+Q:/0 MP$E"4>(&V-QI%N,TI'1!J2[LWYG_\$27$S,TG<:^VH!V -137S]I^U]CP@97 MT'$"*OI>ME&H;L2F,8%"GKK!4QVOQ;$O2X:>K0_]F MNCRL8O3$;,XKN_]:NP'J=24-RW[N.ZFYR+] +-BW/E33YG/DT-JSGU$[C+(3GXU2XFES&IX_GYEVN[NAR2TJJ,8JCJ8$^94K\2![C23Z+ MQD(ML]&J?5.U?0%^0C;[62"1[5BVQJ&Z-^;36+ODAC+M7D>CK4:BQXTNM&H_ MW%BS/HVURQ5 O79+HVW]D.AD,*C7LFH_]G8]3EWX]@-4SAI M"!M,?/@H\-V!'_CIXA+R/1\6(M$)*^=^-S4/7UT@-ESU&GO$KS2%/LN=-*T] M$G(T99XG%@!A:OE9PWNY@O]9S\XS=;;G@6_Q5]+5 RS3HC ZUF.E"\,'A3U) M+Z4!\97S[%F&.I](9WYJ+-A:57";R\ (QH:T)M([7H@E4 M8X*8-W]&WN3'Z7(UN9#'*JWU\[2N281BJ<&+ZHT!&T4Q,U+WQX9,J(N9@F[V M6WH,^O$\#6>!1+9=_\S59\"A(R6O:JQ]:+%2OU'[C'W-^NJ-1';+:FH!IGK=R>4%FAYH MI/ MOVD"\GE1-@A8;J@\SFJL!WA>'A$J-;3I'+-W:C[H ]S$Z7EJGHHH:X*& M/4LC89WNXTF\W%K^:/E3(7_:)Q:_TO+G_.2/W;)JWS&Y#EBH!9 60.Q8E M/HYF>!.SP$W]>_9V[GOI1*RK/B= V"@><0< K2Q=_X@"J"'#RD#XFK95K$G M!]@$[BQA;^1?WN)0XL!=O/%#.BP]M QF6IWO2NR@[;2M;IO(2+@/Q7O$!JU& ME..737OWA85/=0D);(<#JY)E[>%[?NQ/ MU^RNM;*[_LHZ^PKS+>BY(\E^\Z_RI_\:Q/_\:>DAY<])7(!JS*X',7._7[LC..8;-YB[B^3%/TO0F/IA ML:TF,8>ZT#7U,^*[6$/7K];2B&,YS>;:KQN6O?:[8RW;VFG9RB!)01[[B+5G MIIU-X@X9T@[R[L_;#Q\_O#=^^W#S^[??WMU\_6 :MY_>665BJ,UN/]Y\NOD5 M-OSIVS_NC/>W=^_^N+N[_?S)N/GT'OZ[^?U_[V[OUA'_^AO><(G\C$^IEA2< MC=9YXZ?PCN$N2MPW=Y %;FRX4]#6T@0;!<0L29AG^*&13J(,WN]T'N6J_Y4EJ3]:'/@P&[?^;<*,$:!Z- >8&D*29M.I&\,:0 M9 M;,3\=)3WF,+/TTG,F#&%I2= 0Z$']+,!-=ZL/3B\8PR"7] $"GWQ"4J.=A41 M'%;61S,AX_M]J]?N/$C$]RV[USVX+.Y:=F/]DYM6W?S&3G?].Q^^UV:O?S)[ MU7#5>VWV'Z'F[F-XKO[V*.)]-S_.-^+J'SE7_[#*U?=)DWJ 35YCR* XVR'N M<%Z'?H5J\+<(-"!C6;NY%!"L*+:7<&A][S^]-$AA?S=QP_'EG?[5VM.?$HW=RDQU[7)'>I-[DZ6_R M;(M2_P2VY =N&L620YE&&(77?GCO)OX](R^,_,=C:DYJD;E2#8/=,U>JSE7# MDA2[;_8[SOG4"9U1!5>[;QVGE>>SG?!)BODTIZGG9=M=T[&/4YVJ.8T9\)I'+/;ZFM&4\.;L3O6<6K2C\1H3MF+M?&8G],)BPTOBRE"/F4> M[H8FM\UP8ILT$"]A0W-&-].UCG,O-==J+A 3;+.E:;26-]/5 M<]PT)@@:=?:>LZQI]%G< X[5NR0B/>4(SF-CSXD;L(0B.?"*>W_(RF'H3J/S MI W8]!IZC;JN<;;&_(?<;">ZSV:S8,$9P278[[;9V[M1HM8[GB4 :G4O2>W0 MF+"!1IO:?J_ES73VSE'0-'J>F-#>NV>_IM#GN)=6X[)<;*=LO6\\YKO/?]Z^ MO[;[8+ GLRA,6(6Q?@GC07IFNZWSB.IX,TY;9RQJ5!"-)7N.[;S59*KO1E-J MK;%!B].ZW@RU [LD*CU;#_L=5\]EJ.TB_.K-_KY<1?L#GH6K6/N6>YVT.T!C MPGH*;1\GOJ+O91N%7E2ZC<:$]11ZG."*OI9MBKEVJ9^82WU-'S+J/10627#[ MVEEZ7,<30Z6&0PB:3;/5RKN8/Z/7[B&.@-.9$W) !\]ES DA]Y!&PQK=R%&J MS+4(NCP1Y#3,9J>G:5^+("V"3@(-M0C2(NB\1)#=-!O=OJ9]+8*.BX>=EN5H M+*S1A>PSHW'=O*I:3['Y99_1-&9>7INBKQ%^\[+9M%H&;";PH] T8--^.(R9 MFS#LAO[2;EJV_-:X@E=^=&>P_HH%2V#[>,G"^CGP= M8. \G1AS-S%FL8\C=H*%X<4^?&L,%L8NR<2X'^-ES^K(_5C&;5@\D$:TGWPE M@+_'IO[0-.;,F+CWS!@P>-D\BK\#WN(NAT&4X $BV+B+HS6-N0][3%(W988[ M9N'0%UN81,D,BYB-9)$ 1!-\61)E\9 960P_3.$P(6,(\]7F0TDVG!AP[ON\ M86UB*O_@%8[P)M.(J(T1GLB/\:M%L8I)^X"-)E$(J\_B*&5#'!Q:_,0RWF,IUPK-?;KZ4#@?_<),D&OHN_K0XZ<:#\+/" M&U)WF!II[ [Q5/+5EO$7P_%E\)0QRF("V>J6::XJO%+BGU> )F93UZA#X&WP5_JQQV8(9;CN**2E M A:. 9EX$^*4 ;12@E ECM+/\!OWW@7 #?Q _)K>K "F@&#I-H@:.?:(7\0 MI_T95JT9W8.HC(; M+L@N ;[CCY##PSKX,S@>+455ZC,0([#U!!FKFQHX,1'.D A6PG>+>!6%XPA? M)^E_IQ&:)T2J-PD*7>3@/M+I[ M*7PXJA*D,=$0_IO] -%#C(#%L0\W1%+ MTF;HSU#?$#L%>*A@BX9#W#>@DI$$T1RU _PQ8!=R%G@EZJF"-R7+>(WO.V$, MHV5V'T3Y+DKHU)(=$;K%48*<.1KYZ>D!X)!J_W ).KGZ;[>LQGKUOUO().*L MMF-;[1TEY$X2VAT.P31%UHC,]&5>L55BYWUBYQRC26,'P6(9>T$@G\EIEI"" MY!72^1A41"9E"IW.G<%/?H#(2%'X=?H@@I$BRQ^W>Z P<&6@>)R/\D1N ?R_ MD#I<]U2)TQV =#)0V,%1X<&=(#8'YCDA)D'2&!YS#8XI^%>0=GB6=6>$%S=; M $W+*+2I7=ZZ'FK[349%?:+3R6$6,]0@\)X!:]:] ;010#$TL9"YC0+&GX"C M( \&_A@3#Q3:R-3_P?5Y>,P-D@@T?Y(;N 3>G^?'*") R8:-$U4L"WNNG_B$ M8W]-?,#L'62'HB\M"_M\AU+97Q$%A8D:1BD),9!H(._P:H=1S.^%[FI(HZGD M"F%&T"6RKMJ_P::S(%HPCVRF 0,5!M[A$QP&^2I!Q"7IE P56"F5L)7J3&Z> M##+0DE"A61)3_#V"/'&L-'R%-C!_?=EFPX4W(1-^'T;Q%)[/#?/$N HKE,77 M^&YNC_&/X(8 3:1M"C G@UZ]!*GW KJ26,;O&*H9W!3<8#0I WH;5F-I1N]> M@D/P\5;?PE5F$9B&<,8W\@1B,B]W7ZG/"4]=HWC$'211 #Q@[2-//$885^>[ M$CMH.VVKRV=2KYDG7!7)$=-)&_+1RJ\W/KOQRY;=LQH/?7CCETU[]X5%UN(2 M$N L^Q?K_/%[] Y[[$_7[*ZULKO^RCK[ALAV<+CNH$%]\Z<@HSZ![? U IMM MU_'NU0[T+\A\G%Z98C3N?KG)"Y -6;7 U /OE^[(SCF&S>8NXODQ3_+ M' ;82[ZM)C&'NM U1=;Y+O:>$^Y83K-Y\%G&3[GL(V8D%^2Q3_3DF6EGD_6! M#&F'L,J?MQ\^?GAO_/;AYO=OO[V[^?K!-&X_O=O)RCS";C_>?+KY%3;\Z=L_ M[HSWMW?O_KB[N_W\R;CY]![^N_G]?^]N[]81__H;WG")3S_1M.!L:^WD:EA< M?7,'6>""1CM%RRM!O2Q&GGMJ_@I-"$5F+[)X3HANA-\&VW);J+'V/I0[!E9W. 9KCX6@>@?&W]WI M[*WA>B":0*..71ZH 44>S,3=-&7G,9KR2;E8DF7@(5I4@RY1_"_-PGF]ZG]I M6LVR9]NQ6NO<+[&/1BDY82QC^2;-C;LAQV'939 'SG*W!MA:K8;5?K6GR<^W MR)]O S[L]3SZD<11=@+K?EL#4 >9QXR7;=LQ 8'H<>$@$+=9+"T#%'",73PF MJH<%N!2W-(N0XLXA+ HN\BW)K:RBVH-O%_T5;<2I_2!W=K'%4C0/O?OH1PN" M?6@:P:SB.GG?B29Y]$EX1Y.5.!K*/+3F%8=)$0TK^ 6Y2J?3R.,! );O4;B> M)%+A%L)%*5RAO&&6#4 4\(V&BR7LII!*1!Z83S=W[V_^GQ&(0 N Y"8;P[T( M'RIZTWP*X42C4<)2"G;FO((4B=B]9X"84T:3>1%N),$Q8D[A/8^[CE8"@.B MBGWR\2$128C@CF&K/$\CW[82RVU8_;*KND6>ZJ68R 0N'1 9GD,?%2:%T-.E MU>F."QPHX05&G^26)LSUR'MM&9_A\U$&/T[!+"U^0=\JFR2^W;)M3!)8977$ M8?O]JB]1OBS)!L<&LK6,+TLWD8H >5(@-,;&" RE0&G)]\HV@5EE?64N1D[" MB1NFV*H_C8;?#; M0PZ.U<\1^0$=D@PIQ$V-D>O'QKT;9$0[ G]C-HMB.H2@ M&,J@2&10O7"G"^]JX0-EP#Q\I*G<[6C( *+8 Z 5VS=NL/0XXGA (6AXO]W MH(!*],MWA)S5VRLK!ZF+HZN@.Q[V4P1]E43B%^[.W=A+I%\W]SL+E> FYP(! ML =TOC(*U -7&+$R+=E%3"@7#"N1'E-)=!!D%;"QX)'H@Q5G&,F;6,-[8&#\9.O>1N&-T%2,?CE&N!PO5 MKTT1_WUT0!,O2GIPR0&/A(KO.:Q+^_1$]9Y6R^\83 !,1==6E&#<8(3H#5@J M,KF*G)+3@\4A+90YLE=$7HHL!;N##4V11I%2A,$[8,ES-ZE$3-42H84X/L-+ M*1F&DA?L5XH:2HF<_"GBN2*?P5P6WD30(V!(::'IKRC1IB'S\J2 @K?X499@ M?D[@#KF?0^C7ZPZ,1P/"],0(BD&2NCRD-:;1RQ=+JN\NF KRC,C98/ ]P2+@6,)?K%\%W!'F!N#V:C$N8B] MB#OB[AP11T5NS ]&3 Q8)9Q\@,@"F/V?/" .OU(TR3762Y%,N90_R6V;(V9/ M%N-$_+4IDR?((/9U\: N<[VJ]9[>P0_JNUD#%<5/4["_53>-PANY[4$)FSOF MD?J)8F*LFH><6KDBCK1:4*"Z::'Z"5V3V^A+NHF[HF5MT)2(6++41_JO>A%R M9J#=A(?T1]4&Q :XRA.1OI/OHZ1:KJHN2&_- M*S?K^!>KRG^)HWL_D68G\(5H"M!R?R@]2D_FZ(=$7*Y6KX.-=._82JU63O0E M]T0)R7-T5#P4Y(>26NBR5[1X9\&_RY4/7*ZXTA\ RKHH[L%G*'59>=>RTELN M\"C[RN5OR9<*.C%L*L54-BS&DJ8 T)*4R.A5$L(B '[OAM*5SG]'JGFN_8+Z M.6*DC>,NW21AJ'C;L9JOGL ?KI/$=)*83A*K7Y)8 M7R>)Z20QG22FD\1TDIA.$CMNDEB-#1Q^*1X&&T@-?T-3V_%7+WYZ=\#^*,M[ M6;F-+7LAV\A/N"& >OTG^-CXR,VQ#]MJR=X<7.LOI="JF]_8Z70/OM>NU>P^;-7GWZN&J]XKX$#3>;BNOH_UO/K;H^@H MNS7&VB+I]NFX_P"_0HT!@S)IA[:5YW5H2L?@\P>^5L\>.'L0K"CGEW!H?>\_ MO31()W]'I?47=_I7:T]_!N,/JX^\!M&WG>NRN@;O?>@:]OZ$/TV[4?O9*/N" M^H1&:)U%3]^3:"O_#$CT?#+I*0;R:?9^;NR]W3-[C=J/'='<77/W4T BS=TU M=Z\3FK1LT^G7?J*'YN[UYN[=1OWG<9PO 'Z8BWFV$S[)'+ES1 6[:S9:;4VE-;P:IV\U M-)5J5$!4<$S;Z6LJK>'5P+U8O4LBT[,-\_Y:-?SC4NW@3L/L-YO:$M;>E,=A MD:4]C>9_&HL=YDFT=)M2\[]2PUD:OK<9;C46/DZ!MK??I M*-K!;WAEW,1JM]Q+B*RU&F:[K7WV];P:ZS@7HWWV=0-4TS:=1E=3:0VOIMW4 M\6^-"@2HOMEL'2=\HV]F"_]L7%;X^PSB:M7'_,H2YL;#B>CGIZ8T&IJ JWAM70N2X2>KU-]VX"?<[8QS7;O.)X@;?UON1FKNLV]T5E/H\U#H<2*.FD+K!BB[K65H'>^E MV=P[L>6D2?1L/>=7O[I^^-H(L&P\"G'*["Q*W #[/,UB'&Z4+BCGA?T[\Q^> M\7)B)N>58[:U(K^.]Z*(1C0FY].PVG;.0 MGH_3\&IR'Y\^7H9_^7,Z8;%QY8?#:,I>X_1>%B8/*Z8\,6OLJFFV^\W=*4[; MR,]S*U;GN>^DYM+P$K' UG19KQOY^]]ZCNV\O23WE<:&S;)S#VVUQC3Z."6N M)O?Q6&VU?H[7ZG8GMZ2F&J,XFBI#Y!_C75W;!::&M+AF&JUMMNU6W9ON[ 7N MNEBRC\&?TT(AJWWJ"'0 ''HV>!_=*W;Z7*]CVIW.J>.L9GI''>>GF9YF>B>' MM6WL6Z/Q5F/1HQ2^5J_^?3K/E_F=032I^IB?HO!:V.7A6 :3UMOGS^R_T6OH M-9YUC3/PPU5S\C_"F,&[_\,\XVI,N9!1:,S=.';#%$X:P@83'SX*?'?@!WZZ MN(0$R(>%2&JR1^: I]ECMI[)/XH2GS/+$ "%/+SQK> MRQ7\SVI<"'V>@7F^O6Z)8NA8H)0N#!\4]B2]E-:\(/W/(G/EC*Y$9Y=I;"@ MU3U.?TE]+=N*E71C7HT)7!NT=>%$[>ZDU;%Z%U(Z<;:.]=LP93'HXC)V9AHA MNXCN :U&7QO^-;R7AM723G.-"90O=YR.DOI>ME'H177ZU)BPHN[+H!RK%U'G@=[T6'@S4FY-*SW=RC36>-Z5.'FDXRU/1 &X5O M^4T3D,^+LD' BBIK@X=6 M[5MTU@$+3]O1K260ED 5C2J;74WZ6@ =/9"J!5"=+D0+("V GD?U;)A-Q]&T MKR70?__3?\$?.Q'Q*@0 .!;0G@7!,,WC@-RVF7T;6\_",!T9> H&7>^"F\ M8[@9;1P$S5=VS\*,K1QKIS,_^6$V;OW;A!FC* BB.?9@I?LTDFP*%P%K)$:4 MQ4;,3T=1_Q1^'L(BQA16GB0&"SWF&7=LEK+I@,5&LV$:3L-IT$!KIV'WWU0 M1;Q%4!6G#3ADX,X2]D;^Y2W.R0[1-OV_UVATX MD'1CB^7YM[:%9UTF:/Y=LV_9O>[:KQN6O?:[3[_IT/ MWVNSUS^9O6JXZKTV^ZV=5MT2V-H>[%O];87.-&18B']\$?T).?-'SID_K'+F M?4)^>X1!3P P*))VL*#/Z]"OC&AD?(M B3&6%91+ 0%J(!=W:'WO/[TT2.=^ M-W'#\>6=_M7:TY]RGL=:FVQ]YD=NN6#WRAANQPT2 TX'XO!;-/.'1J_E/,:Q MNI-=?^Q9 WJ3>I.GO\FSK:_X$]B2'[AI%$L.91IA%%[[X;V;^/>,/"GR'X_) MGZQ%#*8:!KO'8*K.5U9')Z7OC0J:T]3SLML-L]]O M:$Y3PZOI=:SC=-C2G*8&L#D[3M,U.SVMTM21T=CMO7NMGS2C.64OUL9C?DXG M+#:\+*8 ^91YN!L:NS+#<2O20+R$L2M=T^[M6SRJ6\<_R\WLW4'VI)O':TQ8 M"ZBFV>IH&JWCS;2M??OC:QH]3TQHFEUG7_> IM%GT=H;W;W;8YPTE9YR".>Q MP>?$#5A"H1QXQ;T_9.4X=*?1>=).(GH-O49=USA;:_Y#;K<3W6>S6;#@C. 2 M#/BFV>\6F]'&@<8$0:/.WF.:-(T^CP%_4::!QH3U[M:.-M_K>"]. M<^_H_DF3Z"E;[QN/^>[SG[?OK^T^&.S)+ H35F&L7T*#:Z=O-AO'28W3 ?YM M5V,=I\%QS=6!"T2%O_^MY]C.6TVF^FXTI=8:&[0\K>W5P)_6<7*F3T5Y/Q4? M^QU7T&6P[2(\Z_W>OLJ@]@@\"U?9FZ>YDY;5?>Y+.165O'[^].K<-]YY*"PRX/8UL73;Z2>&2@V; MR\*?IMVH_>2#@]_%"3EW+J/O-+F&-!K6Z$:.4F2N9=#ER:!VS^PU>IKVM0C2 M(N@DT%"+("V"SDL$M6S3Z==^ &D=:%^+H*?$PV[#JOT,J#I@X9$DT.;A.^+! M5M_"63FS*/%3/X*3L,!-_7LF!J;P==7G! @;Q2/N *"5I>L?66E^#5\?<+H+ MKLYW)7;0=MI6MTW$NV;,2Y6(%4,C&O+1RJ\W/KOQRY;=LQH/?7CCETU[]X6% M/WD)"6R' ^M07<\?^M,UNVNM[*Z_2Z/UC;K+%O31 MO/AG>;B6'Q;;:A)SJ M=D\G#=['W^";'??G[8>/']X;OWVX^?W;;^]NOGXPC=M/[ZQ=AJ@=8;?-%%P-EIG M]]875]_<01:XL>%.05M+$X/]F,4L21AV,3?2293!^[P$9Y3\ O M>9L6?.TPFLY$WX>T5,#",4"&SRU(69C@LK 6?I=O$Y#) M8U-_2#_#;]Q[.)\[\ /Q:WHS6VVAX0/DO7ZI8("]O2POH>$2=-$HWB ML1O"G0O:000:HDEJW!?KS\!(Q0L?P**6<0L_ 9Z-UB@N@MN\7[L7OJRY_+&" M+>\_?H!?@5+_,J_>+>T86W+!EN<3'Y"O(.LA -Q/4C@D(.8LCKQLN-3?"0 V MS)($%[IG20I7\>7F2V+2]40_%F-&I!&[LX5E?(K":^4ZX2BP<('I%7P";F8 M^.$IT 86\[)A=6[(C0+8X25$NBD9^>'@ .J!P.EX"3*XG-ON6LUQ$=I] @.6<% M+:VWHZS<9X>Y:F^6[HS$"9+A&!4_R?+IY>X,?O(#.'K*@)%TT=> !%/^N-.P M^J^XNLJIA\]53X@S%_* JX0JV4P TL9]%&13 L0N2H=E_ 9<"7@19VVXRM3] M%_R;JW'J /&)2Z),B,R5MN;[@<[<3<5VAT.T(QD7;JALTWA,0H2"QZ63+"'E M'1D:!Q:'G&44:MAN*MBZ>]QK>CI:%9T.[%7:'*AQ(#+"OM:]P(I_X,K__ 8P#XB-0U6QR40H3P_1I$"&CGLF\AH63G@ M^@SG'08Q?PZ MZ(J&-/)2KA!F!%6B_ZI]&VPZ"Z(%\\B@&C!0=> =/IU_D*\21%SB3LF:@952 M"5.I]N0VS" #;0H5GR5QQM^#/P$0H"\$OL+&_OSU2$.%08<+;\(A_#Z,XBD\ M'\%7+EYR8ER%%4KE:WPW-]H,&?U1M%FXD[F/LA?YF4 /, -C."1\%I/XQN]8 MZ$E[<8.1Q:F&_)$-J]$N>U?J)6#VE+!WH/T <@%ILQ 'AA_=Z>SMV"73/T0 MX!@37.GZ@"=;&_9 6 MJ1";HC84,A@("K;;?K47.S?%)OGS[2:8Q88TMW9; T]3]@<4+IK=O0/+U_-@ M>"#[;G? V-P+#&?GH4'1G.,JVD;W"-5@'S(PN$J4(P<)0L!B:;L+C(:K2-/8 M!WE-B(X*G_"**&*D\"44)$;ZSW0:>=Q\8OD>A2"6^(-;"!>JK:>\8)8-@%/R M?<*/\N6Y3$&$Y.Z=3S=W[V_^GQ$(*Q4@DN>*N H2U8DJL* O/ 42FNXL0$]6UJ2[K6X]Q(NH+TN]S%AKD=JJ&5\ MAL]'&?PX]4$19L5.X5MEB\3>6K:-/M559D!LJ-^O^A*YS1(+=6RK!8KDER7P MIX*5) 42HS>!P/#25EQ+)>V35<)68K.\#X')!9,B=0F4LQ1[H:?1\+LQ"]R0 M@V/UF,?Z2A7P SIUIR2T^7775@;K9>E0A]Z8ZZ+; O55?]+C+! M%.@JB(V;>HH\+!-J?BW(=>9N["52P\UM X+C";I,-COE(WJ-]Q/+YC[R+UBM I0N,2HD@0+U80A)_!> MNN F7:-XG0!M&G'LG>1^!^711'R]8KD<'*MUFIU.L]-I=O5+L[-UFIU.L]-I M=CK-3J?9Z32[XZ;9'OP1Y,$G01H*R($HP74/(*W+U(\\HC<&=F M\>WGM)ZC*P'M&(HGC3%8LA/0>*18SNG(_=WY3] M463"C491#+0NO:ZK;M]2[B E"\*.1+*>=,. 9>4#>\"\G< = M(:!QK[0K7>>+AR M.;D*UP2=K+2F:KK*Q^G2BL?@+H49"U 3$;7E,)IBCI*YBLXT&5[C;%>$8Q7/ MZICR*!JL\\##L"/IE +@NX_WHE2T>6./H+_(XEU(W.9!KGKAY@G&!/3DR M'^Q^Y8>8_O!:QPKA3XX%'")*7LZF4*#R9;53C@(GPHN)1(UY8OX]\?69NR!T MS)_[$D?W/J9"?\6X_\CX)>/.(F0/^5LPA &K!B)^]84ODFQ9!?4J(B"/BX'< M54Z1@""=#'D>#G^4L_, 4RQD%^/">3?ER7BYHPP^1&>MQ[/@! M8YQI!V)3XU=+.DR$H%$U)2G4LI"(+I!["2 MB[49*)G0IAV'?F[@P>9&C-0T7-]-,-E%-?K+\?8-F5U^DO^8\H' /(53IYBD MRJ8F%Y2 (5,>W9=GD>X!>@2/9#N42OQ\F+KN.=_[[Q=^;]1J-QI.I]_TFJV> M-W";/=<9>(U>K]5MMEO#_^MW7QR1+%;\A4 6W(7IH>N"[O]-AE64^*L7/V$Y MUZ\W-U^X3^$7/P2TP.S>CSR!Y=SX V;L3-T0-!V1NS]&-S30&/ *K$E*%R.6AA+0T=H??)=\8H\M:.J;R[&F7W")"3I&;)$*/##D* "LF VRE"Q'&'B-K$)<@VA!4<*L2B/Y/GXZGH (+M5 MM1'0P?W$A.?% FXPS-#/I^3JE11T>>]YMA<]"P_C%YAN%M(;LW@6"1-;X<:S MF*%2I992Y&@)3V9%&CX\,,@\P$Z>/G/EW]/V&!<://NR=*_H896"*%3H( )5.^8QQYTJ]^6 &,W\THX7EY4T*.SP$CA1G+IM00 M":]=3A/"CSDJHH0LY/8(I?BO"C5E(H1=XH1890B:^SV+B?-Y$0FA@@%B3NMP M@KH!(!<; C/E>K^H@RMIW93J*PK1D4SS!Y4LV3('Q/*WY('XI[,$=9:@SA*L M7Y:@4Z98G26HLP1UEJ#.$M19@CI+\(FR!+4ELKLE@@Y^CG.\4=52O&K.>"*$ M$<7%E\)@A>^X'9*RG6T8O%/\K"'(S"M$X/\2"G]O=(>R==+ M-V^_8M>\XX1;&$YN[L>*0I&XAJNN^MJ6G65E'^!Z)EV">JMK.8]IV:!Q>W?< M_B/,,_QDAN[Y:D4T0*2B%=R M9Q/P>_HM5RJ1XR<\DV\ 2_LN[S.6U]4R+YJBWR;EM;7*:Z@&=B*:#$D7IUB; M0E,)Q>ZXL4X/<7\R]Y=1JS&?>PRP/CE@4P7S><1EP;O5P58X@>1@,D4$CSJ' M)48V$UX&!:22A(JG,[;1#12BE"MBD8CH I2L$J%YZ)"&,E1D2MK MDY5@JP.&=%!VVI9]5GG&H#PC1_TA!>H302QC]/_&?IY"F*AEODR$>J:N5T[/ M*EI_4EXEZFBD8_)P-D]%IJ?IR3Q7?0DNV%;IFMHJB8P WK)RBJ72LSR%)>\M M)0,AP^(0)D\U=I%C1/P,?I)DU0EBPOWIQAB]Y]%.$5,#V_WGN:61=H M$(TB3#JB(!K=@,]+<0#80U"!\DCAISQD9A;I$%P*459?GB1($3@1=S/Q)E;B MFQ1Y5^I:*/*^A'.H^'GP+3SW9EOP5_@"4#]2PL'M*N/_L#[.:/9XWZ;=MUJM M]L&=D';#:C>[!U^V:S5Z_2=8M>VL__81('#:3[*LAJQEV[LYSBN]>9N&Z@V' MC"E#]6H[8E(FM,K6EI3,^J"!GMM/_/2.R]W.O.JW//,#_T\6LDLYZT[G=][5+F]G?F"%) MM#\;3- VX\Z"!XZY/9%AW]69-P\=]EWW6=[5IW7,7J/UJ)G&3SHX6R/JHW& UT:&JH;S*A.NZ^A>G"HMEH/C*%JJ&Z JM/7.L#AH6IWN\>#ZH%, MUSKKZLLMI!^DKU<_K#=YPKT]%J:<&T^:^W$_#="M,]W8B:YANU=3W MSN;1,-T&T[9FIP='TWUM= W2K2#56'IHD.[M23H@2"_ CZYTM;D:E\9/;FIN M=VI3X+S5]K:&JX:KAJN&ZX'A>M5K-%YK>!Y0]WQ@=HZ&Z7KO2$?'A@Y. M]XY]'+J_ $_[UM&I9VPHVJ;3W#?FJ,WO':)C?>W4> *HMFT-U0-#M=_0L8S# M8VJCH[GJ$T!5RZJ#0[77TQ&-@\-T[UX8VO^^7V[,2F_5*]%8><5(.D=K$#2A MUKZ:D+:QM]K8';/3ZFCOV@'QM'?$',$SA>E#ZU#5//2@_O5=2+[X1,Y M->4?'*;."2:QEV?-->'M7I1A]W@)I--N&[G4F']?$^IPT*E%$X5J&.W>1.'P M4#DJ&5>#HVMVB][0SYCC\! 3_Z#4>_!&(YJ(+I:([([I]+J:BNI 19J$MH"D MAO33-7N=_MF33_UI1Y//J4J@MMF^ K21*2)Z G!T3)[O:8F(DU$FH@>0T2V MW=%$I(E($]%CB*C5T42DB4@3T>/4N;XFHKU":O^DL<@_G=XT[!4,H"&Y?R0T M\/M3%%[3$.M?_- -A["J\9&/LT[.;/SW4@#02"91%G@X.EV.6J<)[P;B"\T! M3R.3)K&[.",\R0:PXS1+:6J[B>/>DXRF=\?TPU$./C$-/#$ FX99@$.]:=GA M$-"4YJS/_71"D\,MXS;%$>3T%OG@5(QLQU'LQ:KJG'8@$1;ST>,XA%X?R%GT++&61ZL; M$]AS $ND5%:5R..&;K @4H8710'M8Q%E*I0DB P?SP\7$ 5B\GM<==E\29S: M+FXE H# ^$8@)ED04JOCMDLBG%WQ>VL;MF+&+_MF(T"-DQIJ+(/D!G2E0^! M";FPHZ&;3(SAQ(W'+!'OP+>-XF@*,$WA/A-C7EPUK0A0!3"+.?)XU[C9_!7+W[ZW?]WY@,O6M"= MO7-G@.F!\94E<%?#LV//[Q#G\:"$_ R.?N\&@&2 /"G7&U8'< MCDQDG$&&FH4QBU+X$3)I=PC;3GSQ"R"+ 0M\AGQW MS#G8)RD\+G$Q;B#@< M X]S3$PW'R*)T>%'031/.+47;R38\"7@[_,+ >$, MVS&F@!P3<6#\W$.N R1;8OY#V\E@;8&Q%H??#C /@D_@B7\?&UP-V,.;&M MD,'/:.-"*X C!Y(ND;_+3X.%27N76YP"'T=>CHN\M!M60V+@ZCW!AG\#X1D- MOQM_3?PT9 O PO [X(D_G- ^@),"KX6KB]UYB/P4'E^EAO7\5!!:JT]U%[.( MH^B;F 7$D-_.?2^="!U=?4ZHW(WB$7< PA+DXMI'%";"ARC#UZ0X%VN2L@Z\ M)'!G"7LC__+6\Q.@L\4;/R3F0 \MJ^6T.M^5V$';:5O=-HU;$#EOXCUB@U:C M-,ZA]&6W(1^M_'KCLQN_;-D]J_'0AS=^V;1W7U@D BXA@>UP8%4F!^XQ!>.Q M/UVSN];*[OHKZ^SK9-B"GCN*N&_^%/C+)S8WOD:@"Z\1=G9C)TOXBSMF1K-9 MIM@-MN9Z :[^.8D+4(W9]2!F[O=K=P3'?.,&1O/AG"1I3/RRVU23F4!>Z MAAT IM,NUM#UJ[4TXEA.L[GVZX9EK_WN6,NV=EJV,K.W((\GR<\]#.UL4@^1 M(>W@L?KS]L/'#^^-WS[<_/[MMW;3S>_PH8_??O' MG?'^]N[='W=WMY\_&3>?WL-_-[__[]WMW3KB7W_#&RZ1G_$I'8L%9Z-UWJ#Z MYP]W@,75-W< EF2<:Z^@,\9HTY/S( 6['-[GD5+S!P +^48,NB3[,005!YT/ MH.:!,B\?+U?2[4830I'9BRR>$Z(;X;>JZ9&>C?;**BC*DN-T;,/=<:JP%G]! M.^G,S& T#U8: M@]@7%($B7WR"M?ICU.7=CN\/4O_=37PFB[ /EI;,OW]0^,#M*QLQN MX-I[HO;QL^00+'Q7 M87L2W>-V@]U5TVRTNKOWH7JB?GSZ5LJW8C=,I^DD3:8U/KO3MA)NU M:6.S(VYV 37MHW>NT[=2+@CO[#O1L 9*QLDV%]K1Z<OEFU5$X&$EO//5R.[405;GG#RV+*?\ L<0RH MBA1QMAI0Y0DQ5 /@]*UF40.P5#=3%#MAHM%+IV.U\Y1LU-3"*+RFO2D_=*GR M94I5"/A0MUB?I^.'):T/GRQ.(P>T^KR>Z67;ZA:;*W*[9VZ,M0,! &(T2F"% MP6+SNFX"O^)+V@W+D6OR#/EMIYC%/J:2P-NH>(C*>OC)B@1UU%\G;C@F0+F8 MBD*E79AK@NP@'64!E7QA,I9IO.P4Y\('/#:+V="GG'_X5BG+P&_'E!(/?\=< MD2AQ _P0L %.)^I<4%F>X69-N0O8C\=&+*9Z#O<'!X#8=:=T'R^;R@?P@V3- M""X.JRSA-T/PHEQX7C#"7\NKHI:AO@9^2Q _G MCN(%O]P"&U^QTF=D_ )"-;$, MS;=WX=MPG<2W;5MEC9OY=L>RBY_NPK/MEBH4]N;:#:MW:*[=+U#H<4R[8_4? MRK1;9;:L,FW)21MUYJ3]XEIX?2G'&OQ./N[EIDE ME:S85C&N:J/R@,DFSFPKN,&K\H0$S>N_R\A]P&+/X*M\B? M(K1>#J ^3-E6&(0I<9QJS0&O>H5:2OI=%@.]"!ZQ3MFKPG30F4L+K=,"8$TP M8#VUA'2K>FD97[9ORYAC*6A!RPIOFS*/F@P4O\528?X=ZAE)M 3K_6D4:*3[!$0JT<1I%YKO*9HD#Y7O5T+ ORZYUXI$@,N1]J.*Y(>' M2?ON)HZC""IX*1!RB)TC M1JA1T6TNN^88.%3Q%0[96+#81&U !CP,!8>$YFBL$20]P\E3PP2GO!G'C''_W UL(N\JZ=US MGQ4M[R=\1T4CR<&_J&5MQ(-T0%HL20TB-P:T%DB'W5]W_T/>/,:_FP590AT9 MLP/D/L,X$/+."CJWL.S@-25/4X%DRM\A@J[4W0& M'G3/Q;8@^ J=@6B=W)]PHEP]<(V!_"E\++K'&J+!Z]IH@O2X"^A9QL\,.!A% M"?XG"P3#70;QU/T._)CT)?A)KB6DT=R-/9Y.%&4I,C#:SL -D$#Y^2K.,W6Y M]S]2K]7I$&\$)K(+6RPR3_!?G FR6&U@S'.W\D=? M\4=W^*-OQ8]>O-[05)B-1KC%>Q:@ZO]#7O^2_!687W&9<'LMJ]-[=8(ZZ#:^ M64A]).IMW!.E>.P=B(7F\'WQ2)ZI&#K5/%-AE4*U(FZ)FQNS$-2(0&&'P$!G M$*%C?YV$:K8?18]A?)==;OA3'>3SO6W[=*H,B^A9=R '=&RJ3.3/$_R,W M%Q U$T69WF([E"_>+ZF>::F+83'%)%<_3Z _X6-2R#;85"7^T8:"%!_$S30 M;!,-G/FI':O[2"RO[K14/RQ'M1RXT?6?Y)TX#'9O/WM=[KG,X1M6KWWF!VY8 M77M;X%FQI\2)KA%7WW2Z%L^XJ[U9JGKR,+KLAROQ#+3SBWC&/F$O7(T[PJJU MRU/,EMX83[WC(P,I6(T5JB=[O#7..SD586M]JO"=/:RGP-)80;NH$; MP3$BJ73TO02I8@S$;K]D [A@];5W$3'2_+T?@+6.63A M894%][,2PS$H@RP(HJ$L[=F\05Q.#IND?001!B=$[:J;IK$_R%(Y3IC>*FL# MX3(\-O6'_.V[PA.'"2CZ*.8?0-$-7-4HTRL@P/):Z/N8/ MB>88W)M+F47RA5CH]/&.CIH/BN&G+=R_Y0=H$G Y]T/.%)85T/@ GWWLTYC. M2%17I!03P<7S;V4\3L 0)XY6O1.!.XT\?^0SS\09S;@)EXOKI3P/D14ADQT6 M^=1I\28!WS2+PQR\%*I;'EE=\G_#E\"U\_IY_&X;P2C""4C%%DB41TC MSX2I6%B'.!"+F>$<5%BYZFW 6EU&HLM(=!G)"961M,L4J\M(=!F)+B/1922Z MC$27D3QW&4FMC>6;-7/K34R@GKC>^J[9O*.)VFSN9/T(U?ZY/W@-R[GZYHI4 MM5*G,#*,E&QVS,7%+'I,:>.)6X@,W/"5/3'RUARFDO5N*C^<1_%WWLB#/Z#: MG);Q^5XXB6Y"9Q9#6K>[(\INH%TZ*A1.\(>D# 4CEUGF2S= C0?=4 M=.591JZ]ZP?2\Y11DJ)P&-!GZ$0PL5S$I0(.R[@=X64@ MKF>A?&S-WN83%M+^T?&A-*F,A)-)\7>P'VR888(B_$K>/4 9DQ;'V',N"SS: MK @,,\R!)P2QKYO@I/H6X/DDRY,\?]K /MW1-78\##S)*\>3.1! MMRS'DXUYN0Q'9,SM'L#&./82U-6/@*#Q+%160PVD$^Y50H F+/3101,9DRC@ MCDU>",@WRU-$BTH\#A4D!I?"23)T)+Q4 #U_F"[!751(%<<12Q=ED\)%YOE! MAFX8V5R(>HJ(;9T@I>WI\/^=NAJ=WC%W.)2(+.9L%413-F45.$2/G(2#!Q)\1T@X#6(&IQ6Y2Q_^BD$)7+1<<4M9R%AD%QH>P%S(4ZJK&^4GXX\,%C(:01+9( \U M#]K7@2\)Y_ZRE*A#!I? C<\,X:UKK*XU;"OOK_&0(@\/-:D\B#;=!9$"\9( M,>(\+H_,%=^![DERDZ)N6$\'J(:6M3N6=.6CEH]^P1]+_8$_NNEP@D@I5HN+ MA4BO$3@MMDC[HBYX&$BUNVT3P"3*Z,%2Q'_(D QH%&Q[$%_:V*:LZJ+2)Z[A MO6QWN\7ZK7:[M/Y..0+5RY^@O-]HGGX>C62ICI%,&$/M*\;PW[0TT^K4#KN= MB- ^"[%V$-1Z%'1H#23#(")K;32Z7@\4SN-):T5;(*9ZP21""V !@N0[JN2H MM^(/7%D^CC\5)=TB/0F5 >I^C98EEP:%28"_5DIK1 #U@,CG>__]PN^-6NU& MP^GTFUZSU?,&;K/G.@.OT>NUNLUV:_A_=J/YHF8HR^65!\*8P^H-Z7#XJQ<_ MW13:!E+O>WZA"'-@55CX>[+X7$V\[] "PC:HRL&_<(>,G*#P 3:%.'ZZ1U]/ MRCP"[TKMKB 8RO;@M$K68 B,?YHK=[_>W'R1OJ,$S7PJ(?X.A"EA19#[5^:- M%7H760KK[<1S=TN0S[1T+,,0-K5;0W MO@G=8 'H@BBH%M+)A";\S=="5'U6O"A(B@KI +?E-RE:P_I$??P^B9+@)45/ ME667&WE[0VHB$*$'CAR_9)?/A%*)2\RQLC?P&??)#!0)S)1LX:$?#[-I0ND^ MZ.T9IAE9M/P4W&4$+UK(A+TRBWG,,>K(ZBVV6X\OOG^XP>><$%N[O#:#^_=!',8J,66 M_ >Z=,#\3B/D(%]NOAA3%R,Z-'>%Q=(_@&DTF/CR8S%FY$Y#6H_Q*8"Z7\KE M2J88+L> B4\_6"ASDS!;"2 23645F(MMZH"MR9YBLMD9-O*CSS 1B_<+)%>6 MF,\HUI!-S0+NR^=X8QYN,_7)S][-*C7?8!HZBW.^HW&O(;?J M].@)+J+4\BGVL_'ME"*;YQ9(C,Q'>8:KL7^B#\P'PU6NJ;$PD4>1%$%A6)>[ MNSC^4V]"'@-&UQJL4O+1I8L917O+X]3<@).$LL0 FP7F4Y\\ZB081UXV%)63 M'@N KX@Z:CF$39;'24]XS \<>R*[1>HYPB54U%B*JEO.VF/F3P?8+IWV5PK( MB9P-/_:NL224NA,22RM!C_Q[W/2QZ"6&4YR=Y!Z,JVH&<_RH>EGF<<&,%"Z/GJ*;T0OG(^RQ/ M" I=WOIZ)/S''NPF7N19365$8.&]'T>A[/V0YW)QLH'['HIK++NHU?ZQ'!EI M1'->AHRN](H!Q=P=ZL?BQP"M_]#GE&%%]:<3[BWF#LV20UF.'/>3[[EC=<&K MBRE6++'^GAK2HG"=>3(!2,E25/WI X;!EJ3PHEO&W8P-B>$&F O!N<%TAGW& M4QIX/"4YJ- *%8ACQ%2E* GK+!3@XP\OT: @7)3E$LKYQ';RJ)\]QTGH'&G&/E&Q.L[0KH,Y"MO$"4)A[,J!;U+0(Q8]:.?W@S2B* M;@V QF)-"159BF,9:W4(M(:+,IIQ'"6)S-P5V@!VV"@^@N4+]!79O#$;!;C! MN=@OE7T$7+A30VS4&6\2LKHY,:S""$/?H!NB[AZ*Q&G2HT60>8B1UW3.Q#6H M^^2=2,1%+6O*&#R@"A N=241AOF_Y3#DZIM#RYV-,%[K(S29%TTQSHKA^<=Q M)TI5$>!3V(%8BJOM60@&!26ZYZ@MVIO+#.VJ1B(HRPNUG*^7\& ^["#_BNR: M(AM>&BHJ]D0$^E,7Q1;"("2S%AA+WM5)D!,A MMWR5R%^HXHK!8C.W _I%Y34-L#(LMPS7]KVGLTNEG>2_>CD$WG5T[B>RK(-3 M8Q@X8I?&X#=Y6%A%@M+?;%* MZLJ9D;.VCK5U?'SK^$)U\Z_494QJW$73.U1K>'TPUY&83S&09048^5>%-J\J M1Z2$&'-"LG3%<.1Z,!;,RA(^-\Q&R/%C%J/?VNZ^3>33"U[62OFW)+=(@.-. M<@DB]:""L1;G*5>Y"8)7M\K+&L*%.DP3XT C(!3D\Y6F0RG5N-#72,*7+1I7 M*M#4.(+/V\L5QM+\S34M)YX'2>L6&+[9G+Z]#2:8!-.P6F=%M7\5TD5D\!<, MMR@)+:279,HY.BJ- 0H#BW#B] 5_US6/?#T]+RW@=K%\F2J:$D!*B2W M3N_5Z;TZO?>$TGN[.KU7I_?J]%Z=WJO3>W5Z[[.D]];/:"FYD*A#.H9DHB2A MKAUYT+1PFXG&5Z0?2P_ML&BKY18-#K!2E[<=P!66VH^1CC_"F?34[*M4.5FR MW9=RHA+Q:NJ$4*ZOY$$M;E1Q;[=LP::&(XJ1RT,:XB6Z\"Q99OQ$HR##5Z2Y M+]Y-5Z84[%0R:!DW8.B*^0C; _[IG_Y,\;H?P<$5MKUFJF^4Q8A;?4V# M];"UE!@032.1?\QXZP2\]9B!@8:#&C#5]2(=+'=K2M3/+,[P5UZ/3HB0=[NK M*LZO:/EU<_?.Z-J]&B3UDEO4>?M.V;#XB&[2>%=QA\^9\\O;,24HG_QDPA*U MG!HA3T)>0-WE_<)D+H17ZNZDN'#)N2+:6M \HU"XDB4+4T6'IS:,XTP8F9QH M328SB6F]Q$_9ROORI'F")\'6?KNFA0,_$<$]FA630)2T 2'7:!8'=W:A]."N\&(69;%PJI^'@DU,&RJ%77(W\ MC;B'TV-$>W+@6SG$G::W)W,PIT_OS-N8KY@Z@YYE?^6\12"$PK)>-A2I'8JH MECJ2[/N!V?[DF"@MQZ.2HA]5_DV>W(Z5&ICM_RE*SZZ5\"_4WY83O*2Z,B?D MO8/7 I^T*'11J\TMA+][@,R1P VZT'>6<@][5.Y@7C9"&/<\!Z8^J4"%#[3'=T(_H4B8%=TUD4 MB@EBOT?A^)JJ7/+?A)ZZ$M=_<:F;X3#.X)/?57!O6E'YH004]M;AO3O?J?;* MSR*H<\>#.F=&?7^IM4YH9A2ICTDI][&:;RECVD0*!L\B6\(SEJ:!2-4@2Y'4 M6(Y\!=;G)I:K)EOPWK=BM5RJ5W6;Q07)6%;4!Y'.15UP,(,U-ZN-"?/&+,F+ MO6*^^Z6XU@;=C L\&@<_!-,\XQ:Y:* /.!>S"6R59\T2=2(SP/1180/NAFT< M)N5!;]7L<$5SXD>'O\K#+Q6V[7%<>5WTPUSL%T6F6,]:A!9E4S630JN;CWM7 M-,N"]]P2I$Z0Q/;6G(J6;*=WV*WV:EP:8JCVGT/\";,IB[&5V+\R$'.>/Q2! MYKN*UE1<+1>I;_#LLIY SB8JB>;>IN)-W M4?%+\M)")T,/)V*Z 1^_85# 3:0% M1D,Y'8"$M2()*CL=\N1@]P??)V64"H>H3":5FA.E"(*6?5V^ 05BD>_(LZ=5;GX*I:1GO M%)[,,8W2_LJ<>L[A2-_Z"MHRC@94N2+]RVB0Y (0'R*9 7)VCE53Z-)4YUH0 M5U>:"9X9?WJ_>F7KT$B610N?@$R,SXVT_'ET;U.C?G+Z+,_+9:!_QDBVZS2K M"H< M"ZQ=[U56]VT\P2;$53C _V_ORI;;1K+LKR#<,3%V!46)I&3+KHB)4$ER6UVV MY9+LJGF; F0Q)@$6%@L<[Y^[IJ9($&)VK@U7KK:$D4D\R$XE(XW&&T_X@Z)+MK; M03%B.A(?%:[IC=7P)6GIBRN@Z3/Q>QFGK9;2-"!4S.$MDZ>)1==+S4I>JCVO MBCOC+:*-82A*DVK];,JR.V;)Q#E^!KM:H^AJ%%V-HML\%-UQC:*K470UBJY& MT=4HNAI%MQLDF7=08O982> "7'18_I(42A(GF)O:12VCZS"D^JS7]@1\X5T7 MX['/(8!;FU1 CS;J. M<>H89XMBG+=/'.,$]Q!$>_UB39'1_6ZDQ_Y9'8?M1!RV H?S:4*MVN^^M]]= M5O-M'=TAY_OL+\A8 W@]K]/T_BBP;).3GT2O"#\8Z;_/',F[$ZH-?&*8UU64 M?5]2O?C.][W#Z*UV]I;SZ3\CH8AA5)SW2Y]&TO/MB[5/QWTVTV$3XQ"DLF3' M':*Z7AC@WGGRB&Z]>Z)Z#LZM:B)$-HZDZ:HF9;U'XL1@24-$"O1=A -5O)2^ MC* [2.S1$'0ET?C_IUML=2--+!2>#J.P[YW_#'L%F:7+/D3,0C/'O[,QK_RN M88@SD0I$F3T4(S)TL'^QP]=C!V/%/I6?E==O8M;/FQ1I5OA<&KXJP EK=?R] MUI%^U[DR8I[T\J;WFX7>^KDS')F$^[\@59")D>WI=?7T>&'0\:[SNO)H\8\B MS$#D[_9:QQ36K&RW1<;FKNB1OY;FI 51 85ZIM'S7CN'$9F8^F' 0DC$FMY+ M7R#F+C>:R_#6#3VK?2U<@"J#$2F;+!ZM#/%7_4A)K8KN&(^1%=QT]Z:VN##. MB4:)Z5F$/&&6BAFFJ&.)Q70;U$&F?()($0L\XF.QT6,9&>60/ NN_' 8\7H< 3,3V#'Y*&1 MW*5719)9>$>%"P[\-&!\A*R17?M?\2&/.F [ M ;&F]OUHI-+:8% R/&&.H5$S1\TH>3:#PRFZ611$K)<"!U:-I--3[Q@8PJ;? M1%DX:UNSD#H0\Z%7?BB\')NXJ*?VU<7X1DJ6.8K&D2*IQ$K->1GX#MDT0W\9 M_G7W_ILU:8RA,KWWPV*,WDV:)I9TESD!2#&*J2%QCM,H$,A6/ESXL*??WIOH MJ#M 6NI9B%D_FSCX+W$[VDOABE8;7F!%L>YZK0%O::*C(,Y>9'0LPXOM@8AT MYHQZ &D.G,N4CT?IF'(BF$9A@G8Z#&?9R';0J/0XXO$RG20T/L@N"VR M!*:.FO@4#M_WD/&DT%I^>"/RY7#/AR?3KY>G'Y^7D*):VC M%W-?N<*Z1ZOI?0P'X#=2;C_$G3:?W-\"]_\]=422YE="_Z7&<&RBZ98:=['C M'_MTDYC2!.R0PQ67AYC.'-%4N-VN$SLMY6B6.KK8E8\RT_AU2SNKTC'AF)1 M@NF.J*<*'/]GQSH5/.A(Z&&Q/"E)=^<)"J2A/PM"\8\M"!2&\)2[ L!#& MRIU(U,##K'4"N[N3OXZ: \R9LEID^&BW/V^6\- /L(E,DR6WP@1QL]F) M-GSD3YBX6-;F'*_7YIPTJ0;OO8>=G:1;:6\N8J,'H^DRIHUPDW4S.3G837\4 M?@H;!Z)[SL[@?GD/G_=:!WM_-+QI4GC9D,DV?>PP5PVE2(L??9XR2KX5BD07 ME6MW3D5H6L@J&4%[$L>%R0NY3_[=] %CXZHD-\["GESIK0;=Y%23":Q@UO7Y M*7[))S^%0W3(UWZ9''0NF5'JRFY4'0;/,D;)&6IBP0?Q]"C:82:T&XZ2&TWR MEK(^YF0ZZ1\ZDC@[.GW20(]&W!:E(BEPEN9)V$HV=(_2URS/T8']MZ>7?UZ< M[<%RPC""-XM/-%*#4=(EI47>"$WO3_&.2FI[S"B! MF<',.6D1 A3P4E7]+B**,S)MXRC+Y/[59Y;\I]1'=K*N;P2/F#>1T?12*\B1 MXVHL+%=(QX.U71*K\\:DGP[>2I$.4/]/_HB*&%(J0,VDC/P>_3 #>4""8N(WDQJ%Z12@!H0Q^F W2?J=F@YDXL"K3N"1 M#7:GZ"^9$@.^<8 9VYA=+%$?(:\5G,&AGRF+483]Z#DK'/6]^3?G,E,,DTB: MG:&RI, AC/FEPURD8$+VC]C]HV(T=^.?*]DF.;JL-^AE?C_,L9^"/M^/4J3L M@UV!#"8-%4_RY=B3DPU^*3IR$YC(@"I%DY'/7&BD6FPH7I7;$SNDJ-K.LDXX M*MCDY9?B)XV3@$ORY0^E29Y@((VO22L.+F<[4_,S!BC0RG9A%8D;&T4@7>X4/ IASM+<$WB9F]*WDU .,5^8S4Q'983= M<8,AO@Q!(N&M44Z+.[Y$'LS*& 6/#P>(=H* MW..V(!C!VL&CDS&^W UI@/H!^ 5D9Q(:\:"(4'(Z%HL6QD,\6($NK2Z?:Z&J MCW\?-_38S[[;7=CT/L +_B#4E@KPY=141(.?H-!0P.0)=,$&NI57M,ZQ8!=4L[G-, MY_/$&NH[QAA$W5$?JR:;IR#3;2:#64\+(<)@[X1(G52SL\J%83O*H_%Q=48) ML1@+BD_CP]WQ!6YQZ(8DJH>KPUZM7YI#TM>)/#4Y M""-&+K L:@8VEZ_\10N&G_V18"V1[!->M;ZU-M:/9-)-5.-*$]A^9ECJH_,; M$%6UTEVI[9M[9??D#F%^X$9P M=!^U+7NH8\J>,DZ"XR0K5_4X^MDPZJ7T#Y;1A?];NF*1OJ@QRU7EF'-10<-$ MA0&W.#H%,&%&TTPQ*T3X @_K]XU5'H3)(/4G$(ZQBU.ES$K)E1%FDIC3#C]G M"^96--M,H*<_F2030P)'3L%L] #+(J@Y=XZRQNSMZF@QF'O%6BL1+871(JSA'RIS(^/6CNGH?;S9]JQI)4 MF-W%M%JA1/B'WT<.()ST?I_ 4M6?P%P$W&B#,*LD8+N_!\*:Z#DZ$N1,8^*U MTIW8-3O]E^5=1H\9)3&H;9DNX*Q ^&;$*"Q8B$ F%@/!T[C/5 MD%B@3.8H%M.=:R34,QN?8=(E#2D@ I?=VMM>BFRRG$FW$>S\$:%Y$RK&H&&8 M(MV1R6\;GI46)\)]2L.J+S1"'*V%%F,%[YIPQ=8$82=X,8*@..SW&3UG=>;5 M8=9#X?AJ5;Y3=598_2<&&%&HN(0G-7_)QW8XCC&4^ZBDK^,H6:O\.8L(\_D4 M ^M@G\1-;U2]-.T1\]I62GOY"8 7QU@!.[08!8Z!+"X)?(Q>E7_B,(CRBB.A M6M1#AC3>T5A*X&B8D9H3:N; #\-<#F0YQ;O@5X%7]$TFBQA%Y3:@ES:^A7-E M89BB 9UU6:RV*)6#2CZ+_9IGMIDF/\$+0[-L@X!259+\KD5!TFNUDHC1B$%J]"311*> M:-40L=.FKRL5+INR7+3U:F!<#8RK@7%;!(QK;3?;7 UQJR%N-<2MAKAM2"SJ M\E:5HS[-TX&O!)Y4+V293N/;VR0K!J<30B E)BF+5-T)Z;\E]$E?VR[FTI.D M!0 A(0:D_6(D<2QFUIRLQYT0FUM+TXW%M>E=2RV\+U(,;!K5D]TP48&D9*NC M%NSI&B\(6YRD)ZQY+\(]DK,6ZP BZA_JK$M,[<(L5#D!\Z"0293'* MY DQ##-)!S.S)A/F/,(61AT%9O^GNB/% 919(9#$NT4^< %#GW.YZ$>421 M;S>BFT<[QR45](EJ[&GH0C:=*F[%WII9]^? ]FV$L<%ZD\Z.]R5UR!C/TF( MGL$8A4($;(ES\BD)4"E D"@GG"1K'QQTG/Y5Q)*%F X46DG!L."??Z 6T6M- M26%^0-5,&9NB*!1<03!&8UU"-1!VJ?T>BXS2H:>""'5'&W'48#8/52Z'H5V: M%"E$^$(7>2/]\PK1S1PQ#7CC;"@5:F<,L'JLY*\BDTZ46SHV01*74C)]G.GP@B$33ZMH4M[0!1[H:[B(DD M\,2S_R)5%94:%Y:7TL+ %M#,\ *CP:.%SVK-),WDHR&C/PAI;-[/P+GMI[M3 M&1E='SHZV4)F>#PL&N?\.&@W-[V3C,0<;9OT0C/7\#!%.3)"=X;?^.6+ZR\G MV8M7V$5*V!VWZ&K> E^WCQJ]/3@U1<77<)UNQ)AI.W07<&5'24I4+ V"#Y]5 M?(/Y8<$6FAJ9*OYY:=IW[11=&_^85@^WRAA&P;@NG4K9@=[?1'M& )HX8.E? M!_+4%<7ED/0\$D<9,XGI>IQ[$E9YY(#P(KF' [[1;(5N&(=8NV)DD=9>9PZD MPS?@%*_U:)>8ZQ]A7 /:FE#6!N21 J788(N.K+:40%VQC1@,1?M']DY,J9L&SQ;&6 I"A(7Y7^%:)DS KIU4"!,X*,%% M!A^?2*>E$H/%$<7!XH:.XA\^Z6<2PP6I!=F-*Z47\$;(B)N?+^>_DB& %;R" MYV->HMTR3M /.C:6T@R^_%\^1&"P2"W^I-9N9D*M=J<)05K,.0'&M5" 6#5Z MN#(X'LEF\$;$1\!3P*TQ4I!\24Q%/XEG&PS-\>O_H$LA<9\6\=R^@MN--Z[P ML_&$E[^@]9:^8'YL>UKZ--^Z[)Q6Q 1-S^"OWRJF;7;AP; $;)P6Q.3X8_2> M*2XV.HU&?$ON1M0WPX3*%WX-<: ;X(:"Q]I3%2Z'RLE"GNTD9#8#L& #9J8( MC!Q5 ]2OZH;X=6@8[]YSC<7?2X*$B)#^$0IL>.Y)M)WLEJ79O01KA'NP_>:6 M"8YRJ8#SM[&0N"P%-S!%NHC++&%'K+ MU5G]?IREUKM#W*Q1DFF/R8(SA1T*168W![=V^IR65QI.-R_?P"TBK:L5O_^# M9TDR!;,?.-[[O=PVBFCD/JT*Q84+UL%<'4OOFVZ9%H]6;@NSC5C]A. M^2L3BGKOS_C6P>PYDVK"+ 7PZ9ZYD6 J8YSM$:L[#9,1A:4R $KXS%PX)DJ& M"_,FA@\/HXE#,D8!*R)M][(;N8OZ46[%-DOCC3 =RLY@ZW4U7>\L6)+ARUBR M6'BN4G2@BPE\*3BA*D%*1KF7I"B,:OIRZ R41F0Z^OT?/MS<\HV+CF,B*0F< M$1&RYL(1 J_'XR1P4)&+OL,"-MD.R"Q00W+J??:SP/_;8$)G]@3UE-F\GW9U M:T:FU9CTVIL6HU-VW)LVJUG^DE8A]JMM;(.M;&<"V$=59ZQKN^+ZW@. MSF$^1:]: SBD25G8FO?^CF4CS9BX:Y)4/@JG!1I#^D0 M=FV)OCIT^9I:3\W;4CM1R+O42;@XG6J2I6#D(%-TS%O'[:U 5F^*LP@KX/$6 M6ZF%7;.&H2((>R-DF,$(?^)'W%E&7;%8^LZ3WG?8+S(-MO=P/$8:-CPS&6)> MD$P':21B)!13]*=RMI@"C#Q+Z"$G_I23-(L?IT6#! N@(?FX4D#P$)984GA@ MYG?FX,#,)29 QOYW:8J%'W<+0Q:H3S MK))V%/6RI^+EV^]INU M+LIAT_N$S1_(3M#)'50?H:>^%9/+X^^!-\VWG^$%V^_;?'1\L M9[;O,];CX^;QT7*#K;2$\R[>6BS=G3E&6DG9CMYG:OTHV;8G\W"WX/6_1ODH MK+KD[O;$._>[_)\VB+C_(Y]ZR\*C5V29:<'^T6ZV5K9+'Q _W7E9]?M/.R4\ MW@#%TBF_\XY0=/@I&(-?Z3#(S?;K>D;E#=.P#PMUMN#5OO-T=%^^+/] M/ZWF,!]K^>R+EI-,\MQCDK@9>"G33;R!>S>_0=;M+Q\^>1\3K)M&OV.V)W#V^S."?QO,&>!M,N_LW(+=%A;H!VP M0)TZOU,;(#% ':3[J),PNF(_#VA6IS8>8CT-U12CJ$>W$JY D80/O+Q\C MI-Q#/$=,VD8<$EF&$TW,$+E^F/'5G+E(9$__)N9%31S*@X4#LI!OB%S,;6.GQE^.3($L$'_C)_+CQ< M\'?7R@U[@A]-PRA>TB8>UB[5CMC$VJ6J;:+:Q/:.V<1/_M0[I-$X$Q;Q[P["O&4HG9:X>Z' M@("L0/, IUJ9W#H';4-BYJ=='\+.O&S;MQ[; M]T;*ISZV6WEL?^G4^-]=/+?MQURW$#H@4>=ITU*H=HX.Z@.ZK@-:7ZP[>$ ? M<['6!W1S#FCKH-6\^'R]LB,JYVV5K5[5;WY!/8[>?_]V]=&[B%%2JQ=Z9TFO MH.S*G@C[R,\#_7F0A*SIZ4\F*%TJG% 7N)0^I['._-R' S *C: (=HW2 IN%AY&).F M%>8TQ[XY&ENW)>=H0F8&NPK"GZH&_>?NTZY9@&H6H-UA 3IK8 S9F2YZBCJA'6:OJLM!+)M\7F''D[ M((Y1TR-$*5$##X;S_>K9Z A7S45X#R+"I1*:&[/RO]#Z!AXBO[&P=Z]4D_L-T"; $71;!-_NI!Q;![PU9 (CTD+K8_)",([(4$P<_ MX4YSNVJ&/5=?BW2A^[QL7E9,)B-J(/!'HZGGPYQ/J%."&B;D69EV,: (TMSH MM$]A1DG/B%/#<\=11MRZ']^L4]TN_/GD5DP;>+ M?WX^^?KMZOSZJ>L#ZV7.=F$_I.3M2HHKJ-9N)+.)L"&1P;6MMYW#AOPM-\+ MMPU]E(,;H597D:'B-U)PL]0ZZX[#OAW$W!2#Z(MN./1'?574(FR3?(#:=(H8 M_HB^SR_R89+"^P6[3-Q\>[#XUP]-J+8.FD>=-T]?=7G3;+]>KIBSI,N\ MT']Y_117SPIOD[NJ,',XNC7.S,HFY>65,17+N,VOMRK:>T:([,H6Z+?INWL$ MAAO[&OO9OG?J9^'4^Y!,\[O]VN?>5@^M*6_&;&[23&[^9%4W0BQA[3JUM:NM MW4.MW=?4#[WW4?Y_@S#U1\'Z#^IVF[R-F\Z-G[$%_25W06UNRP>M:/AO$+]R MYN?A.^]S\H,A0X>,&'J8"&LM6%I#E6NH\B-S=\\ 53YZ8JCR?C<)IO"?83X> M_=?_ U!+ P04 " !&BV114; EFG4- "/BP $ '9M9"TR,#(P,#DS M,"YX5E>JN&8(-S(=7I*4)(-U4)9 +=/?LT)6P!VK8M MQI*3\.]7%SL8; N;)$-V3%57VM@ZWY'.)QT=72Q_^NW)<\$#"B@F_D7-/#)J M /DV<; _NZA]&U_7SVJ_??[PX=._ZO4_+N]OP!6Q0P_Y#'0#!!ERP"-F<_## M0?0GF ;$ S](\!,_P'K]LQ3JDL4RP+,Y TVC:6P^#O/,L>M6 M^VQ:AV=3LWYF6Q,33E&S"8U?9^=6RSIM3LZ,NF,B5.?7)W5XZIS43TXFQK1I MF<;9Z9D$?:+GU)XC#P)>,)^>/]&+VIRQQ7FC\?CX>/38.B+!K-$T#+/QQ^W- M2":M16E=[/]<2_TT"=PX?:LA'D\@17'R!\]92_V D8><(YMX#5%6H]TRXJ0" M"&N@L4\9].UG:)_X?NAE"S@L:+#E C5XHCI/A0)L/\MM%XH%(&,!GH0,79/ MNT)3&+KLHA;Z?X70Q5.,'%X17"2H7DN0>,Q@,$-L #U$%]!&6VWQ^0, @A_L M+4C @)\2G$(ZD;FE 9-B=<.LM\P:4(S>$!LR64VC]+)T*:$&;C72=DNGKXK)N-LNI MS:NEI?=\K%K M)B041?;1C#PT'(2W-@Z:)R0NH&OR58/8^IO4?3 MV,NF''A&^Y'_GJ\D!_SYP#SP*M+>-1: ^+>M_M^7O A M5:JD,5:,MJI]GPT>#O)_H+X*;^M 2GUJ;*;=0 DI89?B[AU4#V+ MHL7OPB+XN*;EWU5G=33F?V][@_%H>-T?=(>WOGMICPSC9B5J.#Z2""K$X@"P,$)E>AA3[B%+H.T,>4LM:!'F6'*\0@=E^#I1A)1Y9E\'_ER0(? M(_ JQ4:CT/-@L"33$9[Y>,I#0Y]U;)N$/L/^[(ZXV.9CUF+$%<32M[.6*4MEA"HE!SHWC1_=H??(1OA!&*GCNN11K/%,27!%P@F;AFZ_%]MH ,Q0_B 7DQI"DE/8XN'Q45I?(:N)F_=,!"+VS<83K"+ M6>$)KPPY?5]EF>GP,P(!"91*F[Y,-Y4KK>^DCEOID"&#ABKV4&F+EO);^>)Z M9W7"AV:%&*F@=[I"$\;]M8L@16Y9%Y4GK/=3IV9Z)"209+\AL8!;27>58\XR M/DL/H7=<9ZUT_Y'/2Q7]5XYU.3(/A;L!)Y*+ Q=,-'@06(;VE48@5 *I\\!^)CNK M4:^TTAU<"@?X&KSKD?6,\[ _M?*I8SPYJ%9L1^H.7"?L=(U]Z(MF(5X)X)?E M%AW*@NH9%K,F91A^5@-B/0=JDYVJ^+WK$*0DII[8EF6F1HK:/EK>2J@Y\)IJ M7>@MZ-T"K6?9LLQ2876D#!S8UK$=[8WT9V_!]U9P/>/'EEEB@ L^/JL[<*XX MOX8X>(!NR,F"PG[%E_@R);73$0B.OG81HGK;2 MDT/9;%1Q B++K+N-0 LAZ=W;0RR#LF7!_4=I.6W/U3+, M]")L$N07H& J;?M2&]+SI+5]5HLSD7*$63Q4L<=*F[1/:8@<\>94R,1I0>+< M,9FJ"Q>80;?L-6TS-2283:E2I]Z7VNE424&DII;EIE:)= K;+0<"&@J323NN[8/-XK M&\WL JRGV+*:J161;(HC3;\"J0NHGR#6=B!ZC8_=1AW%X?2D'EO-].M>>E(K M/@+)M;R(Z[^+L+[#.S)/W7L=3G7(>GI/K&;Z!2T]O7)X(K6!A+H#U\I0]XBR M -L,.=*W?>.J7DJR#E+/[JG53+]/E>,NF,%$2Q<86Y%+LN,!/S)^($B2Z1[_H@O_C+\#H _9Q!V\S8 M"[E"D^.8-;P#+7;I?:K;<;1-RC*L9FH27$M2)5O1D,U1T/>YV5$Q7I("VE9B MF69Z]YR4!DJ\FE8NU0@RY/25OFDU4[-H29M7LHZKHH_A4]&>(2F@K^,M,[U5 M,+*T%*^FE4O5\0PY?1WGM3PU8Y^T>27K> \&/N_)Z!T*9&18S/8I*7UM/S;3 MVR1C"'$P@PI**VSU,NLD.;+:51+KI)5>K4HS4,4UDDUSEO)!><)Z1\3'X*EA M0!89%71'HW!"T5\A+T!/',=1^/"(#2F].SHSTWMZ5Q! 8538Z"4/[L@6UC>! MMM5,K_UL4O!/;P&?&NO?VE"_U[['(;[&$7T62%+UX#E_7H;8%'LX]3RDTGG"Q1@XHSE1P&<4!V M60.4,\,P"\6O+P$)%Q []S0G[I"FFT*7/MOA;=)T1"_(')#H#\FTO[W0GEN!2@JOKV8ZE-118'M/HH8BVO$=6=O4X2'R1*6E^CM&3^S2)?;/W/+N O56%+-8 M15F6^SY#O$-BG!MT[1(2B(N"%.?([I7?G;W0(!2-<#B53VGG@7?LHA#7)/@B M]C!&Y_/QYW*SP6HWS^O[P]US\OJUJXSI;Y+O//%&H(9^V]O15KEWT&BVDCG) M(3/JPA(T\583\ : ;;7^'=DDKZ_X&Q2_NGG5';$\RY5N->UUR(>6XHSS3N+( M(7T'JA79=R\J.X$KKH+G(>K@G_-X+P)_E^I+5P)@[V7U?#P)Z1T/L;:4*9UP MWWE?>W]K.2"^K8Y]R?=3N0(E>KR-H-261RJ\451:+"#[/80![\?=Y2U\PE[H MO3"^2\.]=CP0R?/F7\!OBSY2;CV!]I[$,0=4?,0VKR\O M"?-6+E7J*S$<&4$7;?$VV6GWW3B_\Q\\[&$\II0>3U^&O-3[+H5H,;R+DHZ# M;NOI=WH%?>.[]8@Y[5AZKQ=[@SR4%\Q9O*DQNL/O_2NS?8_H@@>* MJ("OT$GLNZUU;)OK=<8!=%!T:@GM;NG1M3+OM K?$I_-W:5R=%' OX4VK5,1K@SER\RY9@KLNRSK7G!;[J^NK]C:Q'M;D\@. MP,=$OKDVX1<=Y[\A9+C-=[0OH@/.?M"4DZGJ>^T:'K[E\*^TR6+;+[E4=I=/LR8(?G! M:SC;'-5A?X=J5!QVGQ4H/J1:S%*PY-32<,)X T5.W^\]V7,Q\W9-@N3!/YHU M@MTAWVG%4>L;7Y'K?/,=M);G+7%($5:W);"\%!ZYN0F"VK/D0<_?_@?4$L#!!0 ( $:+9%', M*%VS2!T !(I 0 4 =FUD+3(P,C P.3,P7V-A;"YX;6SE?6ES6[>2]O?[ M*_QZOKZ(L2^IFSNER'+B*D?V6,[-S"<6EH;-"47JAC M3U4B2]01T,MST L:C;__^\?+P9-K&$_ZH^%/3]D/].D3&,91Z@_?__3T]W63/T;C/_O7GI!_S/_H='3U:=Q__V'ZA%-.[_]V_&,P3 I' ^$V12*=S<3; MS(B-,C"?@7-/___['Z60A@=+26( !+_7Q)NDB=:!9BX9M<;.!QWTAW_^6+X$ M/X$GR-QP,O_QIZ+9\NFGB\<_/GC^ M+S%_FCGGGLU_^_G127_5@S@L>_:?O[VZB!_@TI/^<#+UPU@FF/1_G,P_?#6* M?CJ7^:-T/5G[1/F)+!\CY2/".!'LAX^3]/0??WORY$8W+ M.U->]^$2T@]Q=/FL_/K9Z0C!@(3._W#ZZ0I^>CKI7UX-8/G9AS'DGYY>7R92 M%$J=H&6V?[OYNV=?)HU^$&>#.8^O\.?%7YSLW<4^_#X^: 5A[$CY9TF5F9=S M#T;QSD.#@KS19QD/?(#!_-/>;$+>>W_5.YE,8#KI&2.=XAY?-QT"D98YXH(6 MA$KALV!<,>'O2FG!RARDV4_"'*F+49\5\3V#P72R_&0N4$+9 K#_=G?Z&_$= MRL3I;#S&U:K'5"Q1//)K/+R_F8I#^%R^7?EY7Y8!U/ M1[4D?*-#)+F.DL]'P[B@0EDT(]IRPJ0V1'H=T4XH0R@/(OJ$I@)L.SU_(60; M5?-O3=5[RKF:ME_U?>@/^M,^3$Z&Z6(ZBG]^& U0EI.S?\WZTT^]++FPU.-2 MG;Q#9R(@BRIS J"H!R^EIZ:%]A\CK"+C/2$$.&,#TD!1E]EK8JVBQ,2H:30\ M,R$;\]BE=:PJ)N[#?E^Y5T/\"GXB:)F"",2DB/QH5%;(^"Z;)$ $;DVTJ87^ M'T/UUUWCFL+@0"U40\/IZ/*R/RW15V'R=#2<8I2&T5J!)T2>-0@@,3DD2 0D M"*PEW.!*+0+3E(L6L-A TS;X$-\#/FKII;);M/3,#%@:T2(3;1U%U@0G#D-F M@BY98#PIY:4^LN^[!_;]Y$,1+OY3-';M!W-Q3T_]>/P)Q?U//YA!3]'D5!2) M2 ,9W9*LB/5.$?#&6%5T#1'8Z9Q( DI>R\$KG)6[&!J"Y9U'H(J::&:L!X M.;S&N4?C3TA(3W";+"A-=);%L0N)>&HC0E-8%0/W0L060+A-1)=,93W%[RWF M:HI^,X8KWT]G'Z]@. %/IIS<#/YRBP(NAOBK^:GDQJ=J>J[0G*AYBOY(FJH'^)O[Y#:8?1JDLV).;0*8GT"\3\^2>,!RY-)YX M%@.)& I%,,*ZV"1J6$-/]URC2HBH(?]J8'@.&9 E)"2.+N&=_[A@%<$ID2!= M$EY1)K3?G$5BN0I$8'C,C9$4E&N!A_4D=<]IJ@2)2EIHF854%+%)=4"K+!&= MRN%W )S8R(0)GHFQ.J6I>\E%%B'!)P[;5>DY"8((I1 MY;+5(%63+:3[A'3)!AZ(@%4)L[UE7L_=2ZE?>/>#-^B.OAR>^JO^U ]N$=?3 MS'+K,R4BZ$ADL(Z$ )EHIFG(*7&1F\0&CY/6)7M8&1V5]5(SG32[+%*&FX@% M";H:PP<,8OK7<+-6OQI-RC+].N.BW=.46IV=(1GC6Y2!S\0R6J3!0JE7LLDW M22SL2&>7S&AM)#746#58O86I[P\AG?GQL#]\/[E%-#H"_=C':#MPF15Z#R*; M$@X@YIU)@5!N<7E406C@+9#T.&E=RE!4!D]EO;2H@NAQ:13C3)$HA"8R89!@ M0:#=U%0EJ]$;-$V2V&N+ 0YB9YG\D1PXJ.A(4K+4A*I$;#(1%WMC8@H*O=XF M&8F'I'3)!]M7[QN*&O81> L&]"*0K&@,I$GV43 MCVLE-5URLAJH?T^Q-T: L $LITB 4H)(+Q0)5@KB2H2;$@VR^=M_>.;U^C+U M7H&?P'+43["J A.P]H\D)M$R/E!]O&K^CB]:>*E[B MMYI$Z\%W-'S_#L:7SR%,;[]*0>=2#D8"TPY?3O0DG<8557"1/'<:'&N2.%U- M3D>7L /!4%$%U:L-WOA/98_[9)CPD_$,TFJV5=!:2:\(E8F6"EJ)L08W1'M% M<["!\MBF4GDG,KL4'-:'3T.5M3"22W?-2;E'*DJSE^T@>12+Q("U]RW,J>K*>JHY:P( MB@.U<# H'D8$2S*2I@$DUT2CHT>D!(GA0.#$)Z,<-1@ML'NF8XL JX,U697T M6D>03>*J)2%46R\Y!0*T9%J=,<1;Q!E3D5EDDL;8I/I@!2W; $!]6P"H)?F* M)UV&T[&/TS_ZTP^GL\D4C<_X 3A=TDSG:(B0Z/Y+9C#*DUQBT >6HO6)R339 M%=F&N&U HK]-D%37S3W4_/W9?9F]PI];'?U_XPN]'V#:QPGO4E2I#\#=&8[1 M%& #3TUZ*5R\PZ^_G9V_NWC]XN7YZ>O?SD[.\8'?WKP]^Q4??OG/LYM/:XEW MZ_D:"7L_?BLU9WA]!6-?#IA]V;_NN:"TC];C^POX.MN$%EJ!)2K;I+.R$$P3 MZ[B"ED-7_E_&.,B;\2B7[57J7)9E@<)8 TT/4.(#4^A-2EW"C^15DTSJ+1JZ M%/$?JOG["_F^HJY75P@#_-7[7V"(C U*]BU=]H?]R;2P>0V+ P(]I[Q(V3,2 M+ UHK/ [*X,GUEMG%#-2IB;Q_G;D[1C\DV\*(@TT5+%N9@(X3#E\^!RN83": MU]$O22JUTM11]%-]YN74H2?!644D3SYK]%JY;)(/V$C5CCF!;PLK]?11+UTT MF#\#Z>(#ND0_8X2;2@D8$C07T)(V):TTBG,"-F.((W'=<[*AK@:0^S/"3D?#:_&HS2+Y8>>H])0D3UA3*"US!JC M&YJ@Q%!2Y.0#94T LY:B'7,2WQ9&ZNBA&BQ^\?UAX>GU\'E_B?ZY#=TJ@N\0R23DX(JDHY0RENDG* -SG(&1HD]E<2].A[.(XMY2)@N:" M:DHTR^@#9AL)"AP#AN03%892H$WV]N]0T:78OA8:[B-_?['770T?.7GQ9C2> M"WXZ'??#;#JO0!C=I#%[.OADA?&$,XXOO@J2! !'N-7*^,2IV!1(Y$'PH0UQ<=VQ)5V')D:'EEV&MJ4837DJ4L+__YH?-AMIQL@ MJ-BE:4'HPD_[&8908#U^Q %59[=5_X_GC> MY.$D_??LIKG-Z_R''X]]Z7(3LO)1:$N,R>7$=3EREM #!.X2M5:6AH M4+61 MJDZMZ%T%6#V]-K(2ZQHK,:=T%@@)Z=$R2A"9..$5\5$KGXU!VIJ<,-V*NBY5 M#7<5>?757!&!-_S=R2_>3CS.>SA)K92(LNR1HP>E==D*!4\@F^2 0@IM.KAO M0UR7JIN[B[_*2NY,JDWXE*0M=VN!0J)SDL3;>5O>B*]3-";Q)A6U55-M=<56 M^EJ_&(S^^A72>UCN-9UD1,!;B ,_F?1S_^8FKY-A*ODT*D5(0C."ZPS*$(Q& M)ZMTNF8NZ0P\2=>D!7E-)KKD8!\3T[OD-YL"H]YF]:T:O^30&=,6(_> "Y'D M@9/YA28&C:,!%O!WQRVGW*?FZQJ&,R@[&>A<4B>(XY!0F+&T#5>I5(5XFD K MTV:;?4E E]Z0?77\L(!K#^%6W ^=X,O\RVB4YC=TP/BZ'V%R,1JDGN5!>>\H M\=EGM*4@T9::3 RU'C*+&,@VV3!?3U*G(L1:^J^D@6,?Y[A=C7_ZZ\GY+V<7 M+\\O?CUY>_;KZU?/S]Y>G/W'[R_?_5>+PP>;ICO"V8.MN6U^ZN/TY.+7%Z]> M_U'M)LW5@Q]#IJLYJ71XHUQ\@7X#OJS7?1SMYT^_3\KAZL_)NI,X[5\O>CPY M8"(S65I!R\BPF=-K^3Y6$-,+*Y@J17;30I-"VE[A,@L_O!TJA-%D)Q..T1$0K=7). MJS8-X&X3T:7:C2/!8&\=5+RK!3DLUY"_&(V?CV9AFF>#95>27@#@&"TQDJ-2 MZ)*R2#Q3CH3$G=?HW !OLCIL(JI+N=HCH:2:CNJ=(5MY;J '(9LDF"+,E]N( MRREGGZ(G.3BM'62C99-,UFIRNI15/1)2*NCE2%N0UFK%&7*9LRL]2\ 2IU*Y MD"Q(IS'*T;G)QO;!6Y#':C)Q),34TU+ENW$N(,[&<_Y>7)_WWX(?]/\'TC+E MUQ-.TY0MJMG3)ID8,R<:A"L':]%KIU(1!2HX"IH9T20GO@UQV^#(?F,XAJZA,J?,5Z,<[KT@)_HD%*=![TQ!5$]]Y(U7; ,A]]P#:5TU'6(AN M-P[M11V9-$Z0K$0NO")9.@H/.F(_'>9J24.B=S,HTVLG>DMHVDM6 M!LZY(%"B3LFC)PX")6H*ZNM/9PNE68N%AD>]G[ MTGC1$.Y4N;A.<0P<%"5&J("^GN09CF<85].X%;B^L[QV*Q4VQ-CB%O7E7;$K M;U/OQ2@,3^5&,L-*KZ5LT4<,:-V]M4EFG62;5A/[D;L5\H[6ZNBK0:^Z9MM= M#WWO;*!26<>2%LF!03GU <1SAJ]&#CI9$[P*32+'1^C:"E??63:]IJIJ'KU? MQ?O-L8V[O&OAC?&XRGJA4VD@7-J]< Q$) ,KO?2\302Y/8D'[W?[3_.3*N]& M)_%?L_X8<$X$P?33FX$?3O%U+XGL>0^]GE-@#7- =-E/E4JRTH8=X[-,<\I" MHQ%J4@NT/8D[%LY\E97[4)@]V QOH\!Z!17WZ9O;CS>+]FG7L+ D+'BT)(&3 MI'0YJ1+1G[$9W1OC%:4V&<.:]%?9CKQ.5=I^+6 =KKB:53H1(,V/9%WX ;S. MZU%OA!!9]4Q\$LH0S//L8/?O@> MWOHIG.4,L5Q^BV^+T.6 4&E>[ PEWE!+LG'">!^MEDT2/<=ELY'K]J(_],-X M#YQ*4)H!2$BE4U]IR.DRPH=[EFD1=I"M*GFW)+%+9;X=1ON*4N$6&/@:X04S MKEQ>HPF7Y09E7I(X2GGBF%5HX=BH#5&5X7_23E\ M2R@G *5;HPY0]D8B 9:YM#&6.H$NG0#YNM[3MX_10S'0&J.KUOD8K$FEK3\H MP?$=\H%8]$V)T4"]YX*!:.(\[6OK#PQXIJ/XY^NK>>^)LX\PCGV MF0JIW+'7,T9( 5P1Q4TF4BI)+'Y$M#$N<)LY^DDMH+.&GF\AV5(;,3544SUE M]V(T1KIF8S0[$PS03T>7EZ/A',\]PZQVO&P%T%*YK'PB+@I&N$,1>$]+9J!E MNFX]:9VZW>98ZTU=A=6[$W=)6,\991C/G.1D2Z4[D^7R;O1;*$4G!1U>Q^]9 MZ/5WX2X'[=25-(TU?9A$FUB0>3KX]EVM/4-6I2VF^@C4Y3$U-,O:+XU1+;PCC"^93%D*1&#EZ0PYI\S2CE>. M9D[1$$V;S9\-1'7IMIJOX+8>I*,FJ'DYF8K8*F6YAK#ZK;?'1R/RK%,&)12%X&>DG,8KGGT MMX74PH?4I/#C4CM9+D8 M_EB27,7-<>3X\%1NN97VKV+L\L,V-_LOF2VI.9:6*LCJ.$I='C5[@U$4AN/^ M/337W(8ICZ6>;;D^C@Z6IY4_H=5>UICY6^5EK16R[?S'TLY>\CB.JA:]?_&U M'N%3A?W6RED_X['4L27/E5I_?NZN[#4P)1008S ,D]H!L52K^5:DPR -A&QR M)FMUZ^K=&?E^SCXOZF5*PCO_=M,$/X#U+B0 / MC$@J!;%&!J*]" [%PI"1AO#?A=8NE>!5@4]K?37,\*RREWO8II7#'&YP'J?N M4#.^:H:] \ -@[6118O@;M4\%_$#I-D 1OE%_R.DFX,R^WLR.T_11GK;K8C9(O$+;ZA-%P1A&G$^2&!#& ML"BC;]-IK18#G:H7; ;!KZ+N([M2YZ7HH)PMK6LL'PS;QD!NIO[@VT]FXW*3 MV.W^2[M+9\4@%6XS>82R^ISO[7*N':J%%%JXFP]GV?]563]6"VFT]!0?]N!: MS-_CAOL4(B-6F')9?,"X$80@1IL(H,L=8TWJE-=2=$A)[6+0>8_$11^HSXQF M&[Q12I'D=232J4R"D8:@5V(IJ&3$_:L&5A;8;IBB2XY>'87?+JZM)=N:[ETA MJ)R-GY1"[OZDW'BQ)"E0T I=!B+GU^0H&XE-+!/+04NC AC3I!?+1JJZE*FJ MBY#Z2JF-DY]'P]GD"Y/"*!JU5L241@F2T42\"(98117ZG98I%QOBXRXU73J@ MV107!RBAWFT1:/E'GP ]BGFLL()1 SY2\)E0A3Q*PR4)((&DR*4++"HGFN2^ M'Z6L2Q?4M,%)7>54[ZAW^Y*<+U?GG)1*\/

Y2Y?:M$'9D=19]\+X]:((/@KI\97P27,4A50D M\$2)RUG@HBJISTWRGIO)ZM+YD#8PJJB6AGFD4@#NAVE0=J$'!R5'UHUT>#2\ M%8V'I@;63+)WKF3S>,V$TB)KLF8JI!9&^117RGZ-U.,^LS03X_:\-1)N"8_* MV3$_*&=]SD=3F+23\3:3-1/USIPVDOB7#=HY#8LL1G59;YZFF91WX*Y25O'. M.34KC4M,::(@!W2,0B)..TN$,BR)Q'QL<[9Y_3'"PQA:6O'HJ0V: Q'E'CJI MLB-NWI"9IQQEY!!3DS9Y*VCI4H)Q;]W?=Z(.E7DU)_LV(>>C85S0XG!VHP0C M,@/&FUI9=!!M((RCXZB\!*6:'+U>34Z7,HA-(+"GY(_O/R\.@:\-L# MRN1WG:&9"=F.IU;.YKQ6ML:^W8X3M',QM^'H0%O\N>_)E\N:I!_& MXZ&"+K?57Y?;ZB]QMMD8]CR/L'*8PT7T.'4M^-\[X;EAL#:R:)'J7#5/A;S; M5L.VD5+;7-JJ&1>]KTY'PVL83^8L+*Q970$^/D\;B>[(W\%G?\O6XX?1 !V9 M22F616][=_FM&*3""=U'**O/^?[=,M8-U4(*3;I@/)BE]'*"5'KIS*:38DO1 M:LZ?.O57_:D?''#V>^^Y6DAS+S[KBWO>!S:4"H#;=0$UA;QYAA:BW8&G^@)= M-/6^U>![T?#L #.QSRPM!+LC;\V$6\%UV7[LAH)LZ\2LG;98_W\6ZW^":]#E MU8'=UO::IJ%0M^:NOGR_W.$Q?T5^'_8/ZLFTT_@M)+HU/_5%^>8#^J*CR_DO MJLMQ[> MA+@=)Y5VI]<6^87'BOQ.ANGV-I2,(6@&1#MMB70Y$>BOUGIZP8R!GXRZ><^W!9CYD"CC98$+A21092;L+,G$G^T&C0UM,D^ M:B7ZN["C\#61O74);4-8=*&3657[##9KYP:KIG$0,EDN+( R88;AGR]9-HU4XY[HMK0>UW45R^Z\/YWTM+169W%_]*P:IRG(3]=X,_ZSHLEW#V+^'\]EE@/'K_+P_ MF)4T39E^EH9IY11@ AAJ66N*=B$1K,%RYR%)NTL9I1SH/#6[63/=@ M'G1W^[$GDF$\.$/0=45/.J02?RE&&/7* !."VB;E[3M1V:7@NR7J[H2>(Z89RD_YY-YIYNSRE%DY0(C7([L]1]907H"A?2JKH'W_[7U!+ P04 " !&BV11D:^8[CI& "@* , % M '9M9"TR,#(P,#DS,%]D968N>&UL[;W;DENWDB9\WT_AWW/[HXWS84?OGI E M>6]%R))'DKUGKA@)("&QS2+5)$N6YNDGP:J22BR2M4@N\%"2PU&JXUI?9GX M,A.)Q'_\SX\7HQ\^X'0VG(S__J/X=_[C#SA.DSPCQY_VDZ?/MN_H/DDB__=/JWZ(16@4?O__;3S_]]==?__XQ3D?_/IF^_4ERKGZZ^>T?KW_]XYW?_TLM M?EN$$'Y:_/3SK\Z&JWZ1'BM^^M^_/G^=WN$%L.%X-H=Q^O(">GV>?_[#VVC, M3U<_I%^=#?\V6_S]\TF"^<(\]XKPP]K?J%^QFU]C]5M,2*;$OW^C_#F>^^F6-:BOQ&Y@C(5SO^H3_MI;TSO",@T749D]%T<5X+WB''5T_?' M_/E9+&.!R]&\1\1WG]TKWLD%#/M4\)U']X!V\2!V@1<1IWU"_>JYMW#>@%Q& M6!_Y88@7F/\]32Y^6H![//G0!=2'B\SJ3,J#XHN77_W=K9>2=8?C89TPGM.7 MUW]<7['MZ_'C',<9\X\_#//??QPZHY3(.I0@A7;.@$(I(@]%RF(\3X,[2+82 M_^6+)T]?O'[ZA#YY_?+YLR>/WCQ]\O.CYX]>/'[Z^I]/G[YYO8MN[G_H_HK; M$OB25H7C/DLAO ]OV&/O[Z],6; MUR]_>?;B\.TL M5U@4US$8"$JG*&A"L]FHK%8;=!?)>S7OXW\^>O&/IZ^?O7C]ST?TSI?/GSQ] M]?KI__K]V9O_T\*ZFU[7WKB=A5VR;0(P-'?&1!$#3:,T:('3_Y(73\L5V/MM MN^G-5>P;P4>3]!604?7.)Y^7SA%$'"V^.[BOYQ0HU9B)-(7/Z-/9 M *)"#088"B>8E@*9I\F>H:JS"\TO/(>5SLC"$2DPBPMOY/H-/U4+_X2C^>SF M.PN;,RZN'?S_L1[*E4UW%^[9.%$@.,,G>/7OL_'K^23]^6XRRA14/OWOR^'\ MTZO):/3+9/H73// E)Q-KI)[QYE6J)C/],')K P%?C3EZA:2;XGS:[5\(?NC MZ8V"KIW*';W.&BKWRI+YY'!VN>(&R??C#Y,I/>[O/_)]:?1X-BWV5/U= M,LA]R? H_]?E;%ZGS=F;R:.<%\J&T6\PS,_&C^']< ZC!8-_)M5DHO5[',\6 MV;2%+"_?UT]GKY"$F0WG^!JG'X8)?\/I<))?89J\O3+?@!1CM2V9>6X+TSDE M%C&J.BGG6$I #$T8=B#Y'C9M3Y$D=\>".MY8>(6S^728YI@7 O].\G00-Q=I M=(R&%9'(/;%),RAHF)0:@&,41HG3&A,[R?E];!R+-'?'B.[%>7@VFUUB?G(Y M)6_F"N&5DW-[M#_]B-,T))$'PJ(M!(R8J)!I@LFB)64G"YI[D"$9UVWD")7)+YG@B=@.M)GWCEBA*38C4," MA/MRB-N_]6'2I;'V[_+$->#)@M1W@7*KL@*;B<&!ID[E-0M:)::"Y\G6?4 I M=Z?)ZI=^*;^DA+7M^CJI9_3">SV2 IHK0%2ZZW _:2WA07(PB*(;11J;KN(E6)B83!^1< M1O!-LL,[H?TF:=>C 5?DD_?>>UC@>87O+Z?I70UR'XTI8IT/IZO&SL Z6W+B ML884AM0C"O,1:((6Y.39XB&+=FSK"/(;(%D+"70R00<[":M2" MN: )*Y3$O J)!4?CPF6N.6^W@';#^)U9NQAK!;'VWOAX.7^'TYJ.F^*[6B?Y M@323)A?XG&;4%SA_6=[ Q]\FTX5QYC3QQLLYQ!&^F5S5) VLMM8G2X!]E#4U MXICG=:F/WH58$)-S+@2",7P /H@XT)*QA#BV%,R?6-50.!6ZY+YDP:[IAVR!EXI,\D M$$\A1(1\W"*.7DH1C$^9O Q7HQ1AC[*U-W6. M&0!P[0L'5C2W1*X<:&Y1GAG+E8&@A95-=ON^AM'C<+YU9J5Y-=8>NEQ50?/# MU0F$OZ71A-R4O_\XGU[BEV].QG/\.'\Z6KSP[S_.\.W%G95S#SIO;B*I'LFPX3+2!/#M8 M>QUQ]M9Z@TJL)4Q/%NMC)U"#I>--?5)B):H^W8!U9[0V$&%_ZTU:J?Y@O- N M"YG0LY!#7?9-9"%ES[+D17LCN95-PML#\N&K,W#'I\,V&F] @UN>UZ\+GYF" M9O)0O52L9&5KL6"5CJ;#G&UV7),!71,*W$%R^*B@!PNMK]'=0;T-:KC75 _= M@$.A"(5E'J-F&C&3J!2@)JN=#$4&,+*%[3>B>@@\Z$_M#>: 1RE=7ER.:J> M=5>/'JC,HM;<&RY0B,Z$'1:TN9 M_^.G)<50,/UGJU.2CU[_\Y?G+__5VS'QU0\_P G(U8(L'\8/2?AD,9;,->H2 M(R@03C@4CHNXYMCXO3)M8Y(7,+^U ;/=K#"YN?M MK?@MX"[I6F$P+B8!1JE:U!^+Y,J*% '021$&G9'WIMXG==2.>M?RS6/;*GLE M^"6=>\20P5OO,&DI);BL B0-Y-22ZM-FG:^08QO5O[Z\N(#IITEY/7P['I9A M@O&<5L[)Y7A>=P$GHV$:XB[*[_C@O=6_BP#+!K ^.FTTN"BT$JX6Y[MDA>?% MD&WL8'M9^C=![*U;]IKK\S>X4) MAQ_J"Q^-1I._:J>R,ID^F5S&>;D7LSG%D=/?<)HH1H&WV)P[&UYY(()T%7IY ME84@8RC>92C:!>Y!E1 L31[&!QM%1Q9L>/N^*=QQ?>"56_5J./OSUG:HS>@4 M9@88(Z.H$.O!;\6\,59Y'DWQC7*YZR#MGZ]>>O(7=8I!]"&X(A)SFFNFLW#, M>V>84HI3T&7(*VV2GMH$ZO#YAY[X<#>5W9/FFW0F6<)VM:FKC"X4$BIFBN), MBR19(!^,2:1U7EORFFV3#>_5< Y5%G$H^V^OXV.72TYZ MTVN/VQH5S0NXP)?E*TS7>=@NH+:H?.AD]+5H#EOQT(>9)JUT?# "Y.RTUF!8 MT8J6*B,\BTX2WWTP1@C/L^O2UNT4#;^FM.%@=M]&M3W:NQ[>_!4S^=U3?#3. M5Y\.\_4N27!*%P.)>>$E3_I6W,] M.G6W05TC@22]U#$P63M#Z!P*\Y!"K<9V)4=!?DW8PH:'-ER/:EYAN!UTU&3P M?19(:5<4>)I.."],6RL99"V93;*$$J5#C)VM=?AAUM):.^FHP=;]'>?OYT]O MZ$\7ZP*:[+.)@@7G:5UP@,Q'*YA11B01")J'@T1-7S ] !^Y;\T?@A05V/7J MT@5:RX+A#=B.4S;FRC^Q:TN/9'[T"\6?(R^.A49M:3Q+I>)11]S@P4%U$[ MKQ0VZ:=]#ZX32-#N:L-E;O1H@$,D:7_^]#..T[L+F/ZY&!>0?"F1AH1(M0R6 MUE@64\A,D>"04E'1I ,Y'E\!>]C>Q^XV:- >]2Z^&W37XZ,+OH/Z(4L 3\89 MV<.L]W*F!YL%BJR+A>(J/'C+[V1[>N-M>J>V-1:::L# &+0&]+HP,.*P&=@'.R ME^GN'FW87^\-7)-7^ ''E_@+:8/D)^'3_%_#^;L;A^K+T2V?D!N&RF:27 ?F MI?),IY0DV*),7'T[W=X'&SJ@>V!,Z=\B:Z>1'D] =*L$>C8FV8B0GV"IQ^P-D@Z%(K+&DTDW_!-#H*;#QY')D+Z7A!@[K) M_+H>TN$GU9ZY9:%&>QR0+6 =O1VBPUX437N6I'VS28J]9+?VM[KP/$EKG-#AB/D][L MW;Y=^;.G<8[$HR $2.-4K>0CJ#$%%J.5%!7K4K01H-J4O1^-/_>D.D^!/MO8 MI.?JK,]PKDJ0;IK.8#W_Z,&PG$NN%U@XYF.L6X).2Y):2-_E\I#53S\A=WA7 M(TQZU6"3_=2+]Y=SG-Y"MX EK1()@=QP%VDEC3*35VXU+:=.2F6<\*'1-NI* M/ ^'"GTJOL'2\,OEE#1[N2A:_&7XL7YVTRG&^0S.:L,,"E^[W@KF:ZFWAA"* M5-JYU,0Q70_IX;&B)_4WJ.O[ ]\-T^@SFI)%],(6%GQ&6NIJ!SJG-1,YUZXI MJ6";!G]?PWAX!-A#S0TJ*7Z^'(YJ^^QK-%YX[ER=FT2M#@^B[I04RSC2&B83 MZJ*:'(W]&L;#,_H>:KYK])V;N]>3(:]@_/;*EU60:$:)D;E4FV GR 3"UVL/ M,RB>O./8I:=_IQ-.G]_Z(!,,N^NUQVG\,XB;,KX.,/H^P7CK_8<_L[BC!99M MN(?Z>CZ<>!L.1D[3CD'&HW)7O3^C3X9%*([<2.ZSZS(QGX85-QQ [->(VVBM M9^/]2IJZN+RX*5P1Q8 &S;R.MOK\M';D(%CQ'G7*0NG8VVG2K]Y\V&.'.^M^ MTH?B>@R>K\["?KP%!$6T*&UDD&BUUA@""T4EA@)3 &VY]%WNS.AX^O_C65MP M9\6=3O'-=6'1K>ON6Y?;K'_C@0IL.HJ\W/PJ(,8$46+T6D012W 0/+E)*>D4 MH6-)S?J7[Q??/!G.X.W;*;Y=5#&\+-?O>?YY)[,VH2E>61:2,TS;S!E@=?H2 MT9/\<%2E21;\/F#[!G;/<3:;3*_[:([?/J_75[W!Z<7+S+1HDB;_&]OSJKK/:0GS@ M52@@ZL5SR7*2._)Z$9FM]]")F$%K%YO<%;46T0/C1C^:;Y GOJ>T]NG'-+JL M*8U'LQG1&_,;^#@(WB6E""CW=:O#656;2T0F1#)HN?#1'*/T>176!T:CUM9J M0-4Y_6$3J$/5US6U?F]:/W9%78TD M?YM.\F6:OYR^QNF'8;I*#+E"X6B!P@I7BX94]>PS$JU%]BDZ7?O-]Q6)KP)P MK!1V?Y:=]*CAGM-FUWAFC\;Y&M'L>ONE"ZB^\]EKT1P^N[V_H>Y:O2]ZJSG9GR+6\B>7$ZOSNLN*N ^[ZU>8;RI>VWKTQP�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